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Chapter 1 
Synthetic Applications of 
Enantiopure Cyanohydrins
N itrile
O Asymmetric
A  ------------ -R H catalysis
OH OH
R R1 R R
O n r 2r3
R 1
X
OH
Modification R CN R CN
Cyanohydrins are synthetically versatile building blocks and can be readily elaborated into a 
large variety o f  molecules, which are o f  relevance for the fields o f  organic chemistry, 
medicinal chemistry, and materials science. This chapter provides an overview o f  the 
synthetic applications o f enantiomerically pure cyanohydrin building blocks that have been 
reported in recent years.
Part of this chapter will be published in: Ritzen, B.; van Delft, F. L.; Rutjes, F. P. J. T. Synthetic 
Applications of Enantiopure Cyanohydrins, manuscript in preparation.
Chapter 1
1.1 Introduction
Since the discovery o f the enantioselective enzyme-catalyzed addition o f hydrogen cyanide 
to aldehydes by Rosentaler in 1908,1 non-racemic cyanohydrins and their derivatives have 
gained considerable interest as valuable building blocks for the synthesis o f  enantiomerically 
pure compounds. Consequently, various methods for cyanohydrin synthesis have been 
reported including metal catalysis, organocatalysis, and enzyme catalysis, and have been 
comprehensively covered in several reviews.2 In turn, these cyanohydrins have been 
extensively used as key building blocks for synthesizing more complex structures and as a 
result have found widespread application in all fields o f  chemistry. Not only the hydroxyl and 
nitrile groups can be modified, but also the cyanohydrin side chain(s) can be altered to further 
enrich the follow-up chemistry. In contrast to the increasing importance as a privileged 
reactive functionality, there has not been any recent comprehensive coverage of the synthetic 
applications o f  this compound class.2b,d,e Hence, this chapter summarizes the recent advances 
in synthetic applications o f cyanohydrins in organic chemistry covering the literature from 
2003 to 2010. Thereby we have restricted ourselves to synthetic applications starting from 
enantiomerically pure cyanohydrins generated through any form o f  asymmetric catalysis.
1.2 M odification o f the nitrile group
1.2.1 N itrile reduction
1.2.1.1 Synthesis o f  am ino alcohols
Catalytic hydrogenation o f  optically active cyanohydrin esters proved to be a viable strategy 
for the synthesis o f  pharmaceutically relevant N-acetylated-P-amino alcohols. Hanefeld et al. 
used a catalyst-solvent combination o f nickel on alumina in dioxane for the hydrogenation o f  
acylated cyanohydrins 1 and 2 (Scheme 1.1).3 Subsequent intramolecular acetyl migration 
smoothly furnished the desired products in fair to good yields for aliphatic substrates (e.g. 3) 
and acceptable yields for more sensitive benzylic substrates such as 4. In case o f the optically 
active benzylic cyanohydrin 1 , a decrease in ee was observed due to the sensitivity o f  the 
benzylic proton under the reaction conditions, while for the aliphatic substrate 2  the optical 
activity remained unchanged.
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Scheme 1.1 Nitrile reduction and intramolecular acetyl transfer.
Me
OH H2,Ni-Al2O3
= ,NHAc
OAc
dioxane/H2O, 140 °C R^ CN
OH
H2,Ni-Al2O3
dioxane, 120 °C crNHAc
3 57%, 95% ee 1 R = Ph (95% ee)
2 R = C5HH (94% ee)
4 45%, 75% ee
The Shibasaki group developed an elegant method for the synthesis o f the morpholine-based 
intermediate 10  o f  neurokinin receptor antagonists by use o f  the asymmetric bifunctional 
catalyst 7 (Scheme 1.2).4 The sequence commenced with the formation o f  ketone 6 , which 
served as a building block in the key catalytic asymmetric cyanosilylation reaction. This 
cyanosilylation provided the unstable cyanohydrin 8 , which was directly reduced by borane 
giving rise to amino alcohol 9 in an enantioselective manner. Condensation with chloroacetyl 
chloride, ring closure under basic conditions, reduction and deprotection furnished the key 
morpholine 10  in excellent enantiopurity after recrystallization.
Scheme 1.2 Asymmetric synthesis o f  a morpholine-based neurokinin receptor antagonist.
TBSCl, Im 
DMF
Cl
S R= H (59%)
B R = TBS (90%)
NH2
OR
Cl
S 100%, 89% ee
1 ) chloroacetyl chloride 
iPr2NEt, CH2Cl2
2) NaOEt, EtOH
3) BH3 SMe2,THF
4) HCl
5) recrystallization
10 33%, 99% ee
Ammann et al. explored an asymmetric route to trifluoromethyl-analogues o f epinephrine. 
In this strategy, the formation o f the enantioenriched cyanohydrin building block 13 was 
accomplished by reacting veratraldehyde derivative 11 with TMSCN in the presence o f  the
3
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chiral (R,.R)-salen ligand 12 and a titanium source (Scheme 1.3). Treatment with LiAlH4, 
followed by monomethylation using ethyl formate and reduction yielded after 
recrystallization (S)-trifluoromethylepinephrine precursor 15. De-O-methylation o f the latter 
compound finally led to the formation o f  the target molecule 16 in 62% yield.
Scheme 1.3 Asymmetric synthesis o f  trifluoromethylepinephrines.
11 13 75%, 80% ee
LiAlH4
CF3 OH
Et2O, 0 °C
NHR BBr3
CH2Cl2, 0 °C
CF3 o h  
H0 ^ ^ ^ / \ ^ N H M e
HO
1) C2H5OCHO, A
2) LÌAIH4, THF, A
14 R = H (53%)
15 R = Me (21%)
16 62%, >99% ee
In 2006, researchers at DSM  (Geleen, the Netherlands) developed a two-step industrially 
scalable chemoenzymatic route to (R)-2-amino-1 -(2-furyl)ethanol (19) via reduction o f  
cyanohydrins, which in principle, could also be attractive for the synthesis o f a large array o f  
amino alcohols bearing a primary amine functionality (Scheme 1.4).6 Thus, the generation o f  
enantiopure cyanohydrin 18 was accomplished by subjection o f  furfural (17) to an enzyme- 
catalyzed hydrocyanation by recombinant HNL from H evea brasiliensis. Reduction o f  the 
crude cyanohydrin 18 to yield the vicinal amino alcohol 19 in 64% yield and excellent ee was 
conveniently accomplished with NaBH 4.
Scheme 1.4 Large scale chemoenzymatic synthesis o f  19.
O (S)-HbHNL
^Ox A  HCN, pH = 4.9
\ J J H -------------------------------!1 MTBE/H2O, 0 °C 
17
OH
, 0
W  l!
NaBH4, CF3 C 02H
CN
THF, rt
18 83-95% 
ee>99.5%
OH
✓o ^ ^ / N H 2w r
19 64%
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Recently, Hashmi et al. converted a series o f  five furfural derivatives with various 
substitution patterns to the corresponding protected enantiopure cyanohydrins 22  using the 
(R)-selective PaHNL enzyme (Scheme 1.5).7 After a sequence o f standard operations, 
including DIBALH reduction, followed by tosylation to sulfonamide 23 and propargylation, 
precursors 24 were obtained. Subsequent treatment o f the alkynyl functionalized furans 24 in 
a gold(I)-catalyzed cycloisomerization delivered the dihydroxytetrahydroisoquinolines 25 in 
good yield and high enantiomeric purity.
Scheme 1.5 Enantioselective chemoenzymatic synthesis o f  tetrahydroisoquinolines.
R\°r h
20
O OR
" (R)-PaHNL, HCN . O I  1) DIBALH, Et2O, -70 °C
- rV oV ^ cn
DIPE/H2O, rt
R2
TBSCI, Im, DMF
2) TsCI, Et3N, DMAP (cat) 
CH2CI2,rt
21 R = H
22 R = TBS
(15-93 %, 95-99% ee)
OTBS
/O'
W h NHTs
23 23-93%
OTBS
C3^Br, CS2CO3
acetone, rt
OH
Au(I)cat R
CH2Cl2 R
NTs
OTBS 
25 45-99%
2R2R
Griengl et al. developed novel chiral ferrocene-based cyanohydrins via  stereoselective (S)- 
HbHNL-catalyzed hydrogen cyanide addition onto formylferrocenes 26.8 As shown in 
Scheme 1.6, the corresponding cyanohydrin 27 was obtained in excellent enantioselectivity 
and an acceptable 58% yield. Further transformation o f  the nitrile functionality by means o f  
different reductive pathways provided direct access to amino alcohols 28 and 29 which are 
useful precursors for e.g. inter- and intramolecularly linked ferrocene analogues,9 and 
ferrocenyl-oxazolidinone-based chiral auxiliaries.10
5
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Scheme 1.6 Chemoenzymatic synthesis o f  chiral ferrocene derivatives.
OTBS
U 1) (C
Fe
O S)-HbHNL 
" HCN, pH = 4.8 
2O/MTBE, 0 °C
OTBS 
CN
2) TBSCN, DMF, rt
Fe
26 27 58%, 99% ee
29 18%
Catalytic asymmetric cyanation o f prochiral ketones provides a useful method for the 
preparation o f  chiral building blocks bearing a quaternary center. W ell aware o f  their 
importance as functional synthons in organic synthesis together with the use o f cinchona 
alkaloids as well-known organocatalysts, the group o f Deng described an asymmetric 
cyanosilylation o f  acetal ketones 30 and 31 catalyzed by readily available cinchona 
alkaloids.11 This cyanosilylation was applied to the synthesis o f  several optically active 
multifunctional chiral building blocks as depicted in Scheme 1.7. Analogously, a similar 
method was used to generate chiral tertiary cyanohydrin carbonates. In this case ethyl 
cyanoformate instead o f TMSCN was used in the catalytic step. 12 The authors also 
demonstrated that these compounds could be successfully converted into chiral P-amino 
alcohols and a-hydroxy acids.
Scheme 1.7 Catalytic asymmetric synthesis o f  amino alcohols.
OnPr-
O nPr
TMSCN
(DHQ)2AQN
CHCl3, -50 °C
30 R= Me
31 R = E-styryl
NC OTMS
.O nPr
OnPr
1) LiAlH4
2) CbzCl, Et3N Me'
NHCbz
OH conditions 
JO"Pr
NHCbz
L oh
32 100%, 92% ee
33 93%, 91 % ee
OnPr 
34 86%, 92% ee
Me R1
35 43-64% 
91-92% ee
R1 = CO2H, CH2OH, CH=CHCO2Et'2 2
O
R
1) LiAlH4
2) CbzCl, Et3N
3) 3N HCl
4) (EtO)2POCH2CO2Et
NHCbz
36 66%, 90% ee
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A  new catalytic asymmetric cyanation-1,2-Brook rearrangement-C-acylation reaction o f  
acylsilanes 37 with chloroformates 38 was studied by Johnson and co-workers.13 The cyano 
ester products 40 o f  the reaction sequence were obtained in high yield and good levels o f  
stereocontrol by invoking Jacobsen’s (salen)aluminum complex 39 (Scheme 1.8). Moreover, 
these compounds could serve as building blocks for further functional group modification as 
shown for the synthesis o f  41 by chem oselective nitrile reduction followed by cyclization into 
lactam 43 . 14
Scheme 1.8 Enantioselective catalytic acylation o f  (silyloxy)nitrile anions and nitrile reduction.
Cl
O
Ar SiEt3 
37
.1.
Cl
NC' 'OR toluene, 45 °C 
38 R= Et, Bn
NC4 /OSiEt3 ^  Raney Ni H2 N—<• OSiEt3
Ph CO2RAr CO2R EtOH 
40 70-93%
61-82% ee Ar = Ph
41 74%
MeMgBr 
Et2O, 0 °C to rt
HN—
O - o
1) NaH, Mel 
THF,-78 °C Mes /.O
► r L*OSiEt3 1— . O H
p h 2) TBAF,THF,0 °C ph
42 67% 43 70%
+
1.2.1.2 A pplications in transim ination reactions
4-(Methylthio)benzaldehyde 44 served for Lu and co-workers as a starting material for the 
preparation o f the antibiotics thiamphenicol (48) and florfenicol (49) (Scheme 1.9) .15 They 
found that the hydroxynitrile lyase (HNL) Prunus communis L. var. dulcis, isolated from the 
kernel o f  Badam u  almonds, stereoselectively produced the corresponding (Æ)-cyanohydrin 45 
in 98% yield and 96% ee, which after recrystallization resulted in pure 45. A  one-pot reaction 
sequence including DIBALH reduction o f  the MIP-protected cyanohydrin, followed by 
benzylamine addition, and a diastereoselective Strecker reaction provided the second  
stereocenter (dr >20:1). Next, transformation o f the resulting aminonitrile 46 via  three 
standard operations gave oxazolidinone 47, which was the key intermediate in the synthesis o f  
thiamphenicol (48) and florfenicol (49).
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Scheme 1.9 Asymmetric synthesis o f  thiamphenicol (48) and florfenicol (49).
MeS
OH
(R)-PcHNL, HCN
AA
1) (Im)2CO, Et3N
2) K2CO3,EtOH
DIPE, rt MeS'
AS 98%, 96% ee
O
A
O NH
1 ) 2-methoxypropene 
POCl3, Et2O
2) DIBALH, Et2O, -7G "C 
CN 3) BnNH2___________ ^
4) NH4Br, NaCN, MeOH MeS
5) HCl, H2O/EtOH
OH
CN 
NHBn-HCl
AS 71%, d.r. >2G:1
3) NaBH4,MeOH MeS
OH
OH
A7 63%
R
NHCOCHCl2
48 R = OH; thiamphenicol
49 R = F; florfenicol
Overkleeft et al. reported a novel chemoenzymatic approach o f  three 1-deoxynojirimycin 
(DNJ) iminosugar derivatives.16 The key step involved application o f  the silyl-protected 
cyanohydrin 50 in an efficient one-step DIBALH reduction-transimination-reduction 
sequence. Boc-protection in heated THF and RCM with the first generation Grubbs catalyst 
delivered the cyclic iminosugar precursor skeleton (Scheme 1.10). Next, application o f  the 
Upjohn dihydroxylation on the latter compound smoothly generated the hydroxylated 
piperidine as a single enantiomer which after deprotection was converted into L-altro-1-DNJ 
(53) in 69% overall yield from 52. In a similar fashion, the authors successfully applied the 
methodology for the synthesis o f  D-allo-1-DNJ and D-galacto-1-DNJ using ent-51.
Scheme 1.10 Chemoenzymatic synthesis o f  L-altro-1-DNJ (53).
1) DIBALH, Et2O, -78 "C 
OTBDPS 2) -9G "C, MeOH, then S1 Me'
OTBDPS 1) (Boc)2O, Et3N 
■ THF, 5G 0C
2) Grubbs I, CH2Cl2
Me ^  'CN 
SG 99% ee
3) NaBH4,G°Ctort 
,NH2
NH
OBn 
S1 >99% ee
S2 78%
3) K2OsO4,NMO 
THF/H2O 
OBn 4)TBAF, THF 
5) H2, Pd/C 
6M HCl/MeOH
HO»,..
HO
OH
OH 
SS 69%
H
MeO2S
The group o f  van der Gen showed that cyanohydrins are valuable building blocks for the 
construction o f  different nitrogen heterocycles (Scheme 1.11) .17 Via an elegant one-pot 
DIBALH reduction-transimination-NaBH4-reduction sequence, the cyanohydrins 50, 54 and
8
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55 were transformed into the secondary amines 56 and protected with a suitable protection 
group i.e. Boc, Cbz or Bn, delivering products 57 in good yields (47-88%). Finally, ring­
closing metathesis with the Grubbs-I catalyst led to the desired ring systems without loss o f  
enantiopurity. Additionally, the investigators showed that via  a similar approach cyclic 
unsaturated 1 ,2 -ethanolamines could be prepared.
Scheme 1.11 Synthesis o f  protected unsaturated carba- and nitrogen heterocycles.
OT
TBDPS
1) DIBALH, Et2O, -78 °C
2) MeOH, -90 °C
OTBDPS
R CN 3) allylamine
4) NaBH4, -20 °C 
50 R = CH=CHMe(99% ee)
54 R = allyl (97% ee)
55 R = homoallyl (97% ee)
Grubbs I
,1 CH2Cl2
(Boc)2O 
or CbzCl 
or BnBr
56 R1 =H
57 R1 = PG (47-88%)
OTBDPS
PG
58 12-94% 
(n = 0-2)
1.2.1.3 A pplications in N -acylim inium  ion chem istry
In a research program aiming at the synthesis o f  5-hydroxypiperidone by partial reduction 
o f enantiopure cyanohydrin 60, Rutjes and coworkers came across a novel biocatalytic 
approach giving access to bicyclic N,N-acetals 61 in good yield (Scheme 1.12) .18 In this 
single-step process, partial reduction o f  the nitrile functionality took place, which in the 
presence o f a suitable (chiral) diamine, ring-closed to give the stable cyclic aminal 61 in a 
stereoselective fashion.
Scheme 1.12 Asymmetric synthesis o f  5-hydroxypiperidone-derived N,N-acetals.
1)(S)-HbHNL M O M O ^^\ M O M O «^\
HCN, pH 4.5 T i l l
O MTBE/H2O OMOM H2, Pd/C A  ^  A
^  1  - ----------------- - HN N O + hn n o
H v  CO2Me 9)MeO^ OMe NC CO2Me MeOH2) MeO OMe 
59 P2O5,CH2Cl2 60 93% ee
A  few  years later, the same group reported the chemoenzymatic synthesis o f  the natural 
product (+)-epiquinamide (66) and elucidated its absolute stereochemistry.19 Key steps in this 
sequence involved chemoenzymatic enantioselective cyanohydrin formation starting from 
succinic semialdehyde 59 using (S)-selective HNL from H evea brasiliensis (HbHNL)
9
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delivering the (<S)-cyanohydrin in excellent yield and enantiopurity (Scheme 1.13). Reductive 
amination followed by diazotation o f the key N,N-acetal and subsequent transformation o f the 
resulting N-acyliminium ion precursor delivered 63 in 82% overall yield (4.2:1 cis'.trans). 
After some standard conversions, intermediate 65 containing the core skeleton, was converted 
into (+)-epiquinamide (66) and its epimer epi-66 .
Scheme 1.13 Chemoenzymatic synthesis o f  (+)-epiquinamide (66) and epi-66.
I~591
1) (S)-HbHNL, HCN 
MTBE/H2O, pH 4.5
2) TBSCl, Im 
CH2Cl2
1) Grubbs II HO
2) H2,Pd/C H*;
3) TBAF
NC
OTBS
1) H2,Pd/C 
NH3/MeOH TBSO
2) NaNO2,AcOH
CO 2Me N OR3) BF3'OEt2
62 95%, 95% ee TMS 63 R = H (82%) _
cis/trans = 4.2:1 
64 R = allyl (90%)*
AcHNv^^
N O  
65 66 (•)-epiquinamide
NaH
allylBr
In a recent publication, the authors used similar methodology as a starting point for the 
synthesis o f  (+)-febrifugine (68) and (+)-isofebrifugine (69) (Scheme 1.14).20
Scheme 1.14 Chemoenzymatic total synthesis o f  (+)-febrifugine (68) and (+)-isofebrifugine (69).
[ m ]
1) Li AlH4, THF
2) (Boc)2O, NaOH
3) MOMCl, DiPEA
4) mCPBA, NaHCO3 NBoc
67 38% 
d.r. = 2.5:1
O
68 (+)-febrifugine
1.2.2 H ydrolysis o f  the nitrile group
1.2.2.1 Synthesis o f  a-hydroxy acids
Enantiopure a-hydroxycarboxylic acids are versatile building blocks in organic 
synthesis.2a,c,21 As part o f  the research on asymmetric HNL-catalyzed cyanide addition to 
saturated heterocyclic ketones, the Griengl group investigated the chemoenzymatic synthesis 
o f  (<S)-2-hydroxy-2-methylbutyric acid (74), an important intermediate in the synthesis o f  a
10
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COX inhibitor (Scheme 1.15).22 Preliminary investigations into the biocatalytic cyanide 
addition on 2-butanone (70) by employing (S)-selective HbHNL provided the corresponding 
cyanohydrin in only low  enantiomeric excess as a result o f  the low  enantiopreference between  
the ethyl and methyl group in the active site o f  the enzyme. Therefore, by using 3- 
tetrahydrothiophen-3-one (71) and 4-phenylthiobutan-2-one (75) as masked equivalents for 2- 
butanone (70) in the cyanohydrin synthesis, both substituents flanking the carbonyl group 
were sufficiently distinguished providing the cyanohydrins 72 and 76 in high enantiopurity. 
Next, both cyanohydrins were hydrolyzed in good yield using concentrated hydrochloric acid 
affording the hydroxy acids 73 and 77 as single enantiomeric products after recrystallization. 
Desulfurization with Raney nickel transformed the thiols into the desired (S)-2-hydroxy-2- 
methylbutyric acid ((S)-74).
Scheme 1.15 HNL-catalyzed chemoenzymatic synthesis o f  (S)-2-hydroxy-2-methylbutyric acid (74).
O
AEt Me 
70
(S)-HbHNL, 
HCN, pH = 4.5
MTBE/H2O, 0 °C
HO CN HCl HO CO2Hconc. HCl 2
H2O, 85 °C 70%'
71 72 79%, 91 % ee
(S)-HbHNL,
O HCN, pH = 4.5 HO CN conc. HCl HO CO2H
73 80%, 99% ee \ Ra-Ni H° ; CO2H
Et Me
(S)-74 99% ee
PhS Me MTBE/H20 , 0 °C PhS me H2
75 76 95%, 96% ee
Me 2O, 85 °C PhS Me 82%
77 65%, 99% ee
O
Sheldon et al. developed a straightforward enzymatic hydrocyanation process based on 
immobilized HNL (LuHNL CLEA).23 (R)-2-Butanone-derived cyanohydrin 78 was 
synthesized on a preparative scale upon catalysis by LuHNL with 87% ee (Scheme 1.16). The 
crude cyanohydrin 78 was readily obtained by simple filtration o f  the catalyst and evaporation 
o f  the volatiles. Acidic hydrolysis afforded (R)-2-hydroxy-2-methylbutyric acid ((R)-74) in 
85% yield and 87% ee.
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Scheme 1.16 LuHNL-CLEA based synthesis o f  (R)-2-hydroxy-2-methylbutyric acid.
LuHNL (CLEA)
HCN, pH = 7.0 HO CN HCl/H2O
[ to)  ------------------ " *
H2O/DIPE, 30 °C Et Me 65-70°C
78 87% ee 85%, 87% ee
A  practical procedure for the synthesis o f an important intermediate o f  the muscarinic 
receptor antagonist (<S)-oxybutynin (83) and analogues thereof was reported by Shibasaki and 
co-workers (Scheme 1.17).24 The key step in this sequence concerned a catalytic asymmetric 
cyanosilylation o f commercially available cyclohexyl phenyl ketone (79). The reaction was 
performed at 100 g scale and proceeded in quantitative yield and high selectivity (94% ee) 
under the influence o f  an in situ  generated gadolinium catalyst. Next, a two-step reduction- 
oxidation approach was used to arrive at the carboxylic acid 82. In this case, other more 
general methods, such as acidic hydrolysis or alcoholysis and basic conditions proved to be 
unsuccessful. Finally, recrystallization gave an enantiomerically pure precursor for the 
oxybutynin (83) synthesis.
Scheme 1.17 Enantioselective synthesis o f  oxybutynin (83).
MeCN, -40 °C
TMSO *CN 1) DIBALH 
toluene, -78 °C
2) NaCIO2, NaH2PO4 
81 100%, 94% ee 2-methyl-2-butene 
H2O/fBuOH
HO XO2H NEt2
82 85%, >99.5% ee 83 oxybutynin
O
Pseudopeptides containing 3-amino-2-hydroxycarboxylic acids or 3-amino-2-hydroxy- 
amines are essential components in many pharmaceutically active compounds. The Shibasaki- 
group also reported the synthesis o f  some important chiral building blocks o f  a HIV protease
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inhibitor and a y^-adrenergic receptor agonist via  stereoselective organocatalyzed 
cyanosilylation (Scheme 1.18).25 By using a catalytic system based on Lewis acid-Lewis base 
bifunctional catalysts 86 , they successfully succeeded in diastereoselective cyanosilylation in 
high yield and stereoselectivity.
Scheme 1.18 Stereoselective cyanosilylation using a bifunctional catalyst.
Ph
BocHN
84
85 = ent-84
Ph
86, TMSCN 
CH2CI2 
-60 "O-
86, TMSCN
CH2CI2, -60 "C
BocHN^^j^
OTMS
87
anti: syn = 96: 4
CN 1) 6 N HCI, 60 °C
Ph
BocHN
OTMS 5) NaBH4,LiCI, MeOH
89 100% 6) MsCI, Et3N, toluene
89 '°°% 7) NaOH, H2O/toIuene 
anti: syn = 97:3 2
Ph
2) recrystfrom MeOH/Et2O
1) 6 N HCI, 60 °C
2) recrystfrom MeOH/Et2O
3) (Boc)2O, NaOH, dioxane
4) Mel, K2CO3, DMF
BocHN^^j^
OH
CO2H
88 75%
B ocH N ^/<°
^Ph
90 42% 
anti: syn = 99: 1
H
O
Most methods for the preparation o f  a-hydroxy acids rely on chemical hydrolysis o f the 
nitrile functionality. Chemical hydrolysis o f nitriles is well established, but requires relatively 
harsh conditions necessitating the protection o f sensitive functional groups. A  more elegant 
approach is to enantioselectively prepare the cyanohydrins under hydroxynitrile lyase- 
mediated conditions and subsequently convert them with the help o f  non-selective nitrilases 
into the corresponding carboxylic acids.
The latter approach has been used in the group o f Sheldon,26 by combining an immobilized 
(S)-selective oxynitrilase from M aniho t esculenta  and a non-selective nitrilase from  
Pseudom onas fluorescens  EBC 191 in a one-pot enzymatic cascade (Scheme 1.19). The final 
carboxylic acid (S)-92 was obtained in high yield and excellent enantiopurity.
Scheme 1.19 Enzymatic cascade reaction fo r  the synthesis o f  (S)-mandelic acid.
(S)-MeHNL (CLEA) OH
PfNLase ?
H HCN, pH = 5.5 ^ < ^ C O 2H
H2O/DIPE, 0 °C 
91 92 >95%, 98% ee
O
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Two important pharmaceutical intermediates, (R)-2-chloromandelic acid (99), the chiral 
intermediate o f  the anti-thrombotic agent clopidogrel (93), and (R)-2-hydroxy-4- 
phenylbutyric acid (98), the key building block for the synthesis o f  several ACE-inhibitors, 
were efficiently prepared on gram scale in two steps using a biocatalytic approach (Scheme
1.20).27 Employing enantiopure cyanohydrins 96 and 97, which were readily prepared using 
hydroxynitrile lyases and a highly active nitrile hydratase/amidase enzyme system present in 
Rhodococcus erythropolis, the desired hydroxy acids 98 and 99 were obtained in high optical 
purity (ee >98%) and isolated yield (98%).
Scheme 1.20 Biocatalytic synthesis o f  enantiopure a-hydroxy acids.
(R)-PaHNL
O HCN, pH = 5.0 OH R. erythropolis
R H h2o /m tb e,o°c r cn DMS0,50°C r C02H
94 R=PhCH2CH2 96 100%, 98% ee 98 98%, 98% ee
95 R = 2-Cl-C6H4 97 100%, 99% ee 99 98%, 99% ee
At the same time Sheldon et al. developed a similar industrially viable synthesis o f  (R )-2- 
chloromandelic acid (99) providing the cyanohydrin 97 in a high yield o f 98% and 
satisfactory ee o f  90%.28 Subsequent chemical nitrile hydrolysis in refluxing concentrated 
HCl followed by recrystallization furnished the target molecule 99 in an excellent ee o f  99%.
1.2.2.2 Synthesis o f  a-hydroxy amides
Soon after, the Griengl group developed an enzymatic hydrolysis process for cyanohydrins 
by using the same recombinant nitrile hydratase and amidase from Rhodococcus erythropolis, 
but now cloned and expressed in E. coli.29 By separation o f  the nitrile hydratase and amidase 
they succeeded in using the single recombinant enzymes for successful synthesis o f  both the 
corresponding a-hydroxy acid 99 and amide 100 with retention o f  optical purity (Scheme
1 .2 1 ).
Cl C02Me
93 clopidogrel
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Scheme 1.21 Enzymatic hydrolysis using recombinant enzymes.
100 82%, >99% ee 97 >99% ee 99 94%, >99% ee
Starting from benzaldehyde 91, the Sheldon group also developed a cost-efficient process 
using immobilized PaHNL for enantioselective cyanohydrin formation delivering the crude 
mandelonitrile 1 0 1  which was further derivatized in a second step without intermediate 
purification (Scheme 1.22).30
Scheme 1.22 PaHNL-CLEA based hydrocyanation and derivatization.
OH
In 2005, Corey et al. showed a highly efficient asymmetric cyanosilylation o f different 
functionalized methyl ketones 103 using a catalytic amount o f  the chiral oxazaborolidinium  
salt 104 (Scheme 1.23).31 This route gives fast access to the synthesis o f many interesting 
chiral building blocks such as the atrolactic acids 107 by hydrolysis o f  the nitrile 
functionality.
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Scheme 1.23 Synthesis o f  (R)-4-nitroatrolactic acid (107).
O2N
MeMe
©
q T * °TfO H
Me
104
Me
Me TMSCN, MePh2PO 
toluene, 45 °C
TMSO^yCN 12N HCl, HCl (g)
Me *rt, 3U min.
O2N
103
I J 
O2N^
105 83%, 96% ee 12NHCI 
8U °C
106 R = NH2 (82%, >99% ee)
107 R = OH (99%)
O
O
Application o f  chiral salen complex 12 in combination with Ti(OiPr)4 was described by 
North et a l.32 They used a two-step catalytic approach for the asymmetric synthesis o f the a- 
acetoxy amides 110 (Scheme 1.24). Treatment o f both aliphatic and aromatic aldehydes with 
chiral titanium salen complexes catalyst systems delivered the corresponding cyanohydrins 
109 in moderate to good yield and ee. Consecutive hydrolysis with the shown palladium(II) 
complex under neutral conditions led to smooth conversion into the a-acetoxy amides 1 1 0  
without any loss o f  optical purity.
Scheme 1.24 Synthesis o f  a-hydroxy amides.
Me2
Ti(O'Pr)4, 12 H/O -P'^.pt^PMe2OH
O KCN,(MeC° )2°  OAC ^ - M : 2 ^ H
A . .  ! -run/u ^ ™ R' 'CONH2R H H2O/iBu°H/CH2CI2, -4U°C R CN THF/H2° 9U-1UU °C
108 109 4U-73% 110 4U-89 %
64-89% ee
R = Ph, 4-MeOC6H4,4-CF3C6H4, styryl, Cy, C8H17
1.2.2.3 Synthesis o f  a-hydroxy esters
In the search for a environmentally benign plant defense strategies to protect cucurbits from 
the striped cucumber beetle Acalym m a vittatum , researchers developed a chemoenzymatic 
approach for the synthesis o f  the natural product (+)-vittalactone (115) and its enantiomer ent- 
115.33 The enantioselective (R)-PaHNL catalyzed chemoenzymatic cyanohydrin formation on 
crotonaldehyde ( 1 1 1 ) was a key reaction step in the synthesis and delivered the corresponding
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cyanohydrin 112 in high enantiomeric purity o f >96% (Scheme 1.25).34 Subjection o f  the 
crude cyanohydrin to a Pinner reaction followed by reduction o f the ester moiety, furnished 
upon protection, silyl ether 113 in good yield and with retention o f  the optical purity. 
Applying the standard Steglich esterification protocol with o-diphenylphosphanylbenzoic acid 
(o-DPPBA) provided the corresponding ester in quantitative yield and with improved ee after 
crystallization. For obtaining the (<S)-enantiomer 116 the authors chose to subject silyl ether 
113 to Mitsunobu conditions thereby using o-DPPBA itself as the nucleophile. Crystallization 
afforded 116 as a single enantiomer and served as an intermediate in the total synthesis o f ent- 
115.
Scheme 1.25 Chemoenzymatic synthesis o f  (+)-vittalactone (115) and ent-115.
Me'
O 1) (R)-PaHNL, HCN 
ÏÏ MTBE/H2O, pH 4.0
u ----------------------»
OH
1) LiAlH4, Et2O
Me CO2Et
1 1 1
2) EtOH, HCl 2) TBDPSCl, Im
112 74%, >96% ee CH2Cl2
o-DPPBA, DCC
Me
O(o-DPPB)
Me Me Me Me
Me
Me
O
Me
^  DMAP, CH2Cl2 OTBDPS O'
OH 114 95% 99% ee 115
OTBDPS
113 76% o-DPPBA, PPh3
O(o-DPPB)
DIAD, CH2Cl
Me ent-115
2 OTBDPS 
116 81%, 99% ee
The group o f Hanessian developed a stereoselective total synthesis o f  natural products 
manassantins A, B, and Bi (121-123), and saucerneol starting from the enantiopure 
cyanohydrin 119 (Scheme 1.26).35 A  vanadium-catalyzed asymmetric hydrocyanation with 
salen-complex 118 developed by Belokon et a l 36 delivered cyanohydrin 119 in 89% yield and 
90% ee, which upon recrystallization was improved to 99%. Methanolysis o f  the nitrile under 
acidic conditions and subsequent esterification furnished methyl ester 12 0  as precursor for the 
total synthesis o f  the manassantin natural products.
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Scheme 1.26 Catalytic asymmetric total synthesis o f  manassantins.
117 119 89%, 99% ee 
Me Me
OMe
OH OH
121 R = OMe; manassantin A
122 R,R = -OCH2O-; manassantin B
123 R,R = -OCH2O-, epi-C-8; manassantin B-|
120 86%
O/= N nM/,N 
( /V 'Bu—^  h—O O
{Bu fBu
118
R
The group o f  Crews et al. developed a stereoselective synthesis o f the C3-18 fragment o f  
amphidinolides G and H (128), which were isolated from the symbiotic marine dinoflagellate 
Am phidinium  sp., and exhibited extremely potent cytotoxic activity against several types o f  
cancer cells .37 Starting from the benzyl-protected aldehyde 124, an asymmetric 
cyanosilylation method developed by Feng and co-workers38 was used to access the TMS- 
protected cyanohydrin 126 (Scheme 1.27). Exposure to acidic ethanolysis, followed by 
amidation o f  the corresponding ester to generate the Weinreb amide and protection o f the 
hydroxyl group as the methylthio methyl ether completed the synthesis o f  building block 127 
in 45% yield over three steps.
Scheme 1.27 Synthesis o f  the C3-18 fragment o f  amphidinolides G and H.
BnO.
BnOv
124
125,Ti(O 'Pr)4 
TMSCN
CH2Cl2, -20 °C
1) HCl/EtOH 
OTMS 2) MeONHMe-HCl 
" iPrMgCl, THF
' c n ------------------------- *
126 75%, 80% ee 3) DMSO, AcOH 
AC2O
MTMO Me 
5 ,N,
BnO
OMe
O
127 45%
Me ^.^Me
i5|
TIPSO is
128 C3-C18 fragment of 
amphidinolides G and H
Me
Ph Ph
^ nh ohMe
OH 125
O
H
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An efficient strategy for the synthesis o f  the natural antibiotic fostriecin (135) and its 
analogue 8-epi-fostriecin (136) was designed by Shibasaki et a l 39 As starting material was 
chosen for benzyl-protected ketone 129 which was subjected to a catalytic asymmetric 
cyanosilylation using a chiral titanium complex derived from ligand 130 and Ti(OiPr)4 
affording the (R)-cyanohydrin 131 in excellent yield and high enantioselectivity (Scheme 
1.28). Transformation o f 131 into primary alcohol 134 via ethanolysis and NaBH4 reduction 
followed by recrystallyzation, and subsequent hydrolysis o f  the p-nitrobenzoyl ester furnished 
enantiopure pure 134 (>99% ee). This key intermediate 134 was then converted into the 
natural product fostriecin (135). The synthesis o f  its analogue 8-epi-fostriecin (136), 
following a similar procedure as for the fostriecin (135) synthesis, commenced with the (S )- 
selective cyanosilylation o f  129 using ligand 80 in combination with gadolinium  
triisopropoxide.
Scheme 1.28 Enantioselective catalytic total synthesis o f  fostriecin (135) and 8-epi-fostriecin (136).
129
1) 6 N HCl 
EtOH, 60 °C
2) NaBH4,MeOH
THF, -25 °C
BnO'
Me
131 93%, 85% ee
CN
OTMS
NaOv OH
R1
9
■R2
1) p-NO2-C6H4COCl 
py, CH2Cl2,100%
2) recryst. from 
CH2Cl2/hexane
-132 R= H(73%)
-133 R = P-NO2-C6H4CO ■ 
(78%, >99% ee)
134 R= H(100%)
135 R1 = Me, R2 = OH; fostriecin
136 R1 = OH, R2 = Me; 8-epi-fostriecin 
K2CO3
MeOH/CH2Cl2
O
Shibasaki and co-workers showed the application o f ligand 139 in combination with 
samarium triisopropoxide in an efficient enantioselective route o f  camptothecin (142), a 
structurally related analogue o f  the approved anti-cancer agents topotecan and irinotecan.40 
After extensive investigation, it was found that the D-glucose-based ligand 139 in the 
presence o f samarium triisopropoxide was most suitable for obtaining intermediate 140 in a 
high yield o f 91% and a fairly good ee o f  90% (Scheme 1.29). After ICl-induced
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iododesilylation, direct lactonization was performed under acidic conditions, followed by 
demethylation to give a-hydroxyl lactone 141, which at this stage could be obtained in fully 
enantiopure form after recrystallization. Similar approach to access the target camptothecin
(142) was also described by Kanazawa and co-workers.41
Scheme 1.29 Asymmetric camptothecin key intermediate synthesis.
p-toI p-tol
OMe O 1) NaBH4, EtOH
2) TBSCI, Im, DMF
3) 'PrMgCI, CuCN TMS ^  I ' . a TMS
137
1) ICI, CH2CI2/CCI4
2) HCI, EtOH, 90 °C
3) TMSI, H2O, MeCN I
LiCI, THF 
4) EtOCI, THF
OTBS
Et
O
138 64%
Sm(O'Pr)3 TMS 
TMSCN 
EtCN/MeCN 
-40 °C
OTBS 
Et
TMSO" 'CN 
140 91%, 90% ee
O
HO Et 
141 75%, >99% ee
The application o f (R)-hydroxnitrile lyases also enabled a simple chemoenzymatic approach 
to (R)-pantolactone 145, which is an important precursor for the synthesis o f  (R)-pantothenic 
acid (vitamine B 5) and its provitamin (R)-panthenol. In recent years, several efforts have been 
made to optimize the enantioselective enzymatic addition o f  HCN to hydroxypivaldehyde
(143). However, so far this process was accompanied by using large amounts o f  highly 
purified enzyme and thus making application on industrial scale rather unattractive.42 For this 
reason, W lostowski et al. set up an experimental design to find the optimal conditions and 
carried out an asymmetric hydrocyanation o f hydroxypivaldehyde (143) catalyzed by an (R)- 
selective HNL from defatted kernel meal from almonds, apples, and plums without isolating it 
from the original material.43 The resulting cyanohydrin 144 was in situ  hydrolyzed affording 
(R)-pantolactone 145 in 74% yield over three steps but in a low  ee o f 30% (Scheme 1.30). A  
few  years later, a similar strategy was applied by Glieder et al.,44 who made use o f  site­
saturation mutagenesis (SSM ) o f  PaHNL5 resulting in a powerful catalyst for highly 
enantioselective conversion (>97% ee) o f  144 in quantitative yield.
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Scheme 1.30 Chemoenzymatic synthesis o f  (R)-pantolactone 145.
O (R)-PaHNL, HCN OH HC| v OH
H0 A  H q|pe/h20 HO A  CN H2O
143 144 145 74%, 30% ee
Orru et al. reported the use o f y,5-unsaturated TBS-protected cyanohydrins 146 in a one-pot 
four-reaction hydrolysis-induced lactonization cascade (Scheme 1.31).45 In this method, 
cyanohydrin 146 was obtained by employing either (R)- or (S)-selective HNL-catalyzed 
hydrocyanation on the corresponding P,y-unsaturated aldehydes, directly followed by 
protection. Cyanohydrin 146 subsequently underwent epoxidation with Oxone® resulting in a 
1:1 ratio o f diastereoisomers 147, which were separated by column chromatography. 
Surprisingly, the hydrolysis-induced lactonization did not afford the anticipated 5 ’-OH- 
substituted lactones. Instead, the corresponding 5 ’-chloro-substituted lactone 148 was formed 
as a result o f  attack o f the chloride ion onto the primary carbon atom o f  epoxide 147. In this 
way, enantiopure 5 ’-chloro-3’-deoxyribolactones 148 were accessed via  a short and efficient 
synthesis.
Scheme 1.31 Asymmetric synthesis o f  chloromethyllactones.
oxone, NaHC03 
OTBS 18-crown-6, CH2Cl2
CN
146 95% ee
acetone, H20
OH OH
C02H
Cl
OTBS 1 ) column separation 
^ ^ C N  *2) 25% HCl 
dioxane, rt-A
Cl
147 94%
d.r. = 1:1
^i",.^Oy ^ O
V
OH 
148 92%
1.2.2.4 Synthesis o f  a-hydroxy aldehydes
Because o f their broad antifungal activity and low  toxicity profile, triazole-containing 
antifungal agents are important in the treatment o f  infectious diseases. For this reason 
Shibasaki et al. developed a short and efficient synthetic pathway for antifungal drug 
intermediates making use o f  an enantioselective cyanosilylation o f ketone 149 catalyzed by a
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gadolinium-ligand system as the key reaction (Scheme 1.32).46 Reduction o f the nitrile 
functionality and acidic work-up, followed by a second reduction o f  the formed aldehyde 151 
and substitution o f  the chloride with triazole anion, delivered the triazole antifungal agent 
152.
Scheme 1.32 Catalytic asymmetric synthesis o f  triazole based antifungal agents.
Cl
7,Gd(HMDS)3
TMSCN
EtCN, -30 °C
TMSO *CN
149
HONCHO 1) NaBH4,THF/H2O 
v  ,Cl 4 2
F ^  F 
150 93%, 83% ee 
OH
HO
C| 1) DIBALH, toluene 
2) 4 M HCl, THF
F v  F 
151 85%
2) 1,2,4-triazole l|
K2CO3,MeCN F ' F
152 63%, >99.9% ee
F
Owing to the general pharmaceutical importance o f  L-sugars, Griengl et al. published a 
novel approach toward pentoses (Scheme 1.33).47 The key steps in this route involved  
enzyme-catalyzed asymmetric HCN addition followed by asymmetric dihydroxylation. The 
starting a,P-unsaturated aldehyde 153 was readily prepared from (Z)-2-buten-1,4-diol. The 
best results in the (<S)-#bHNL-catalyzed reaction were obtained when an allyl-protecting 
group was used. To prevent chemoselectivity problems in the dihydroxylation step, the allyl 
protecting group was replaced by a TBS group. Additionally, the bulky TBDPS group was 
introduced to maximize the stereodirecting effect o f  the substituents at the chiral center in the 
dihydroxylation reaction. A  catalytic amount o f OsO4 in combination with hydrogen peroxide 
as the stoichiometric oxidant gave the most satisfactory results and delivered diol 156 in 67% 
yield as a 3.5:1 mixture o f diastereoisomers. Finally, diol protection and nitrile reduction gave 
the pentose precursor 157.
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Scheme 1.33 Asymmetric synthesis o f  pentoses.
1) (S)-HbHNL,
HCN, pH = 4.2 1 ) Se02, AcOH
MTBE/H20, 0 °C 0 TBDpS d'oxa™5, A 0TBDpS
AllO 'H 2) TBDPSCl, Im, DMF A ll0^^^= / ^CN 2) TBSCl, Im TBS0^^^=^^C N
153 154 64%, 92% ee CH2Cl2 155 61%
0TBDpS 1 ) 2,2-dimethoxypropane 0TBDPS
0 s 0 4, H20 2 ° TBDpS ppTS, CH2Cl2 ^ \ ^ H
acetone/H20 h0 0h  2) DIBALH 0^ 0 0
pentane, -78 °C / \
156 67% 157 21% 
d.r. = 3.5:1
1.2.3 G rignard addition
The van der Gen group developed a convenient general route for a fully stereoselective 
chemoenzymatic synthesis o f  a-hydroxy-P-amino acid derivatives starting from furfural (17) 
(Scheme 1.34).48 Thus, 17 was readily converted into the corresponding (S)-cyanohydrin in 
excellent enantioselectivity in the presence o f the (P)-selective PaH N L .49 TBS protection o f  
the hydroxyl group proceeded in high yield, followed by introduction o f the amino acid side 
chain via  a one-pot two-step process involving a Grignard addition-reduction sequence. In 
case o f a-hydroxy-P-glycine (R 1 = H), a double reduction process was carried out. Subsequent 
Fmoc-protection o f the crude ethanolamines delivered the products 160 in good yield and 
high diastereoselectivity. Finally, oxidation o f the furan-ring under ozonolysis conditions with 
concomitant TBS-removal furnished the corresponding carboxylic acids 161 in one step.
Scheme 1.34 Chemoenzymatic asymmetric synthesis o f  a-hydroxy-fi-amino acids.
W //
0 (R)-PaHNL 
0 X  HCN, pH = 5.5
' H -------------------- ’
MTBE/H20, 0 °C
17 TBSCl, Im
DMF
0R
.0
W  h CN
1) RMgX or DIBALH 0TBS 
Et20 _____^R1
2) Me0H, NaBH4 — ' nh2
18 R = H
158 R = TBS
(89 %, >99.5% ee)
159
R1 = H, Me, ipr, iBu, ph, Bn
FmocCl, NaHC03 
CH2Cl2/H20
0TBS 1) 0 3,Me0H 0H
NFmoc
160 (43-80% yield 
up to 90% de)
2) THF/MeCN/H20
H0 1R
0 NFmoc 
161 52-80%
R
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Deng et al. developed the first enantioselective total synthesis o f  bisorbicillinol (164), and 
its structural analogues bisorbicillinolide and bisorbibutenolide.50 Starting from (R)- 
cyanohydrin 32 which on multigram scale in quantitative yield and 92% ee (Scheme 1.35). 
Grignard addition, Wittig olefination, followed by protection o f the hydroxyl functionality 
and acidic hydrolysis o f  the acetal smoothly provided the precursor 162 in 67% yield. 
Knoevenagel condensation o f  162 with an acetylene-containing P-keto ester in the presence o f  
NM M  gave 163 and proceeded with excellent yield and Z-selectivity (Z/E ratio > 50:1). After 
several transformations, final [4+2] dimerization completed the synthesis o f  bisorbicillinol 
(164).
Scheme 1.35 Asymmetric synthesis o f  bisorbicillinol (164).
r 3 2 i
1) EtMgBr, Et2O/THF
2) Ph3PCH3Br 
Et(Me)2COK, benzene
** H' X  Et
3) PMBOC(=NH)CCl3, Et2O Me OPMB
4) HCl, acetone
162 67%
nPr
CO2Et
TiCl4,NMM, THF
CO2Et
nPr Et
Me OPMB
163 93%, Z/E >50:1 164 bisorbicillinol
O
1.3 M odification o f the alcohol group
1.3.1 A llylic substitution
Saa et al. were the first to report an enantioselective cyanophosphorylation o f aldehydes 
catalyzed by a bifunctional catalyst system .51 To demonstrate the application o f  the resulting 
building blocks, the cyanohydrin O-phosphates 166 and 167 were converted into the 
corresponding O-phosphorylated hydroxy esters, P-amino alcohols or into y-cyanoallylic 
alcohols 168 and 169 by subjection to a palladium(0)-catalyzed stereospecific [3,3] 
sigmatropic rearrangement, followed by basic hydrolysis o f  the acetates (Scheme 1.36). The 
corresponding y-cyanoallylic alcohols 168 and 169 were obtained as separable E/Z-mixtures 
in a ratio o f  1:0.2 and 1:0.25, depending on the nature o f the phosphine. The E-selectivity was
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a result o f  the double inversion (net retention) caused by the favored affinity o f palladium for 
the nitrile group, while the Z-products were formed via  inversion o f  configuration. In all cases 
no loss o f enantiopurity was observed.
Scheme 1.36 Palladium-catalyzed allylic substitution o f  cyanohydrin O-phosphates.
O
NEt2
OH
OH
NEt2
Me2AlCl
.P(OEt)2 Pd(OAc)2 
O PPh3 OAc K2CO3
R H CNPO(OEt)2 R ^  CN
111 R= Me toluene, rt 166 89%, 88% ee 
165 R = n-C5Hn 167 90%, 94% ee
*■ R^ ^ “V N
NaOAc R CN MeOH
168 R = Me (88% ee)
(E:Z = 1:0.2)
169 R = C5H11 (94% ee) 
(E:Z = 1:0.25)
OH
CN
170 75%, 88% ee
171 83%, 94% ee
O
Cyanophosphates proved also viable building blocks in other applications as was shown by 
the synthesis o f  the two structurally related natural products (-)-aegeline and (-)-tembamide, 
both showing high hypoglycaemic activity.52 Moreover, the use o f the same catalytic system  
appeared also an effective catalyst in promoting a one-pot synthesis o f  enantioselective O- 
methoxycarbonyl cyanohydrins.53 In the latter approach, the same group performed 
comprehensive studies on palladium- and iridium-catalyzed allylic substitution reactions o f  
P,y-unsaturated cyanohydrin O-phosphates and their O-carbamate equivalents,54 and 
investigated copper-mediated allylic substitution reactions.55 In contrast to the palladium- 
catalyzed sequence which only allows for soft nucleophiles, the latter approach has the 
advantage o f  being compatible with hard nucleophiles such as Grignard reagents.
North et al. developed an enantio- and diastereoselective approach for the synthesis o f  
cyanohydrin carbonates in the presence o f chiral titanium(salen) complex and potassium  
cyanide as co-catalyst.56 After application o f  optimal conditions on a,P-unsaturated aldehyde 
111 to obtain the corresponding P,y-unsaturated cyanohydrin 172, they demonstrated the 
utility o f the latter adduct by reacting 172 with sodium azide and a palladium catalyst 
(Scheme 1.37). Compound 173 was formed as a mixture o f  isomers in a ratio o f  4:1 in favor 
o f the E-olefin. Hydrogenation o f the double bond followed by benzoylation to verify the 
enantiomeric excess provided the nitrile derivative 175 in an optical purity o f 80%. This
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observation was in agreement with the findings on partial racemization o f  substrates during
palladium-catalyzed allylic substitution, as previously reported by Deardorff. 57
Scheme 1.37 Derivatization o f  ß,y-unsaturated cyanohydrins.
Ti(0;Pr)4, 12, KCN 
ethyl chloroformate
NaN3 
0C02Et Pd(PPh3)4
Me CN THF/H20, rt Me' CN18-crown-6
93%ee CH2Cl2, - 40°C 172 100%, 93% ee 173 81%, E/Z =4:1
H2,Pd/C NH2
MeOH, rt Me CN
PhCOCI
Et3N
CH2CI2, rt
17417%
NHCOPh 
M e^^^^C N  
175 81%, 80% ee
In early investigations, the group o f  Chen demonstrated that racemic unsaturated carbonates 
are excellent synthons which can undergo palladium(0)-catalyzed allylic substitutions in a 
completely regiospecific manner affording the resulting y-azido-a,P-unsaturated nitriles as 
cis/trans mixtures. Based on these findings, in a more recent study, they showed that 
enantiopure variants o f these substrates could lead to (P)-vinologous (P)-amino esters 
(Scheme 1.38).58 Via a PaHNL-catalyzed asymmetric hydrocyanation with HCN in a biphasic 
mixture o f  buffer at pH 5.5 and diisopropyl ether the chirality was installed at the aldehyde 
carbon atom in good yield and >95% ee. After successful transformation o f 177 into the 
corresponding ester carbonates 178, they were able to synthesize the desired products 179 
with retention o f  configuration and exclusive P-double bond geometry.
Scheme 1.38 Enantioselective synthesis o f  E-vinylogous (R)-amino esters.
O (R)-PaHNL 
HCN, pH = 5.5
OH
H ------------------- R
H20/DIPE, 0 °C
1) TMSCI 
EtOH, 0 °C 
CN ---------------- ** R'
176
R = Me, Pr, CH=CHCH3
TMSN3,PPh3
Pd2(dba)3
CH2CI2, 0 °C R
N3
2) ClC02Et 
pyr, 0 °C
177 77-91 %, >95% ee
1) SnCl2, MeOH
0C02Et 
CO2Et
178 >80%
NHBoc
C02EtC02Et 2) (Boc)20, NaHC03 R 
H20/dioxane
179 84-87% 180 R= Me (86%)
181 R= Pr (80%)
3
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In 2002, the group o f Shibasaki reported a novel catalytic asymmetric cyanation- 
ethoxycarbonylation reaction o f aldehydes with ethyl formate in the presence o f a YLi3- 
tris(binaphthoxide) complex (YLB).59 This elegantly provided direct access to optically active 
cyanohydrin carbonates 183 in excellent yield and high ee (Scheme 1.39). In order to 
demonstrate their potential as unique chiral building blocks, the allylic cyanohydrins 183 were 
converted into the chiral y-oxy-a,P-unsaturated nitriles 184 with retention o f  configuration via 
a [3,3]-sigmatropic rearrangement under thermal conditions. When Lewis acids were used to 
promote the rearrangement reaction, higher trans/cis ratio’s o f  up to >98:2 were obtained, 
however, partial racemization was also observed.
Scheme 1.39 Synthesis o f  chiral y-oxy-a,fi-unsaturated nitriles.
O (S)-YLB, BuLi Ar3P(O), ethyl formate °C O2Et -I 2 ,4-trichlorobenzene
182
H2O/THF, -78 °C
R CN 200 °C
183 96-100% yield 
up to 93% ee
OCO2Et
^  R ^ ^ ^ ^ C N
184 93-99% yield 
up to trans/cis = 86/14
R = CH3(CH2)2,Ph(CH2)2,Ph, c-C6H11
To further elaborate the scope o f  this two-step conversion, a concise catalytic 
enantioselective total synthesis o f  the natural product (+)-patulolide C (187) was developed.
Scheme 1.40 Catalytic asymmetric total synthesis o f  (+)-patulolide C (187).
OCO2Et
Me'
1 ) K2CO3 
CH3OH/H2O
2) TBSCl, Im, DM F
OH OTBS Me»,,
CN Me ()6
3) catecholborane 
185 99% yield (S)-CBS, toluene 186 87%
trans/cis = 85:15 
87% ee (trans)
CN
OH
O
187 (+)-patulolide C
R H
Knochel et al. investigated a highly stereo- and regioselective Cu(I)-mediated SN2 ’ allylic 
substitution reaction o f enantiopure difluorobenzoylated allylic cyanohydrins with 
diorganozinc reagents (Scheme 1.41).60 The enantioselective (<S)-#&HNL-catalyzed HCN  
addition on aldehydes 188 and 189 in a monophasic citrate buffer system provided the 
corresponding cyanohydrins 190 and 191 in acceptable yield and ee’s o f  90 and 96% for n = 0 
and n = 1, respectively. Subsequent esterification with 2,6-difluorobenzoyl chloride afforded
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both esters 192 and 193 without racemization. A llylic substitution on ester 193 occurred in 
excellent diastereoselectivity, for primary alkyl substituents, while more sterically hindered 
nucleophiles such as i-Pr2Zn or c-Hex2Zn were not selective. On the contrary, reaction o f  
cyclopentyl cyanobenzoate 192 did not suffer from these limitations and reacted smoothly 
with various diorganozinc reagents providing the a,P-unsaturated nitriles 194 in excellent 
diastereoselectivity.
Scheme 1.41 Cu(I)-mediated allylic substitution on difluorobenzoylated cyanohydrins.
188 n = 0
189 n= 1
OH 2 ,6-difluoro benzoyl 
chloride, DMAP, pyrH (S)-HbHNL, HCN , / \ ^ ^ CN
pH 5, 10-15 "C S v' ) ^ Me Et20, 0 "C
190 55%, 90% ee
191 58%, 96% ee
0
F2C6H3
o^ o
O T cn
X  Me
192 89%
193 73%
R2Zn
CuCN2LiCl
THF/NMP, -30 "C
CN
J
194 40-91%, 90% ee
195 65-75%, 96% ee
R = Et, Pent, /-Pr, c-Hex, Ph(CH2)2,Piv0(CH3)3
1.3.2 Stereospecific Suzuki cross-coupling reactions
Inspired by the fact that suitably functionalized a-cyanohydrins are known to undergo 
displacement by a variety o f  nucleophiles, Falck et al. exploited the traditional Suzuki cross­
coupling reaction on cyanohydrin triflates 196 (Scheme 1.42).61 After extensive optimization 
o f  the reaction parameters, they were eventually able to couple a functionalized sp3- 
hybridized stereogenic carbon to aryl, heteroaryl, and vinyl boronic acids in a stereospecific 
manner. The coupling proceeded with complete inversion o f configuration. Further 
manipulation, e.g. hydrolysis o f  the resulting nitrile was performed to provide facile and fast 
access to various interesting organic building blocks (e.g. 198).
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Scheme 1.42 Stereospecific Suzuki cross-coupling o f  cyanohydrin triflates.
OTf (HO)2B-RSp2 R1 Ph
CN
toluene/H2O
Pd cat/KF
CN
50 °C 
R1 = Ph
aq.HCl
CO2H
196 96% ee R = Ar, vinyl 197 up to 93% yield
and 98% ee
198 80%, 94% ee
1.3.3 Substitution by M itsunobu reaction
The group o f  Faul et al. developed two asymmetric syntheses o f  2-aminothiazolone AMG  
221 (203), a potential therapeutic agent for the treatment o f type 2 diabetes.62 The 
enantioselective preparation o f  TMS-protected cyanohydrins 201 was accomplished using the 
chiral aluminum salen complex 200 and N,N-dimethylaniline N-oxide (Scheme 1.43). From 
there, the authors chose to utilize a Mitsunobu approach to generate sulfide 202 with a slight 
decrease in ee to 81% and 39% overall yield. Reaction o f  a-mercoptoacid 202 with M eSCN in 
refluxing toluene and treatment o f the resulting 2-thiothiazolone with S-(exo)-2- 
aminonorbornane in methanol furnished AM G 221 (203) in 45-47% yield over two steps as a 
9:1 mixture o f C-5 epimers. In a second route, the enantioenriched cyanohydrin 201 was also 
employed as chiral starting material, but with net retention of configuration featuring a 
Vilsmeier-Haack reaction followed by treatment with enantiopure thiourea under basic 
conditions to afford 203 as a mixture o f epimers in a 84:16 ratio.
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Scheme 1.43 Two asymmetric syntheses o f  AMG-221 (203).
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85% ee
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HO T  Me
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4) KOH, 95 °C
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SH
202 39%
81% ee
1) MeSCN 
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2) MeOH
HCI, 85 °C
Ph Ph
W
200
45-47% 
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1) PO(OMe)CI2 
DMF
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OH 2) iPr2EtN, 2-MeTHF 
204 45-50% S^ NH2
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1.4 M iscellaneous applications
Chiral cyanohydrins in combination with ethyne were subjected to a light-promoted 
cobalt(I)-catalyzed [2+2+2]-cyclotrimerization as was recently reported by the group o f  
Hapke (Scheme 1.44).63 They presented a novel two-step catalytic approach for the 
enantioselective synthesis o f  pyridyl alcohols using cyanohydrins as precursors. Using the 
chiral vanadium(IV)-salen complex (S,S )-118 in combination with TMSCN, O-trimethylsilyl- 
protected cyanohydrins 206 were synthesized in high yield and ee. Applying the chiral 
cyanohydrins 206 in the presence o f ethyne and the cobalt(I) catalyst to the photochemical 
cyclotrimerization reaction afforded the desired pyridyl alcohols 207 without racemization. 
After recrystallization, the products were isolated in enantiopure form. In contrast, the 
corresponding acetate cyanohydrins gave only low  yields in the cyclotrimerization process.
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Scheme 1.44 Asymmetric synthesis o f  pyridyl alcohols via [2+2+2]-cyclotrimerization.
1) [CoCp(cod)] OH
O (S.S)-V-salen 118 OTMS C2H2, THF, hv T
A  -------------------- X  — - -----------"R H TMSCN, CH2Cl2 R CN 2) TBAF (cat), THF N ^
205 206 71-94% yield 207 72-91 % yield
up to 93% ee up to 93% ee
R = Ph, 4-MeOC6H4,3-MeOC6H4,4-CIC6H4, B
Friestad et al. designed a novel stereochemically controlled approach for the synthesis o f  
1,5-polyols based on a modified Julia-Kocienski olefination for carbon-carbon construction 
using configuration-encoded building blocks.64 By selection o f  the proper stereogenic module 
during each stage o f  the iterative coupling sequence, (un)saturated 1,5-polyols could be 
created bearing all possible configurational permutations independent from the coupling 
chemistry. During the development o f  a reliable method, the investigators searched for a 
functional equivalent for the aldehyde being orthogonal to both O-silylation and olefination. 
They finally identified the nitrile moiety o f a cyanohydrin as the best option for a masked 
aldehyde. As starting point, preparation o f  the a-silyloxy-y-sulfononitrile 210 commenced 
with conjugate addition o f PTSH to acrolein (208), followed by asymmetric cyanosilylation 
using 10 mol% o f  a chiral BINOL derivative 209 and Ti(O'Pr)4 furnishing after TBS- 
protection the resulting cyanohydrin in 83-88%  ee (Scheme 1.45). Sulfur-oxidation and 
recrystallization finally led to enantiopure sulfone 2 10  in 88% yield over four steps. 
Subjection o f  210 to Julia-Kocienski olefination using various aldehydes smoothly provided 
the products 211 in excellent E/Z-selectivity (ratios ranging from 95:5 to >98:2) and yields up 
to 99%.
Application o f the developed strategy proceeded through the synthesis o f  the C 27-C 40  
fragment o f tetrafibricin (2 1 2 ), a nonpeptide fibrinogen receptor antagonist, which was 
prepared in five steps in 42% overall yield using 210 as the recurring unit.
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Scheme 1.45 Novel stereoselective approach to 1,5-polyols.
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In a research project on the direct synthesis of substituted pyrimidines and quinazolines, 
researchers condensed the protected amide 213 with mandelonitrile 214 (Scheme 1.46).65 In 
this single-step procedure, amide activation with T f2O in the presence of 2-chloropyridine, 
followed by addition of the (R)-mandelonitrile 214 to the activated amide derivative and 
cyclization, gave the desired azaheterocycle 215 under mild heating and without loss of 
optical activity.
Scheme 1.46 One-step synthesis o f  pyrimidine 215.
"y^O ?
I OTBS Tf2O,2-ClPyr Ph^ NV ^ h
H N ^ ^ _  + ? ---------- ► N I
N C ^Ph  CH2Cl2, 45 °C ^ ^ ^ O  
213 214 96% ee 215 71%, 96% ee
As part of a research program on synthetic insecticides, researchers from Dow 
AgroSciences developed a high yielding radiochemical synthesis of y-cyhalothrin (220) 
(Scheme 1.47).66 Incorporation of a carbon-14 label in the cyclopropyl ring moiety was 
accomplished starting from readily available 14C-labeled Boc-protected glycine (* = 14C). 
Deprotection and treatment of the amine salt with sodium nitrite gave the diazoester 217, 
which served as a key building block in the intramolecular cyclopropanation reaction. W ith
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the aid of a homogeneous copper catalyst in refluxing 1 ,2 -dichloroethane, the resulting 
bicyclic lactone was obtained which was then transformed into the desired 
cyclopropanecarboxylic acid 218 via  zinc-mediated P-elimination of the lactone. The final 
stage of the synthesis was completed by recrystallization affording pure, but racemic Z-olefin 
isomer 218 (Z/E  ratio >98%) which was then coupled with optically active cyanohydrin 219 
(>99% ee) followed by separation of the 1:1 mixture of diastereoisomers.
Scheme 1.47 Total synthesis o f  radiolabeled y-cyhalothrin-1-14C.
216
1) F3CCHCl2 
NaOiBu, THF
2) Boc-Gly*-OH 
DIPCDI, DMAP
3) HCl, H2O/dioxane
4) NaNO2, CH2Br2/H2O
CN
1)
, k
F3CCl2C
O )2 Cu
1,2-dichloroethane, A
2) Zn, MeOH, A
217 62%
O
H
1.5 Purpose and outline of the thesis
This thesis details our efforts and research on the development of novel synthetic 
methodology for the synthesis of biologically relevant functionalized heterocyclic 
compounds. Facile and efficient access to these scaffolds - preferentially in enantiomerically 
pure form - would provide a wide array of synthetic opportunities which are of relevance for 
the fields of organic chemistry, medicinal chemistry, and materials science. The starting 
materials in these investigations are enantiopure cyanohydrins, which are readily accessible in 
both enantiomeric forms via chemoenzymatic HNL-mediated hydrocyanide addition as has 
been previously developed in collaboration with D SM  Research (Geleen, The Netherlands).
In this chapter, an overview has been given of recent synthetic applications of enantiopure 
cyanohydrins illustrating that these compounds have been broadly recognized as versatile 
building blocks.
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The chemoenzymatic synthesis of frans-substituted aziridines is discussed in Chapter 2. A  
new method for the preparation of these compounds in high enantiomeric purity, based on a 
one-pot Grignard addition-reduction sequence, CuII-catalyzed diazotransfer, and reductive 
cyclization is described.
In Chapter 3, a novel approach for the synthesis of 4-hydroxy-2-pyrrolidines involving Au- 
catalyzed 5-endo-dig  cyclization of aryl-substituted acetylenic amino alcohols is highlighted.
Inspired by the synthetic methodologies explored in the previous chapters, Chapter 4 
discloses two attempts to synthesize a potent antitumor phenanthroindolizidine alkaloid using 
a chemoenzymatic approach. A  third route details an attempt to synthesize the natural product 
via  stereocontrolled acetylide addition reaction on Boc-(<S)-prolinal.
Finally, Chapter 5 details the chemoenzymatic diastereoselective synthesis of both cis- and 
frans-2,5-disubstituted morpholines via  a tandem reduction-transimination-reduction 
sequence and reductive radical detosylation.
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Enantioselective Chemoenzymatic 
Synthesis of /raws-Aziridines
OA OHR ^ C N N >R1
A  straightforward five-step procedure for the synthesis of enantiomerically pure 2,3- 
disubstituted trans-aziridines has been developed starting from commercially available 
aldehydes. Hydroxynitrile lyase-mediated cyanohydrin formation provided cyanohydrins in 
excellent enantioselectivities and good yields. Subsequent formation of diastereomerically 
pure anti-am ino alcohols via a one-pot Grignard addition-reduction sequence, Cun-catalyzed 
diazotransfer, and triphenylphosphine-mediated reductive cyclization provided the 
corresponding trans-aziridines in good yields and excellent diastereoselectivities.
Part of this chapter has been published in: Ritzen, B.; van Oers, M. C. M.; van Delft, F. L.; Rutjes, F. 
P. J. T. J. Org. Chem. 2009, 74, 7548-7551.
Chapter 2
2.1 Introduction
Since the first synthesis by Gabriel in 1888,1 aziridines have gained increasing interest in 
organic synthesis and medicinal chemistry.2 Aziridines are highly reactive, but nevertheless 
occur in several natural products exhibiting potent biological activity. For instance, 
mitomycins A, B  and C (1-3), together with porfiromycin 4 and mitiromycin 5, represent an 
important class of naturally occurring m itosanes, first isolated from soil extracts of 
Streptom yces versticillatus (Figure 2.1).3 These mitosanes4 display both antibiotic and 
antitumor activity, the latter resulting from their ability to cross-link DNA. Structure-activity 
relationships5 have identified the aziridine ring as being essential for such anti-tumor activity 
and extensive research has concentrated on synthesizing derivatives of these natural products 
with increased potency.6
Figure 2.1 Naturally occurring biologically active mitosanes.
O O O
1 R 1 = OMe, R2 = H; mitomycin A 2 mitomycin B 5 mitiromycin
3 R 1 = NH2, R2 = H; mitomycin C
4 R 1 = NH2, R2 = Me; porfiromycin
The ability of aziridines to undergo regio- and stereoselective ring opening reactions, as 
well as ring expansions, provides direct access to various structural motifs and renders them 
attractive building blocks in organic synthesis. They have been applied in the total synthesis 
of natural products including alkaloids,7 amino sugars,8 amino acids9 and lactam antibiotics 
such as (+)-thienamycin.10 Other applications are found in asymmetric synthesis, where chiral 
aziridines have been utilized both as ligands and auxiliaries. Amongst these reactions are the 
asymmetric dihydroxylation of alkenes11 and the enantioselective addition of dialkylzinc to 
various aliphatic and aromatic aldehydes. 12
As a consequence, the development of efficient synthetic routes to aziridines has been an 
important subject of investigation over the past decades. Two of the most fundamental 
pathways involve (i) the metal-catalyzed addition of nitrenes to alkenes13 and (ii) the addition 
of ylides to imines (Scheme 2.1) .14 Although frequently applied in the past, both methods lack
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full stereocontrol over the outcome of the reaction and often require harsh conditions or the 
use of expensive catalysts. Other known methods for the synthesis of aziridines include (iii) 
addition of metal carbenoids to imines, 15 addition across a-halogenated imines, 16 (v) addition 
across azirines17 and (vi) addition of carbenes to imines.18 Furthermore, alkenes can readily be 
transformed into aziridines via (vii) cyclic sulfates, obtained from asymmetric dihydroxylation 
products and via (viii) epoxides, generated by application of the Sharpless asymmetric 
epoxidation. 19 However, the oldest and conceptually perhaps most obvious synthesis of 
aziridines utilizes (ix) 1,2-amino alcohols as precursors. In 1935, Wenker already 
demonstrated that addition of sulfuric acid to amino alcohols at elevated temperatures can 
yield enantiopure aziridines.20 Direct ring closure of amino alcohols to provide aziridines is 
known to be difficult, and previous reports show only moderate yields.21 Better results are 
obtained when the hydroxyl group is converted into a powerful leaving group, thus inducing 
an intramolecular displacement reaction. Several methods are described and extensive 
investigations of this reaction showed that aziridines can be isolated in high yield and 
stereoselectivity.22
Scheme 2.1 Overview o f  synthetic methodologies toward aziridines.
s
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2.2 Retrosynthetic strategy
Inspired by these examples and the relevance of the molecules we set out to investigate a 
new and readily applicable concise pathway for the synthesis of enantiomerically pure trans- 
aziridines (6). Our approach is outlined retrosynthetically in Scheme 2.2. W e envisioned that 
the aziridine skeleton could arise via a direct closure of the aforementioned 1 ,2 -amino 
alcohols (7), which would occur in a stereospecific manner. Furthermore, we hypothesized 
that optically active cyanohydrins (8) could be used as strategic synthons for the synthesis of 
the amino alcohols (7), exploiting the electrophilicity of the cyano group toward 
stereoselective addition of organometallic reagents. Finally, chemoenzymatic cyanohydrin 
formation was envisioned to provide these precursors in high ee using aldehydes (9) as 
substrates.
Scheme 2.2 Retrosynthetic route to aziridines.
OTBSH
N  = *  R V  ^  X = *  X’R1 * R CN R H
R R NH2
6 7 8 9
2.3 Chemoenzymatic asymmetric cyanohydrin formation
Inspired by previous work from the group of Effenberger23 and due to our own general 
interest in the synthesis and application of chiral cyanohydrins,24 the first step in our 
envisioned route was realized via  hydroxynitrile lyase (HNL)-mediated cyanohydrin 
formation. Hydroxynitrile lyases are designed by nature to convert cyanohydrins into the 
corresponding aldehydes and hydrogen cyanide, which is used by some plants as a defense 
mechanism. Since their first application over a century ago,25 H N Ls have become more and 
more relevant biocatalysts for technical applications. B y  using a two-phase system of water, 
an immiscible organic solvent like methyl tert-butyl ether (M T B E ), and a large excess of 
HCN, the equilibria can be efficiently directed to the cyanohydrin.26
In the past, considerable effort has been spent to determine the substrate specificity of the 
enzymes. This specificity is known to be relatively wide, including both saturated and 
unsaturated aliphatic and aromatic aldehydes, heteroaromatic aldehydes, as well as aliphatic 
methyl ketones, albeit varying with different sources of H N L. In case of aliphatic aldehydes, 
it is known that longer chain lengths (> C6) are usually not accepted. To have more insight
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and to enlarge the scope of the H N L reaction, it was decided to first screen a series of eleven 
interesting aldehydes on substrate acceptance using the (R)-selective H N L from Prunus 
am ygdalus (PaH N L) and the (<S)-selective H N L  from H evea brasiliensis (H bH N L) as 
catalysts for conversion into the corresponding hydroxynitriles 8 (Table 2.1). The 
chemoenzymatic reactions were carried out under common H N L reaction conditions in a 1:1 
buffer/MTBE mixture (pH 5) using 10 equiv of K C N  at 0 °C . Conversions are reported on 
basis of H PLC  measurements of the crude reaction products.
Table 2.1 Screening o f  substrates for HNL-mediated cyanohydrin formation.
OH (S)-HNL, pH = 5.0 O (R)-HNL, pH = 5.0 QH
ï  HCN, H2O/MTBE, 0 °C  H HCN, H2O/MTBE, 0 °C I
R IS 'C N  ,, . R H „  , ,  R (R )C N
Hevea brasiliensis Prunus amygdalum
(S)-8 9 (R)-8
(rubber tree) (almonds)
entry aldehyde (S)-HNL (R)-HNL
conversion (% )a ee (% )a conversion (% )a ee (% )a
CHO
>99 >99 >99 >99
84
>99
< T
CHO
87
95
>99
47
>99
75
>99
54
90
>99
69
>99
>99
>99
>99
>99
93
>99
84
>99
93
>99
>99
>99
>99
>99
20
>99
1
2
3
b b4
5
6
7
8
9
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JC H O
10 ^ ^ ^ C H O  >99 >99 >99 >99
'N
11 ,u
a Conversion and ee were determined by chiral HPLC using iPrOH:hexane, 20:80. b No 
reaction observed. c No product could be isolated.
c
As can been seen from Table 2.1, the (R)-selective H N L gives in nearly all cases excellent 
ee’s and high conversions. On the other hand, subjection of some of the substrates to (S)-HNL 
is attended with lower conversions and moderate ee’s. In entries 2 and 5, the aldehydes were 
converted rather slowly and, due to the longer reaction time needed, the non-enzymatic 
reaction had become more competitive, resulting in a lower ee and conversion. p - 
Ethynylbenzaldehyde turned out also to be not a suitable substrate for this enzyme and was 
not accepted at all, while (R )-HNL converts the aldehyde smoothly and in high ee (entry 4). In 
entry 8 , usage of both enzymes led to low conversions and optical purities. However, in this 
case not only electronic interactions, but also steric effects of the ortho-substituent (nitro 
group) probably play a more decisive role. It is known that ortho-substituted substrates 
perform poorly in the chemoenzymatic synthesis of chiral cyanohydrins, resulting in low 
yields, TOF values, and/or low ee’s.27 Unfortunately, in entry 11 no product was detected at 
all. Attempts to isolate this cyanohydrin from the water layer also failed.
On the basis of this screening, we selected five different aldehydes for synthetic 
applications (Table 2.2). B y  using both (R)- and (^-selective H N L as catalysts the 
corresponding hydroxynitriles 8 were obtained as crude products after filtration and 
extraction. Subsequent protection of the hydroxyl group (T BSC l, D M AP, imidazole) to 
prevent racemization and regeneration of the aldehyde, provided cyanohydrins 10-14 in good 
to high yield and excellent enantiomeric excess (Table 2.2).
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Table 2.2 HNL-mediated cyanohydrin formation and protection.
,A HNL, HCN
pH = 5.0
OH TBSCl OTBS
T DMAP, Im > T
R 1 CN CH2Cl2 "  R1 CN
8 0 °C  tort 10-14
entry R 1 enzyme product yield (% )a ee (% ) config.
4
5
(S)-HNL
(R)-HNL
(R)-HNL
(R)-HNL
(R)-HNL
10
1 1
12
13
14
90
79
81
70
67
>99b
>99c
>99b
>99c
>99d
(S)
(R)
(R)
(S)e
(R)
a Isolated yield after chromatography. b Determined by GC analysis. c Determined by HPLC 
analysis. d Determined by derivatization with Mosher’s acid chloride and comparison with the 
diastereomeric esters prepared from their racemic counterparts. e The stereochemical arrangement is as 
expected for the (R)-HNL: however, due to priority changes following the Cahn-Ingold-Prelog rules, 
the product has the (S)-configuration.
2.4 Stereocontrolled im ine reduction
1
2
3
In order to introduce the second stereogenic center, we used an elegant method developed 
by Brussee e t a!.,28 which relied on a tandem Grignard addition-NaBH4 reduction sequence 
providing the desired products in high yield and excellent diastereoselectivity. Thus, addition 
of phenylmagnesium bromide to cyanohydrin 10 in diethyl ether at 0 °C  smoothly afforded 
the metallo imine, as was monitored by mass analysis. Dry methanol was added to destroy the 
excess of Grignard reagent and to protonate the primary imine anion intermediate (Scheme 
2.3). In situ  reduction by adding an excess of N aBH 4 took place in a diastereoselective fashion 
according to Cram’s chelation model,29 affording 16 in 92% yield with excellent 
diastereoselectivity (dr 99%, entry 1, Table 2.3).
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Scheme 2.3 Tandem Grignard addition-NaBH4 reduction sequence.
1) PhMgBr
Et2O, G°C to rtOTBS
P h ^ C N  2) MeOH, G°C 
iG
OTBS
P h ^ NH
Ph
15
S) NaBH4 
G°C to rt
OTBS
P ^ Ph
NH2
16
A  stereochemical explanation is given in Scheme 2.4 where according to the Felkin-Anh 
model30 the possible trajectories of the two thermodynamically most stable conformers of the 
intermediate imines are shown. The hydride w ill attack along the less hindered pathway, 
along the Burgi-Dunitz angle,31 affording the syn-diastereoisomer (equation 1, Scheme 2.4). 
When chelation is possible, e.g. in the presence of a Grignard reagent, the magnesium w ill 
chelate between the imine and oxygen, changing the conformation of the intermediate imine. 
Attack is still along the less hindered pathway, but the stereochemical outcome is reversed, 
resulting in the anti-diastereoisomer (equation 2, Scheme 2.4).
Scheme 2.4 Stereoselective imine reduction.
OTBS 
PhP h ^ ^  
NH2
OTBS
NH2
(1)
(2)
Pleased with these results, we applied the one-pot reaction sequence on cyanohydrins 10-14 
by using various Grignard reagents. Gratifyingly, the desired anti-am ino alcohols 16-25 could 
be isolated in reasonable to good yields (Table 2.3). In case of entry 3, the addition of 3- 
chlorophenylmagnesium bromide proceeded much slower and produced only 2 1 %  of alcohol 
18. Prolonged stirring or other attempts to improve the yield led to considerable side product 
formation. It seems conceivable that steric interactions play an important role in this reaction. 
Additionally, we were pleased to find that in all cases the dr of the reaction sequence was
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>95%, except for entry 10, which showed a significantly lower dr of 72%. This discrepancy is 
presumably caused by the decreased size of the butenyl side chain of the cyanohydrin, 
resulting in a smaller difference between both diastereofaces. Synthetic efforts to react 
cyanohydrin 14 with aliphatic Grignard reagents provided the desired amino alcohols in rather 
poor dr. For this reason we decided to focus on the synthesis of the aromatic amino alcohols.
2.5 Azirid ine formation
In a first attempt to cyclize the amino alcohols to the corresponding aziridines, simultaneous 
nosylation of both the alcohol and amino functionality was investigated. Various reaction 
conditions were explored, but unfortunately this approach afforded only mixtures of N- 
sulfonylated product with small amounts of the desired precursor. W ith this precursor in hand, 
however, we continued with the base-catalyzed cyclization. Much to our surprise, all 
cyclization efforts failed, even after prolonged reaction times. Heating of the reaction mixture 
up to 50 °C  to force the ring closure merely led to formation of side products. Considering 
these results, we concluded that direct ring closure of the free amino alcohol using 
Mitsunobu-type conditions might be more successful. Subjection of the amino alcohol to PPh3 
in combination with either D EA D  or D IA D  in various solvents, however, did not result in any 
reaction despite some literature precedent on similar substrates.223,32 A  modified synthetic 
route involving protection of the nitrogen atom to enhance the Mitsunobu reaction would be 
less attractive since this requires an additional deprotection step to afford the unprotected 
aziridine. Consequently, an alternative approach was conceptualized involving the 
introduction of an azide functionality. The chosen conditions for a CuII-catalyzed 
diazotransfer reaction were based on comparison between two different literature procedures, 
namely with imidazole-1-sulfonyl azide33 and triflic azide34 as reagents. Because the latter 
reaction gave the highest yield (near quantitative) for the conversion of 16 to the 
corresponding azido alcohol 26, we decided to conduct all diazotransfer reactions under these 
conditions. Thus, subjection of the amino alcohols 16-25 under the aforementioned 
conditions, afforded the azido alcohols 26-35 in good yields (64-99%, Table 2.3).
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Table 2.3 Grignard addition, reduction and diazotransfer.
OTBS
1) R1MgBr
2) MeOH, NaBH4
OTBS TfN3 
? ,R1 Et3N, Cu SO4
R CN Et2O
0°C tort
10-14
Or
nh2
16-25
MeOH/
H2O/CH2Cl2
OTBS
< \ R
N3
26-35
entry s.m. R 1 amino yield (% )a/ azido alcohol yield (% )a config.
alcohol dr (%)b
1 10
2 10
3 10
4 10
5 11
6 1 1
7 13
8 13
9 12
10 14
Cl
MeO'
MeO'
MeO'
\
\
\
\
\
\
\
\
\
\
16
17
18
19
20
21
22
23
24
25
92/99
70/99
21/99
64/95
51/99
49/99
52/99
53/99
91/99
52/72
26
27
28
29
30
31
32
33
99
93
99
91
87
(S,R)
(S,R)
(SR )
(SR )
(R,S)
76 (R,S)
66 (S,S)
64 (SS )
34 90 (R,S)
35 76 (R,S)
a Isolated yield after chromatography. Determined by :H NM R analysis of the crude product.
W ith the anti-azido alcohols in hand, the stage was set for the synthesis of the trans- 
aziridines (Table 2.4). Deprotection with T B A F  in TH F resulted in clean conversion into the 
corresponding free azido alcohols, which upon a simple extraction without further purification
could be used in a phosphine-mediated Staudinger-type ring closure.35
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Performing the cyclization in TH F or D M F at elevated temperatures (70-90 °C ) in 
combination with trimethylphosphine initially led to poor conversion into the desired 
trans-aziridine. A  more rewarding result was obtained by stirring the anti-azido alcohols in 
the presence of triphenylphosphine in refluxing acetonitrile. Much to our satisfaction, the 
aziridines 37-42 and 45-46 could be isolated in moderate to good yields (46-89%, Table 2.5). 
In an attempt to avoid the tedious purification from triphenylphosphine oxide, polymer-bound 
triphenylphosphine was also used. As anticipated, this decreased the reaction rate 
dramatically, but did not improve the yield.
Table 2.5 Desilylation and ring closure.
OTBS
26-35
R1 TBAF
THF, rt
OHór
36
R1 PPh 3
MeCN, 90 °C
H
N
r^ V
37-46
entry s.m. R R 1
Yield (% )a/ 
product , config.
dr (% )b
1 26
2 27
3 28
4 29
5 30
6 31
7 32
8 33
Br
Br
\
\
\
\
X
< r
\
MeO'
A,
A
\
\
MeO'
37
38
39
40
41
42
43
44
60/99
47/99
89/99
51/99
73/99
53/99
(R,R)
(RR)
(R,R)
(R,R)
(5.5)
(5.5)
N N3 3
c
c
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9 34
MeO
45 54/99 (S,S)
a Isolated yield after chromatography. b Determined by 1H NM R analysis of the crude product.
Product decomposed during reaction.
Unfortunately, in case of entries 7 and 8 no product could be isolated. Although mass 
spectrometry of the reaction mixture showed formation of the intermediate 
oxazaphospholidine and a product with the expected mass, we were unable to isolate the 
desired aziridines. A  suitable mechanistic explanation is lacking, although a partial answer 
may lie in the electron-donating capacity of the furanyl substituent.
Furthermore, we proved by using chiral H PLC  analysis of acetylated 37 that no (partial) 
racemization had taken place during the whole sequence. Optical rotation measurements were 
compared to literature values and proved the formation of the trara-substituted aziridine 47.36
A  mechanistic rationale for this reaction is provided in Scheme 2.5. The first part of this 
particular sequence revolves around the reaction of the hydroxyazide with trialkyl- or 
triarylphosphine, leading to the iminophosphorane 49 through nucleophilic addition of the 
phosphine at the terminal nitrogen atom of the azide and expulsion of nitrogen. Subsequently, 
the oxazaphospholidine 51 is formed, which upon thermal activation cyclizes with inversion 
of configuration to yield the aziridine 37.
Scheme 2.5 Mechanism o f  the phosphine-mediated Staudinger-type ring closure.
37 53 52 51
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2.6 Conclusions
In summary, a novel and straightforward procedure has been developed that allows for the 
synthesis of unprotected trans-aziridines starting from commercially available aldehydes. The 
key step in this relatively mild sequence involves chemoenzymatic enantioselective 
HNL-mediated cyanohydrin formation. W e also demonstrated that the corresponding anti­
amino alcohols could be synthesized in good yields and excellent diastereoselectivities. The 
last two steps in the sequence, diazotransfer and phosphine-mediated ring closure, produced 
the target aziridines in high yield and enantiomeric purity.
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2.8 Experimental section 
General information
All reactions were performed under an argon atmosphere, unless stated otherwise. Solvents were 
purified from water and oxygen (MBraun SPS-800 solvent purification system) prior to use. Et3N was 
distilled and stored over KOH. A ll other chemicals were purchased from commercial suppliers and 
were used without further purification, unless stated otherwise. Reactions were followed, and R f 
values are obtained using thin layer chromatography (TLC) on silica gel-coated plates (Merck 60 
F254) with the indicated eluens and compounds were detected with UV-light and/or by charring at ca. 
150 °C  after dipping into a solution of potassium permanganate, anisaldehyde, or ninhydrin. Column 
or flash chromatography was carried out using ACROS silica gel (0.035-0.070 mm, pore diameter ca. 
6 mm). IR  spectra were recorded on an ATI Mattson Genesis Series FT IR  spectrometer. High­
resolution mass spectra were recorded on a JEO L AccuTOF (ES I) or a MAT900 (EI, CI, and ESI). 
Low-resolution ES I mass spectra were recorded on a Thermo Finnigan LCQ Advantage Max Ion Trap 
mass spectrometer. Melting points were analyzed with a Buchi melting point B-545 and are not 
corrected. High Performance Liquid Chromatography (HPLC) measurements were conducted on a 
HPLC apparatus equipped with a Chiralpak AD-H column (dimensions: 250 x 4.6 mm) and peaks 
were detected using a UV-detector. Gas chromatography (GC) was performed on a Hewlett Packard 
5890, containing a HP1 column (dimensions: 25 m x 0.32 mm x 0.17 ^m), FID  detection, and
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equipped with a HP3393A integrator. GC measurements were conducted on a GC apparatus equipped 
with a GAM M A D EX 120 column (dimensions: 30 m x 0.25 mm, 0.25 ^m film) and peaks were 
detected using a UV-detector. NM R spectra were recorded at 298 K  on a Bruker DM X 300 (300 MHz) 
and a Varian 400 (400 MHz) spectrometer in the solvent indicated. Chemical shifts are given in parts 
per million (ppm) with respect to tetramethylsilane (0.00 ppm), or CHD2OD (3.31 ppm) as internal 
standard for 'H-NMR; and CDCl3 (77.16 ppm), or CD3OD (49.00 ppm) as internal standard for 13C- 
N M R .37 Coupling constants are reported as J  values in hertz (Hz). The gene encoding for (S)-HNL, 
originating from the rubber tree Hevea brasiliensis, was cloned and efficiently expressed in the yeast 
strain Pichia pastoris as an intracellular protein; the enzyme preparation was obtained by 
homogenization (French press) of the cells, removal of insolubles by filtration, and subsequent 
concentration of the clear filtrate using ultrafiltration/diafiltration.38 The wild type gene encoding for 
(R)-HNL, originating from bitter almonds (Prunus amygdalus), was cloned and efficiently expressed 
in the yeast strain P. pastoris. The enzyme was secreted from the cells (P. pastoris), and was obtained 
from cell free supernatant by concentration using ultrafiltration/diafiltration.39 The crude lysates (cell- 
free extracts) containing (R)-HNL and (S)-HNL were kindly provided by DSM Research (Geleen, The 
Netherlands).
(S)-2-(teri-Butyldimethylsilyloxy)-2-phenylacetomtrne (10)
OTBS A solution of benzaldehyde (500 mg, 4.71 mmol) in M TBE (40 mL) was added to a 
cooled (0 °C ) solution of KCN (3.07 g, 47.1 mmol, 10 equiv) in citrate buffer (40 mL, 
pH = 5.0). After addition of (S)-HNL (800 ^L) the reaction mixture was stirred at 0 °C  
for 1.5 h and quenched with 5 M HCl (5 mL), causing the enzyme to precipitate. The precipitate was 
filtrated over a glass funnel filled with cotton. The filtrate was extracted with CH2Cl2 (3 x 50 mL) and 
the organic layers were combined, dried (Na2SO4) and concentrated in vacuo. The residue was 
dissolved in dry CH2Cl2 (15 mL) at 0 °C  and TBSCl (781 mg, 5.18 mmol, 1.1 equiv), imidazole (641 
mg, 9.42 mmol, 2.0 equiv, dissolved in 1 mL CH2Q 2) and DMAP (58 mg, 10 mol % ) were added 
successively. The reaction mixture was stirred overnight at 0 °C. After diluting the reaction mixture 
with H2O (15 mL) and Et2O (15 mL), the organic layer was washed with H2O (2 x 30 mL) and brine 
(2 x 30 mL). The resulting organic fraction was dried (Na2SO4) and concentrated in vacuo. Column 
chromatography (EtOAc/heptane, 1:7—>1:1) yielded compound 10 (1.05 g, 90%) as a colorless oil. Rf 
0.65 (EtOAc/heptane, 1:3). [a]D° +16.8 (c 1.05, CHC^). {ref. [a]D° +17.5 (c 1 .00, CHCl3)}. e.e >99% 
(GC, isothermic, 120 °C ); Ru = 13.90 min (S), Ru  = 14.38 min (R).'H  NM R (CDCl3, 400 MHz): 5 
7.49-7.38 (m, 5H), 5.53 (s, 1H), 0.95 (s, 9H), 0.24 (s, 3H), 0.16 (s, 3H). 13C NM R (CDCl3, 75 MHz): 5
136.5, 129.2, 128.9, 126.0, 119.3, 64.0, 25.5, 18.2, -5.1, -5.2. Data are in agreement with literature.40
(W)-2-(4-Bromophenyl)-2-(teri-butyldimethylsilyloxy)acetomtrne (11)
OTBS Prepared as described above starting from p-bromobenzaldehyde (500 mg, 2.36 
[f^ l[ CN mmol) and (R)-HNL. Column chromatography (EtOAc/heptane, 1:7— 1:1) yielded 
B r^ ^ ^  11 (608 mg, 79%) as a colorless oil. Rf 0.60 (EtOAc/heptane, 1:1). [a]D0 +6.3 (c
1.16, CH2Cl2). e.e >99% (HPLC eluent hexane:ethanol = 98:2, flow 1.0 mL/min); Rt,i = 4.38 min (R), 
Ru = 5.09 min (S). IR  (ATR): 2954, 2926, 2858, 1256, 1093, 841 cm-1. 'H  NM R (CDCl3, 400 MHz): 5 
7.62-7.57 (m, 2H), 7.45-7.40 (m, 2H), 5.46 (s, 1H), 0.94 (s, 9H), 0.23 (s, 3H), 0.16 (s, 3H). 13C NM R
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(CDCl3, 75 MHz): 5 135.7, 131.8, 127.9, 123.5, 118.9, 63.6, 25.7, 18.3, -4.9, -5.1. HRMS (E I) m/z 
calcd for C ^ ^ B rN O S i (M)+: 327.0478, found: 327.0472.
(W)-2-(3,4-Methylenedioxylphenyl)-2-(teri-butyldimethylsilyloxy)acetomtrHe (12)
OTBS Prepared as described above starting from piperonal (500 mg, 3.33 mmol) and (R)- 
/O^ ^ !*p ''CN  HNL. Column chromatography (EtOAc/heptane, 1:7— 1:1) afforded 12 (671 mg, 
o 70%)  as a colorless oil. Rf 0.66 (EtOAc/heptane, 1:1). [a]D0 +12.9 (c 1.41, CH2Q 2) 
{ref. [a]D0 +17.0 (c 1.00, CHCl3)}  e.e. >99% (HPLC eluent hexane:isopropanol = 90:10, flow 1.0 
mL/min); R t1 = 3.72 min (S), Rt2 = 4.27 min (R). IR  (ATR): 2954, 2928, 2894, 2868, 1489, 1249, 839 
cm-1. 1H NM R (CDCl3, 400 MHz): 5 6.96 (d, J  = 1.8 Hz, 1H), 6.91 (dd, J  = 1.8, 8.0 Hz, 1H), 6.81 (d, J  
= 8.0 Hz, 1H), 6.00 (s, 2H), 5.40 (s, 1H), 0.93 (s, 9H), 0.22 (s, 3H), 0.14 (s, 3H). 13C NM R (CDCl3, 75 
MHz): 5 148.5, 148.4, 130.6, 120.1, 119.4, 108.5, 106.9, 101.6, 63.9, 25.5, 18.3, -5.0, -5.1. HRMS 
(FAB) m/z calcd for C 15H22NO3Si (M+H)+: 292.1369, found: 292.1362. Data are in agreement with
literature.41
(£)-2-(teri-Butyldimethylsilyloxy)-2-(furan-2-yl)acetomtrile (13)
° TBS Prepared as described above starting from furfural (1.00 g, 10.4 mmol) and (R)-HNL. 
^OV ^ X N  Column chromatography (EtOAc/heptane, 1:7— 1:1) afforded 13 (906 mg, 81%) as a 
yellow oil. Rf 0.65 (EtOAc/heptane, 1:1). [a]D0 +10.9 (c 1.11, CH2Cl2) {ref.42 [a]D0 
+18.9 (c 5.00, CHCl3)}. e.e. >99% (GC, isothermic, 120 °C ); Rt,1 = 15.72 min (R), R t2 = 17.74 min (S). 
IR  (ATR): 2954, 2933, 2859, 1256, 1087, 840 cm-1. 1H NM R (CDCl3, 400 MHz): 5 7.45 (dd, J  = 0.8,
1.8 Hz, 1H), 6.53 (dd, J  = 0.7, 3.3 Hz, 1H), 6.40 (dd, J  = 1.9, 3.3 Hz, 1H), 5.55 (s, 1H), 0.91 (s, 9H), 
0.17 (s, 3H), 0.14 (s, 3H). 13C NM R (CDCl3, 75 MHz): 5 148.5, 143.7, 117.2, 110.7, 109.4, 58.1, 25.4,
18.2, -5.3. HRMS (CI) m/z calcd for C 12H20NO2Si (M+H)+: 238.1263, found: 238.1266.
(W)-2-(teri-Butyldimethylsilyloxy)hex-5-enemtrile (14)
OTBS Prepared as described above starting from 4-pentenal (700 mg, 8.32 mmol) and (R)- 
^ 5^ ' s /^ cn HNL. Column chromatography (EtOAc/heptane, 1:7— 1:1) afforded 14 (1.26 g, 67%) 
as a colorless oil. Rf 0.72 (EtOAc/heptane, 1:2). [a]D0 +0.55 (c 1.17, CH2Cl2). e.e. >99% ((R)-Mosher 
acid). IR  (ATR): 3075, 2954, 2846, 1460, 1170, 1013, 719 cm-1. 1H NM R (CDCl3, 400 MHz): 5 5.78 
(ddt, J  = 10.2, 16.9, 6.6 Hz, 1H), 5.11-5.03 (m, 2H), 4.44 (t, J  = 6.6 Hz, 1H), 2.27-2.21 (m, 2H), 1.92­
1.87 (m, 2H), 0.91(s, 9H), 0.19 (s, 3H), 0.14 (s, 3H). 13C NM R (CDCl3, 75 MHz): 5 136.4, 120.1,
116.3. 61.3, 35.6, 28.7, 25.7, 18.2, -5.0, -5.2. HRM S (CI) m/z calcd for C „H 23OSi (M-CN)+: 
199.1518, found: 199.1518. Data are in agreement with literature.43
(1.R,2lS)-2-(teri-Butyldimethylsilyloxy)-1,2-diphenylethanamme (16)
A solution of cyanohydrin 10 (1.00 g, 4.04 mmol) in dry Et2O (30 mL) was cooled 
to 0 °C  and phenylmagnesium bromide (4.04 mL of a 3.0 M solution in Et2O, 12.1 
mmol, 3.0 equiv) was added dropwise. The reaction mixture was allowed to warm 
to rt and stirred for 2 h, after which MeOH (30 mL) and NaBH4 (611 mg, 16.2 
mmol, 4 equiv) were added. After 30 min, the mixture was quenched with saturated aqueous NaHCO3 
(60 mL) and the product was extracted with EtOAc (3 x 60 mL). The organic layers were combined, 
dried (Na2SO4) and concentrated in vacuo. Column chromatography (EtOAc/heptane, 1:7— 1:1) 
afforded pure 16 (1.19 g, 90%) as a colorless oil. Rf 0.41 (EtOAc/heptane, 1:1). [a]D0 +31.6 (c 1.07, 
CH2Cl2). IR  (ATR): 2953, 2926, 2855, 1093, 836, 699 cm-1. 1H NM R (CDCl3, 400 MHz): 5 7.30-7.19 
(m, 10H), 4.64 (d, J  = 6.5 Hz, 1H), 4.02 (d, J  = 6.5 Hz, 1H), 1.37 (br s, 1H), 0.75 (s, 9H), -0.25 (s,
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3H), -0.32 (s, 3H). 13C NM R (CDCl3, 75 MHz): 5 142.7, 142.0, 127.9, 127.8, 127.4, 127.2, 127.1,
80.2, 62.9, 29.7, 25.7, 18.0, -5.0, -5.7 HRMS (ES I) m/z calcd for C20^ 0NOSi (M+H)+: 328.2097, 
found: 328.2103.
(1.R,2lS)-2-(teri-Butyldimethylsilyloxy)-1-(4-fluorophenyr)-2-phenylethanamme (17)
F Prepared as described above starting from cyanohydrin 10 (500 mg, 2.02 mmol) 
and p-fluorophenylmagnesium bromide (6.06 mL of a 1 M solution in THF, 6.06 
mmol, 3.0 equiv). Column chromatography (EtOAc/heptane, 1:7— 1:1) yielded 
17 (488 mg, 70%) as a yellowish oil. Rf 0.38 (EtOAc/heptane, 1:1). [a]D0 +33.5 
(c 1.27, CH2Cl2). IR  (ATR): 2954, 2925, 2850, 1509, 1093, 836 cm-1. 1H NM R (CDCl3, 400 MHz): 5
7.31-7.16 (m, 7H), 7.00-6.92 (m, 2H), 4.58 (d, J  = 6.4 Hz, 1H), 4.00 (d, J  = 6.5 Hz, 1H), 1.45 (br s, 
1H), 0.75 (s, 9H), -0.24 (s, 3H), -0.32 (s, 3H). 13C NM R (CDCl3, 75 MHz): 5 161.6 (d, J  = 244.7 Hz),
141.8, 138.3 (d, J  = 2.6 Hz), 129.3 (d, J  = 7.9 Hz), 127.9, 127.6, 127.1, 114.5 (d, J  = 21.1 Hz), 80.0,
62.2, 25.6, 18.0, -5.0, -5.6. HRMS (ES I) m/z calcd for C20H29FNOSi (M+H)+: 346.2002, found: 
346.1995.
(1.R,2lS)-2-(teri-Butyldimethylsilyloxy)-1-(3-chlorophenyl)-2-phenylethanamme (18)
Prepared as described above starting from cyanohydrin 10 (300 mg, 1.21 mmol) 
and 3-chlorophenylmagnesium bromide (7.26 mL of a 0.5 M solution in THF, 
3.63 mmol, 3.0 equiv). Column chromatography (EtOAc/heptane, 1:7— 1:1) 
yielded 18 (114 mg, 26%) as a yellowish oil. Rf 0.46 (EtOAc/heptane, 1:1).
[a]D0 +31.9 (c 1.60, CH2Cl2). IR  (ATR): 2950, 2928, 2850, 1593, 1467, 1251, 1091, 835 cm-1. 1H 
NM R (CDCl3, 400 MHz): 5 7.34-7.12 (m, 9H), 4.56 (d, J  = 6.7 Hz, 1H), 3.97 (d, J  = 6.7 Hz, 1H), 0.75 
(s, 9H), -0.26 (s, 3H), -0.34 (s, 3H). 13C NM R (CDCl3, 75 MHz): 5 145.1, 142.0, 133.8, 129.0, 128.3,
128.0, 127.7, 127.2, 127.1, 126.1, 80.2, 62.7, 25.8, 18.1, -4.9, -5.6. HRM S (ES I) m/z calcd for 
C20H29ClNOSi (M+H)+: 362.1707, found: 362.1703.
(1£,2W)-2-Ammo-1-(teri-butyldimethylsilyloxy)-1-phenylpent-4-ene (19)
Prepared as described above starting from cyanohydrin 10 (250 mg, 1.01 mmol) 
and allylmagnesium bromide (3.03 mL of a 1 M solution in Et2O, 3.03 mmol, 3.0 
equiv). Column chromatography (EtOAc/heptane, 1:7— 1:1) yielded 19 (118 mg, 
40%) as a yellowish oil. Rf 0.30 (EtOAc/heptane, 1:1). [a]D0 +34.9 (c 0.97, CH2Q 2). IR  (ATR): 2954, 
2927, 2856, 1254, 1087, 1065, 837 cm-1. 1H NM R (CDCl3, 400 MHz): 5 7.30-7.17 (m, 5H), 5.76 
(dddd, J  = 6.1, 8.2, 10.2, 16.5 Hz, 1H), 5.09-5.01 (m, 2H), 4.43 (d, J  = 5.9 Hz, 1H), 2.89 (ddd, J  = 3.9,
5.7, 9.3 Hz, 1H), 2.43-2.33 (m, 1H), 1.93-1.85 (m, 1H), 0.84 (s, 9H), -0.01 (s, 3H), -0.25 (s, 3H). 13C 
NM R (CDCl3, 75 MHz): 5 142.1, 136.1, 127.9, 127.4, 127.0, 117.3, 78.7, 57.2, 37.4, 18.1, -4.6, -5.1. 
HRMS (ES I) m/z calcd for C 17H30NOSi (M+H)+: 292.2097, found: 292.2085. Data are in agreement 
with literature.44
(1£,2^)-2-(4-Bromophenyl)-2-(teri-butyldimethylsnyloxy)-1-(4-fluorophenyl)ethanamme (20)
F Prepared as described above starting from cyanohydrin 11 (150 mg, 0.46 
mmol) and p-fluorophenylmagnesium bromide (1.38 mL of a 1 M solution in 
THF, 1.38 mmol, 3.0 equiv). Column chromatography (EtOAc/heptane, 
1:7— 1:1) yielded 20 (99 mg, 51%) as a yellowish oil. Rf 0.43 
(EtOAc/heptane, 1:1). [a]D0 -27.2 (c 0.93, CH2Cl2). IR  (ATR): 2958, 2931, 2890, 2858, 1508, 1223,
1085, 835, 777 cm-1. 1H NM R (CDCl3, 400 MHz): 5 7.41-7.37 (m, 2H), 7.21-7.17 (m, 2H), 7.06-7.03
OTBS
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(m, 2H), 6.98-6.94 (m, 2H), 4.57 (d, J  = 6.1 Hz, 1H), 3.98 (d, J  = 6.1 Hz, 1H), 1.50 (br s, 1H), 0.77 (s, 
9H), -0.21 (s, 3H), -0.30 (s, 3H). 13C NM R (CDCl3, 75 MHz): 5 162.1 (d, J  = 245.0 Hz), 140.7, 137.9,
131.0, 129.3 (d, J  = 7.9 Hz), 128.8, 121.4, 114.6 (d, J  = 21.1 Hz), 79.4, 62.0, 25.8, 18.0, -4.9, -5.5. 
HRMS (ES I) m/z calcd for C20H28BrFNOSi (M+H)+: 424.1108, found: 424.1103.
(1£,2W)-2-(4-Bromophenyl)-2-(teri-butyldimethylsilyloxy)-1-(4-methoxyphenyl)ethanamme (21)
O^Me Prepared as described above starting from cyanohydrin 11 (116 mg, 0.36 
mmol) and p-methoxyphenylmagnesium bromide (2.14 mL of a 0.5 M 
J[ Nh2 solution in THF, 1.08 mmol, 3.0 equiv). Column chromatography
(EtOAc/heptane, 1:7— 1:1) yielded 21 (77 mg, 49%) as a yellowish oil. Rf 
0.42 (EtOAc/heptane, 1:1). [a]D0 -14.2 (c 1.00, CH2Cl2). IR  (ATR): 2954, 2924, 2850, 1511, 1248,
1086, 835, 777 cm-1. 1H NM R (CDCl3, 400 MHz): 5 7.39-7.35 (m, 2H), 7.14-7.08 (m, 2H), 7.05-7.00 
(m, 2H), 6.83-6.78 (m, 2H), 4.61 (d, J  = 5.8 Hz, 1H), 3.96 (d, J  = 4.6 Hz, 1H), 3.79 (s, 3H), 1.46 (br s, 
1H), 0.78 (s, 9H), -0.18 (s, 3H), -0.28 (s, 3H). 13C NM R (CDCl3, 75 MHz): 5 158.8, 141.0, 134.3,
130.8, 128.8, 128.9, 121.2, 113.2, 79.4, 62.0, 55.3, 25.7, 18.0, -4.9, -5.4. HRMS (ES I) m/z calcd for 
C21H31BrNO2Si (M+H)+: 436.1307, found: 436.1301.
(1£,2£)-2-(teri-Butyldimethylsnyloxy)-1-(4-fluorophenyl)-2-(furan-2-yr)ethanamme (22)
f Prepared as described above starting from cyanohydrin 13 (200 mg, 0.84 mmol)OTBSO IF IL l| and p-fluorophenylmagnesium bromide (2.53 mL of a 1 M solution in THF, 2.53
\\ // l mmol, 3.0 equiv). Column chromatography (EtOAc/heptane, 1:7— 1:1) yieldedNH o 22 (138 mg, 49%) as a yellowish oil. Rf 0.37 (EtOAc/heptane, 1:1). [a]D0 -42.1 
(c 1.02, CH2Q 2). IR  (ATR): 2953, 2928, 2856, 1509, 1225, 1091, 837, 778 cm-1. 1H NM R (CDCl3, 
400 MHz): 5 7.38 (dd, J  = 0.8, 1.8 Hz, 1H), 7.31-7.27 (m, 2H), 7.01-6.95 (m, 2H), 6.32 (dd, J  = 1.8,
3.2 Hz, 1H), 6.20 (dd, J  = 0.4, 3.2 Hz, 1H), 4.59 (d, J  = 7.2 Hz, 1H), 4.19 (d, J  = 7.2 Hz, 1H), 1.51 (br 
s, 1H), 0.71 (s, 9H), -0.22 (s, 3H), -0.27 (s, 3H). 13C NM R (CDCl3, 75 MHz): 5 161.6 (d, J  = 244.7 
Hz), 154.2, 141.4, 137.9, 128.7 (d, J  = 7.9 Hz), 114.2 (d, J  = 21.2 Hz), 109.6, 107.6, 73.5, 59.6, 29.2,
17.9, -5.9, -6.1. HRMS (ES I) m/z calcd for C 18H27FNO2Si (M+H)+: 336.1795, found: 336.1779.
(1£,2£)-2-(teri-Butyldimethylsnyloxy)-2-(furan-2-yl)-1-(4-methoxyphenyr)ethanamme (23)
OTBS^^i^OMe Prepared as described above starting from cyanohydrin 13 (200 mg, 0.84 
^ ^  L  J  mmol) and p-methoxyphenylmagnesium bromide (5.04 mL of a 0.5 M
%_// Nh solution in THF, 2.52 mmol, 3.0 equiv). Column chromatography
2 (EtOAc/heptane, 1:7— 1:1) yielded 23 (155 mg, 53%). Rf 0.38
(EtOAc/heptane, 1:1) as a yellowish oil. [a]D0 -26.6 (c 1.01, CH2Cl2). IR  (ATR): 2953, 2926, 2855, 
1512, 1248, 1902, 835, 777 cm-1. 1H NM R (CDCl3, 400 MHz): 5 7.37 (dd, J  = 0.8, 1.8 Hz, 1H), 7.25­
7.21 (m, 2H), 6.85-6.82 (m, 2H), 6.31 (dd, J  = 1.8, 3.2 Hz, 1H), 6.20 (dd, J  = 0.4, 3.2 Hz), 4.61 (d, J  =
7.2 Hz, 1H), 4.16 (d, J  = 7.1 Hz, 1H), 3.80 (s, 3H), 1.50 (br s, 1H), 0.72 (s, 9H), -0.22 (s, 3H), -0.27 
(s, 3H). 13C NM R (CDCl3, 75 MHz): 5 158.8, 155.0, 141.7, 134.8, 128.6, 113.4, 110.1, 107.9, 74.1,
60.1, 55.3, 25.6, 18.0, -5.4, -5.6. HRMS (ES I) m/z calcd for C19H30NO3Si (M+H)+: 348.1995, found: 
348.1994.
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(1£,2W)-2-(3,4-Methylenedioxylphenyl)-2-(teri-butyldimethylsilyloxy)-1-(4-methoxyphenyl)ethan 
amine (24)
Prepared as described above starting from cyanohydrin 12 (150 mg, 0.52 
mmol) and p-methoxyphenylmagnesium bromide (3.12 mL of a 0.5 M 
solution in THF, 1.56 mmol, 3.0 equiv). Column chromatography 
(EtOAc/heptane, 1:7— 1:1) yielded 24 (189 mg, 91%) as a yellowish oil. 
Rf 0.28 (EtOAc/heptane, 1:1). [a]D0 -18.7 (c 0.44, CH2Q 2). IR  (ATR): 2958, 2928, 2889, 2850, 1246, 
1039, 835 cm-1. 1H NM R (CDCl3, 400 MHz): 5 7.21-7.16 (m, 2H), 6.85-6.80 (m, 2H), 6.75 (s,1H), 
6.70 (d, J  = 7.9 Hz, 1H), 6.64 (d, J  = 8.0 Hz, 1H), 5.95 (d, J  = 1.3 Hz, 1H), 5.93 (d, J  = 1.4 Hz, 1H), 
4.50 (d, J  = 6.4 Hz, 1H), 3.91 (d, J  = 6.4 Hz, 1H), 3.80 (s, 3H), 1.42 (br s, 1H), 0.75 (s, 9H), -0.24 (s, 
3H), -0.29 (s, 3H). 13C NM R (CDCl3, 75 MHz): 5 158.9, 147.5, 146.9, 136.5, 135.1, 129.0, 120.8,
113.4, 107.6, 107.5, 101.0, 80.2, 62.4, 55.4, 25.9, 18.2, -4.7, -5.3. HRMS (ES I) m/z calcd for 
C22H32NO4Si (M+H)+: 402.2101, found: 402.2092
(1£,2W)-2-(teri-Butyldimethylsilyloxy)-1-phenylhex-5-en-1-amme (25)
O TBS^'ij Prepared as described above starting from cyanohydrin 14 (200 mg, 0.89 mmol) 
and phenylmagnesium bromide (0.89 mL of a 3.0 M solution in Et2O, 2.67 mmol, 
N H 2 3.0 equiv). Column chromatography (EtOAc/heptane, 1:7— 1:1) yielded 25 (142 
mg, 52%) as a yellowish oil. Rf 0.43 (EtOAc/heptane, 1:1). [a]D0 -3.9 (c 1.60, CH2Cl2). IR  (ATR): 
2952, 2928, 2885, 2855, 1254, 1081, 835, 774, 700 cm-1. 1H NM R (CDCl3, 400 MHz): 5 7.37-7.27 (m, 
5H), 5.71 (ddt, J  = 10.2, 16.9, 6.5 Hz, 1H), 4.95-4.86 (m, 2H), 4.04 (d, J  = 4.3 Hz, 1H), 3.85 (ddd, J  =
4.3, 4.3, 7.6 Hz, 1H), 1.66-1.55 (m, 2H), 1.34-1.24 (m, 2H), 0.91 (s, 9H), 0.07 (s, 3H), 0.03 (s, 3H). 
13C NM R (CDCl3, 75 MHz): 5 142.7, 138.6, 128.1, 127.3, 126.9, 114.3, 76.3, 59.8, 30.3, 29.7, 25.9,
18.1, -4.5, -4.6. HRMS (ES I) m/z calcd for C 18H32NOSi (M+H)+: 306.2253, found: 306.2235.
(1£,2W)-2-Azido-1-(teri-butyldimethylsilyloxy)-1,2-diphenylethane (26)
To a solution of NaN3 (261 mg, 4.01 mmol, 6.0 equiv) in a mixture of H2O/CH2Cl2 
(4 mL, 1:1 v/v) at 0 °C, was added Tf2O (337 ^L, 2.01 mmol, 3.0 equiv). The 
reaction mixture was stirred at 0 °C  for 2h. After quenching with saturated aqueous 
NaHCO3, the layers were separated and the aqueous layer was extracted with 
CH2Cl2 (1 x 3 mL). The organic layers were combined to afford 5 mL of TfN3 solution. This TfN3 was 
then added to a solution of amino alcohol 16 (219 mg, 0.67 mmol) in MeOH (15 mL), followed by 
H2O (5 mL), a solution of CuSO4 (11 mg, 10 mol % ) in MeOH (0.5 mL), and Et3N (297 ^L, 2.01 
mmol, 3.0 equiv). The reaction mixture was stirred overnight at rt. Then saturated aqueous NaHCO3 
(25 mL) was added and the organic solvents were evaporated. The aqueous residue was extracted with 
EtOAc (3 x 25 mL) and the organic layers were combined, dried (Na2SO4), and concentrated in vacuo 
to give a yellow oil. Purification by column chromatography (EtOAc/heptane, 1:7— 1:3) afforded 26 
(235 mg, 99%). Rf  0.71 (EtOAc/heptane, 1:1). [a]D° -0.8 (c 0.96, CH2Cl2). IR  (ATR): 2950, 2928, 
2855, 2103, 1255, 1099, 838, 700 cm-1. 1H NM R (CDCl3, 400 MHz): 5 7.30-7.21 (m, 10H), 4.71 (d, J  
= 6.6 Hz, 1H), 4.57 (d, J  = 6.6 Hz, 1H), 0.74 (s, 9H), -0.22 (s, 3H), -0.29 (s, 3H). 13C NM R (CDCl3, 
75 MHz): 5 140.9, 137.0, 128.2, 128.1, 127.9, 127.3, 78.7, 72.2, 25.6, 18.0, -5.0, -5.6.
(1£,2W)-2-Azido-1-(teri-butyldimethylsilyloxy)- 2-(4-fluorophenyl)-1-phenylethane (27)
O T BS^ 'ji^  Prepared as described above starting from amino alcohol 17 (194 mg, 0.56 
mmol). Column chromatography (EtOAc/heptane, 1:7— 1:3) yielded 27 (194 mg, 
n3 93%) as a colorless oil. Rf 0.74 (EtOAc/heptane, 1:1). [a]D0 +3.6 (c 1.63,
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CH2Cl2). IR  (ATR): 2954, 2929, 2856, 2104, 1510, 837, 778 cm-1. 1H NM R (CDCl3, 400 MHz): 5
7.32-7.14 (m, 7H), 7.03-6.96 (m, 2H), 4.70 (d, J  = 6.3 Hz, 1H), 4.56 (d, J  = 6.3 Hz, 1H), 0.76 (s, 9H), 
-0.17 (s, 3H), -0.27 (s, 3H). 13C NM R (CDCl3, 75 MHz): 5 162.5 (d, J  = 246.6 Hz), 140.7, 132.7 (d, J  
= 2.9 Hz), 129.9 (d, J  = 8.1 Hz), 127.9, 127.2, 115.0 (d, J  = 21.5 Hz), 78.5, 71.4, 25.6, 18.0, -4.9, 
-5.5.
(1£,2^)-2-Azido-1-(teri-butyldimethylsilyloxy)- 2-(3-chlorophenyl)-1-phenylethane (28)
Prepared as described above starting from amino alcohol 18 (87 mg, 0.24 
Ci mmol). Column chromatography (EtOAc/heptane, 1:7— 1:3) yielded 28 (89 mg, 
99%) as a yellowish oil. Rf 0.70 (EtOAc/heptane, 1:1). [a]D0 -0.6 (c 1.28, 
CH2Cl2). IR  (ATR): 2952, 2923, 2889, 2851, 2103, 1469, 1258, 1093, 840 cm-1. 
1H NM R (CDCl3, 400 MHz): 5 7.34-7.20 (m, 8H), 7.12-7.07 (m, 1H), 4.67 (d, J  = 6.6 Hz, 1H), 4.53 
(d, J  = 6.6 Hz, 1H), 0.76 (s, 9H), -0.20 (s, 3H), -0.29 (s, 3H). 13C NM R (CDCl3, 75 MHz): 5 140.8,
139.3, 134.2, 129.3, 128.5, 128.2, 128.1, 128.0, 127.2, 126.3, 78.5, 71.5, 25.6, 18.0, -5.0, -5.6.
(1£,2^)-2-Azido-1-(teri-butyldimethylsilyloxy)-1-phenylpent-4-ene (29)
Prepared as described above starting from amino alcohol 19 (63 mg, 0.22 mmol). 
Column chromatography (EtOAc/heptane, 1:7— 1:3) yielded 29 (62 mg, 91%) as a 
yellowish oil. Rf  0.73 (EtOAc/heptane, 1:1). [a]D0 +100.1 (c 1.03, CH2Cl2). IR  
(ATR): 2954, 2929, 2894, 2858, 2110, 1257, 1094, 856, 837, 777, 701, 603 cm-1. 1H NM R (CDCl3, 
400 MHz): 5 7.37-7.25 (m, 5H), 5.79 (dddd, J  = 6.5, 7.2, 10.2, 17.1 Hz, 1H), 5.18-5.06 (m, 2H), 4.71 
(d, J  = 4.8 Hz, 1H), 3.45 (ddd, J  = 4.0, 4.8, 9.6 Hz, 1H), 2.35-2,26 (m, 1H), 2.24-2.14 (m, 1H), 0.91 (s, 
9H), 0.08 (s, 3H), -0.17 (s, 3H). 13C NM R (CDCl3, 75 MHz): 5 140.9, 134.4, 128.1, 127.8, 126.9,
117.7, 77.3, 67.8, 33.5, 25.8, 18.1, -4.7, -5.2.
(1.R,2lS)-2-Azido-1-(4-bromophenyl)-1-(teri-butyldimethylsilyloxy)-2-(4-fluorophenyl)ethane (30)
f  Prepared as described above starting from amino alcohol 20 (84 mg, 0.20 
mmol). Column chromatography (EtOAc/heptane, 1:7— 1:3) yielded 30 (78 
mg, 87%) as a yellowish oil. Rf 0.68 (EtOAc/heptane, 1:1). [a]D0 -18.4 (c
1.03, CH2Cl2). IR  (ATR): 2954, 2928, 2855, 2105, 1509, 838, 779 cm-1. 1H 
NM R (CDCl3, 400 MHz): 5 7.43-7.38 (m, 2H), 7.18-7.12 (m, 2H), 7.07-6.97 (m, 4H), 4.67 (d, J  = 6.1 
Hz, 1H), 4.53 (d, J  = 6.1 Hz, 1H), 0.78 (s, 9H), -0.16 (s, 3H), -0.25 (s, 3H). 13C NM R (CDCl3, 75 
MHz): 5 162.6 (d, J  = 246.9 Hz), 139.6, 132.2 (d, J  = 2.8 Hz), 131.1, 129.8 (d, J  = 8.1 Hz), 128.8,
121.9, 115.1 (d, J  = 21.5 Hz), 78.0, 71.2, 25.6, 18.0, -4.9, -5.5.
(1.R,2£)-2-Azido-1-(4-bromophenyl)-1-(teri-butyldimethylsilyloxy)-2-(4-methoxyphenyl)ethane
(31)
OMe Prepared as described above starting from amino alcohol 21 (77 mg, 0.18 
mmol). Column chromatography (EtOAc/heptane, 1:7— 1:3) yielded 31 
(64 mg, 76%) as a yellowish oil. Rf 0.73 (EtOAc/heptane, 1:1). [a]D0 -2.7 
(c 0.88, CH2Cl2). IR  (ATR): 2954, 2927, 2855, 2104, 1513, 1251, 839, 
779 cm-1. 1H NM R (CDCl3, 400 MHz): 5 7.42-7.37 (m, 2H), 7.12-7.02 (m, 4H), 6.86-6.81 (m, 2H), 
4.68 (d, J  = 5.9 Hz, 1H), 4.51 (d, J  = 5.9 Hz, 1H), 3.81(s, 3H), 0.78 (s, 9H), -0.15 (s, 3H), -0.25 (s, 
3H). 13C NM R (CDCl3, 75 MHz): 5 159.5, 139.9, 130.9, 129.3, 128.9, 128.4, 121.7, 113.6, 78.1, 71.4,
55.3, 25.6, 18.0, -4.9, -5.4.
OTBS
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(1S,2S)-2-Azido-1-(teri-butyldimethylsilyloxy)-2-(4-fluorophenyl)-1-(furan-2-yl)ethane (32)
OTBS^^>^f Prepared as described above starting from amino alcohol 22 (138 mg, 0.41 
mmol). Column chromatography (EtOAc/heptane, 1:7— 1:3) yielded 32 (98 mg, 
\ J  N 66% ) as a yellowish oil. Rf 0.73 (EtOAc/heptane, 1:1). [a]D0 -0.8 (c 0.96,
3 CH2Cl2). IR  (ATR): 2958, 2928, 2855, 2105, 1510, 838, 779 cm-1. 1H NM R
(CDCl3, 400 MHz): 5 7.40 (dd, J  = 1.8, 0.8 Hz, 1H), 7.29-7.24 (m, 2H), 7.06-7.00 (m, 2H), 6.35 (dd, J  
= 3.3, 1.8 Hz, 1H), 6.25 (dd, J  = 3.3, 0.8 Hz, 1H), 4.77 (d, J  = 7.4 Hz, 1H), 4.70 (d, J  = 7.4 Hz, 1H), 
0.70 (s, 9H), -0.20 (s, 3H), -0.25 (s, 3H). 13C NM R (CDCl3, 75 MHz): 5 162.6 (d, J  = 246.8 Hz),
153.4, 142.1, 132.9 (d, J  = 3.0 Hz), 129.7 (d, J  = 8.2 Hz), 115.1 (d, J  = 21.5 Hz), 110.4, 108.6, 72.0,
68.9, 25.4, 17.9, -5.4, -5.7.
(1£,2£)-2-Azido-1-(teri-butyldimethylsilyloxy)-2-(4-methoxyphenyl)-1-(furan-2-yl)ethane (33)
^i^jOM e Prepared as described above starting from amino alcohol 23 (155 mg, 0.45 OTBSf^ |i|
O JL J l  mmol). Column chromatography (EtOAc/heptane, 1:7— 1:3) yielded 33 (107
mg, 64%) as a yellowish oil. Rf 0.70 (EtOAc/heptane, 1:1). [a]D0 +18.8 (cN3 1
0.90, CH2Cl2). IR  (ATR): 954, 2924, 2850, 2104, 1514, 1250, 838, 778 cm-1. 
1H NM R (CDCl3, 400 MHz): 5 7.40 (dd, J  = 1.8, 0.8 Hz, 1H), 7.24-7.19 (m, 2H), 6.89-6.84 (m, 2H),
6.34 (dd, J  = 3.2, 1.8 Hz, 1H), 6.25 (dd, J  = 3.2, 0.7 Hz, 1H), 4.73 (d, J  = 7.4 Hz, 1H), 4.70 (d, J  = 
7.4Hz, 1H), 3.81 (s, 3H), 0.71 (s, 9H), -0.19 (s, 3H), -0.24 (s, 3H). 13C NM R (CDCl3, 75 MHz): 5
159.5, 153.8, 141.9, 129.1, 128.3, 113.7, 110.3, 108.4, 72.0, 69.2, 55.3, 25.5, 17.9, -5.4, -5.6.
OMe
(1.R,2£)-2-Azido-1-(3,4-methylenedioxylphenyl)-1-(teri-butyldimethylsilyloxy)-2-(4-methoxy 
phenyl)ethane (34)
Prepared as described above starting from amino alcohol 24 (175 mg, 
0.44 mmol). Column chromatography (EtOAc/heptane, 1:7— 1:3) yielded 
34 (167 mg, 90%) as a yellowish oil. Rf 0.77 (EtOAc/heptane, 1:1). [a]D0 
+10.9 (c 1.30, CH2Q 2). IR  (ATR): 2950, 2924, 2885, 2850, 2101, 1245, 
‘H NM R (CDCl3, 400 MHz): 5 7.17-7.12 (m, 2H), 6.88-6.83 (m, 2H), 6.76 (d, J  = 1.6 Hz, 
1H), 6.71 (d, J  = 7.9 Hz, 1H), 6.63 (dd, J  = 8.0, 1.6 Hz, 1H), 5.96 (d, J  = 1.5 Hz, 1H), 5.95 (d, J  = 1.5 
Hz, 1H), 4.61 (d, J  = 6.4 Hz, 1H), 4.47 (d, J  = 6.4 Hz, 1H), 3.81 (s, 3H), 0.76 (s, 9H), -0.18 (s, 3H), 
-0.24 (s, 3H). 13C NM R (CDCl3, 75 MHz): 5 159.6, 147.5, 147.2, 135.3, 129.5, 129.2, 120.9, 113.7,
107.7, 107.6, 101.1, 78.5, 71.9, 55.4, 25.8, 18.1, -4.8, -5.3.
835 cm-1 1
(1£,2^)-1-Azido-2-(teri-butyldimethylsilyloxy)-1-phenylhex-5-ene (35)
OJ B S [ l l  Prepared as described above starting from amino alcohol 25 (142 mg, 0.46 
mmol). Column chromatography (EtOAc/heptane, 1:7— 1:3) yielded 35 (115 mg, 
n3 76%) as a yellowish oil. Rf 0.77 (EtOAc/heptane, 1:1). [a]D0 +44.3 (c 1.79,
CH2Cl2). IR  (ATR): 2950, 2928, 2885, 2855, 2100, 1253, 835, 775 cm-1. 1H NM R (CDCl3, 400 MHz): 
5 7.40-7.26 (m, 5H), 5.75 (ddt, J  = 10,2, 16.9, 6.6 Hz, 1H), 5.01-4.90 (m, 2H), 4.56 (d, J  = 5.1 Hz, 
1H), 3.91 (ddd, J  = 6.6, 5.0, 4.3 Hz, 1H), 2.23-2.10 (m, 1H), 2.10-1.97 (m, 1H), 1.75-1.65 (m,1H), 
1.53-1.43 (m, 1H), 0.89 (s, 9H), 0.05 (s, 3H), -0.07 (s, 3H). 13C NM R (CDCl3, 75 MHz): 5 138.3,
137.1, 128.4, 128.0, 127.8, 114.6, 75.4, 69.7, 31.5, 29.0, 25.8, 18.0, -4.6, -4.7.
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(2^,3^)-2,3-Diphenylaziridine (37)
H To a solution of azide 26 (142 mg, 0.41 mmol) in THF (4 mL) at 0 °C  was added
O TBAF (480 ^L of a 1.0 M solution in THF, 0.48 mmol, 1.2 equiv). The reaction mixture was stirred at rt for 1 h. After quenching with saturated aqueous NH4Cl (4 
mL) the product was extracted with EtOAc (3 x 8 mL). The resulting organic layers 
were combined, washed with H2O (25 mL) and brine (25 mL), dried (Na2SO4) and concentrated in 
vacuo. Then, the crude product was redissolved in MeCN (4 mL) and PPh3 (129 mg, 0.48 mmol, 1.2 
equiv) was added. After refluxing the reaction mixture for 2 h, the solution was allowed to cool to rt. 
The solvent was then evaporated and the product was purified by column chromatography 
(EtOAc/heptane, 1:7— 1:2) to give pure 37 (36 mg, 60%) as a colorless oil. Rf 0.56 (EtOAc/heptane, 
1:1). [a]D0 +331 (c 1.27, CH2Cl2) {ref.8 [a]D0 +328.8 (c 1.25, CHCl3)}. IR  (ATR): 3287, 3058, 3023, 
1498, 1191 cm-1. 1H NM R (CDCl3, 400 MHz): 5 7.5-7.2 (m, 10H), 3.3-2.8 (br s, 2H), 1.6-1.2 (br s, 
1H). 13C NM R (CDCl3, 75 MHz): 5 139.5, 128.6, 127.3, 125.5, 43.7. HRMS (ES I) m/z calcd for 
C 14H14N (M+H)+: 196.1126, found: 196.1115. Data are in agreement with literature.45
(2^,3^)-2-(4-Fluorophenyl)-3-phenylaziridine (38)
h  Prepared as described above starting from azide 27 (301 mg, 0.81 mmol).
/ \ Column chromatography (EtOAc/heptane, 1:7— 1:2) yielded 38 (82 mg, 47%)
as a yellowish oil. Rf 0.41 (EtOAc/toluene, 1:4). [a]D0 +232 (c 1.35, CH2Cl2). IR  
F (ATR): 3028, 1511, 1230, 694 cm-1. 1H NM R (CDCl3, 400 MHz): 5 7.38-7.23 
(m, 7H), 7.07-7.00 (m, 2H), 3.12 (d, J  = 2.0 Hz, 1H), 3.03 (d, J  = 2.0 Hz, 1H). 13C NM R (CDCl3, 75 
MHz): 5 161.7 (d, J  = 245.4 Hz), 139.3, 134.8 (d, J  = 3.1 Hz), 128.7, 127.4, 126.7 (d, J  = 8.0 Hz),
125.4, 115.0 (d, J  = 21.6 Hz), 43.8, 42.8. HRMS (ES I) m/z calcd for C 14H 13FN (M+H)+: 214.1032, 
found: 214.1037.
(2^,3^)-2-(3-Chlorophenyl)-3-phenylaziridine (39)
Prepared as described above starting from azide 28 (64 mg, 0.16 mmol). 
Cl Column chromatography (EtOAc/heptane, 1:7— 1:2) yielded 39 (27 mg, 89%) 
as a yellowish oil. Rf 0.54 (EtOAc/heptane, 1:1). [a]D0 +204 (c 0.47, CH2Cl2). 
IR  (ATR): 3068, 3022, 2922, 1598, 776, 698 cm-1. 1H NM R (CDCl3, 400 MHz): 
5 7.40-7.15 (m, 9H), 3.11 (s, 1H), 3.05 (s, 1H), 1.81 (br s, 1H). 13C NM R (CDCl3, 75 MHz): 5 141.8,
139.1, 134.6, 129.8, 128.7, 127.5, 127.4, 125.7, 125.4, 123.9, 44.1, 42.7. HRM S (ES I) m/z calcd for 
C 14H13ClN (M+H)+: 230.0737, found: 230.0738.
(2^,3^)-2-Allyl-3-phenylaziridine (40)
Prepared as described above starting from azide 29 (85 mg, 0.27 mmol). Column 
chromatography (EtOAc/heptane, 1:7— 1:2) yielded 40 (22 mg, 51%) as a 
yellowish oil. Rf  0.48 (EtOAc/heptane, 1:1). [a]D0 +36 (c 0.55, CH2Cl2). IR  (ATR): 
2924, 2850, 915, 747, 698 cm-1. 1H NM R (CDCl3, 400 MHz): 5 7.34-7.17 (m, 5H),
5.89 (dddd, J  = 6.5, 6.5, 10.2, 16.9 Hz, 1H), 5.20-5.13 (m, 1H), 5.13-5.08 (m, 1H), 2.73 (d, J  = 2.7 Hz, 
1H), 2.43-2.29 (m, 2H), 2.19 (s, 1H). 13C NM R (CDCl3, 75 MHz): 5 140.2, 134.2, 128.5, 127.0, 125.6,
117.1, 40.5, 38.6, 37.8. HRMS (ES I) m/z calcd for C „H 14N (M+H)+: 160.1126, found: 160.1135.
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(2£,3£)-2-(4-Bromophenyl)-3-(4-fluorophenyl)aziridme (41)
N Prepared as described above starting from azide 30 (50 mg, 0.11 mmol).
Column chromatography (EtOAc/heptane, 1:7—>1:2) yielded 41 (24 mg, 
73%) as a yellowish oil. R/ 0.64 (EtOAc/heptane, 1:1). [a ]“  -216 (c 1.18, 
Br- ^  ' F c h 2C12). IR  (ATR): 3300, 2920, 2846, 1510, 1488, 1228, 805 cm-1. 'H
NM R (CDCl3, 400 MHz): 5 7.49-7.44 (m, 2H), 7.26-7.10 (m, 4H), 7.09-7.00 (m, 2H), 3.02 (br s, 2H), 
1.36 (s, 1H). 13C NM R (CDCl3, 75 MHz): 5 162.2 (d, J  = 245.9 Hz), 138.4, 134.9, 131.7, 127.2, 127.0 
(d, J  = 8.3 Hz), 121.1, 115.6 (d, J  = 21.6 Hz), 43.1. HRMS (ES I) m/z calcd for C^H^BrFN (M+H)+: 
292.0137, found: 292.0127.
(2£,3£)-2-(4-Bromophenyl)-3-(4-methoxyphenyl)aziridme (42)
H Prepared as described above starting from azide 31 (58 mg, 0.12 mmol).
Column chromatography (EtOAc/heptane, 1:7— 1:2) yielded 42 (19 mg, 
53%) as a yellowish oil. R/ 0.59 (EtOAc/heptane, 1:1). [a]D0 -171 (c 
b^  ^  'OMe 0.38, CH2Cl2). IR  (ATR): 2954, 2922, 2853, 1514, 1249, 802 cm-1. 1H
NM R (CDCl3, 400 MHz): 5 7.49-7.44 (m, 2H), 7.21-7.14 (m, 4H), 6.92-6.87 (m, 2H), 3.81 (s, 3H),
3.05 (br s, 1H), 2.97 (br s, 1H), 1.51 (br s, 1H). 13C NM R (CDCl3, 75 MHz): 5 159.1, 138.8, 131.6,
131.2, 127.2, 126.5, 120.1, 114.2, 55.3, 43.7, 42.5. HRMS (ES I) m/z calcd for C 15H15BrNO (M+H)+: 
304.0337, found: 304.0340.
(2£,3£)-2-(3,4-Methylenedioxylphenyl)-3-(4-methoxyphenyl)aziridme (45)
h Prepared as described above starting from azide 34 (140 mg, 0.33 mmol).N
O^ ^_ Column chromatography (EtOAc/heptane, 1:7— 1:2) yielded 45 (47 mg,
(  54%) as a yellowish oil. R/0.48 (EtOAc/heptane, 1:1). [a]D0 -133 (c 0.81,
O OMe CH2Cl2). IR  (ATR): 3006, 2958, 2898, 1513, 1247, 1306, 800 cm-1. 1H
NM R (CDCl3, 400 MHz): 5 7.21-7.16 (m, 2H), 6.92-6.86 (m, 2H), 6.79-6.74 (m, 3H), 5.95 (s, 2H), 
3.81 (s, 3H), 3.01 (s, 1H), 2.97 (s, 1H), 1.46 (br s, 1H). 13C NM R (CDCl3, 75 MHz): 5 159.0, 148.0,
146.8, 133.8, 131.6, 126.5, 119.1, 114.1, 108.3, 105.7, 101.0, 55.3, 43.1. HRM S (ES I) m/z calcd for 
C 16H 16NO3 (M+H)+: 270.1130, found: 270.1134.
(2^',35')-2-(But-3-enyl)-3-phenylaziridine (46)
N Prepared as described above starting from azide 35 (115 mg, 0.35 mmol).
Column chromatography (EtOAc/heptane, 1:7— 1:2) yielded 46 (27 mg, 46%) as 
a yellowish oil. R/ 0.40 (EtOAc/heptane, 1:1). [a]D0 -51.8 (c 1.15, CH2Cl2). IR  
(ATR): 3067, 2980, 2920, 2842, 742, 698 cm-1. !H NM R (CDCl3, 400 MHz): 5 
7.35-7.15 (m, 5H), 5.87 (ddt, J  = 10.2, 16.9, 6.7 Hz, 1H), 5.10-5.03 (m, 1H), 5.02-4.97 (m, 1H), 2.71 
(d, J  = 1.9 Hz, 1H), 2.37-2.00 (m, 3H), 1.73-1.60 (m, 2H), 0.69 (br s, 1H). 13C NM R (CDCl3, 75 
MHz): 5 140.3, 137.8, 128.4, 126.9, 125.5, 115.1, 41.3, 36.9, 31.7, 31.5. HRMS (ES I) m/z calcd for 
C 12H16N (M+H)+: 174.1283, found: 174.1289.
(2^,3^)-1-Acetyl-1,2-diphenylaziridine (47)
Ac To a solution of aziridine 37 (20 mg, 0.10 mmol) in CH2Cl2 (2 mL) were added,
/N\ pyridine (24.8 ^L, 0.30 mmol, 3.0 equiv) and acetic anhydride (29.0 ^L, 0.30
(j i| ] mmol, 3.0 equiv). The reaction mixture was stirred for 1% h at rt, after which the
mixture was quenched with H2O (2 mL). The product was then extracted with 
CH2Cl2 (3 x 2 mL) and the resulting organic layers were combined, dried and concentrated in vacuo.
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Column chromatography (EtOAc/heptane, 1:7—>1:2) afforded pure 47 (7 mg, 29%). Rf 0.57 
(EtOAc/heptane, 1:1). [a]D0 +160 (c 0.20, CH2C12). e.e 96% (HPLC eluent hexane: ethanol = 80:20, 
flow 1.0 mL/min); Ru = 7.69 min (trans), Ru = 8.32 min (cis). IR  (ATR): 1629, 1365, 1208, 698, 618, 
610 cm-1. 'h  NM R (CDC13, 400 MHz): 5 7.40-7.25 (m, 10H), 3.77 (s, 2H), 1.88 (s, 3H). 13C NM R 
(CDC13, 75 MHz): 5 179.8, 135.7, 128.8, 128.0, 126.3, 48.1, 24.8. HRMS (ES I) m/z calcd for 
C 16H16NO (M+H)+: 238.1232, found: 238.1230.
2.9 References and notes
(1) Gabriel, S. Ber. Dtsch. Chem. Ges. 1888, 21, 1049-1049.
(2) a) Sweeney, J. B. Chem. Soc. Rev. 2002, 31, 247-258. b) Singh, G. S.; D ’hooghe, M.; De 
Kimpe, N. Chem. Rev. 2007, 107, 2080-2135. c) Gansäuer, A. Angew. Chem., Int. Ed. 2006, 45, 
5733.
(3) Lefemine, D. V.; Dann, M.; Barbatschi, F.; Hausmann, W. K.; Zbinovsky, V.; Monnikendam,
P.; Adam, J.; Bohonos, N. J. Am. Chem. Soc. 1962, 84, 3184-3185.
(4) Kasai, M.; Kono, M. Synlett 1992, 778-790.
(5) a) Tomasz, M. Chem. Biol. 1995, 2, 575-579. b) Han, I.; Kohn, H. J. Org. Chem. 1991, 56, 
4648-4653.
(6) a) Kinoshita, S.; Uzu, K.; Nakano, K.; Shimizu, M.; Takahashi, T.; Matsui, M. J. Med. Chem. 
1971, 14, 103-109. b) Katoh, T.; Itoh, E.; Yoshino, T.; Terashima, S. Tetrahedron 1997, 53, 
10229-10238.
(7) Nakagawa, M.; Kawahara, M. Org. Lett. 2000, 2, 953-955.
(8) Crotti, P.; Di Bussolo, V.; Favero, L.; Macchia, F.; Pineschi, M. Tetrahedron: Asymmetry 1996, 
7, 779-786.
(9) Davis, F. A.; Deng, J.; Zhang, Y.; Haltiwanger, R. C. Tetrahedron 2002, 58, 7135-7143.
(10) Tanner, D.; Somfai, P. Tetrahedron Lett. 1987, 28, 1211-1214.
(11) Tanner, D.; Harden, A.; Johansson, F.; Wyatt, P.; Andersson, P. G. Acta Chem. Scand. 1996, 89, 
2357-2364.
(12) a) Tanner, D.; Korn0, H. T.; Guijarro, D.; Andersson, P. G. Tetrahedron 1998, 54, 14213­
14232. b) Lawrence, C. F.; Nayak, S. K.; Thijs, L.; Zwanenburg, B. Synlett 1999, 1571-1572. c) 
Pu. L.; Yu, H.-B. Chem. Rev. 2001, 101, 757-824.
(13) Atkinson, R. S. Tetrahedron 1999, 55, 1519-1559.
(14) Ochiai, M.; Kitagawa, Y. Tetrahedron Lett. 1998, 39, 5569-5570.
(15) a) Hansen, K. B.; Finney, N. S.; Jacobsen, E. N. Angew. Chem., Int. Ed. 1995, 34, 676-678. b) 
Antilla, J. C.; Wulff, W. D. Angew. Chem., Int. Ed. 2000, 39, 4518-4521.
(16) a) Denolf, B.; Mangelinckx, S.; Törnroos, K. W .; De Kimpe, N. Org. Lett. 2006, 8, 3129-3132. 
b) Denolf, B, Leemans, E.; De Kimpe, N. J. Org. Chem. 2007, 72, 3211-3217. c) Leemans, E.; 
Mangelinckx, S.; De Kimpe, N. Synlett, 2009, 1265-1268. d) Colpaert, F.; Mangelinckx, S.; 
Leemans, E.; Denolf, B.; De Kimpe, N. Org. Biomol. Chem. 2010, 8, 3251-3258. e) Van 
Nguyen, T.; De Kimpe, N. Tetrahedron 2000, 56, 7299-7304.
(17) Verstappen, M. M. H.; Ariaans, G. J. A.; Zwanenburg, B. J. Am. Chem. Soc. 1996, 118, 8491­
8492.
(18) Deyrup, J. A.; Greenwald, R. B. J. Am. Chem. Soc. 1965, 87, 4538-4545.
(19) Lohray, B. B.; Gao, Y.; Sharpless, K. B. Tetrahedron Lett. 1989, 30, 2623-2626.
(20) Wenker, H. J. Am. Chem. Soc. 1935, 57, 2328-2328.
(21) Davis, F. A.; McCoull, W. Synthesis 2000, 1347-1365.
(22) a) Pfister, J. R. Synthesis 1984, 969-970. b) Kametani, T.; Kigawa, Y.; Ihara, M. Tetrahedron 
1979, 35, 313-316.
(23) a) Effenberger, F.; Ziegler, T.; Forster, S. Angew. Chem., Int. Ed. 1987, 26, 458-460. b) 
Effenberger, F.; Stelzer, U. Tetrahedron: Asymmetry 1995, 6, 283-286. c) Effenberger, F.; 
Förster, S.; Wajant, H. Curr. Opin. Biotechnol. 2000, 11, 532-539.
59
Chapter 2
(24) Wijdeven, M. A.; Wijtmans, R.; van den Berg, R. J. F.; Noorduin, W.; Schoemaker, H. E.; 
Sonke, T.; van Delft, F. L.; Blaauw, R. H.; Fitch, R. W.; Spande, T. F.; Daly, J. W.; Rutjes, F. P. 
J. T. Org. Lett. 2008, lG, 4001-4003.
(25) Rosenthaler, L. Biochem. Z. 1908, lé , 238-253.
(26) Fechter, M. H.; Griengl, H. In Enzyme Catalysis in Organic Synthesis; Drauz, K.; Waldmann,
H., Eds.; Wiley-VHC: Weinheim, 2002; Vol. 3. pp. 974-990.
(27) Glieder A.; Weis, R.; Skranc, W.; Pöchlauer, P.; Dreveny, I.; Majer, S.; Wubbolts, M.; Schwab,
H.; Gruber, K. Angew. Chem., Int. Ed. 2003, 42, 4815-4818.
(28) Brussee, J.; Dofferhoff, F.; Kruse, C. G.; Gen, A. Tetrahedron 1990, 4ó, 1653-1658.
(29) a) Cram, D. J.; Kopecky, K. R. J. Am. Chem. Soc. 1959, S l, 2748-2755. b) Cram, D. J.; Wilson, 
D. R. J. Am. Chem. Soc. 1963, SS, 1245-1249.
(30) a) Chérest, M.; Felkin, H.; Prudent, N. Tetrahedron Lett. 1968, P, 2199-2204. b) Anh, N. T.; 
Eisenstein, O. Nouv. J. Chim. 1977, l, 61-70.
(31) Bürgi, H. B.; Dunitz, J. D.; Shefter, E. J. Am. Chem. Soc. 1973, Pâ, 5065-5067.
(32) Wipf, P.; Miller, C. P. Tetrahedron Lett. 1992, SS, 6267-6270.
(33) Goddard-Borger, E. D.; Stick, R. V. Org. Lett. 2007, P, 3797-3800.
(34) a) Cavender, C. J.; Shiner, V. J. J. Org. Chem. 2002, S?, 3567-3569. b) Nyffeler, P. T.; Liang,
C. H.; Koeller, K. M.; Wong, C. H. J. Am. Chem. Soc. 2002, l24, 10773-10778.
(35) a) Ramón, R.; Alonso, M.; Riera, A. Tetrahedron: Asymmetry 2007, lS, 2797-2802. b) Tanner,
D.; Birgersson, C.; Gogoll, A.; Luthman, K. Tetrahedron 1994, SG, 9797-9824. c) Pöchlauer, P.; 
Müller, E. P. Helv. Chim. Acta 1984, Ó?, 1238-1247.
(36) Arroyo, Y.; Meana, Á.; Rodríguez, J. F.; Santos, M.; Sanz-Tejedor, M. A.; García-Ruano, J. L. 
Tetrahedron 2006, Ó2, 8525-8532.
(37) Gottlieb, H. E.; Kotlyar, V.; Nudelman, A. J. Org. Chem. 1997, Ó2, 7512-7515.
(38) Hasslacher, M.; Schall, M.; Hayn, M.; Bona, R.; Rumbold, K.; Luckl, J.; Griengl, H.; Kohlwein, 
S. D.; Schwab, H. Protein Expression an dPurif 1997, l l ,  61-71.
(39) Glieder, A.; Weis, R.; Skranc, W.; Poechlauer, P.; Dreveny, I.; Majer, S.; Wubbolts, M.; 
Schwab, H.; Gruber, K. Angew. Chem., Int. Ed. 2003, 42, 4815-4818.
(40) Warmerdam, E. G. J. C.; Brussee, J.; Kruse, C. G.; van der Gen, A. Tetrahedron 1993, 4P, 
1063-1070.
(41) Brussee, J.; Loos, W. T.; Kruse, C. G.; Van Der Gen, A. Tetrahedron 1990, 4Ó, 979-986.
(42) Tromp, R. A.; Brussee, J.; van der Gen, A. Org. Biomol. Chem. 2003, l, 3592-3599.
(43) Perkins, M. V.; Jacobs, M. F.; Kitching, W.; Cassidy, P. J.; Lewis, J. A.; Drew, R. A. I. J. Org. 
Chem. 1992, ö?, 3365-3380.
(44) Cainelli, G.; Giacomini, D.; Mezzina, E.; Panunzio, M.; Zarantonello, P. Tetrahedron Lett. 
1991,S2, 2967-2970.
(45) Reyes, A.; Juaristi, E. Chirality 1998, lG, 95-99.
60
Chapter 3 
Enantioselective Chemoenzymatic 
Synthesis of 4-Hydroxy-2-pyrrolines
A  novel route toward functionalized pyrrolines starting from propargylic aldehydes was 
developed. Key steps involve hydroxynitrile lyase-catalyzed asymmetric hydrocyanation of 
propargylic aldehydes and gold-catalyzed cyclization of substituted acetylene-containing 
amino alcohols. The resulting 2,5-disubstituted-4-hydroxy-2-pyrrolines are potentially useful 
scaffolds and could be used for the synthesis of functionalized pyrrolidines and biologically 
active natural products.
Part of this chapter w ill be published in: Ritzen, B.; Richelle, G. J. J.; Brocken, L.; van Delft, F. L.; 
Rutjes, F. P. J. T. Enantioselective Chemoenzymatic Synthesis of 4-Hydroxy-2-pyrrolines, manuscript 
in preparation.
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3.1 Introduction
Functionalized pyrrolidines and pyrrolines are important classes of nitrogen heterocyclic 
compounds and constitute common motifs displayed in a wide array of biologically active 
compounds, including natural products and pharmaceutically relevant molecules.1,2 Members 
of these compound classes show therapeutic potential such as anti-depressant,3 anti- 
histaminic,4 anti-inflammatory,5 anti-tumor,6 analgesic7 and anti-parkinson activity.8 A  few 
examples include codonopsinine ( 1 ) which has been shown to possess hypotensive activity,9 
preussin (2 ) which is known to induce apoptosis in human tumor cells, 10 and indicine N-oxide 
(N SC  132319, 3), an alkaloid isolated from H eliotropium  indicum, which was used in clinical 
trials as an antineoplastic agent (Figure 3.1) .11
Figure 3.1 Biologically active pyrrolidines and pyrrolines.
1 codonopsinine 2 preussin 3 indicine N-oxide
Apart from the pharmaceutical applications, these moieties have also witnessed widespread 
use as organocatalysts and chiral auxiliaries or ligands for asymmetric synthesis. Since the 
pioneering studies in the early 1970s, the field of organocatalysis has grown spectacularly. By  
now, many more pyrroli(di)ne-based reagents12 and catalysts13,14 have been designed some of 
which are depicted in Figure 3.2.
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Figure 3.2. Representative pyrrolidine-based structures in asymmetric synthesis.
Over the last two decades, a plethora of synthetic methods for the synthesis of 
functionalized nitrogen heterocycles have been developed15 and the search for new synthetic 
methodologies is still ongoing. 16 Recently, increasing attention has been drawn to the use of 
gold-catalysis for the synthesis of nitrogen heterocyclic ring systems.17 The ability of gold to 
act as a soft Lewis acid toward unsaturated carbon-carbon bonds has opened new doors for 
organic chemists to synthesize complex carbo- and heterocyclic structures in an efficient and 
mild way.
A  recent example is provided by the group of Uriac, who reported a convenient route for 
synthesizing substituted pyrrolin-4-ones via  gold catalysis. 18 B y  using a catalytic amount of 
Au2O3, they were able to isolate 12 in nearly quantitative yield without any epimerization 
(Scheme 3.1).
Scheme 3.1 Gold-catalyzed synthesis o f  pyrrolin-4-ones.
R
O Au2O3 (10 mol%) — ,
R - R 1
THF, 60 °C  R N RNHBoc R1 'Boc
11 12, 85-95% yield
R = Me, iPr, Bn, sec-Bu up to 99%  ee
R 1 = nPr, Ph
Inspired by the opportunities of gold-catalysis and the general relevance of pyrrol(id)ines, 
we set out to develop new and flexible strategies that would allow for stereoselective 
construction of highly functionalized pyrrol(id)ine-based building blocks. In addition, such a 
new approach may also be used to prepare series of pyrrol(id)ine derivatives, which could be
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relevant in medicinal chemistry applications. Recently, we reported a novel strategy for the 
synthesis of functionalized aziridines19 and morpholines20 starting from enantiopure 
cyanohydrins obtained from the corresponding aldehydes via  hydroxynitrile lyase (HNL)- 
mediated asymmetric hydrogen cyanide addition. W e anticipated that the latter 
chemoenzymatic reaction in combination with gold-catalysis should also provide a basis for 
efficient entries into a variety of functionalized hydroxylated pyrrol(id)ines 13-15.
3.2 Retrosynthetic strategy
Retrosynthetic analysis of the target 4-hydroxy-2-pyrrolines 15, which can be considered as 
key precursor for synthesis of various pyrrolidines 13 and 14, might be synthesized via  a 
gold-catalyzed 5-endo-dig cyclization of the acetylenic amino alcohol 16 (Scheme 3.2). 
Installation of the homopropargylic stereogenic center may occur by performing a Grignard 
addition on cyanohydrin 17 followed by stereocontrolled imine reduction. The cyanohydrin 
17, in turn, could arise from HNL-mediated addition of hydrogen cyanide onto 3- 
(trimethylsilyl)-2-propynal (23), followed by substrate diversification at the terminal position 
of the alkyne. W e reasoned that such a transformation would hold considerable potential since 
facile removal of the TM S group would offer the possibility to introduce a range of aromatic 
and aliphatic groups via  Pd-catalyzed cross-coupling.
Scheme 3.2 Retrosynthetic strategy to enantiopure 4-hydroxy-2-pyrrolines.
HO *PH
R N R
Boc
13
OH
R y'""lR1
R N R
Boc
14
TMS
OTBS 
-R1
nh2
16
OTBS 
'CN
23 17
R
O
H
R
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3.3 Chemoenzymatic asymmetric cyanohydrin formation
In the first generation synthesis, we commenced by making key intermediate 31 from the 
commercially available TMS-protected acetylenic aldehyde 23 via HNL-mediated 
asymmetric hydrogen cyanide addition. W e were pleased to find that 3-(trimethylsilyl)-2- 
propynal (23) was well accepted by (S)-HNL providing the desired product 31, after TBS- 
protection of the hydroxyl group, in good yield (83% ) and excellent ee of 99% (Table 3.1, 
entry 1). The intrinsic instability of unprotected cyanohydrins required immediate O- 
protection (T BSC l, D M A P, imidazole) in order to prevent racemization. For the next step in 
the synthesis, being removal of the trimethylsilyl group, we chose to use slightly basic 
conditions (K 2CO3, M eO H) in order to prevent deprotection of the hydroxyl group. 
Unfortunately, after having screened several conditions, all deprotection attempts failed and 
led merely to decomposition of the starting compound. Subjection to various fluoride sources 
(T B A F , HF, H 2S iF6) under different conditions again only showed decomposition of the 
starting material. Replacement of the TBS-group by a THP-protecting group did not improve 
the results either.
In response to these results, the initial strategy to the target molecules 15 was redesigned. 
Instead of starting from the TMS-protected aldehyde 23, which would be diversified after the 
enzymatic step, we now chose to use functionalized propargylic aldehydes that were then 
subjected to the HNL-catalyzed hydrocyanation. It is interesting to note that among the 
numerous examples of HNL-catalyzed hydrocyanations of aldehydes, additions onto a,P- 
acetylenic aldehydes are significantly less abundant.21 During examination of the substrate 
scope, it appeared that a rather limited number of a,P-acetylenic aldehydes were commercially 
available. In fact, 3-phenyl-2-propynal (24) was the only substrate that could directly be 
purchased from chemical suppliers. From a practical point of view, fast and facile access to 
these building blocks is a prerequisite. Therefore, our first synthetic subgoal was the 
development of an efficient route toward these compounds. Previously, Journet e t al. reported 
a highly efficient approach for the synthesis of a,P-acetylenic aldehydes from terminal 
alkynes using D M F as the formylating reagent.22 W e were pleased to find that using this 
methodology, substrates 25-27 could be readily obtained in acceptable yields of 61-73% 
(entries 3-5). Since terminal alkyne aldehyde 28 is also not commercially available, access 
was accomplished by performing a two-step Corey-Fuchs23 reaction sequence on piperonal 
furnishing in the first step the dibromoalkene by reaction with tetrabromomethane and
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triphenylphosphine. Next, dehydrohalogenation under basic conditions with lithium base 
(LD A ) generates a bromoalkyne intermediate which undergoes a metal-halogen exchange 
providing terminal alkyne 21 in 53% yield over two steps. Subsequent subjection to the above 
mentioned formylating conditions led to aldehyde 28 in a satisfactory yield of 68%  (entry 6). 
In case of aldehyde 29, a different strategy was undertaken. In our hands, rapid access to this 
compound was achieved by PCC-oxidation of commercially available 2-hexynol (22) 
furnishing the desired precursor in an acceptable yield of 42% (entry 7).
Table 3.1 HNL-mediated cyanohydrin formation and protection.
R 1
HNL, HCN
H2O/MTBE
OH
CN
pH =5.0
nBuLi, DMF i---- 18-21 R2 = H
THF 23-29 R2 = CHO
TBSCl 
DMAP, Im
CH2Cl2 
0 °C to rt
OTBS 
CN
30 31-37
product yield (% )a enzyme product yield (% )a ee (% )b config.entry s.m. R 1
1
2
3
4
5
TMS
a \
23c
24c
25
26
27
28 
29
(S)-HNL 31 
(R)-HNL 32
71 (S)-HNL 33
61 (S)-HNL 34
73 (S)-HNL 35
68 (S)-HNL 36
42 (S)-HNL 37
83
86
81
80
22
92
>99 (S)
>95 (R)
>99 (S)
>99 (S)
93 (S)
>99 (S)
a Isolated yield after column chromatography. b Determined by chiral HPLC analysis. ~  
Commercially available. d Obtained via Corey-Fuchs reaction on piperonal. e Obtained via PCC- 
oxidation of 2-hexynol (2 2 ).
As can be seen from Table 3.1, the enantiomeric purity and the chemical yield after the 
H N L reaction are for the aryl-substituted aldehydes in virtually all cases excellent. The only 
exception seems to be 3-(4-fluorophenyl)propiolaldehyde (27), which is obviously not a good
2
R R
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substrate for the enzyme (entry 5). In parallel to the enzyme catalyzed-reaction, the non- 
enzymatic cyanohydrin formation also took place although at a lower rate at this pH value. 
However, with difficult substrates, like the fluorinated aldehyde 27, the spontaneous addition 
reaction of HCN, competed in such a way that the enantiopurity of the product (35) was 
reduced. To obtain a most optimal result for substrate 27, the reaction was stopped at a 
preliminary stage before reaching full conversion, resulting in a lower isolated yield of 2 2 % , 
but a rather good ee of 93%.
In a publication by Griengl e t a!.,21 the aliphatic aldehyde 29 was obtained in 62% isolated 
yield and 98% enantioselectivity. Remarkable is that in contrast to their findings, in our hands 
no transformation of aldehyde 29 into the desired product 37 was observed. For the latter two 
substrates 27 and 29, addition of larger amounts of the enzyme also did not seem to improve 
the yield or enantiopurity.
3.4 Synthesis of the acetylenic amino alcohols
W ith the availability of a suitable procedure for the synthesis of the acetylenic cyanohydrins 
32-37, the stage was set for performing the Grignard addition. Much to our satisfaction, when 
submitted to Grignard reagents, TLC  and mass analyses of the crude reaction mixture 
revealed that cyanohydrin 32 underwent a successful transformation into the corresponding 
imine.
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Table 3.2 Grignard addition and reducing agent screening.
entry reducing reagent T (°C ) yield (% )a syn/antib de (%)b
1 NaBH4 -2 0 44 1:3 50
2 NaBH4 -78 46 1:3.5 52
3 LiBH 4 -78 42 1:2.5 43
4 L-selectride -78 - -
5 LiEt3BH -78 - -
6 N aBH 3CN -78 - -
7 Zn(BH4)2 -78 57 1:8 78
a Isolated yield after two steps after column chromatography. b Determined 
by 'H-NMR of the crude reaction mixture.
Stereoselective imine reduction to the corresponding acetylenic amino alcohols was first 
investigated using sodium borohydride. As already pointed out in Section 2.4, sodium 
borohydride reduction at 0 °C  has been proven to be very effective for this type of reduction 
furnishing almost exclusively the anti-stereoisomer. However, our first attempt afforded 
amino alcohol 38 in 44% yield as a mixture of distereoisomers with a disappointing 1:3 
syn/anti ratio (Table 3.2, entry 1). Analyzing this result, we reasoned that lowering the 
reaction temperature might be beneficial for the stereoselectivity and the yield of amino 
alcohol 38. Unfortunately, lowering the temperature to -78 °C  only slightly improved the 
syn/anti ratio to 1:3.5, while the yield remained the same (entry 2). Replacement of N aBH 4 by 
L iB H 4 was not a fortuitous choice, since the syn/anti ratio even decreased to 1:2.5 giving the 
product in comparable yield (entry 3). It was clear from these results that both hydride sources 
would not be the reducing agent of choice so that we turned our attention to more bulky 
hydride sources. However, subjection of the imine to L-selectride and L iE t3B H  (entries 4 and 
5) failed to give the desired product. Considering this, it was concluded that these reducing 
agents were too sterically hindered thereby hampering attack onto the imine. In case of 
N aBH 3CN, no conversion was observed at all indicating that this reagent might be too mild 
for reducing the imine at -78 °C  (entry 6). Fortunately, this problem could be overcome by 
switching to Z n (BH 4)2 at low temperature giving the amino alcohol 38 in an acceptable yield
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of 57% as an inseparable mixture of diastereoisomers with a syn/anti ratio of 1:8 (entry 7). In 
comparison to L iB H 4 and N aBH 4, the usage of Z n (BH 4)2 seems to considerably improve the 
chelation process. Indeed, literature reports on Zn (BH 4)2 indicate that in case of 
chemoselective reduction of P-keto esters to the corresponding P-hydroxy esters, improved 
stereocontrol can be easily achieved due to the better coordinating ability of zinc with the 
carbonyl group of the ester.24
Encouraged by these results, we set out to apply this one-pot methodology in the synthesis 
of substituted cyanohydrins 33-36 using various Grignard reagents (Table 3.3). As expected, 
applying these conditions to the other cyanohydrins resulted in the formation of the anti­
amino alcohols in satisfactory yields of 42-73% and with satisfactory syn/anti-ratios. The first 
attempts to separate the major anti-isomer from the minor syn-amino alcohol via  column 
chromatography proved to be hard. To prevent tedious and lengthy chromatographic 
purification, we decided to separate both isomers in a later stage of the synthesis.
Surprisingly, no conversions into the desired products were observed in case of aliphatic 
Grignard reagents and aromatic Grignard reagents bearing a methoxy or methyl substituent. 
After closer examining these results, it occurred to us that the more-electron rich Grignard 
reagents refused to give the desired products. A  logical explanation for these results can lie in 
the fact that these reagents tend to act more as a base because of the higher reactivity of the 
reagent, favoring competitive a-deprotonation of the cyanohydrin.
Table 3.3 Grignard addition, reduction, and Boc-protection.
OTBS
CN
1) R 1MgBr
2) MeOH, Zn(BH4)2 OTBS (Boc)2O, NaHCO3 
.R 1 ___________________ ,
OTBS 
,R
R '  Et2O, -78 °C  tort R
32-36 38-51
■fu, dioxane/H2O, rt NH2 2 R NHBoc
52-65
amino yield syn/antib prod yield syn/anti0 config.entry s.m. R R 1
alcohol (% )a (% )a
\
1 32 38 58 1:8 52 73 1:17 (R,S)
A
2 32 '  ”X X  39 57 1:7 53 72 1 :10  (R,S)
3 32 H '1  40
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4 32
5
6
7
8
9
10
11
a 41 55
42 42 1:30 56 70 1:60 (S,R)
43 - c - 57 - - -
44 - c - 58 - - -
45 - c - 59 - - -
46 53 1:6 60 75 1:6 (S,R)
47 73 1:7 61 80 1:12 (S,R)
48 - c - 62 - - -
49 66 1:6 63 85 1:7 (S,R) 
13 35 || '| [| '1 50 56 1:5 64 79 1:5 (S,R)
51 69 1:7 65 74 1:8 (S,R)
a Isolated yield after two steps after column chromatography. b Determined by 1H-NMR of the crude 
reaction mixture. c n.d. = not determined.
3.5 Synthesis of the pyrroline scaffold
Having the desired acetylenic amino alcohols in hand, subsequent protection of the amine 
functionality with an electron-withdrawing group was necessary in order to enhance the 
stability of the corresponding pyrroline. Without the protecting group, the formed enamine 
ring system, being in equilibrium with the corresponding imine, would be prone to side 
reactions and degradation. Thus, standard Boc-protection conditions smoothly furnished the 
corresponding carbamate analogues 52-65 in 70-85% yield. A t this stage, the diasteromeric 
ratio for most of the substrates could be improved through chromatographic purification.
c
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Completion of the synthetic route required, as the final step, gold-catalyzed 5-endo-dig 
cyclization. W e decided to explore the strategy developed by Uriac as a basis for the 
construction of our 4-hydroxy-2-pyrroline systems. Unfortunately, initial experiments showed 
that treatment of 52 with the aforementioned catalyst led to rapid formation of the cyclic 
pyrrole 69 in almost quantitative yield (Scheme 3.3). In case of sulfonamide 66, which was 
easily obtained from 38 in 85% yield, exposure under the exact same conditions as for the 
Boc-protected precursor 52 exclusively led to the formation of the corresponding Ts-protected 
pyrrole 70 in 95% yield .25 The formation of 69 and 70 can be explained by complexation of 
the Au(III)-catalyst to the O TBS group which is now sufficiently activated to act as a good 
leaving group. Clearly, the nitrogen atom in the formed pyrroline 67 is sufficiently 
nucleophilic to donate its lone pair into the ring system, thereby expelling the protected 
hydroxyl group under formation of the N-acyl- or N-sulfonyliminium intermediate 68 .
69 97% 68
70 95%
To circumvent the elimination problem, we reasoned that transformation into the free 
hydroxyl group of substrate 52 could offer a solution. As expected, deprotection of the TBS- 
protected amine 52 proceeded cleanly and afforded the product 72 in quantitative yield. Next, 
we turned our attention to the aforementioned cyclization conditions. Unfortunately, 
cyclization of the unprotected precursor was again attended with formation of large quantities 
of undesired pyrrole 69. Moreover, during column chromatography we found that the 
pyrroline 71 was rather unstable toward silica gel since only pyrrole 69 was isolated. Luckily, 
treatment of silica gel with Et3N  (1 %  v/v) circumvented the latter problem. Repeating the 
same experiment, however, gave the desired product 71 in a poor yield of 37% (Table 3.4,
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entry 1). Attempts at lower reaction temperature (entry 2), and using a lower amount of 
catalyst (entry 3) only drastically decreased the reaction rate and had a negative influence on 
the yield. A  more successful result was obtained when the reaction was carried out at 50 °C  
(entry 4). Subjection of 52 to these conditions led to the rapid formation of pyrroline 71 as the 
sole product in a moderate 66%  yield. Consequently, in identifying the optimal conditions we 
set out to investigate the cyclization of substrate 52 with a series of catalysts. Switching to 
other gold species such as AuCl, AuC l3, and A uBr3 proved to be less successful (entries 5-7). 
However, for many gold-catalyzed transformations, a most convenient catalyst proved to be 
the [Au(PPh3)Cl] complex. Indeed, when using this catalyst a higher yield o f7 1 %  was 
achieved (entry 8). In our hands, however, NaAuCl4-2H2O turned out to be a superior catalyst 
giving pyrroline 71 in 92% yield (entry 9). When a catalyst, in situ generated from 
Au(PPh3)C l and an equimolar amount of A gO Tf was used,26 a somewhat lower yield of 83% 
was obtained (entry 10 ).
In addition to gold species, silver salts were also proven to be highly effective.2^27 
Interestingly, exposure of 52 to AgO Tf under the otherwise same conditions gave rise to the 
formation of 71 in a moderate 55% yield (entry 11). Subjection of 52 to other catalysts in 
heated TH F did not lead to formation of pyrroline 71, but gave an almost quantitative 
recovery of the starting material or to isolation of pyrrole 69 (entries 12-15). In case of 
Pd(O Ac)2 the formation of pyrroline 71 was comparable to that when AgO Tf was used (entry 
16).
Table 3.4 Catalyst screening fo r 5-endo-dig cyclization o f  52.
entry catalyst“ temperature (°C ) yield (% )b
1 AU2O3 60 37
2 AU2O3 30 02
3 AU2O3 60 31d
4 AU2O3 50 66
5 AuCl 50 49
6 AuCl3 50 39
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7 AuBr3 50 43
8 Au(PPh3)C l 50 71
9 NaAuCL,-2H2O 50 92
10 AgOTf/Au(PPh3)Cl 50 83
11 AgOTf 50 55
12 PtCl2 50 e
13 InCl3 50 j
14 HgCl2 50 j
15 Cu(OAc)2 50 j
16 Pd(OAc)2 50 53
a A ll reaction were conducted in THF using 10 mol% of 
the indicated catalyst. b Isolated yield after two steps after 
column chromatography. c Isolated yield after 17 h. d 5 mol 
%  AU2O3. e Mainly pyrrole formation.f  Only starting 
material was isolated.
The first step in the mechanism catalyzed by gold proceeds via  initial coordination of the 
metal to the alkyne thereby polarizing the triple bond (Scheme 3.4). Nucleophilic attack from 
the nitrogen atom on the activated alkyne proceeds via  ^-complex 73 to give alkenyl gold 
complex 74 as intermediate. Finally, rapid replacement of the gold by a proton in a process 
called protodeauration, releases the desired pyrroline 71 and regenerates the catalytic species.
Scheme 3.4 Gold catalyzed 5-endo-dig cyclization.
TBAF, THF I----  52 R = TBS
0 °C  to rt --- 72 R= H
quant
Encouraged by the facile 5-endo-dig  cyclization of 52, we deprotected the other compounds 
53-65 as well prior to the gold-catalysis. Clean conversions were observed for all compounds
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rendering further column chromatographic purification redundant (Table 3.5). Instead, a 
simple extraction was sufficient so that compounds 52-65 were directly used for the next step. 
To our great delight, subjection of all the precursors toward NaAuCl4-2H2O in TH F at 50 °C  
furnished the desired pyrrolines 71-81 in excellent yields of 88-95% over two steps. An 
unexpected bonus was that at this point we were successful in fully separating both 
diastereoisomers via  column chromatography.
Table 3.5 Deprotection and gold-catalyzed cyclization.
OTBS ^ THF, 0°C tort,R '
NHBoc 2) NaAuCl4*2 H2°  
THF,50 °C
52-65
OH
R ^ N' ' " V  i
Boc
M -
71-81
entry s.m. R R 1 pyrroline yield (% )a config.
1 52 0* ax 71 92 (R,S)
2 53 av & 75 88 (R,S)
3 56
o<u2
76 92 (S,R)
4 60
£O<u5 a" 77 95 (S,R)
5 61
O<u5 & 78 89 (S,R)
6 63 79 90 (S,R)
7 64 axrx 80 91 (S,R)
8 65 ccf ax 81 93
- -b ______ •
(S,R)
by 'H-NMR of the crude reaction mixture.
R
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To expand the synthetic opportunities of the resulting pyrrolines, we also briefly 
investigated functionalization of the double bond by stereoselective reduction of 71 which 
would be an effective manner for obtaining highly functionalized pyrrolidine derivatives. 
Therefore, pyrroline 71 was subjected to straightforward hydrogenation conditions using Pd 
on carbon under a hydrogen atmosphere (Scheme 3.5). Disappointingly, these conditions did 
not lead to the desired reduction of the enamide moiety, but instead gave partial 
decomposition of the starting material, probably as a result of hydrogenolysis at the benzylic 
position. A t this stage only a small amount of material was left due to extensive investigations 
in the previous steps, and in combination with the relatively instable character of the hydroxy- 
pyrroline 71, we were not able to accomplish the formation of the corresponding pyrrolidine 
82.
Scheme 3.5 Hydrogenation o f  pyrrolidine 82.
H2 ,Pd/Cx
MeOH, rt, 16h
3.6 Conclusions
In conclusion, we have developed a new and facile diastereoselective route to aryl- 
substituted 4-hydroxy-2-pyrrolines proceeding via 5-endo-dig  Au-catalyzed cyclization of 
acetylene-containing amino alcohols in excellent yield. Moreover, it has been demonstrated 
that these compounds can be readily accessed using a one-pot Grignard addition-Zn(BH4)2 
reduction sequence starting from acetylenic cyanohydrins in reasonable yield and good 
diastereomeric ratio. A t this moment, subsequent follow-up chemistry on the formed 
pyrrolines to elaborate the resultant pyrrolidines appeared to be surprisingly troublesome, 
mostly due to the labile character of the pyrrolines. Extension of this methodology to other 
members of the same class of molecules is currently under investigation in our group.
75
Chapter 3
3.7 Acknowledgements
Gaston J. J. Richelle and Laurens Brocken are gratefully acknowledged for their 
contribution to this chapter. D SM  Pharma Chemicals (Geleen, the Netherlands) is kindly 
acknowledged for providing the H N L  enzymes.
3.8 Experimental section 
General information
For general experimental details, see section 2.8. High Performance Liquid Chromatography 
(HPLC) measurements were conducted either on a HPLC apparatus equipped with a Chiralpak AD-H 
column (dimensions: 250 x 4.6 mm) or on a HPLC apparatus equipped with a Chiralcel OD-H column 
(dimensions: 250 x 4.6 mm) and peaks were detected using a UV-detector.
3-(4-Methoxyphenyl)-2-propynal (25)
O To a solution of 1-ethynyl-4-methoxy benzene 18 (2.00 g, 15.0 mmol) in dry 
^ y ^ " H THF (40 mL) was added dropwise ra-butyllithium (9.38 mL of a 1.6 M solution 
in hexane, 1.0 equiv) at -78 °C. After 5 min, dry DMF (3.00 mL, 2.0 equiv) was 
MeO^ ^ ^  added all at once at -78 °C. The reaction mixture was allowed to increase to rt
and the mixture was stirred for 3h. Next, the reaction mixture was quenched 
with 10% aqueous KH 2PO4 (40 mL) and Et2O (100 mL) was added. The aqueous layer was extracted 
with Et2O (3x 50 mL) and the organic layers were washed with H2O (50 mL), dried (Na2SO4) and 
concentrated in vacuo. The crude product was purified with column chromatography (CH2Cl2/pentane, 
0:1^3:2) to afford 25 (1.66 g, 71% yield) as a yellow solid. R/ 0.38 (CH2Cl2/pentane, 1:4). IR  (ATR) 
3019, 2933, 2855, 2180, 1653, 1597, 1247, 1027, 975, 840.8, 702.5 cm-1. 'H-NMR (CDCl3, 400 MHz) 
5 9.40 (s, 1H), 7.58-7.55 (m, 2H), 6.93-6.90 (m, 2H) 3.86 (s, 3H). 13C-NMR (CDCl3, 75 MHz) 5
176.8, 162.3, 135.6, 114.6, 111.3, 96.7, 88.9, 55.6. HRMS (E I) m/z calcd for C 10H8O2 160.0524, 
found: 160.0525.
3-(3-Methoxyphenyl)-2-propynal (26)
Prepared as described above starting from 1-ethynyl-3-methoxybenzene 19 (2.50 g, 
H 19.0 mmol). Purification by column chromatography (CH2Cl2/pentane, 0:1^3:2) 
afforded 26 (1.90 g, 61% yield) as a yellow oil: R/ 0.42 (EtOAc/heptane, 1:3). IR  
(ATR) 3308, 2963, 2846, 2185, 1658, 1290, 1165, 1051, 1009, 715 cm-1. 'H-NMR 
(CDCl3, 400 MHz) 5 9.42 (s, 1H), 7.33-7.29 (m, 1H), 7.22-7.19 (m, 1H), 7.12-7.10 
(m, 1H), 7.06-7.02 (m, 1H), 3.82 (s, 3H). 13C-NMR (CDCl3, 75 MHz) 5 176.9, 159.6, 130.0, 125.9,
120.5, 118.2, 117.8, 95.1, 88.2, 55.5. HRMS (E I) m/z calcd for C 10H8O2 160.0524, found: 160.0522.
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3-(4-Fluorophenyl)-2-propynal (27)
0 Prepared as described above starting from 1-ethynyl-4-fluorobenzene 20 (1.69 g, 
14.1 mmol). Purification by column chromatography (EtOAc/heptane, 0:1—>2:3) 
afforded 27 (1.52 g, 73% yield) as a yellow solid: Rf 0.48 (EtOAc/heptane, 1:3). 
Mp 47.9 °C. IR  (ATR) 2194, 1658, 1601, 1506, 1230, 971, 841 cm-1. 'H-NMR 
(CDCl3, 400 MHz) 5 9.41 (s, 1H), 7.64-7.59 (m, 2H), 7.14-7.08 (m, 2H). 13C-NMR (CDCl3, 75 MHz) 
5 176.7, 164.5 (d, J  = 254.7), 135.8 (d, J  = 9.0 Hz), 116.5 (d, J  = 22.4 Hz), 115.8, 94.1, 88.5. HRMS 
(E I) m/z calcd for C9H5FO 148.0324, found: 148.0326.
3-(3,4-Methylenedioxyphenyl)-2-propynal (28)
0 5-(2,2-Dibromovinyl)benzo[1,3]dioxole: CBr4 (27.6 g, 2.5 equiv) was added to a 
H solution of PPh3 (43.7 mg, 5.0 equiv) in dry CH2Cl2 (500 mL) at 0 °C. After 
stirring for 10 min, a solution of piperonal (5.00 g, 33.3 mmol) in dry CH2Cl2 (20 
mL) was added dropwise with a dropping funnel. After 5 min the mixture was 
allowed to warm to rt and the mixture was stirred for 1 h. Next, the mixture was quenched with brine 
and the product was extracted with CH2Cl2 (3 x 100 mL). The combined organic layers were dried 
(Na2SO4), filtered and concentrated in vacuo. Purification by column chromatography 
(EtOAc/heptane, 0:1—3:7) afforded the dibromide (6.61 g, 65%) as a yellow solid: Rf 0.53 
(EtOAc/heptane, 1:3). Mp 38.0 °C. IR  (ATR) 3006, 2889, 2181, 1658, 1506, 1493, 1446, 1251, 1044, 
932, 875, 836, 802, 512 cm-1. 'H-NMR (CDCl3, 400 MHz) 5 7.36 (s, 1H), 7.19-7.18 (m, 1H), 6.96­
6.93 (m, 1H) 6.81-6.79 (m, 1H), 5.99 (s, 2H). 13C-NMR (CDCl3, 75 MHz) 5 147.9, 147.8, 136.4,
129.3, 123.5, 108.4, 108.3, 101.5, 88.0; HRMS (E I) m/z calcd for C9H6Br2O2 303.8735, found: 
303.8738.
5-Ethynylbenzo[1,3]dioxole: n-Butyllithium (15.3 mL of a 1.6 M solution in hexanes, 3.5 equiv) was 
added dropwise to a solution of diisopropylamine (3.23 mL, 3.5 equiv) in dry THF (33 mL) at -78 °C. 
After 5 min the reaction mixture was warmed to rt and stirred for 15 min. Then the mixture was cooled 
to -78 °C  and added dropwise to a solution of the dibromide (2.0 g, 6.5 mmol) in dry THF (65 mL) at 
-78 °C. The reaction mixture was stirred for 1 h. Then the mixture was quenched with saturated 
aqueous NH4Cl (50 mL) and the product was extracted with CH2Cl2 (3 x 80 mL). The organic layers 
were dried (Na2SO4), filtered and concentrated in vacuo. Purification by column chromatography 
(EtOAc/heptane, 0:1—3:7) afforded the terminal alkyne (777 mg, 81%) as a brown oil. Rf 0.65 
(EtOAc/heptane, 1:4). IR  (ATR) 3287, 2894, 2098, 1502, 1489, 1247, 1031, 923, 815 cm-1. 'H-NMR 
(CDCl3, 400 MHz) 5 7.03 (dd,J = 1.6, 8.0 Hz, 1H), 6.93 (d, J  = 1.6 Hz, 1H), 6.75 (d, J  = 8.0, 1H) 5.98 
(s, 2H), 2.97 (s, 1H). 13C-NMR (CDCl3, 75 MHz) 5 148.4, 147.5, 127.0, 115.4, 112.2, 108.6, 101.5,
83.7, 75.7. HRMS (E I) m/z calcd for C9H6O2 146.0368, found: 146.0366.
Prepared as described above starting from the corresponding alkyne (756 mg, 5.18 mmol). Purification 
by column chromatography (EtOAc/heptane, 0:1 ^  3:7) afforded aldehyde 28 (614 mg, 68%  yield) as 
a yellow solid. Rf  0.42 (EtOAc/heptane, 1:3). Mp 68.6 °C. IR  (ATR) 2906, 2176, 1653, 1485, 1446, 
1256, 1213, 1031, 890 cm-1. 'H-NMR (CDCl3, 400 MHz) 5 9.38 (s, 1H), 7.19 (dd, J  = 1.6, 8.1 Hz, 
1H), 7.02 (d, J  = 1.6 Hz, 1H) 6.83 (dd, J  = 8.1Hz, 1H) 6.04 (s, 2H). 13C-NMR (CDCl3, 75 MHz) 5
176.7, 150.8, 147.9, 129.7, 112.8, 112.5, 109.1, 102.1, 96.2, 88.2. HRMS (E I) m/z calcd for C 10H6O3 
174.0317, found: 174.0316.
2-Hexyn-1-al (29)
Pyridinium chlorochromate (3.47 g, 1.63 equiv) was dissolved in dry CH2Cl2 (35 
'h mL) at 0 °C. To this solution, silica (5.5 g) was added followed by dropwise
Me'
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addition of a solution of 2-hexynol (1.00 g, 10.2 mmol) in dry CH2Cl2 (3 mL). The reaction 
temperature was increased to rt and the mixture was stirred for 7h. Then the mixture was filtered over 
a glass filter and rinsed with pentane. Concentration afforded 29 (411 mg, 42% yield) as a colorless 
oil. Rf  0.46 (EtOAc/heptane, 1:3). IR  (ATR) 2962, 2933, 2872, 2237, 1684, 1273 cm-1. 1H-NMR 
(CDCl3, 400 MHz) 5 9.19 (s, 1H), 2.40 (t, 7.0 Hz, 2H), 1.68-1.59 (m, 2H), 1.03 (t, J  = 7.4 Hz, 3H). 
13C-NMR (CDCl3, 75 MHz) 5 177.5, 99.4, 92.4, 21.3, 20.8, 13.6. HRMS (C I) m/z calcd for C6H9O 
(M+H)+ 97.0654 found: 97.0651. Data in agreement with literature.28
(S)-2-[(teri-Butyldimethylsnyl)oxy]-4-(trimethylsnyl)but-3-ynemtrile (31)
o ies A solution of commercially available 3-trimethylsilylpropynal 23 (2.00 g, 15.8 
.A . mmol) in M TBE (15 mL) was added to a cooled (0 °C ) solution of KCN (10.3 g, 158s&s CNTMS mmol, 10.0 equiv) in citrate buffer (15 mL, pH = 5.0). After addition of (S)-HNL (4
mL) the reaction mixture was stirred at 0 °C  for 4 h and quenched with 5 M HCl (10 mL) causing the 
enzyme to precipitate. The precipitate was filtered over a glass funnel filled with cotton. The filtrate 
was extracted with CH2Cl2 (3 x 50 mL) and the organic layers were combined, dried (Na2SO4) and 
concentrated in vacuo. The residue was dissolved in dry CH2Cl2 (150 mL) at 0 °C  and TBSC l (2.86 g,
1.2 equiv) and imidazole (2.15 g, 2.0 equiv) were added. After 5 min the reaction was stirred at rt 
overnight. After quenching with saturated aqueous NH4Cl the aqueous layer was extracted with 
CH2Cl2 (3 x 40 mL). Organic layers were combined, dried (Na2SO4) and concentrated in vacuo. The 
crude product was purified with column chromatography (EtOAc/heptane, 0:1—>1:5) to afford 31 
(3.51 g, 83% yield) as a colorless oil. R/ 0.73 (EtOAc/heptane, 1:3). [a]D0+18.7 (c 1.03 CH2Cl2). ee 
99% (chiral GC of THP-protected cyanohydrin, isothermic, 120 °C ); Rt,i = 13.11 min and R t2 = 14.25 
min (R). Rt,3 = 14.67 min and Rt,4 = 16.57 min (S). IR  (ATR) 2954, 2924, 2855, 2889, 2358, 2332, 
1253, 1101, 1044, 840, 783 cm-1. 1H NM R (CDCl3, 400 MHz): 5 5.24 (s, 1H), 0.915 (s, 9H), 0.23 (s, 
3H), 0.21 (s, 3H), 0.20 (s, 9H). 13C NM R (CDCl3, 75 MHz): 5 116.4, 97.2, 93.5, 52.5, 25.6, 18.2, -0.5, 
-4.6, -4.5. HRMS (E I) m/z calcd for C 13H25NOSi2 (M)+: 267.1475, found: 267.1484.
(Ä)-2-[(teri-Butyldimethylsilyl)oxy]-4-phenylbut-3-ynenitrile (32)
OTBS Prepared as described above starting from 3-phenyl-2-propynal 24 (2.42 g, 15.4 
y ^ r ' c N  mmol) and (R)-HNL. Purification by column chromatography (EtOAc/heptane, 
0:1 —>1.5:8.5) afforded 32 (3.60 g, 86%  yield) as a yellow oil. Rf 0.69 
^  (EtOAc/heptane, 1:3). [a]D0 -7.2 (c 1.33, CH2Q 2). ee 95% (Chiralpak AD-H
column: HPLC eluent hexane: iPrOH = 85:15, flow 1.0 mL/min); R t1 = 6.12 min (S), Rt2 = 7.01 min 
(R). IR  (ATR) 2958, 2928, 2855, 2228, 2202, 1489, 1256, 1091, 836, 780, 759, 694 cm-1. 1H-NMR 
(CDCl3, 400 MHz) 5 7.49-7.46 (m, 2H), 7.42-7.33 (m, 3H), 5.50 (s, 1H), 0.95 (s, 9H), 0.28 (s, 3H), 
0.26 (s, 3H). 13C-NMR (CDCl3, 75 MHz) 5 132.0, 129.7, 128.6, 121.0, 116.5, 87.1, 81.9, 52.7, 25.6,
18.3, -4.6. HRMS (E I) m/z calcd for C ^ N O S i 271.1392, found: 271.1394.
(£)-2-[(teri-Butyldimethylsilyl)oxy]-4-(4-methoxyphenyl)but-3-ynenitrile (33)
OTBS Prepared as described above starting from 4-ethynylanisole 25 (1.13 g, 6.06 
mmol) and (S)-HNL. Purification by column chromatography (EtOAc/heptane, 
0:1— 1.5:8.5) afforded 33 (1.48 g, 81% yield) as a yellow oil. Rf 0.58 
MeO ^  (EtOAc/heptane, 1:3). [a]D0 +9.6 (c 2.50 CH2Cl2). ee >99% (Chiralcel OD-H
column: HPLC eluent hexane: iPrOH = 80:20, flow 1.0 mL/min); R t1 = 6.41 min (S), R t2 = 9.27 min 
(R). IR  (ATR) 2954, 2937, 2855, 2229, 1610, 1506, 1290, 1247, 1087, 825, 780 cm-1. 1H-NMR 
(CDCl3, 400 MHz) 5 7.42-7.39 (m, 2H), 6.88-6.85 (m, 2H), 5.48 (s, 1H), 3.82 (s, 3H), 0.94 (s, 9H),
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0.27 (s, 3H), 0.25 (s, 3H). 13C-NMR (CDCl3, 75 MHz) 5 160.7, 133.6, 116.7, 114.3, 113.0, 87.3, 80.7,
55.5, 52.8, 25.6, 18.3, -4.6. HRMS (E I) m/z calcd for CnH23NO2Si 301.1498, found: 301.1493.
(£)-2-[(teri-Butyldimethylsnyl)oxy]-4-(3-methoxyphenyl)but-3-ynemtrile (34)
otbs Prepared as described above starting from 3-ethynylanisole 26 (1.10 g, 5.90 mmol) 
cn and (S)-HNL. Purification by column chromatography (EtO Ac/heptane, 
0:1— 1.5:8.5) afforded 34 (1.42 g, 80% yield) as a yellow oil. Rf 0.63 
(EtOAc/heptane, 1:3). [a]D° +6.7 (c 0.60, CH2Cl2). ee >99% (Chiralcel OD-H 
column: HPLC eluent hexane: iPrOH = 80:20, flow 1.0 mL/min); Rt,1 = 6.41 min
(S), Rt,2 = 8.68 min (R). IR  (ATR) 2949, 2932, 2854, 2228, 1597, 1467, 1264, 1100, 841, 776 cm-1. 'H- 
NM R (CDCl3, 400 MHz) 5 7.28-7.24 (m, 1H), 7.08-7.05 (m, 1H), 6.99-6.98 (m, 1H), 6.96-6.93 (m, 
1H), 5.49 (s, 1H), 3.81 (s, 3H), 0.95 (s, 9H), 0.28 (s, 3H), 0.25 (s, 3H). 13C-NMR (CDCl3, 75 MHz) 5
159.5, 129.7, 124.5, 122.0, 116.9, 116.5, 116.2, 87.0, 81.6, 55.5, 52.7, 25.6, 18.3, -4.6. HRMS (E I) 
m/z calcd for C17H23NO2Si 301.1498, found: 301.1502.
(£)-2-[(teri-Butyldimethylsnyl)oxy]-4-(4-fluorophenyl)but-3-ynemtrile (35)
0TBS Prepared as described above starting from 1-ethynyl-4-fluorobenzene 27 (1.00 g, 
cn 3.53 mmol) and (S)-HNL. Purification by column chromatography 
(EtOAc/heptane, 0:1— 1.5:8.5) afforded 35 (334 mg, 20% yield) as a yellow oil. 
Rf  0.61 (EtOAc/heptane, 1:3). [a]D0 +9.3 (c 2.57, CH2Cl2). ee 93% (Chiralcel OD- 
H column: HPLC eluent hexane: iPrOH = 90:10, flow 1.0 mL/min); R^ = 7.97 min (S), Rt2 = 9.23 min 
(R). IR  (ATR) 2954, 2928, 2859, 2236, 1510, 1230, 1096, 1005, 832, 776 cm-1. :H-NMR (CDCl3, 400 
MHz) 5 7.48-7.43 (m, 2H), 7.08-7.02 (m, 2H), 5.48 (s, 1H), 0.95 (s, 9H), 0.27 (s, 3H), 0.25 (s, 3H). 
13C-NMR (CDCl3, 75 MHz) 5 163.4 (d, J  = 251.6 Hz), 134.1 (d, J  = 8.6 Hz), 117.1 (d, J  = 3.4 Hz),
116.4, 116.0 (d, J  = 22.2 Hz), 86.0, 81.7, 52.7, 25.6, 18.3, -4.6. HRM S (E I) m/z calcd for 
C 16H20FNOSi 289.1298, found: 289.1298.
(£)-2-[(teri-Butyldimethylsnyl)oxy]-4-(3,4-methylenedioxyphenyl)but-3-ynemtrile (36)
0TBS Prepared as described above starting from aldehyde 28 (710 mg, 3.53 mmol) 
cn and (S)-HNL. Purification by column chromatography (EtOAc/heptane, 
01——15:8.5) afforded 36 (1.03 g, 92% yield) as a yellow oil. Rf 0.58 
(EtOAc/heptane, 1:3). [a]D0 +28.9 (c 0.27, CH2Q 2). ee >99% (Chiralcel OD-H 
column: HPLC eluent hexane: iPrOH = 80:20, flow 1.0 mL/min); Rt,i = 7.00 min (S), R t2 = 8.74 min 
(R). IR  (ATR) 2959, 2923, 2889, 2863, 2228, 1485, 1446, 1247, 1208, 1092, 1031, 836, 780 cm-1. 1H- 
NM R (CDCl3, 400 MHz) 5 7.00 (dd,J = 1.6, 8.0 Hz, 1H), 6.90 (d, J  = 1.6 Hz, 1H), 6.77 (d, J  = 8.0, 
1H) 6.00 (s, 2H), 5.46 (s, 1H),0.94 (s, 9H), 0.26 (s, 3H), 0.24 (s, 3H). 13C-NMR (CDCl3, 75 MHz) 5
149.1, 147.7, 127.1, 116.6, 114.1, 111.8, 108.8, 101.7, 87.2, 80.4, 52.8, 25.6, 18.3, -4.6. HRMS (E I) 
m/z calcd for C17H21NO3 Si 315.1291, found: 315.1293.
General procedure for the preparation of Zn(BH4)2
In a typical procedure, a flame dried Schlenk tube was charged with a suspension of dry ZnCl2 (5.0 
equiv compared to s.m.) and NaBH4 (5.5 equiv) in a THF/Et2O mixture (1:1, 0.5 M solution) which 
was stirred for 16 h at rt.29 The clear supernatant was used as such.
OMe
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(1£,2Ä)-2-[(teri-Butyldimethylsilyl)oxy]-1,4-diphenylbut-3-yn-1-amine (38)
To a solution of cyanohydrin 32 (1.00 g, 3.68 mmol) in dry Et2O (37 mL) was 
added dropwise PhMgBr (3.68 mL of a 3.0 M solution in diethyl ether, 3.0 
equiv) at 0 “C. After 5 min the reaction mixture was allowed to stir at rt for 2 h. 
Then dry MeOH (15 mL) was added and the reaction mixture was cooled to - 
78 “C, A  solution of freshly prepared Zn(BH4)2 (vide supra) was added dropwise in 30 min and the 
reaction mixture was stirred overnight. Then the mixture was quenched with saturated aqueous 
NaHCO3 (20 mL) and the product was extracted with EtOAc (3 x 20 mL). The organic layers were 
combined, dried (Na2SO4) and concentrated in vacuo. The crude product was purified by column 
chromatography (EtOAc/heptane, 0:1—3:7) to afford 38 (742 mg, 58% yield) as a yellow oil and as an 
inseparable mixture of diastereoisomers (1:8). Major diastereoisomer: Rf 0.34 (EtOAc/heptane, 1:3). 
[a]D0 -12.4 (c 1.71, CH2Cl2). IR  (ATR) 3031, 2957, 2922, 2850, 1666, 1593, 1493, 1359, 1251, 1091, 
836, 788, 758, 702 cm-1. 1H-NMR (CDCl3, 400 MHz) 5 7.44-7.27 (m, 10H), 4.61 (d, J  = 5.9 Hz, 1H),
4.10 (d, J  = 5.9 Hz, 1H), 1.99 (bs, 2H), 0.85 (s, 9H), 0.04 (s, 3H), -0.01 (s, 3H). 13C-NMR (CDCl3, 75 
MHz) 5 141.5 131.7, 128.5, 128.4, 128.2, 127.7, 127.6, 122.9, 88.6, 86.4, 69.9, 61.5, 29.9, 25.9, -4.6, 
-5.1. HRMS (ES I) m/z calcd for C22H30NOSi (M+H)+ 352.2097 found: 352.2086.
(1£,2Ä)-2-[(teri-Butyldimethylsilyl)oxy]-1-(4-fluorophenyl)-4-phenylbut-3-yn-1-amine (39)
F Prepared as described above starting from cyanohydrin 32 (1.00 g, 3.68 
mmol) and p-FCßH4MgBr (5.53 mL of a 2.0 M solution in diethyl ether, 3.0 
equiv). Purification by column chromatography (EtOAc/heptane, 0:1—3:7) 
afforded 39 (772 mg, 57% yield) as a yellow oil and as an inseparable 
mixture of diastereoisomers (1:7). M ajor diastereoisomer: Rf 0.19 (EtOAc/heptane, 1:3). [a]D° -8.4 (c 
0.96, CH2Cl2). IR  (ATR) 3381, 3053, 2959, 2928, 2850, 2224, 1506, 1256, 1217, 1095, 832, 776, 754, 
694 cm-1. 1H-NMR (CDCl3, 400 MHz) 5 7.43-7.28 (m, 7H), 7.05-7.00 (m, 2H), 4.56 (d, J  = 6.0 Hz),
4.08 (d, 6.0 Hz), 1.78 (bs, 2H), 0.85 (s, 9H), 0.04 (s, 3H), -0.01 (s, 3H). 13C-NMR (CDCl3, 75 MHz) 5
162.3 (d, J  = 245.3 Hz), 137.3 (d, J  = 2.3 Hz), 131.6, 129.3 (d, J  = 7.9 Hz), 128.5, 128.4, 122.7, 114.9 
(d, J  = 21.2 Hz), 88.4, 86.5, 69.7, 60.7, 25.8, 18.3, -4.6, -5.1. HRMS (ES I) m/z calcd for 
C22H29FNOSi (M+H)+ 370.2002 found: 370.1997.
(1Ä,2£)-2-[(teri-Butyldimethylsilyl)oxy]-1-(4-fluorophenyl)-4-(4-methoxyphenyl)but-3-yn-1- 
amine (42)
Prepared as described above starting from cyanohydrin 33 (417 mg,
1.38 mmol) and p-FCßH4MgBr (2.00 mL of a 2.0 M solution in diethyl 
ether, 3.0 equiv). Purification by column chromatography 
(EtOAc/heptane, 0:1— 1:1) afforded 42 (229 mg, 42% yield) as a 
yellow oil and as an inseparable mixture of diastereoisomers (1:30). 
Major diastereoisomer: Rf 0.24 (EtOAc/heptane, 1:3). [a]D0 +13.5 (c 0.29, CH2Cl2). IR  (ATR) 2954, 
2932, 2850, 2228, 1610, 1511, 1251, 1221, 1091, 828 cm-1. 1H-NMR (CDCl3, 400 MHz) 5 7.42-7.38 
(m, 2H) 7.33-7.29 (m, 2H), 7.04-7.02 (m, 2H), 6.84-6.81 (m, 2H), 4.55 (d, J  = 6.0 Hz, 1H), 4.06 (d, J  
= 5.9 Hz, 1H), 3.80 (s, 3H), 2.01 (bs, 2H), 0.85 (s, 9H), 0.04 (s, 3H), -0.01 (s, 3H). 13C-NMR (CDCl3, 
75 MHz) 5 162.4 (d, J  = 245.2 Hz), 159.8, 137.4, 133.1, 129.3 (d, J  = 7.9 Hz), 115.0, 114.9 (d, J  =
21.2 Hz), 114.1, 87.0, 86.5, 69.8, 60.8, 55.4, 25.9, 18.3, -4.58, -5.09. HRM S (ES I) m/z calcd for 
C23H31FNO2Si (M+H)+ 400.2108 found: 400.2100.
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(1.R,2£)-2-[(teri-ButyMimethylsnyl)oxy]-4-(3-methoxyphenyl)-1-phenylbut-3-yn-1-amme (46)
Prepared as described above starting from cyanohydrin 34 (305 mg, 1.01 
mmol) and PhMgBr (1.01 mL of a 3.0 M solution in diethyl ether, 3.0 equiv). 
Purification by column chromatography (EtOAc/heptane, 0:1— 1:3) afforded
46 (204 mg, 53% yield) as a yellow oil and as an inseparable mixture of 
OMe diastereoisomers (1:6). Major diastereoisomer: Rf 0.26 (EtOAc/heptane, 1:3).
[a]D0 +9.2 (c 0.72, CH2Q 2). IR  (ATR) 2950, 2924, 2855, 1606, 1489, 1286, 1247, 1091, 841, 780, 612 
cm-1. 1H NM R (CDCl3, 400 MHz): 5 7.44-7.41 (m, 2H), 7.36-7.32 (m, 2H), 7.29-7.26 (m, 1H), 7.23­
7.18 (m, 1H), 6.99-6.96 (m, 1H), 6.92-6.83 (m, 2H), 4.60 (d, J  = 6.0 Hz, 1H), 4.09 (d, J  = 6.0 Hz, 1H), 
3.79 (s, 3H), 1.77 (bs, 2H), 0.85 (s, 9H), 0.04 (s, 3H), -0.01 (s, 3H). 13C NM R (CDCl3, 75 MHz): 5
159.4, 141.6, 129.5, 128.2, 127.8, 127.6, 124.2, 123.9, 116.7, 114.9, 88.5, 86.3, 69.9, 61.5, 55.4, 25.9,
18.4, -4.6, -5.1. HRMS (ES I) m/z calcd for C23H32NO2Si (M+H)+ 382.2202 found: 382.2193.
(1^,2^')-2-[(ieri-Butyldimethylsilyl)oxy]-1-(4-fluorophenyl)-4-(3-methoxyphenyl)but-3-yn-1- 
amine (47)
Prepared as described above starting from cyanohydrin 34 (654 mg, 2.17 
mmol) and p-FC6H4MgBr (3.25 mL of a 2.0 M solution in diethyl ether, 3.0 
equiv). Purification by column chromatography (EtOAc/heptane, 0:1— 1:1) 
afforded 47 (635 mg, 73% yield) as a yellow oil and as an inseparable 
mixture of diastereoisomers (1:7). Major diastereoisomer: Rf 0.17 
(EtOAc/heptane, 1:3). [a]D0 +15.4 (c 0.20, CH2Cl2). IR  (ATR) 2963, 2924, 2855, 1601, 1511, 1092, 
841, 780, 685 cm-1. ’H-NMR (CDCl3, 400 MHz) 5 7.42-7.37 (m, 2H), 7.23-7.19 (m, 1H), 7.05-7.00 
(m, 2H), 6.99-6.96 (m, 1H), 6.90-6.86 (m, 2H), 4.55 (d, J  = 6.0, 1H), 4.08 (d, J  = 6.0, 1H), 3.79 (s, 
3H), 1.80 (bs, 2H), 0.85 (s, 9H), 0.04 (s, 3H), -0.01 (s, 3H). 13C-NMR (CDCl3, 75 MHz) 5 162.4 (d, J  
= 245.2 Hz), 159.4, 137.4, 129.5, 129.3 (d, J  = 7.9 Hz), 124.2, 123.8, 116.8, 115.0 (d, J  = 21.1 Hz),
114.9, 88.3, 86.4, 69.7, 60.8, 55.4, 25.9, 18.3, -4.6, -5.1. HRMS (ES I) m/z calcd for C23H31FNO2Si 
(M+H)+ 400.2108 found: 400.2095.
(1^,2^')-2-[(ieri-Butyldimethylsilyl)oxy]-1-(4-chlorophenyl)-4-(3-methoxyphenyl)but-3-yn-1- 
amine (49)
Cl Prepared as described above starting from cyanohydrin 34 (398 mg, 1.32 
mmol) and p-ClCeH4MgBr (3.96 mL of a 1.0 M solution in diethyl ether,
3.0 equiv). Purification by column chromatography (EtOAc/heptane, 
0:1— 1:3) afforded 49 (362 mg, 66%  yield) as a yellow oil and as an 
inseparable mixture of diastereoisomers (1:6). M ajor diastereoisomer: Rf 
0.56 (EtOAc/heptane, 1:3). [a]D0 +16.1 (c 0.38, CH2CL2). IR  (ATR) 2950, 
2924, 2855, 1606, 1489, 1286, 1247, 1091, 841, 780, 612 cm-1. !H NM R (CDCl3, 400 MHz): 5 7.39­
7.30 (m, 4H), 7.24-7.18 (m, 1H), 6.98-6.95 (m, 1H), 6.92-6.85 (m, 2H), 4.57 (d, J  = 5.8 Hz, 1H), 4.07 
(d, J  = 5.8 Hz, 1H), 3.79 (s, 3H), 1.77 (bs, 2H), 0.85 (s, 9H), 0.04 (s, 3H), -0.01 (s, 3H). 13C NM R 
(CDCl3, 75 MHz): 5 159.4, 140.1, 133.3, 129.5, 129.2, 128.3, 124.2, 123.7, 116.7, 115.0, 88.1, 86.5,
69.6, 60.8, 55.4, 25.9, 18.3, -4.6, -5.1. HRMS (ES I) m/z calcd for C23H31ClNO2Si (M+H)+ 416.1813 
found: 416.1803.
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(1.R,2lS)-2-[(tert-Butyldimethylsnyl)oxy]-1-(4-chlorophenyl)-4-(4-fluorophenyl)but-3-yn-1-amme
(50)
Cl Prepared as described above starting from cyanohydrin 35 (159 mg, 
0.549 mmol) and p-ClCeH4MgBr (1.65 mL of a 1.0 M solution in diethyl 
ether, 3.0 equiv). Purification by column chromatography 
(EtOAc/heptane, 0:1—3:2) afforded 50 (123 mg, 56%) as a yellow oil 
and as an inseparable mixture of diastereoisomers (1:5). Major 
diastereoisomer: Rf 0.22 (EtOAc/heptane, 1:3). [a]D0 +12.5 (c 0.24, CH2Q 2). IR  (ATR) 2950, 2924, 
2855, 1601, 1502, 1226, 1100, 837, 780 cm-1. 1H-NMR (CDCl3, 400 MHz) 5 7.38-7.28 (m, 6H), 7.02­
6.96 (m, 2H), 4.56 (d, J  = 5.8 Hz, 1H), 4.07 (d, J  = 5.8 Hz, 1H), 1.81 (bs, 2H), 0.86 (s, 9H), 0.04 (s, 
3H), -0.01 (s, 3H). 13C-NMR (CDCl3, 75 MHz) 5 162.7 (d, J  = 249.8 Hz), 140.1, 133.6, (d, J  = 8.4 
Hz), 133.3, 129.2, 129.1, 128.3, 115.8 (d, J  = 22.1 Hz), 88.0, 85.5, 69.5, 60.8, 25.9, 18.3, -4.6, -5.1. 
HRMS (ES I) m/z calcd for C22H28ClFNOSi (M+H)+ 404.1613 found: 404.1607.
(1.R,2£)-2-[(tert-ButyMimethylsnyl)oxy]-4-(3,4-methylenedioxyphenyl)-1-phenylbut-3-yn-1-amme
(51)
Prepared as described above starting from cyanohydrin 36 (201 mg, 0.637 
mmol) and PhMgBr (0.63 mL of a 3.0 M solution in diethyl ether, 3.0 
equiv). Purification by column chromatography (EtOAc/heptane, 0:1— 1:3) 
afforded 51 (173 mg, 69% yield) as a yellow oil and as an inseparable 
mixture of diastereoisomers (1:7). Major diastereoisomer: Rf 0.24 (EtOAc/heptane, 1:3). [a]D0 +11.2 
(c 0.13, CH2Cl2). IR  (ATR) 3067, 2954, 2933, 2850, 2220, 1489, 1247, 1213, 1092, 1035, 832, 780, 
698 cm-1. 1H-NMR (CDCl3, 400 MHz) 5 7.43-7.40 (m, 2H), 7.35-7.31 (m, 2H), 7.29-7.26 (m, 1H),
6.90 (dd, J  = 1.6 Hz, 8.0 Hz, 1H), 6.81 (d, J  = 1.6 Hz, 1H), 6.73 (d, J  = 8.0 Hz, 1H), 5.96 (s, 2H), 4.58 
(d, J  = 5.9 Hz, 1H), 4.07 (d, J  = 5.9 Hz, 1H), 1.83 (bs, 2H), 0.85 (s, 9H), 0.04 (s, 3H), -0.01 (s, 3H). 
13C-NMR (CDCl3, 75 MHz) 5 148.1, 147.5, 141.6, 128.2, 127.7, 127.6, 126.3, 116.2, 111.7, 108.5,
101.4, 86.9, 86.2, 69.9, 61.4, 25.9, 18.4, -4.6, -5.1. HRMS (ES I) m/z calcd for C23^ N O 3Si (M+H)+ 
396.1995 found: 396.1987.
tert-Butyl {(1S,2.R)-2-[(tert-butyMimethylsnyl)oxy]-1,4-diphenylbut-3-ynyl}carbamate (52)
To a solution of amino alcohol 38 (400 mg, 1.14 mmol) in dioxane/H2O (1:1,
11 mL) were added NaHCO3 (134 mg, 1.2 equiv) and (Boc)2O (348 mg, 1.2 
equiv) and the reaction mixture was stirred for 2 h at rt. After evaporation of 
dioxane, EtOAc (20 mL) was added. The aqueous layer was extracted with 
EtOAc (3 x 20 mL) and the organic layers were combined, dried (Na2SO4), filtered and concentrated 
in vacuo. The product was purified by column chromatography (EtOAc/heptane, 0:1— 1:4) to afford
52 (374 mg, 73% yield) as a white solid and as an inseparable mixture of diastereoisomers (1:17). 
Major diastereoisomer: Rf 0.65 (EtOAc/heptane, 1:3). Mp 116.2 °C. [a]D0 -27.4 (c 0.59, CH2Cl2). IR  
(ATR) 3434, 3351, 2954, 2928, 2850, 2358, 1718, 1493, 1359, 1247, 1169, , 1100, 836, 776, 754, 698 
cm-1. 1H-NMR (CDCl3, 400 MHz) 5 7.41-7.39 (m, 2H), 7.35-7.24 (m, 8H), 5.37-5.32 (m, 1H), 4.92­
4.87 (m, 2H), 1.43 (s, 9H), 0.92 (s, 9H), 0.13 (s, 6H). 13C-NMR (CDCl3, 75 MHz) 5 155.5, 138.8,
131.6, 128.6, 128.4, 128.1, 128.0, 127.7, 122.6, 87.4, 87.1, 79.7, 67.0, 59.8, 28.5, 25.9, 18.4, -4.4, -
4.9. HRM S (ES I) m/z calcd for C27H38NO3Si (M+H)+ 452.2621, found: 452.2613.
82
Enantioselective Chemoenzymatic Synthesis o f 4-Hydroxy-2-pyrrolines
tert-Butyl {(1£,2.R)-2-[(tert-butyldimethylsHyl)oxy]-1-(4-fluorophenyl)-4-phenylbut-3-ynyl}carba- 
mate (53)
F Prepared as described above starting from amino alcohol 39 (400 mg, 1.08 
mmol). Purification by column chromatography (EtOAc/heptane, 0:1— 1:4) 
afforded 53 (367 mg, 72% yield) as a yellow solid and as an inseparable 
mixture of diastereoisomers (1:10). Major diastereoisomer: Rf 0.62 
(EtOAc/heptane, 1:3). Mp 112.4 °C. [a]D -28.8 (c 0.99, CH2Q 2). IR  (ATR) 2959, 2924, 2855, 1710, 
1511, 1485, 1256, 1221, 1161, 1100, 837 cm-1. 1H-NMR (CDCl3, 400 MHz) 5 7.39-7.27 (m, 7H), 
7.05-6.99 (m, 2H), 5.34-5.29 (m, 1H), 4.88-4.85 (m, 2H), 1.43 (s, 9H), 0.92 (s, 9H), 0.14 (s, 3H), 0.13 
(s, 3H). 13C-NMR (CDCl3, 75 MHz) 5 162.4 (d, J  = 245.3 Hz), 155.3, 134.6, 131.6, 129.6 (d, J  = 8.0 
Hz), 128.7, 128.4, 122.5, 114.9 (d, J  = 21.4 Hz), 87.2, 79.9, 66.8, 59.2, 53.6, 28.5, 25.9, 18.4, -4.4, -
4.9. HRM S (ES I) m/z calcd for C27H37 FNO3Si (M+H)+ 470.2527, found: 470.2520.
tert-Butyl {(1.R,25’)-2-[(tert-butyldimethylsilyl)oxy]-1-(4-fluorophenyl)-4-(4-methoxyphenyl)but-
Prepared as described above starting from amino alcohol 42 (210 mg, 
0.526 mmol). Purification by column chromatography (EtOAc/heptane, 
0:1— 1:4) afforded 56 (184 mg, 70%) as a white solid and as an 
inseparable mixture of diastereoisomers (1:60). M ajor diastereoisomer: 
Rf 0.59 (EtOAc/heptane, 1:3). [a]D0 +36.6 (c 0.75, CH2Cl2). IR  (ATR) 
3438, 3335, 2963, 2924, 2850, 2232, 1722, 1511, 1251, 1165, 1091, 828, 776 cm-1. :H-NMR (CDCl3, 
400 MHz) 5 7.38-7.35 (m, 2H), 7.23-7.21 (m, 2H), 7.03-6.99 (m, 2H), 6.83-6.80 (m, 2H), 5.33-5.31 
(m, 1H), 4.87-4.82 (m, 2H), 3.80 (s, 3H), 1.42 (s, 9H), 0.92 (s, 9H), 0.13 (s, 3H), 0.12 (s, 3H). 13C- 
NM R (CDCl3, 75 MHz) 5 164.0, 162.0 (d, J  = 309.2 Hz), 155.4, 133.1, 132.4, 129.6 (d, J  = 8.1 Hz),
119.7, 114.9 (d, J  = 21.1 Hz), 114.1, 87.4, 85.8, 79.9, 66.9, 59.2, 55.5, 28.5, 26.0, 18.4, -4.3, -4.9. 
HRMS (ES I) m/z calcd for C28H39 FNO4Si (M+H)+ 500.2632, found: 500.2937.
tert-Butyl {(1.R,2£)-2-[(tert-butyldimethylsnyl)oxy]-4-(3-methoxyphenyl)-1-phenylbut-3-yn-1-yl}- 
carbamate (60)
Prepared as described above starting from amino alcohol 46 (200 mg, 0.524 
mmol). Purification by column chromatography (EtOAc/heptane, 0:1— 1:3) 
afforded 60 (189 mg, 75% yield) as a yellow solid and as an inseparable 
mixture of diastereoisomers (1:6). Major diastereoisomer: Rf 0.56 
OMe (EtOAc/heptane, 1:3). Mp 64.5 °C. [a]D0 +27.3 (c 0.62, CH2Cl2). IR  (ATR)
2954, 2921, 2859, 2232, 1714, 1489, 1286, 1160, 1087, 910, 845, 776, 741 cm-1. !H NM R (CDCl3, 
400 MHz): 5 7.36-7.28 (m, 5H), 7.22-7.17 (m, 1H), 6.91-6.85 (m, 2H), 6.80-6.78 (m, 1H), 5.36-5.29 
(m, 1H), 4.87-4.84 (m, 2H), 3.78 (s, 3H), 1.42 (s, 9H), 0.92 (s, 9H), 0.14 (s, 3H), 0.13 (s, 3H). 13C 
NM R (CDCl3, 75 MHz): 5 159.4, 155.3, 133.5, 129.5, 129.5, 128.7, 128.2, 124.1, 123.4, 116.7, 115.1,
86.9, 80.0, 66.6, 59.2, 55.4, 28.5, 25.9, 18.4, -4.4, -4.9. HRMS (ES I) m/z calcd for C28H40NO4Si 
(M+H)+ 482.2727 found: 482.2726.
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tert-Butyl {(1.R,2£)-2-[(tert-butyldimethylsnyl)oxy]-1-(4-fluorophenyl)-4-(3-methoxyphenyl)but- 
3-ynyl}carbamate (61)
F Prepared as described above starting from amino alcohol 47 (595 mg, 1.49 
mmol). Purification by column chromatography (EtOAc/heptane, 0:1— 1:4) 
afforded 61 (597 mg, 80% yield) as a yellow solid and as an inseparable 
mixture of diastereoisomers (1:12). Major diastereoisomer: Rf 0.60 
OMe (EtOAc/heptane, 1:3). [a]D0 +27.1 (c 0.28, CH2Q 2). IR  (ATR) 3451, 3334,
2954, 2928, 2854, 1718, 1506, 1489, 1298, 1225, 1164, 841, 780 cm-1. 1H-NMR (CDCl3, 400 MHz) 5 
7.39-7.35 (m, 2H), 7.21-7.17 (m, 1H), 7.04-6.99 (m, 2H), 6.89-6.85 (m, 2H), 6.80-6.79 (m, 1H), 5.35­
5.30 (m, 1H), 4.89-4.83 (m, 2H), 3.78 (s, 3H), 1.42 (s, 9H), 0.92 (s, 9H), 0.14 (s, 3H), 0.13 (s, 3H). 
13C-NMR (CDCl3, 75 MHz) 5 162.5 (d, J  = 245.4 Hz), 159.4, 155.4, 137.2, 129.7 (d, J  = 8.1 Hz),
129.5, 128.7, 124.1, 123.5, 116.7, 115.0, 114.9 (d, J  = 20.3 Hz), 87.3, 87.1, 80.0, 66.7, 59.1, 55.4,
28.5, 25.9, 18.4, -4.4, -4.9. HRMS (ES I) m/z calcd for C28H39FNO4Si (M+H)+ 500.2632, found: 
500.2633.
tert-Butyl {(1.R,2£)-2-[(tert-butyldimethylsnyl)oxy]-1-(4-chlorophenyl)-4-(3-methoxyphenyl)but-
3-yn-1-yl}carbamate (63)
ci Prepared as described above starting from amino alcohol 49 (201 mg, 0.484 
mmol). Purification by column chromatography (EtOAc/heptane, 0:1— 1:3) 
afforded 63 (212 mg, 85% yield) as a yellow solid and as an inseparable 
mixture of diastereoisomers (1:7). Major diastereoisomer: Rf 0.49 
(EtOAc/heptane, 1:3). Mp 88.9 °C. [a]D0 +28.0 (c 0.69, CH2Cl2). IR  (ATR) 
3443, 3330, 2954, 2937, 2859, 1720, 1485, 1282, 1251, 1174, 1091, 1044, 
836, 776, 681, 612 cm-1. 1H NM R (CDCl3, 400 MHz): 5 7.35-7.29 (m, 4H), 7.21-7.17 (m, 1H), 6.90­
6.85 (m, 2H), 6.79-6.78 (m, 1H), 5.34-5.30 (m, 1H), 4.88-4.84 (m,2H), 3.78 (s, 3H), 1.42 (s, 9H), 0.92 
(s, 9H), 0.14 (s, 3H), 0.13 (s, 3H). 13C NM R (CDCl3, 75 MHz): 5 159.4, 155.3, 133.5, 129.6, 129.5,
128.7, 128.2, 124.1, 123.4, 116.7, 115.1, 87.4, 86.9, 80.0, 66.6, 59.2, 55.4, 28.5, 25.9, 18.4, -4.4, -4.9. 
HRMS (ES I) m/z calcd for C28H39ClNO4Si (M+H)+ 516.2337 found: 516.2334.
tert-Butyl {(1.R,2£)-2-[(tert-butyldimethylsnyl)oxy]-1-(4-chlorophenyl)-4-(4-fluorophenyl)but-3- 
ynyl}carbamate (64)
Cl Prepared as described above starting from amino alcohol 50 (111 mg, 
0.275 mmol). Purification by column chromatography (EtOAc/heptane, 
0:1— 1:4) afforded 64 (109 mg, 79% yield) as a yellow solid and as an 
inseparable mixture of diastereoisomers (1:5). Major diastereoisomer: Rf 
0.66 (EtOAc/heptane, 1:3). Mp 108.3 °C. [a]D0 +20.5 (c 1.29, CH2Cl2). 
IR  (ATR) 3438, 3339, 2954, 2929, 2859, 1714, 1506, 1251, 1234, 1165, 1087, 837, 780 cm-1. !H- 
NM R (CDCl3, 400 MHz) 5 7.39-7.24 (m, 6H), 7.03-6.95 (m, 2H), 5.49-5.25 (m, 1H), 4.84-4.71 (m, 
2H), 1.43 (s, 9H), 0.92 (s, 9H), 0.14, (s, 3H), 0.13 (s, 3H). 13C-NMR (CDCl3, 75 MHz) 5 162.8 (d, J  = 
250.0 Hz), 155.3, 137.3, 133.5 (d, J  = 8.4 Hz), 129.4, 128.7, 128.2, 118.5, 115.8 (d, J  = 22.1 Hz),
86.8, 86.3, 80.0, 66.6, 59.2, 28.5, 25.9, 18.4, -4.4, -4.9. HRMS (ES I) m/z calcd for C27H36ClFNO3Si 
(M+H)+ 504.2137, found: 504.2148.
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tert-Butyl {(1.R,2£)-2-[(tert-butyldimethylsnyl)oxy]-4-(3,4-methylenedioxyphenyl)-1-phenylbut-3- 
ynyl}carbamate (65)
Prepared as described above starting from amino alcohol 51 (146 mg, 0.369 
mmol). Purification by column chromatography (EtOAc/heptane, 0:1— 1:4) 
afforded 65 (135 mg, 74% yield) as a colorless oil and as an inseparable 
mixture of diastereoisomers (1:8). Major diastereoisomer: Rf 0.60 
(EtOAc/heptane, 1:3). [a]D0 +28.9 (c 0.27, CH2Q 2). IR  (ATR) 3434, 2954, 2928, 2855, 2358, 2220, 
1723, 1489, 1247, 1161, 1087, 1039, 841, 776, 698 cm-1. 1H-NMR (CDCl3, 400 MHz) 5 7.40-7.38 (m, 
2H), 7.34-7.30 (m, 2H), 7.28-7.24 (m, 1H), 6.84-6.80 (m, 1H), 6.74-6.69 (s, 2H), 5.92 (s, 2H), 5.36­
5.35 (m, 1H), 4.88-4.84 (m, 2H), 1.42 (s, 9H), 0.92 (s, 9H), 0.12 (s, 6H). 13C-NMR (CDCl3, 75 MHz) 
5 155.4, 148.1, 147.5, 138.8, 128.1, 128.0, 127.7, 126.3, 115.9, 111.6, 108.5, 101.4, 87.0, 85.7, 79.7, 
67.0, 59.8, 28.5, 25.9, 18.4, -4.4, -4.9. HRMS (ES I) m/z calcd for C28H38NO5Si (M+H)+ 496.2519, 
found: 496.2530.
tert-Butyl 2,5-diphenyl-1.ff-pyrrole-1-carboxylate (69)
To a solution of carbamate 52 (50 mg, 0.11 mmol) in dry THF (2.0 mL) was 
added NaAuCl4-2H2O (4.4 mg, 0.1 equiv) at rt. The reaction temperature was 
increased to 50 °C  and the mixture was stirred for 2h. After cooling to rt, the 
solvent was removed in vacuo. Purification by column chromatography (EtOAc/heptane, 0:1— 1:3) 
afforded 69 (34 mg, 97% yield) as an off-white solid. Rf 0.88 (EtOAc/heptane, 1:3). :H NM R (CDCl3, 
400 MHz): 5 7.41-7.29 (m, 10H), 6.26 (s, 2H), 1.17 (s, 9H). 13C NM R (CDCl3, 75 MHz): 5. 150.0,
136.4, 134.3, 129.0, 128.0, 127.3, 112.3, 84.1, 27.2. Data in agreement with literature.30
(4.R,5£)-N-tert-Butoxycarbonyl-2,5-diphenyl-4-hydroxy-2-pyrrolme (71)
__»oh To a solution of carbamate 52 (50.0 mg, 0.11 mmol) in dry THF (2 mL) was
added dropwise TBAF (110 ^L, 1.1 equiv) at 0 °C. The reaction mixture was
N \  #  allowed to reach rt and the mixture was stirred for 1h. The reaction mixture was Boc
quenched with saturated aqueous NH4Cl (10 mL) and diluted with CH2Cl2 (10 
mL) and the product was extracted from the aqueous layer using CH2Cl2 (3 x 10 mL). The organic 
layers were combined, dried (Na2SO4) and concentrated in vacuo. The resulting colorless oil was 
dissolved in dry THF (2 mL) and NaAuCl4-2H2O (4.4 mg, 0.1 equiv) was added at rt. The reaction 
temperature was increased to 50 °C  and the mixture was stirred for 6h. After cooling to rt, Et3N (10 
^L, 5.0 equiv) was added and the solvent was removed in vacuo. The crude product was purified by 
column chromatography (EtOAc/heptanes/1 v/v %  Et3N, 0:1— 1:3) to afford 71 (34 mg, 92% yield) as 
a yellowish oil. Rf 0.17 (EtOAc/heptanes/1 v/v %  Et3N, 1:3). [a]D0 +22.4 (c 0.71, CH2Q 2). IR  (ATR) 
3408, 2980, 2924, 1698, 1636, 1367, 1166, 1018, 752, 697 cm-1. !H NM R (CDCl3, 400 MHz): 5 7.52­
7.48 (m, 2H), 7.42-7.36 (m, 7H), 7.32-7.26 (m, 1H), 5.34 (dd, J  = 0.4, 3.3 Hz, 1H), 5.10 (d, J  = 1.2 Hz, 
1H), 4.35 (dd, J  = 1.2, 3.3 Hz, 1H), 1.15 (s, 9H). 13C NM R (CDCl3, 75 MHz): 5 154.4, 149.6, 142.5,
135.3, 129.8, 129.5, 128.9, 128.5, 126.3, 112.2, 82.1, 79.5, 74.2, 60.2, 28.1. HRMS (ES I) m/z calcd for 
C21H24NO3 (M+H)+: 338.1756, found: 338.1769.
(4.R,5£)-N-tert-Butoxycarbonyl-5-(4-fluorophenyl)-4-hydroxy-2-phenyl-2-pyrrolme (75)
*oh Prepared as described above starting from carbamate 52 (14 mg, 0.03 mmol).
< ^ Purification by column chromatography (EtOAc/heptanes/1 v/v %  Et3N,
N " 'L F 0:1— 1:3) afforded 75 (9.0 mg, 88%  yield) as a yellowish oil. Rf 0.16Boc
(EtOAc/heptanes/1 v/v %  EtsN, 1:3). [a]D0 +37.6 (c 0.62, CH2Q 2). IR  (ATR)
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3376, 2980, 1631, 1339, 1143, 702 cm-1. 'H  NM R (CDCl3, 400 MHz): 5 7.50-7.47 (m, 2H), 7.42-7.36 
(m, 5H), 7.14-7.08 (m, 2H), 5.35 (dd, J  = 0.4, 3.3 Hz, 1H), 5.08 (bs, 1H), 4.34 (dd, J  = 1.2, 3.3 Hz, 
1H),1.15 (s, 9H). 13C NM R (CDCI3, 75 MHz): 5 HRMS 161.6 (d, J  = 243.1 Hz), 154.4, 149.5, 138.6,
135.3, 129.5, 128.9, 128.5, 128.3 (d, J  = 8.1 Hz), 116.5 (d, J  = 21.8 Hz), 112.2, 82.2, 79.4, 73.6, 28.1. 
(ES I) m/z calcd for C21H23FNO3 (M+H)+: 356.1662, found: 356.1670.
(4£,5^)-N-teri-Butoxycarbonyl-5-(4-fluorophenyl)-4-hydroxy-2-(4-methoxyphenyl)-2-pyrrolme
(76)
Prepared as described above starting from carbamate 56 (20 mg, 0.04 
mmol). Purification by column chromatography (EtOAc/heptanes/1 v/v 
f %  Et3N, 0:1 —>1:3) afforded 76 (14 mg, 92% yield) as a yellowish oil. R/ 
0.19 (EtOAc/heptanes/1 v/v %  Et3N, 1:3). [a]D° -57.4 (c 0.73, CH2Q 2). 
IR  (ATR) 3384, 2976, 2928, 2855, 1693, 1671, 1634, 1607, 1508, 1367, 1343, 1249, 1175, 1156, 
1031, 833 cm-1. 1H NM R (CDCl3, 400 MHz): 5 7.44-7.41 (m, 2H), 7.39-7.35 (m, 2H), 7.13-7.08 (m, 
2H), 6.97-6.93 (m, 2H), 5.28 (d, J  = 3.3 Hz, 1H), 5.08 (bs, 1H), 4.30 (dd, J  = 1.1, 3.3 Hz, 1H), 3.83 (s, 
3H), 1.19 (s, 9H). 13C NM R (CDCl3, 75 MHz): 5 163.5 (d, J  = 244,1 Hz), 161.5, 154.4, 149.3, 138.6,
129.8, 128.2 (d, J  = 8.1 Hz), 127.5, 116.4 (d, J  = 21.8 Hz), 114.3, 111.0, 82.1, 79.3, 73.7, 55.8, 28.2. 
HRMS (ES I) m/z calcd for C22H25FNO4 (M+H)+: 386.1768, found: 368.1756.
(4£,5^)-N-teri-Butoxycarbonyl-4-hydroxy-2-(3-methoxyphenyl)-5-phenyl-2-pyrrolme (77)
Prepared as described above starting from carbamate 60 (22 mg, 0.05 mmol). 
Purification by column chromatography (EtOAc/heptanes/1 v/v %  Et3N, 
0:1— 1:3) afforded 77 (16 mg, 95% yield) as a yellowish oil. R/ 0.16 
(EtOAc/heptanes/1 v/v %  EtsN, 1:3). [a]D0 -42.5 (c 0.71, CH2Q 2). IR  (ATR) 
3385, 2971, 2924, 1670, 1633, 1335, 1143, 1101, 697 cm-1. 1H NM R (CDCl3, 
400 MHz): 5 7.40-7.26 (m, 6H), 7.10-7.07 (m, 1H), 7.03-7.02 (m, 1H), 6.96-6.93 (m, 1H), 5.36 (d, J  =
3.3 Hz, 1H), 5.10-5.09 (m, 1H), 4.34 (dd, J  = 1.2, 3.3 Hz, 1H), 3.83 (s, 3H), 1.16 (s, 9H). 13C NM R 
(CDCl3, 75 MHz): 5 160.8, 154.3, 149.4, 142.5, 136.6, 130.0, 129.8, 128.5, 126.3, 121.0, 114.8, 114.4,
112.3, 82.1, 79.5, 74.2, 55.8, 28.1. HRM S (ES I) m/z calcd for C22H26NO4 (M+H)+: 368.1862, found: 
368.1840.
(4£,5^)-N-teri-Butoxycarbonyl-5-(4-fluorophenyl)-4-hydroxy-2-(3-methoxyphenyl)-2-pyrrolme
(78)
¿pH Prepared as described above starting from carbamate 61 (18 mg, 0.04
mmol). Purification by column chromatography (EtOAc/heptanes/1 v/v %  
F Et3N, 0:1— 1:3) afforded 78 (12 mg, 89% yield) as a yellowish oil. R/ 0.17 
(EtOAc/heptanes/1 v/v %  Et3N, 1:3). [a]D0 -61.1 (c 0.67, CH2Q 2). IR  
(ATR) 3380, 2971, 2924, 1635, 1336, 1223, 1100, 619 cm-1. 1H NM R 
(CDCl3, 400 MHz): 5 7.41-7.35 (m, 2H), 7.33-7.29 (m, 1H), 7.15-7.10 (m, 2H), 7.09-7.06 (m, 1H),
7.02-7.01 (m, 1H), 6.96-6.93 (m, 1H), 5.37-5.36 (m, 1H), 5.07 (bs, 1H), 4.32 (dd, J  = 1.2, 3.3 Hz, 1H), 
3.83 (s, 3H), 1.17 (s, 9H). 13C NM R (CDCl3, 75 MHz): 5 162.0 (d, J  = 242.1 Hz), 160.8, 154.3, 149.3,
138.5, 136.5, 130.0, 128.3 (d, J  = 8.1 Hz), 121.0, 116.5 (d, J  = 21.8 Hz), 114.8, 114.4, 112.2, 82.2,
79.4, 73.6, 55.8, 28.1. HRMS (ES I) m/z calcd for C22H25FNO4 (M+H)+: 386.1768, found: 386.1761.
MeP
MeP
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Cl
(4£,5^)-N-teri-Butoxycarbonyl-5-(4-chlorophenyl)-4-hydroxy-2-(3-methoxyphenyl)-2-pyrrolme
(79)
Prepared as described above starting from carbamate 63 (21 mg, 0.04 
mmol). Purification by column chromatography (EtOAc/heptanes/1 v/v %  
Et3N, 0:1—>1:3) afforded 79 (15 mg, 90% yield) as a yellowish oil. Rf 0.18 
MeO (EtOAc/heptanes/1 v/v %  Et3N, 1:3). [a]D0 -32.8 (c 0.89, C ^C ^ ). IR
0 (ATR) 3406, 2967, 2928, 1696, 1638, 1601, 1579, 1490, 1366, 1348, 1165,
1145, 1014, 804, 779 cm-1. 'H  NM R (CDCl3, 400 MHz): 5 7.41-7.29 (m, 5H), 7.09-7.06 (m, 1H),
7.02-7.01 (m, 1H), 6.96-6.93 (m, 1H), 5.36 (d, J  = 3.3 Hz, 1H), 5.07 (bs, 1H), 4.33 (dd, J  = 1.2, 3.3 
Hz, 1H), 3.83 (s, 3H), 1.17 (s, 9H). 13C NM R (CDCl3, 75 MHz): 5 160.8, 154.3, 149.3, 141.3, 136.4,
134.2, 130.0, 129.9, 128.1, 121.0, 114.8, 114.5, 112.2, 82.3, 79.3, 73.6, 55.8, 28.1. HRM S (ES I) m/z 
calcd for C22H24ClNO4Na (M+Na)+: 424.1292, found: 424.1310.
(4£,5^)-N-teri-Butoxycarbonyl-5-(4-chlorophenyl)-2-(4-fluorophenyl)-4-hydroxy-2-pyrrolme
(80)
Prepared as described above starting from carbamate 64 (25 mg, 0.05 
mmol). Purification by column chromatography (EtOAc/heptane/Et3N (1 
v/v % , 0:1— 1:3) afforded 80 (18 mg, 91% yield) as a yellowish oil. Rf 
0.18 (EtOAc/heptanes/1  v/v %  EtsN, 1:3). [a]D° -47.5 (c 0.63, CH2Q 2). 
IR  (ATR) 3378, 2980, 2928, 2855, 2488, 2073, 1748, 1698, 1493, 1367, 1144, 1118,974, 837, 793 
cm-1. !H NM R (CDCl3, 400 MHz): 5 7.54-7.49 (m, 2H), 7.41-7.34 (m, 4H), 7.16-7.11 (m, 2H), 5.35 
(d, J  = 3.3 Hz, 1H), 5.08 (d, J  = 0.4 Hz, 1H), 4.33 (dd, J  = 1.3, 3.3 Hz, 1H), 1.19 (s, 9H). 13C NM R 
(CDCl3, 75 MHz): 5 164.3 (d, J  = 246.5 Hz), 154.2, 148.3, 141.3, 134.2, 131.4, 130.6 (d, J  = 8.1 Hz),
129.9, 128.1, 115.7, (d, J  = 22.1 Hz), 112.4, 82.4, 79.5, 73.7, 28.1. HRMS (ES I) m/z calcd for 
C21H22ClFNO3 (M+H)+: 390.1272, found: 390.1271.
OH
Cl
rOH
(4£,5^)-N-teri-Butoxycarbonyl-4-hydroxy-2-(3,4-methylenedioxyphenyl)-5-phenyl-2-pyrrolme
(81)
Prepared as described above starting from carbamate 65 (21 mg, 0.04 mmol). 
Purification by column chromatography (EtOAc/heptanes/1 v/v %  Et3N, 
0:1— 1:3) afforded 81 (15 mg, 93% yield) as a yellowish oil. Rf 0.19 
(EtOAc/heptanes/1 v/v %  Et3N, 1:3). [a]D° -52.6 (c 0.82, CH2Q 2). IR  (ATR) 
3403, 2971, 2932, 2850, 1666, 1633, 1489, 1336, 1101 cm-1. 1H NM R (CDCl3, 400 MHz): 5 7.41-7.26 
(m, 5H), 7.02 (dd, J  1.7, 8.0, 1H), 6.96-6.95 (m, 1H), 6.86-6.84 (m, 1H), 5.98 (s, 2H), 5.29 (dd, J  = 
0.4, 3.3 Hz, 1H), 5.08 (bs, 1H), 4.32 (dd, J  = 1.2, 3.3 Hz, 1H), 1.21 (s, 9H). 13C NM R (CDCl3, 75 
MHz): 5 149.4, 149.2, 148.7, 142.5, 129.8, 129.6, 129.1, 128.5, 126.3, 122.4, 111.6, 109.1, 108.7,
102.6, 82.1, 79.4, 74.3, 28.2. HRMS (ESI) m/z calcd for C22H23NO5N  (M+Na)+: 404.1474, found: 
404.1472.
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Chapter 4 
Towards an Asymmetric Synthesis of 
an Antitumor Tylophora Alkaloid
i +
TMS
N H
Boc OH
OMe OMe
H
For many years, natural products have served as an inspiration for organic chemists for the 
development of new synthetic methodologies in organic chemistry.1 Moreover, natural 
products are a rich source of compounds displaying interesting bioactivity, which often 
renders them relevant leads for drug development. In  this chapter three approaches toward a 
potential antitumor phenanthrene-based alkaloid are described making use of the chemistry 
developed in previous chapters.
Chapter 4
4.1 Introduction
Phenanthroindolizidine and phenanthroquinolizidine alkaloids represent a group of 
pentacyclic natural products isolated mainly from the Cynanchum, P ergularia , and Tylophora  
species.2 The leaves of these plants have been used since ancient times for the treatment of 
various ailments of the respiratory tract such as i.e. asthma, bronchitis, and rheumatism. 
Current research supports this traditional use, demonstrating that extracts from these plants 
have health benefits including anti-inflammatory, anti-histaminic, and immunomodulatory 
effects.3 Most promising, however, is the remarkable cytotoxic activity of many compounds 
of this class with IC 50 values in the low nanomolar range.4 Consequently, since the first 
isolation of (-)-tylophorine (1) in 1935 from the perennial climbing plant Tylophora indica  
native to the plains, hills and forests of southern and eastern India, the class of “ tylophora 
alkaloids”  has grown considerably. To date, over sixty compounds have been isolated and 
characterized, such as (-)-tylophorine (1), (-)-antofine (2), (-)-cryptopleurine (3), and (+)- 
tylocrebine (4) (Figure 4.1).
Figure 4.1 Representative structures o f  tylophora alkaloids.
OMe OMe OMe
R OMe
1 R = OMe; (-)-tylophorine 3 (-)-cryptopleurine 4 (+)-tylocrebrine
2 R = H; (-)-antofine
5 R = H
6 R = OMe
Recently, Wakabayashi et al. reported the presence of cytotoxic substances in extracts of the 
Danaid butterfly Ideopsis sim ilis, insects feeding on the leaves of the Tylophora tanakae .5 
Soon afterwards, they were able to isolate and identify two cytotoxic substances being a new 
phenanthroindolizidine alkaloid (5), and the already known compound 6.6 Since the leaves of 
T. tanakae are known to contain various phenanthroindolizidine alkaloids, compounds 5 and 6 
are presumably metabolically converted from such alkaloids in larvae of I. sim ilis. During the 
investigations it was found that both compounds showed IC 50 values for human gastric cancer 
cells in the low nanomolar range of 0.5 ng/mL and 0.7 ng/mL, respectively, comparable to
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that of clinically employed cytotoxic drugs.7 Moreover, similar cytotoxic potential was shown 
with four other cancer cell lines including lung, cervical, colon carcinomas and leukemia. 
Notably, based upon the N C I’s C O M PA R E 8 analysis, their mode of action appears to be 
different from other known anticancer compounds.9
As can be seen from Figure 4.1, a common structural motif in these pentacyclic natural 
products is the highly oxygenated phenanthrene ring fused to a saturated nitrogen heterocycle. 
Previous structure-activity relationships (SA R ) of these alkaloids have shown that the rigid 
phenanthrene structure is required to maintain potent cytotoxicity, and that the lack of an 
indolizidine ring or the presence of a methyl ether at the 2-position (Figure 4.1) leads to loss 
of cytotoxicity.10
A  serious drawback, however, is that in clinical trials these natural alkaloids showed severe 
central nervous system (C N S) side effects such as ataxia and disorientation thereby 
prohibiting therapeutic use. Recently, it was suggested that application of more polar 
derivatives might offset such CNS-toxicity, since such analogues should be less prone to pass 
the blood-brain barrier. 11 Moreover, tissue specific drug delivery techniques could also be 
envisaged. 12 From literature it becomes clear that only a few polar antofine analogues with a 
C-14 hydroxyl group have been synthesized.10c
Due to their diverse and potent pharmacological and medicinal properties, the 
phenantroindolizidines and quinolizidines continue to be targets for synthesis, modification, 
and determining SA R  profiles.13 Consequently, numerous synthetic routes to these alkaloids 
have been designed. 14 Since the first publication, 15 the use of the arenediazonium salt 8 to 
effect intramolecular coupling providing 9-phenanthrenecarboxylic acid 10, the so-called 
Pschorr reaction, 16 stands out as the most viable method, followed by intramolecular 
electrophilic addition (Scheme 4.1) .17 More recent total syntheses are based on the latter 
methods in combination with key steps such as a chiral auxiliary-mediated asymmetric 
alkylation, 18 an Overmann rearrangement, 19 an enantioselectively catalyzed intramolecular 
alkene carboamination,20 Friedel-Crafts acylation,21 and enantioselective phase-transfer
alkylation.22
93
Chapter 4
Scheme 4.1 Pschorr phenanthrene synthesis.
7
CO2H HCl, Cu0
NaNO2
8 9
CO2H radical cyclization
6-endo-trig
10
c o 2h
Remarkably, up till now, no total synthesis of (+)-frans-3,14a-dihydroxy-6,7-dimethoxy- 
phenanthroindolizidine (5) has been reported. To this end and intrigued by the exquisite 
structural futures and promising biological profile, we embarked on a project aimed at the 
development of a novel but flexible approach to compound 5.
4.2 Retrosynthetic strategy
At the outset, we felt that the pentacyclic skeleton of the target natural products might be 
constructed by employing a Pictet-Spengler annulation23 of 2-arylmethylpyrrolidine 11 
(Scheme 4.2). The cyclization precursor 11 should be accessible from the syn-amino alcohol
12 by sequential ozonolysis, and hydrogenation. The intermediate 12 was in turn envisioned 
to arise from the enantiopure cyanohydrin 13, via addition of an organometallic reagent and 
stereoselective reduction. It occurred to us that the cyanohydrin functionality might be 
introduced by an asymmetric HNL-mediated addition of hydrogen cyanide onto the 
corresponding aldehyde. Further analysis indicated that the requisite cyanohydrin 13 should 
be accessible from the readily available bromide 14 obtained via  a Perkin condensation24 of 
fragments 15 and 16. We were confident that the synthetic methodologies explored in the 
previous chapters, would be well-suited for application in the aforementioned synthetic plan.
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Scheme 4.2 Retrosynthetic strategy.
OMe
5
Pictet-Spengler
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4.3 Synthesis of the phenanthrene-based cyanohydrin
The synthesis o f phenanthrene aldehyde 20, based on a modified Pschorr process, 
commenced with the Perkin condensation of in situ generated potassium 4-benzyloxyphenyl 
acetate (21) and commercially available 2-bromo-4,5-dimethoxybenzaldehyde (16) in the 
presence o f Ac2O (22) to yield the bromo-substituted cinnamic acid derivative 14 as single 
isomer after recrystallization (Scheme 4.3).25 Esterification of the latter compound 14 using 
DBU and MeI in acetonitrile provided the corresponding methyl ester 17 in 87% yield. 
Compound 17 was then subjected to a radical process by treatment with Bu3SnH in the 
presence of a catalytic amount o f azobis(cyclohexanecarbonitrile) (ACN) in boiling toluene to 
afford product 18 in a good yield o f 79%. Reduction of the ester group with LiAlH4 gave 
phenanthrenyl methanol 19, which smoothly underwent a Swern oxidation to yield aldehyde 
20.
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Scheme 4.3 Synthesis o f phenanthrene 20.
DBU, MeI ,--------- 14 R = O H (61% ) 1 8 ,79 %
MeCN, rt I------ »  17 R = OMe (87%)
DMSO, (COCl)2 .--------- 19 R 1 = C H 2OH (95%)
Et3N, - 60 °C I------ ► 20 R 1 = CHO (97%)
Generally, the mechanism o f  the Perkin transformation starts with addition o f the alkali salt 
o f acid 21 to A c2O (22) (Scheme 4.4). After formation o f  enolate 23, aldol condensation takes 
place, followed by intramolecular acyl transfer. The last step in the mechanism includes E2 
elimination providing the cinnamic acid derivative 14 as a mixture o f  geometric isomers.
Scheme 4.4 Mechanism o f the Perkin condensation.
OH -  AcOH
14
Inspired by the successful enzyme-catalyzed hydrocyanation reactions described in the 
previous chapters, the proposed key transformation into cyanohydrin 13 was investigated. 
Unfortunately, subjection o f substrate 20 to both (R)- and (S)-HNL under the known 
conditions did not afford any reaction at all. A  logical explanation for this observation could 
be that the steric bulk o f  the aromatic system hinders the substrate from being accepted by the 
enzyme.
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4.4 Revised synthesis o f the phenanthrene-based cyanohydrin
As mentioned above, we were unsuccessful in accessing the phenanthrene cyanohydrin 13 
via chemoenzymatic cyanohydrin formation. Building on methodology that had already been 
developed in Chapter 3, the retrosynthetic planning to arrive at key structure 13 was 
redesigned (Scheme 4.5). Enzymatic studies on acetylene-containing aldehydes revealed that 
these aldehydes were well accepted by the HNL-enzymes (see: Chapter 3). For this reason we 
believe that compound 26 could serve as an important building block in the synthesis of the 
phenanthrene cyanohydrin 13. Thus, formation o f 13 was intended to proceed by transition 
metal-catalyzed cycloisomerization of ortho-alkylated biphenyl 26 which in turn could arise 
from a Suzuki reaction with a suitably functionalized boronic acid. The acetylenic aldehyde
27 was envisaged to arise from commercially available veratrylaldehyde (28).
Scheme 4.5 Revised synthetic strategy o f compound 13.
cycloisomerization 
reaction j Suzuki 
cross-coupling
MeO
13 26 formation
MeO
OMe
27
OMe
28
O
H
Attention was now directed to preparation of the requisite cyanohydrin precursor 27. Silver 
trifluoroacetate-mediated iodination of the electron rich aromatic system of 28 delivered the 
corresponding iodide 29 in fairly good yield (Scheme 4.6). Next, aldehyde 29 was converted 
in one step into alkyne 31 by reaction with lithio trimethylsilyl diazomethane.26 The rather 
modest yield o f 41% was attributed to the sensitivity of aldehyde 29 under the reaction 
conditions. A much improved yield was obtained by applying the Corey-Fuchs protocol27 
allowing for one-carbon elongation of aldehyde 29 to dibromoolefin 30 and consecutive 
treatment with LDA to afford the terminal alkyne 31 in 75% yield over two steps. The final 
reaction prior to arrival at the targeted aldehyde structure 27 proceeded by reaction of the 
lithium acetylide o f alkyne 31 with DMF as the formylating agent under the conditions 
developed by Journet et al.28
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Scheme 4.6 Synthesis o f aldehyde 27.
LDA, TMSCHN2
THF, -78 °C, 41%
CF3COOAg,I2 |------  28 R=H 30 92% LDA, DMF I------  31 R1 = H (82%)
CH2Cl2, A 1 *■ 29 R= I (70%) THF, -40 °C 27 R1 = CHO (55%)
With the acetylenic aldehyde 27 in hand, the stage was set to investigate the HNL-mediated 
asymmetric hydrogen cyanide addition reaction. Unfortunately, subjection o f this compound 
to the enzymatic hydrocyanation conditions with both enzymes again showed no product 
formation. W e presume that due to the steric bulk o f  the substituents on the aromatic ring -  
mainly the iodide- the substrate has become too big for the enzyme. After these unsatisfactory 
results, we decided to abandon our investigations into the enzyme-based synthesis and 
focused on an alternative approach which might lead to 5.
4.5 Stereocontrolled acetylide addition
As already pointed out in previous sections, w e have encountered severe difficulties in 
forming the phenanthrene cyanohydrin 13 and therefore chose a non-enzymatic route. The 
retrosynthetic analysis o f 5 is shown in Scheme 4.7. Upon first inspection, it appears that the 
pentacyclic skeleton o f the target natural product could be constructed by employing the 
known Pictet-Spengler annulation o f pyrrolidine 26, which was previously synthesized via a 
different synthetic route. Fragments 32 and 33 are the basic modules in the synthetic plan as 
they may serve as precursors ligated via a Sonogashira cross-coupling to access 26. Further 
analysis indicated that synthesis o f  fragments 32 and 33 calls for preparation o f  
diiodoveratrole 34 and application o f  Boc-(S)-prolinal 35.
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Scheme 4.7 Retrosynthetic analysis.
6-endo-dig  cycloisomerization
Our intention was to identify a simple way o f accessing each diastereomeric 
hydroxypyrrolidine 33, which in principle, would give access to all four diastereoisomers o f  
the target natural product. For the initial study, the stereocontrolled ethynylation o f Boc-(S)- 
prolinal 35 with the Grignard reagent prepared from trimethylsilylacetylene was investigated. 
The two possible products 33 and epi-33 were expected (Scheme 4.8) to be derived either 
from a chelation-controlled transition state in the case o f 33 (1 ’S), or from Felkin-Anh-type 
attack leading to the ( l ’R)-alcohol epi-33.
Scheme 4.8 Diastereoselective magnesium acetylide addition to aldehyde 35.
TMS
EtMgBr
Boc O 
35
THF, 0°C to rt N H .  
Boc OH
TMS
33 45%
N H
Boc OH
TMS
epi-33 22%
H +
In this first experiment, the magnesium acetylide gave the Boc-protected acetylenic amino 
alcohol in a 2:1 ratio favoring the desired anti-Felkin-Anh product 33. However, conversion 
o f aldehyde 35 into the product was accomplished in rather poor stereoselectivity and modest 
total yield o f  67%.29 The latter result is presumably due to competing enolization leading to 
regeneration o f the aldehyde upon workup. To establish the absolute/relative stereochemistry 
o f  products 33 and epi-33, both diastereoisomers were subjected to high field 2D-NOESY.
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Unfortunately however, at this stage o f  the synthesis we were unable to give a solid 
assignment o f the stereochemistry.
4.6 Explanation o f  the stereochem ical outcom e
In case o f  Felkin-Anh control, the outcome can be explained by looking at the two possible 
conformers that are involved (Scheme 4.9, equation 1). Nucleophilic attack would take place 
at the least hindered side (Re-face), perpendicular to the carbonyl moiety giving epi-33 as the 
major diastereoisomer. In our case, introduction o f  the acetylenic side chain takes place in the 
opposite direction by chelation control (equation 2). During the stereoinduction, the 
magnesium ion coordinates to the carbonyl oxygen and the amine nitrogen, enforcing a syn- 
periplanar relationship between the amine and carbonyl groups which leads to the anti­
diastereomer 33.
Scheme 4.9 Rationale for the stereochemical outcome.
4.7 E lucidation o f  the diastereochem istry
To ascertain the absolute/relative stereochemistry, we decided to convert both 
diastereoisomers 33 and epi-33 into the corresponding oxazolidinones by two routine 
operations (Scheme 4.10). Stirring under acidic conditions using a solution o f 2M  HCl in 
ethyl acetate allowed for clean removal o f  the Boc protecting group. Next, the crude products 
were subjected to 1,1’-carbonyldiimidazole in THF (50 °C) furnishing the desired 
oxazolidinones 36 and epi-36 in 70% and 6 6 % yield, respectively, over two steps.
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Scheme 4.10 Synthesis o f  oxazolidinones 36 and epi-36.
N h .
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1) HCl/EtOAc, rt
2) Im2CO, Et3N 
THF, 50 °C
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}~ O  H
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N hBoc OH
TMS
epi-33
1) HCl/EtOAc, rt
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V /  ▼
y i  h
O
epi-36 6 6 % ( 2  steps)
With the cyclized compounds in hand, the stage was set to probe the envisaged high field 
2D-NOESY experiments (Figure 4.2). Both 1H-NM R spectra show clear signals and the 
protons relevant to determine the stereochemistry are easy to distinguish. Inspection o f the 
NOE spectra clearly shows a cross signal between Ha and Hb (marked with a box) in the 
spectrum o f  oxazolidinone epi-36 indicating a cis-relationship between these protons. The 
absence o f  the signal between Ha and Hb in the spectrum o f 36 implicates a trans-relation. 
Furthermore, examination o f the 1H-NM R spectrum o f oxazolidinone epi-36 showed H a as a 
doublet located at 5 5.28 with a coupling constant J(H a-Hb) o f 8.0 Hz while the same signal o f  
the (1S)-diastereoisomer oxazolidinone 36 appeared at 5 4.86 with a coupling constant J(Ha- 
Hb) o f only 4.0 Hz, thereby confirming the aforementioned conclusion. In addition, X-ray 
structure analysis o f  the crystals obtained from prolinol derivative 38 (Figure 4.3) 
unequivocally confirmed the stereochemistry as already evidenced by the 2D-NOESY  
measurements.
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Figure 4.2 2D-NOESY spectrum o f oxazolidinones 36 and epi-36. Cross peaks are boxed.
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Figure 4.3 Crystal structure o f prolinol derivative 38.
4.8 D iastereoselective acetylide addition
To overcome the rather disappointing results in terms o f yield and stereoselectivity, we 
turned our attention to additional reagent control. Carreira et al. have developed an effective 
method for the diastereocontrolled addition o f  zinc acetylides to aldehydes employing 
inexpensive (+)-N-methylephedrine as a chiral ligand.30 W e were surprised to find that under 
these conditions, in our hands w e were not able to see any product formation at all (Table 4.1, 
entry 1). After some unsuccessful variation o f reaction conditions (different preparation o f  
Zn(OTf)2 and various bases), a paper by Zhou et al. stimulated us to investigate the 
asymmetric acetylide addition to aldehyde 35 by using 1,1’-bi-2-naphthol (BINOL) in 
combination with Et2Zn, Ti(O'Pr)4, and HMPA at room temperature.31 Gratifyingly, these 
conditions allowed for clean conversion into product (entry 3). After comparison o f the 1H- 
NM R spectra it was concluded that when (S)-BINOL was used, product epi-33 was obtained 
in 79% yield in a diastereomeric ratio o f  1:10. Fortunately, both diastereoismomers could be 
separated by repeated column chromatography. Subsequently, we also examined the 
application o f  (R)-BINOL, which would hopefully lead to the formation o f the other 
diastereoisomer 33. Interestingly, (R)-BINOL failed to give the desired isomer 33 but instead 
led to smooth conversion into epi-33 in a comparable diastereomeric ratio (entry 4). As a test 
case for the stereoinduction, we also performed the same reaction without the presence o f  a 
chiral BINOL auxiliary. When the reaction was setup and allowed to proceed without BINOL, 
adduct epi-33 was isolated at a much slower rate and in only 54% yield and with a decreased 
diastereomeric ratio o f  1:2.5 (entry 5). Pleasingly, this inherent diastereoselectivity in the 
undesired Felkin-Anh direction could be overturned by replacement o f  BINOL and Ti(O'Pr)4 
with (+)-N-methylephedrine. In the event, the chelation-controlled compound 33, required for
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natural product 5, was obtained as the major isomer in 82% yield and a diastereomeric ratio o f  
6.6:1 (entry 6). On the contrary, (-)-N-methylephedrine as chiral auxiliary was not able to 
deliver an acceptable diastereomeric ratio probably due to a mismatched case (entry 7). For 
the time being, w e opted that further fine tuning and optimization o f  the diastereocontrolled 
addition reaction onto aldehyde 35 could be performed after completion o f  the total synthesis.
Table 4.1 Screening o f acetylide addition on aldehyde 35.
,H
H
TMS
N h
Boc O
0  °C to  rt
TMS
N H T
Boc OH
TMS
N H o h
Boc OH
35 33 epi-33
entry conditions catalyst yield ( % ) a 33/ epi-33 ratiob
1 Zn(OTf)2, Et3N, toluene (+)-N-methylephedrine - -
2 ZnCl2, THFc - -
3 Et2Zn, Ti(O'Pr)4, HMPA, C ^ C h (S)-BINOL 79 1 :10
4 Et2Zn, Ti(O'Pr)4, HMPA, CH2Ch (R)-BINOL 80 1 :10
5 Et2Zn, Ti(O'Pr)4, HMPA, C ^ C h - 54 1:2.5
6 Et2Zn, HMPA, CH2Cl2 (+)-N-methylephedrine 82 6.6:1
7
a
Et2Zn, HMPA, CH2Cl2 (-)-N-methylephedrine
b u 1tt ata/ti
80 2.2:1 
C A _____________ * 1 1
available lithium (trimethylsilyl)acetylide solution in THF (0.5 M) was used. 
4.9 Synthesis o f the phenanthrene scaffold
With key intermediate 33 in hand, w e turned our attention to the preparation o f the biphenyl 
fragment 32, which was easily prepared in two steps as shown in Scheme 4.11. Aromatic 
diiodination provided the desired veratrole derivative 34 in quantitative yield. Standard 
Suzuki cross-coupling reaction employing commercially available 3-benzyloxyphenyl boronic 
acid afforded substituted biphenyl iodide 32 in a high yield o f 84%.
+
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Scheme 4.11 Synthesis o f fragment 32.
MeO
M - O ®
37
32 84%
With multigram quantities o f  32 in hand we began the second stage o f  our synthesis by 
cleavage o f  the TMS-protecting group with K2CO3 in methanol affording terminal alkyne 38 
and its epimer epi-38 in 98 and 97% yield, respectively, after column chromatography 
(Scheme 4.12). The next step in the assembly process was the coupling o f the two fragments 
38 and 32 via palladium catalysis. Our system turned out to be not reactive enough, however, 
so that only starting material was recovered. Remarkably, in further experiments this 
seemingly routine transformation was low  yielding or failed to give the desired product at all. 
Gratifyingly, an alternative route for successful assembly o f  the fragments was initiated by 
simply altering the order o f steps. Thus, terminal alkyne 38 was first reacted in a Sonogashira 
cross-coupling in the presence o f  5 mol % o f [Pd(PPh3)2Cl2] and 20 mol % o f Cul to provide 
product 39 in 92% yield. Suzuki reaction with 3-benzyloxyphenyl boronic acid then 
constituted the phenanthrene precursor 26 in a good yield o f 81%. The reactions with epimer 
epi-38 delivered epi-26 in comparable yield.
Scheme 4.12 Synthesis o f  building block 26.
N H *
Boc OH
K2CO3 
MeOH, 0 °C
Et2 NH, CuI, 32 
[Pd(PPh3)2Cl2]
Et2 NH, CuI, 34 
R [Pd(PPh3)2Cl2]
benzene, rt
MeO
33/epi-33  R = TMS 
38 R = H (98%) 
epi-38 R = H (97%)
x
benzene, rt
HO H
OMe
39 92% 
epi-39 93%
BnO.
LiCI, Na2CO3 
[PdCI2 (dppf)2
DME, 80 °C 
BnO. MeO'
B(OH )2
HO H
OMe 
26 81% 
epi -26 84%
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The next goal was to investigate the transition metal-catalyzed cycloisomerization. Recent 
investigations from the Furstner lab have shown that exposure o f  biaryl derivatives bearing an 
alkyne moiety on one o f  the ortho-positions to a variety o f  carbophilic Lewis acids engenders 
an efficient 6-endo-dig cycloisomerization to form polycyclic (hetero)arenes.32 Interestingly, 
after numerous experiments o f  26 and epi-26 with an assortment o f transition metal catalysts 
and (Bransted) acids under different experimental conditions, it was becoming clear that this 
did not lead to the anticipated formation o f phenanthrenes 40 and epi-40 (Scheme 4.13). 
Instead, a complex mixture o f products was obtained, from which most likely an elimination 
product, being the major product, could be identified by mass analysis. All attempts to further 
analyze or isolate this compound were unsuccessful.
These results led us to believe that the sensitivity o f the free hydroxyl at C-14 toward 
elimination under the conditions applied must be the main reason for preventing success. W e 
were hoping that changing the free hydroxyl in a less good leaving group such as a cyclic 
carbamate would be more fruitful. In response to this analysis, the convergent route to the 
cyclization precursors 41 and epi-41 summarized in Scheme 4.13 was designed. Our first 
attempt to remove the Boc group under acidic conditions using a cold solution o f  2M  HCl in 
ethyl acetate failed completely and led to instantaneous product decomposition instead. 
Luckily, this problem was overcome by conducting the deprotection under particularly mild 
conditions in the presence o f TM SOTf buffered with 2,6-lutidine.33 After extraction, the crude 
products were immediately treated with 1,1’-carbonyldiimidazole in heated THF (50 °C) 
affording the desired compounds 41 and epi-41 in good yield over two steps. Direct 
oxazolidinone formation by exposure o f alcohol 26 to NaH in dry THF was also attempted, 
but merely led to formation o f  side products.
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Scheme 4.13 Synthesis o f  the phenanthrene scaffold.
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Having both oxazolidinones in hand, the cycloisomerization was investigated. 
Unfortunately, despite extensive variation o f the conditions and catalysts (vide supra), we 
were unable to establish a successful protocol for the transformation into 42 and its epimer 
epi-42. The starting compounds 41 were inreactive in all cases and analysis o f  the reaction 
mixtures only indentified starting material.
Alternatively, w e anticipated that a tandem Pictet-Spengler reaction on deprotected 26 
would provide an elegant entry into the final antofine skeleton via 6 -endo-trig cyclization and 
consecutive attack o f  the (electron rich) aromatic system on the intermediate cation. Indeed, 
stirring the free amine at rt in either a formic acid/paraformaldehyde mixture, or in the 
presence o f MOMCl showed the formation o f  the corresponding N-acyliminium ion 43 as 
could be determined by mass spectrometry analysis o f  the crude reaction mixtures. However, 
both the anticipated tandem sequences gave multiple products and, in case o f MOMCl, only 
led to traces o f  the desired product 44 (R = MOM). Monitoring the reaction in formic acid 
showed a small amount o f  addition product being the result o f  intermolecular attack o f formic 
acid onto the N-acyliminium ion 43.
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Among the conditions already used in the cycloisomerization reaction o f 26 and epi-26, we 
also investigated the possibility o f  intramolecular cyclization with highly electrophilic sources 
o f  iodonium ions, such as I(py)2BF4, which was first used by Barluenga in the presence o f  a 
strong acid to cyclize 1,4-diphenyl-1-butyne to the corresponding iododihydronaphthalene.34 
However, under these conditions complete decomposition took place, most probably due to 
the strong TfOH that was used. Another way o f  synthesizing polycyclic aromatic and 
heteroaromatic compounds was developed by Larock and co-workers.35 They successfully 
developed an iodine monochloride (ICl)-induced electrophilic cyclization. A  notable feature 
in this strategy is the preference for 6-endo-dig cyclization to give phenanthrenes over the 
alternative 5-exo mode o f cyclization. Encouraged by these results, we treated compound 41 
with a slight excess o f  ICl in cold dichloromethane (Scheme 4.14). This route allowed 
conversion o f  starting material into a product which upon isolation and 1H-NM R analysis 
showed a mixture o f two inseparable products in a moderate yield o f 54% in a 1:3 ratio. 1H- 
NM R temperature experiments indicated that the two products were no conformational 
isomers. W e therefore assume that this mixture is a result o f 6-endo-dig and 5-exo-dig 
cyclization. To provide more insight, various mass spectrometry techniques (CI, ESI, 
MALDI) were utilized for elucidating the molecular mass o f the two products. Although CI 
did show the expected peak o f 596 m/z (M+H)+, many unidentifiable (fragmentation) signals 
were also visible and therefore no full proof could be withdrawn from these results. 
Unfortunately, due to the complexity o f the spectra and the fact that no crystalline material 
could be obtained, full elucidation o f the regio- and/or stereochemistry appeared impossible. 
Other ways to obtain more structural information on these compounds, such as removal o f  the 
carbamate moiety or radical deiodination, failed in all cases.
Scheme 4.14 ICl-mediated electrophilic cyclization o f 41.
OMe
41
OMe
45
OMe 
46
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In the search for more success, we investigated the ^-selective reduction of acetylene 26 
using LiAlH4. This partial reduction, however, did not proceed efficiently and the reduced 
product 47 was isolated in a low yield o f 19% (Scheme 4.15). The in our hands most 
rewarding result for preparation o f 47 involved exposure of acetylene 26 to Red-Al. These 
conditions afforded the vinylic alcohol 47 in one step and a high yield o f 85%. Notably, with 
the same treatment, partial reduction of ep i-26 proceeded less smoothly to furnish epi-47 in a 
modest yield of 58%.
Scheme 4.15 Synthesis o f vinylic alcohols 47.
26 47 85% 40
epi-26 epi-47 58% epi-40
From all the possible cyclization conditions, we first opted for a photochemical ring closure. 
To our disappointment, irradiation of the vinylic alcohol 47 with ultraviolet light (300 nm) in 
acetonitrile at rt completely destroyed the starting material and led to the formation of 
multiple products. Alternatively, we investigated various other cycloisomerization conditions 
to obtain 40 and epi-40, but they unfortunately did not provide any of the desired product.
4.10 Conclusions
We aimed to develop a concise, convergent, and diastereoselective route for the synthesis of 
alkaloid 5 and its isomers, with which both the relative and absolute stereochemistry could be 
predictably installed. In the first two synthesis routes, we investigated the preparation o f a key 
phenanthrene cyanohydrin starting from two different acetylenic aldehydes. Synthesis o f the 
cyanohydrin precursors proceeded without difficulties, however, we were not able to form the 
desired product from the asymmetric HNL-mediated hydrogen cyanide additions.
The third route describes the synthesis starting from diastereocontrolled trimethylsilyl- 
acetylide addition onto Boc-(S)-prolinal. To our delight, depending on the nature of the 
catalyst, we were successful in obtaining both diastereoisomers in a selective manner. This
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result in principle would enable us to access all four diastereoisomers depending on the 
stereochemistry o f  the Boc-protected prolinal and o f the type o f catalyst. Unfortunately, 
numerous attempts to cycloisomerize biphenylic intermediates in a later stadium o f the 
synthesis remained unsuccessful and prevented us from completing the total synthesis.
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4.12 Experimental section
General information
For general experimental details, see section 2.8.
OMe
(£)-2-[4-(Benzyloxy)phenyl]-3-(2-bromo-4,5-dimethoxyphenyl)acrylic acid (14)
To a solution of 4-benzyloxyphenylacetic acid 15 (950 mg, 3.92 mmol) in dry 
THF (4 mL) was added KOiBu (449 mg, 1.02 equiv), and the mixture was stirred 
at rt for 2 h. After evaporation of the solvent, 2-bromo-4,5- 
dimethoxybenzaldehyde 16 (961 mg, 1.0 equiv) and freshly distilled Ac2O (5 
mL) were added to the residue. After heating the reaction mixture at 105 °C for 
16 h, hot H2O (10 mL) was added and stirring was continued at rt for 3h. The 
precipitate was filtered off and the filtrate was extracted with CH2Cl2 (3 x 10 mL). The organic layers 
were combined and washed successively with saturated aqueous NaHCO3 (10 mL) and brine (10 mL), 
and concentrated in vacuo. The residue and the above precipitate were combined giving the crude 
product as a mixture of geometric isomers (E:Z = 9:1). Recrystallization from EtOH/hexane afforded 
14 (1.12 g, 61% yield) as white crystals and as single isomer. R/ 0.34 (EtOAc/heptane, 1:1). Mp 196.0 
°C. IR (ATR) 3002, 2941, 2842, 2595, 2509, 2263, 1679, 1596, 1500, 1261, 1213, 1163, 733, 612 
cm-1. 'H NMR (CDCl3, 400 MHz): 5 8.11 (s, 1H), 7.42-7.30 (m, 5H), 7.18-7.14 (m, 2H), 7.01 (s, 1H), 
6.98-6.94 (m, 2H), 6.36 (s, 1H), 5.06 (s, 2H), 3.85 (s, 3H), 3.21 (s, 3H). 13C NMR (CDCl3, 75 MHz): 5
172.6, 158.7, 150.3, 147.5, 140.7, 136.9, 131.6, 131.3, 128.8, 128.2, 127.6, 127.5, 126.8, 117.6, 115.3,
115.2, 113.6, 70.1, 56.3, 55.3. HRMS (EI) m/z calcd for C24H21BrO5 (M)+: 468.0572, found: 468.0560.
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(£)-2-[4-(Benzyloxy)phenyl]-3-(2-bromo-4,5-dimethoxyphenyl)acrylic acid methyl ester (17)
To a suspension of acrylic acid 14 (400 mg, 0.85 mmol) in dry MeCN (3 mL) 
were added DBU (204 ^L, 1.6 equiv), and Mel (265 ^L, 5.0 equiv) at rt and 
the mixture was stirred at the same temperature for 2.5 h. The reaction mixture 
was diluted with saturated aqueous NH4Cl (3 mL), and extracted with Et2O (3 
x 10 mL). The organic layer was washed with saturated aqueous NaHCO3 (10 
mL) and brine (10 mL), dried (Na2SO4), filtered and concentrated in vacuo. 
The residue was purified by column chromatography (EtOAc/heptane, 0:1—>1:2) to afford 17 (357 mg, 
87% yield) as a colorless oil. Rf  0.55 (EtOAc/heptane, 1:1). IR (ATR) 2954, 2842, 2254, 1708, 1597, 
1500, 1265, 1239, 1210, 1172, 1026, 733 cm-1. 1H NMR (CDCl3, 400 MHz): 5 7.96 (s, 1H), 7.39-7.26 
(m, 5H), 7.14-7.10(m, 2H), 6.97 (s, 1H), 6.95-6.91 (m, 2H), 6.30 (s, 1H), 5.02 (s, 2H), 3.79 (s, 3H), 
3.78 (s, 3H), 3.19 (s, 3H). 13C NMR (CDCl3, 75 MHz): 5 168.0, 158.3, 149.7, 147.3, 138.5, 136.7,
132.0, 131.4, 128.5, 127.9, 127.8, 127.2, 126.8, 116.9, 114.9, 113.4, 69.8, 55.9, 55.1, 52.3. HRMS 
(ESI) m/z calcd for C25H24BrO5 (M+H)+: 483.0807, found: 483.0804.
[3-(Benzyloxy)-6,7-dimethoxyphenanthrene-9-yl]acrylic acid methyl ester (18)
To a boiling solution of acrylic methyl ester 17 (550 mg, 1.14 mmol) in dry 
degassed toluene (10 mL) was dropwise added a solution of Bu3SnH (460 ^L,
1.5 equiv) and ACN (167 mg, 0.6 equiv) in dry degassed toluene (6  mL) over a 
period of 1 h. The resulting solution was refluxed for another 3 h before it was 
quenched with saturated aqueous NH4Cl (20 mL). The product was extracted 
from the aqueous layer with EtOAc (3 x 20 mL) and the organic layers were 
combined, dried (Na2SO4), filtered and concentrated in vacuo. The residue was purified by column 
chromatography (EtOAc/heptane, 0:1— 1:4) to afford 18 (362 mg, 79% yield) as a colorless oil. Rf 
0.52 (EtOAc/heptane, 1:1). Mp 147.7 °C. IR (ATR) 3006, 2954, 2928, 2859, 2362, 2250, 1708, 1615, 
1510, 1566, 1236, 1201, 1120, 1025, 909, 842, 733, 697 cm-1. !H NMR (CDCl3, 400 MHz): 5 8.94 (d, 
J  = 9.3 Hz, 1H), 8.31 (s, 1H), 7.96 (d, J  = 2.6 Hz, 1H), 7.78 (s, 1H), 7.55-7.53 (m, 2H), 7.44-7.41 (m, 
2H), 7.37-7.34 (m, 2H), 7.25 (s, 1H), 5.29 (s, 1H), 4.10 (s, 3H), 4.03 (s, 3H), 4.01 (s, 3H). 13C NMR 
(CDCl3, 75 MHz): 5 168.3, 157.4, 151.1, 149.9, 137.1, 131.8, 129.8, 128.9, 128.5, 128.3, 127.7, 126.9, 
125.7, 123.9, 123.5, 116.4, 109.4, 106.2, 103.3, 70.6, 56.2, 56.1, 52.2. HRMS (EI) m/z calcd for 
C25H22O4 (M)+: 402.1467, found: 402.1473.
[3-(Benzyloxy)-6,7-dimethoxyphenanthren-9-yl]methanol (19)
To a suspension of LiAlH4 (30 mg, 1.8 equiv) in dry THF (4 mL) at rt was added a 
solution of ester 18 (166 mg, 0.41 mmol) in dry THF (5 mL). The reaction mixture 
was heated at reflux temperature for 1 h and then cooled to rt. After dilution with 
Et2O (30 mL), the mixture was carefully quenched with 1.0 M aqueous NaOH 
solution. After stirring for 20 min, the layers were separated and the organic layer 
was washed with H2O (20 mL), dried (Na2SO4), filtered and concentrated in vacuo. 
The residue was purified by recrystallisation from benzene to afford 19 (147 mg, 95% yield) as white 
crystals. Rf  0.27 (EtOAc/heptane, 1:1). Mp 178.5 °C. IR (ATR) 3455, 3006, 2915, 2889, 2833, 1610, 
1449, 1431, 1256, 1236, 1200, 1154, 1069, 1018, 882, 827, 735 cm-1. !H NMR (CDCl3, 400 MHz): 5
8.09 (d, J  = 9.0 Hz, 1H), 7.97 (d, J  = 2.1 Hz, 1H), 7.76 (s, 1H), 7.55-7.52 (m, 3H), 7.44-7.40 (m, 2H),
7.37-7.29 (m, 2H), 7.16 (s, 1H), 5.28 (s, 2H), 5.11 (s, 2H), 4.07 (s, 3H), 4.00 (s, 3H), 1.82 (bs, 1H). 13C 
NMR (CDCl3, 75 MHz): 5 157.4, 149.7, 149.4, 137.2, 132.9, 131.8, 128.9, 128.3, 127.7, 127.1, 126.2,
BnO.
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124.6, 124.4, 123.4, 115.8, 108.5, 106.5, 103.5, 70.6, 64.4, 56.2, 56.1. HRMS (EI) m/z calcd for 
C24H22O4 (M)+: 374.1518, found: 374.1511.
[3-(Benzyloxy)-6,7-dimethoxyphenanthrene-9-yl]carbaldehyde (20)
To a solution of DMSO (57 ^L, 3.0 equiv) in dry CH2Cl2 (3 mL) was added oxalyl 
chloride (46 ^L, 2.0 equiv) at -60 °C. To this stirred solution was slowly added 
alcohol 19 (100 mg, 0.27 mmol). After 15 min Et3N (0.20 mL, 5.5 equiv) was 
added and the cold bath was removed after which stirring was continued for 30 
min. The reaction mixture was quenched with H2O (5 mL) and the product was 
extracted from the aqueous layer with CH2Cl2 (3 x 10 mL). The organic layers 
were combined, dried (Na2SO4), filtered and concentrated in vacuo. The residue was purified by 
column chromatography (EtOAc/heptane, 0:1— 1:2) to afford 20 (98 mg, 97% yield) as a white solid. 
Rf  0.43 (EtOAc/heptane, 1:1). Mp 198.5 °C. IR (ATR) 3023, 2924, 2816, 2362, 2332, 1675, 1611, 
1594, 1253, 1203, 1157, 1046, 854, 752, 710 cm-1. 1H NMR (CDCl3, 400 MHz): 5 10.24 (s, 1H), 9.32 
(d, J  = 9.2 Hz, 1H), 7.98 (s, 1H), 7.92 (d, J  = 2.6 Hz, 1H), 7.74 (s, 1H), 7.55-7.53 (m, 2H), 7.45-7.41 
(m, 2H),7. 39-7.33 (m, 2H), 7.29 (s, 1H), 5.28 (s, 2H), 4.11 (s, 3H), 4.05 (s, 3H). 13C NMR (CDCl3, 75 
MHz): 5 193.6, 157.9, 152.1, 149.9, 138.6, 137.0, 131.8, 129.0, 128.9, 128.3, 127.9, 127.7, 125.7,
122.5, 116.8, 109.6, 106.3, 103.5, 70.6, 56.3, 56.2. HRMS (EI) m/z calcd for C24H20O4 (M)+: 
372.1362, found: 372.1363.
BnO
MeO
OMe
H
2-Iodo-4,5-dimethoxybenzaldehyde (29)
I O To a flask charged with dry silver trifluoroacetate (4.00 g, 1.1 equiv) was added a 
vH solution of veratrylaldehyde 28 (2.74 g, 16.5 mmol) in dry CH2Cl2 (120 mL) at rt. 
MeO_ To this stirred suspension a solution of iodine (4.60 g, 1.1 equiv) in dry CH2Cl2 (250
OMe mL) was added over a period of 2 h. The solution was refluxed for 12 h, at which 
point the reaction mixture was filtrated, washed with saturated aqueous Na2S2O3 (200 mL), and 
concentrated in vacuo. The residue was purified by column chromatography (EtOAc/heptane, 
0:1— 1:7) to afford 29 (3.36 g, 70% yield) as a yellowish solid. Rf 0.39 (EtOAc/heptane, 1:2). IR 
(ATR) 9.87 (s, 1H), 7.42 (s, 1H), 7.31 (s, 1H), 3.96 (s, 3H), 3.92 (s, 3H). 13C NMR (CDCl3, 75 MHz): 
5 194.9, 154.5, 149.8, 121.8, 111.1, 92.8, 56.6, 56.1. Data are in agreement with literature.36
1-(2,2-Dibromovinyl)-2-iodo-4,5-dimethoxybenzene (30)
To a solution of PPh3 (2.24 g, 5.0 equiv) in dry CH2Cl2 (26 mL) was added CBr4
Br
(1.42 g, 2.5 equiv) and the resulting yellow mixture is stirred for 10 min at 0 °C. 
MeO^ ^ ^  Br A solution of aldehyde 29 (500 mg, 1.71 mmol) in dry CH2Cl2 (17 mL) is slowly 
OMe introduced and stirring is continued for 1 h at that temperature. The reaction
mixture was quenched with brine (50 mL), and the product was extracted with CH2Cl2 (3 x 50 mL). 
The organic layers were combined, dried (Na2SO4), filtered and concentrated in vacuo. The residue 
was purified by column chromatography (EtOAc/heptane, 0:1— 1:4) to afford 30 (705 mg, 92% yield) 
as a white solid. Rf  0.52 (EtOAc/heptane, 1:2). Mp 92.0 °C. IR (ATR) 3002, 2954, 2933, 2907, 2842, 
1589, 1496, 1436, 1375, 1257, 1207, 1162, 1026, 8 6 8 , 826. 1H NMR (CDCl3, 400 MHz): 5 7.36 (s, 
1H), 7.25 (s, 1H), 7.11 (s, 1H), 3.87 (s, 6H). 13C NMR (CDCl3, 75 MHz): 5 149.6, 149.0, 140.6, 132.1,
121.2, 112.7, 92.2, 87.5, 56.3, 56.2. HRMS (EI) m/z calcd for C ^ I B ^  (M)+: 445.8015, found: 
445.8012.
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1-Ethynyl-2-iodo-4,5-dimethoxybenzene (31)
1 - To a solution of dibromide 30 (6.00 g, 13.4 mmol) in dry THF (250 mL) at -78 °C 
was added LDA (27.0 mL of a 2.0 M solution in THF, 53.6 mmol, 4.0 equiv) and 
MeO^ ^ ^  stirring is continued at that temperature for 5h. The reaction mixture was quenched 
OMe with saturated aqueous NH4Cl (250 mL), and the product was extracted from the 
aqueous layer with CH2Cl2 (3 x 200 mL). The organic layers were combined, dried (Na2SO4), filtered 
and concentrated in vacuo. The residue was purified by column chromatography (EtOAc/heptane, 
0:1— 1:9) to afford 31 (3.17 g, 82% yield) as a white solid. Rf 0.47 (EtOAc/heptane, 1:2). Mp 106.8 
°C. IR (ATR) 3287, 2967, 2933, 2842, 1588, 1500, 1252, 1211, 1159, 1026, 855, 785, 612 cm-1. 'H 
NMR (CDCl3, 400 MHz): 5 7.21 (s, 1H), 6.99 (s, 1H), 3.88 (s, 3H), 3.87 (s, 3H), 3.31 (s, 1H). 13C 
NMR (CDCl3, 75 MHz): 5 150.2, 149.0, 121.1, 121.0, 115.6, 89.8, 85.5, 79.4, 56.3, 56.1. HRMS (EI) 
m/z calcd for Ci0H9IO2 (M)+: 287.9648, found: 287.9651.
3-(2-Iodo-4,5-dimethoxyphenyl)propynal (27)
O To a solution of alkyne 31 (1.65 g, 5.73 mmol) in dry THF (15 mL) at -40 °C 
! - ^ ^ H  was slowly added LDA (3.15 mL of a 2.0 M solution in THF, 6.30 mmol, 1.1 
\ || equiv) maintaining the temperature between -35 °C and -40 °C. After
MeO y completion of the addition, anhydrous DMF (887 ^L, 2.0 equiv) was added in
OMe one portion and the cold bath was removed. The reaction mixture was stirred for
another 2 h at ambient temperature after which it was poured into a vigorously stirred biphasic 
solution prepared from a 10% aqueous solution of KH2PO4 (30 mL, 22.9 mmol) and MTBE (30 mL) 
at 0 °C. After separation of the layers, the organic layer was washed with H2O (3 x 20 mL), dried 
(Na2SO4), filtered and concentrated in vacuo. The residue was purified by column chromatography 
(EtOAc/heptane, 0:1— 1:6) to afford 27 (996 mg, 55% yield) as a yellowish solid. Rf 0.42 
(EtOAc/heptane, 1:2). Mp 148.1 °C. IR (ATR) 3079, 3002, 2928, 2846, 2738, 2178, 1649, 1503, 1229, 
1207, 1010, 902, 612. cm-1. 'H NMR (CDCl3, 400 MHz): 5 9.47 (s, 1H), 7.28 (s, 1H), 7.06 (s, 1H), 
3.92 (s, 3H), 3.97 (s, 3H). 13C NMR (CDCl3, 75 MHz): 5 176.6, 152.2, 149.2, 121.5, 118.2, 116.6,
97.4, 92.5, 90.4, 56.5, 56.2. HRMS (EI) m/z calcd for C11H9IO3 (M)+: 315.9597, found: 315.9600.
(£)-N-feri-Butoxycarbonyl-2-[(lS)-1-hydroxy-3-(trimethylsilyl)prop-2-yn-1-yl]pyrrolidine (33)
j— y ^ ^ tms To a stirred solution of (+)-ALmethylephedrine (880 mg, 0.4 equiv), HMPA (4.30 
mL, 2.0 equiv), and trimethylsilylacetylene (6.85 mL, 4.0 equiv) in dry CH2Q 2 
Boc oh (155 mL) at rt is slowly added Et2Zn (49.0 mL of a 1.0 M solution in hexane, 48.8
mmol, 4.0 equiv). After the solution is stirred at rt for 16 h, Boc-(S)-prolinal 35 (2.43 g, 12.2 mmol) is 
added in one portion and the reaction is allowed to proceed at rt for 4 h. The reaction mixture was 
slowly quenched with a 1.0 M solution of tartaric acid (100 mL), and the product was extracted with 
CH2Q 2 (3 x 80 mL). The organic layers were combined, dried (Na2SO4), filtered and concentrated in 
vacuo. The residue was purified by column chromatography (EtOAc/heptane, 0:1— 1:4) to afford 33 
(3.31 g, 71% yield) as a colorless oil. Rf 0.74 (EtOAc/heptane, 1:1). [a]D° -79.6 (c 1.02, CH2Q 2). IR 
(ATR) 3382, 2975, 2880, 2172, 1695, 1670, 1400, 1366, 1249, 1165, 1120, 1052, 843, 760 cm-1. 'H 
NMR (CDCl3, 400 MHz): 5 5.06 (bs, 1H), 4.32 (d, J  = 5.2 Hz, 1H), 4.01-3.98 (m, 1H), 3.43-3.29 (m, 
2H), 2.08-1.74 (m, 4H), 1.45 (s, 9H), 0.15 (s, 9H). 13C NMR (CDCl3, 75 MHz): 5 157.7, 105.3, 89.9,
80.8, 67.7, 62.9, 47.8, 28.9, 28.6, -0.1. HRMS (ESI) m/z calcd for CisH2sNO3Si (M+H)+: 298.1838, 
found: 298.1837.
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(£)-N-feri-Butoxycarbonyl-2-[(.R)-1-hydroxy-3-(trimethylsilyl)prop-2-yn-1-yl]pyrrolidine (epi-33)
tms To a stirred solution of (S)-BINOL (1.44 g, 0.4 equiv), HMPA (4.37 mL, 2.0 
^ equiv), and trimethylsilylacetylene (7.04 mL, 4.0 equiv) in dry CH2Cl2 (160 mL) at
Oh rt is slowly added Et2Zn (50.2 mL of a 1.0 M solution in hexane, 50.2 mmol, 4.0
equiv). After the solution is stirred at rt for 16 h, Ti(O!Pr) 4 (3.73 mL, 1.0 equiv) 
and stirring is continued for 1h. Next, Boc-(S)-prolinal 35 (2.50 g, 12.5 mmol) is added in one portion 
and the reaction is allowed to proceed at rt for 4 h. The reaction mixture was slowly quenched with a
1.0 M solution of tartaric acid (100 mL), and the product was extracted with CH2Cl2 (3 x 100 mL). 
The organic layers were combined, dried (Na2SO4), filtered and concentrated in vacuo. The residue 
was purified by column chromatography (EtOAc/heptane, 0:1—>1:4) to afford epi-33 (2.95 g, 72% 
yield) as a colorless oil. R /0.72 (EtOAc/heptane, 1:1). [a]D0 -126.8 (c 1.01, CH2Q 2). IR (ATR): 3391, 
2967, 2876, 2168, 1692, 1668, 1397, 1249, 1163, 1126, 1048, 841, 759 cm-1. 'H NMR (CDCl3, 400 
MHz): 5 6.14 (d, J  = 9.2 Hz, 1H), 4.37 (d, J  = 9.2 Hz, 1H), 4.05 (m, 1H), 3.57-3.51 (m, 1H), 3.34-3.28 
(m, 1H), 2.16-2.07 (m, 1H), 2.04-1.95 (m, 1H), 1.82-1.69 (m, 2H), 1.49 (s, 9H), 0.16 (s, 9H). 13C 
NMR (CDCl3, 75 MHz): 5 157.3, 104.5, 89.7, 80.6, 67.9, 63.5, 48.5, 29.5, 28.6, 24.0, 0.0. HRMS 
(ESI) m/z calcd for C15H28NO3Si (M+H)+: 298.1838, found: 298.1833.
(1£,7lS)-Tetrahydro-1-[2-(trimethylsilyl)ethynyl]-1.ff,3.ff-pyrrolo[1,2-c]oxazol-3-one (36)
To a flask charged with TMS-acetylene 33 (57 mg, 0.19 mmol) was added a 2 M 
N X " ' " "TMS solution HCl/EtOAc (3 mL) which was stirred at rt for 2 h. After concentration in 
^ - o  H vacuo, the crude product was dissolved in dry THF (3 mL) and Et3N (46 ^L, 1.5
O equiv) and (Im)2CO (72 mg, 2.0 equiv) were added successively at rt. The
resulting reaction mixture was heated to 50 °C and stirred overnight. After cooling to rt the mixture 
was concentrated in vacuo. Column chromatography (EtOAc/heptane, 0:1— 1:3) afforded the desired 
product 36 (30 mg, 70%) as a colorless oil. R/ 0.59 (EtOAc/heptane, 1:1). :H NMR (CDCl3, 400 
MHz): 5 4.86 (d, J  = 4.0 Hz, 1H), 3.88 (ddd, J  = 4.0, 7.0, 9.7 Hz, 1H), 3.61 (ddd, J  = 7.5, 11.3 Hz, 
1H), 3.16 (ddd, J  = 4.5, 9.0, 11.3 Hz, 1H), 2.15-1.99 (m, 2H), 196-186 (m, 1H), 1.46 (ddd, J  = 8.9,
12.0, 17.7 Hz, 1H), 0.17 (s, 9H). 13C NMR (CDCl3, 75 MHz): 5 171.7, 100.7, 93.6, 69.5, 66.2, 46.0,
30.5, 25.6, -0.3. HRMS (ESI) m/z calcd for C„H18NO2Si (M+H)+: 224.1107, found: 224.1106.
(1.R,7£)-Tetrahydro-1-[2-(trimethylsilyl)ethynyl]-1.ff,3.ff-pyrrolo[1,2-c]oxazol-3-one (epi-36)
1— 1 Prepared as described above starting from TMS-acetylene epi-33 (50 mg, 0.17
/ \>H .^-TMS
n m m o l ) .  Purification by column chromatography (EtOAc/heptane, 0:1— 1:3) 
^—o H afforded epi-36 (25 mg, 6 6% yield) as a colorless oil. R/ 0.53 (EtOAc/heptane,
O 1:1). IR (ATR): 2958, 2898, 2353, 2340, 2172, 1756, 1372, 1247, 1217, 1039,
843, 762 cm-1. !H NMR (CDCl3, 400 MHz): 5 5.28 (d, J  = 8.0 Hz, 1H), 4.02-3.96 (m, 1H), 3.72-3.65 
(m, 1H), 3.20-3.13 (m, 1H), 2.10-2.01 (m, 1H), 1.97-1.85 (m, 3H), 0.18 (s, 9H). 13C NMR (CDCl3, 75 
MHz): 5 160.2, 97.6, 95.9, 67.5, 62.1, 46.7, 27.9, 25.4, -0.3. HRMS (ESI) m/z calcd for C„H18NO2Si 
(M+H)+: 224.1107, found: 224.1096.
(lS)-N-feri-Butoxycarbonyl-2-[(£)-1-hydroxyprop-2-ynyl]pyrrolidine (38)
_H To a solution of TMS-acetylene 33 (2.39 g, 8.03 mmol) in MeOH (80 mL) at 0 °C 
N g ^  was added K2CO3 (1.34 g, 1.2 equiv). The solution was stirred for 1.5 h at rt after
N H 4Boc oh which the reaction mixture was quenched with saturated aqueous NH4Cl (80 mL) and
CH2Cl2 (100 mL) was added. The product was extracted with CH2Cl2 (3 x 80 mL). The organic layers 
were combined, dried (Na2SO4), filtered and concentrated in vacuo. The residue was purified by
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column chromatography (EtOAc/heptane, 0:1— 1:1) to afford 38 (1.77 g, 98% yield) as a white solid. 
R /0.42 (EtOAc/heptane, 1:1). Mp 65.4 °C. [a]D0 -90.0 (c 0.30, CH2Q 2). IR (ATR) 3386, 3296, 2971, 
2928, 2881, 1667, 1401, 1367, 1163, 1121, 1053, 655 cm-1. 1H NMR (CDCl3, 400 MHz): 5 5.26 (bs, 
1H), 4.33-4.31 (m, 1H), 4.09-4.01 (m, 1H), 3.47-3.42 (m, 1H), 3.35 (ddd, J  = 5.1, 7.3, 10.8 Hz, 1H),
2.43 (d, J  = 2.2 Hz, 1H), 2.13-1.77 (m, 4H), 1.47 (s, 9H). 13C NMR (CDCl3, 75 MHz): 5 157.8, 83.5,
80.9, 73.2, 67.3, 62.7, 47.8, 28.8, 28.7, 23.9. HRMS (ESI) m/z calcd for C12H20NO3 (M+H)+: 
226.1443, found: 226.1445.
Crystal data and structure refinement for compound 38.
Crystal color translucent colourless
Crystal shape rough fragment
Crystal size 0.28 x 0.23 x 0.10 mm
Emperical formula Ci2Hi9NO3
Molecular mass 225.28
Temperature 208(2) K
Radiation / wavelength MoKa (graphite mon.) / 0.71073 Â
Crystal system, space group Monoclinic, P 21
Unit cell dimensions a = 10.3970(5) Â, a = 90.00° 
b = 9.0783(4) Â, P = 100.496(4)° 
c = 13.7165(7) Â, y = 90.00°
Volume 1273.00(11) Â3
Z, calculated density 4, 1.175 mg/m3
Absorption coefficient 0.084 m m 1
Diffractometer / scan Nonius Kappa CCD with area detector f  and w scan
F(000) 488
0 range for data collection 1.51° -  27.51°
Index ranges -13< h >13, - 1 1< k >11, -17< l >17
Reflections collected / unique 39971 / 5852 [R(int) = 0.0331]
Reflections observed 4760 ([Io > 2o(Io)])
Absorption correction SADABS multiscan correction (Sheldrick, 1996)
Refinement method Full-matrix least-squares on F2
Computing SHELXL-97 (Sheldrick, 1997)
Data / restraints / parameters 5852 / 1 /309
Goodness-of-fit on F2 1.087
SHELXL-97 weight parameters 0.0527, 0.2229
Final R indices [I>2o(I)] R1 = 0.0492, WR2 = 0.1059
R indices (all data) R1 = 0.0652, wR2 = 0.1144
Absolute structure parameter -0.2(10)
Largest diff. peak and hole 0.199 and -0.179 e Â -3
(£)-N-feri-Butoxycarbonyl-2-[(.R)-1-hydroxyprop-2-ynyl]pyrrolidine (epi-38)
,—> Prepared as described above starting from TMS-acetylene epi-33 (1.50 g, 5.04 mmol).
^ N Purification by column chromatography (EtOAc/heptane, 0:1— 1:1) afforded epi-38 
BoH oh (1.10 g, 97% yield) as a white solid. R/ 0.65 (EtOAc/heptane, 1:1). Mp = 121.2. [a]D0 
-93.7 (c 0.84, CH2Cl2). IR (ATR): 3399, 3253, 2971, 2125, 16.42, 1424, 1176 cm-1. !H NMR (CDCl3,
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400 MHz): 5 6.16 (d, J  = 8.8  Hz, 1H), 4.42 (d, J  = 8.8  Hz, 1H), 4.06 (m, 1H), 3.58-3.53 (m, 1H), 3.38­
3.32 (m, 1H), 2.36 (m, 1H), 2.17-2.08 (m, 1H), 2.04-1.95 (m, 1H), 1.83-1.70 (m, 2H), 1.48 (s, 9H). 13C 
NMR (CDCI3, 75 MHz): 5 157.4, 82.6, 80.8, 73.2, 67.1, 63.2, 48.5, 29.3, 28.6, 24.0. HRMS (ESI) m/z 
calcd for C12H19NO3Na (M+Na)+: 248.1263, found: 248.1257.
1,2-Diiodo-4,5-dimethoxybenzene (34)
To a solution of orthoperiodic acid (8.25 g, 0.5 equiv) in EtOH (450 mL) were
II .1 successively added at rt veratrole 37 (10.0 g, 72.4 mmol), and iodine (16.5 g, 0.9 
MeO ! equiv). After stirring for 16 h at 70 °C, the mixture was cooled to ambient temperature
and saturated aqueous Na2S2O3 (200 mL) was added by which the color of the reaction mixture 
changed from purple to white. White precipitates were filtered off, and the filtrate was washed with 
H2O (2 x 200 mL) and brine (200 mL), dried (Na2SO4), and concentrated in vacuo. The residue was 
purified by column chromatography (EtOAc/heptane, 0:1 —> 1: 4) to afford 34 (280.1 g, 99% yield) as a 
white solid. Rf  0.64 (EtOAc/heptane, 1:2). 'H NMR (CDCl3, 400 MHz): 5 7.23 (s, 2H), 3.83 (s, 2H). 
13C NMR (CDCl3, 75 MHz): 5 149.7, 121.7, 96.2, 56.3. Data are in agreement with literature.37
3'-(Benzyloxy)-2-iodo-4,5-dimethoxybiphenyl (32)
To a solution of diiodide 34 (0.13 g, 0.33 mmol) in DME (2.5 mL) were successively 
added a solution of aqueous 2.0 M Na2CO3 (0.83 mL, 5.0 equiv) and LiCl (42 mg, 3.0 
! equiv). After degassing the solution for 20 min by bubbling a stream of argon through 
the solution Pd(dppf)2Cl2 (14 mg, 5.5 mol %) and 3-(benzyloxy)phenylboronic acid (82 
mg, 1.08 equiv) were added in one portion. After stirring for 3 h at 70 °C, the reaction 
mixture was quenched with saturated aqueous NH4Cl (10 mL) and the product was 
extracted from the aqueous layer with MTBE (3 x 10 mL). The organic layers were combined, dried 
(Na2SO4), filtered and concentrated in vacuo. The residue was purified by column chromatography 
(EtOAc/heptane, 0:1— 1:3) to afford 32 (125 mg, 84% yield) as a colorless oil. Rf 0.48 
(EtOAc/heptane, 1:3). IR (ATR) 3062, 3032, 2997, 2933, 2833, 2258, 1601, 1597, 1502, 1482, 1241, 
1207, 1167, 1025, 855, 775, 733, 699 cm-1. 1H NMR (CDCl3, 400 MHz): 5 7.45-7.44 (m, 2H), 7.39­
7.36 (m, 2H), 7.34-7.29 (m, 3H), 7.00-6.92 (m, 3H), 6.81 (s, 1H), 5.10 (s, 2H), 3.88 (s, 3H), 3.83 (s, 
3H). 13C NMR (CDCl3, 75 MHz): 5 158.4, 149.2, 148.8, 145.5, 139.1, 137.1, 129.1, 128.7, 128.0,
127.6, 122.3, 121.8, 116.2, 114.2, 113.1, 86.1, 70.2, 56.3, 56.0. HRMS (EI) m/z calcd for C21H19IO3 
(M)+: 446.0379, found: 446.0382.
(5')-N-ieri-Butoxycarbonyl-2-[(5')-1-hydroxy-3-(2-iodo-4,5-dimethoxyphenyl)prop-2-
To a flask charged with Pd(PPh3)2Cl2 (426 mg, 5 mol %) and CuI (281 mg, 
20 mol %) was added a solution of diiodide 34 (6.32 g, 2.5 equiv) in 
degassed benzene (45 mL). Then the mixture was cooled to 0 °C and Et2NH 
(5.31 mL, 7.0 equiv) and alkyne 38 (1.66 g, 7.37 mmol) were added 
successively. After being stirred for 4 h at rt, the reaction was quenched with 
saturated aqueous NH4Cl (50 mL) and the product was extracted with MTBE (3 x 60 mL). The 
organic layers were combined, dried (Na2SO4), filtered and concentrated in vacuo. The residue was 
purified by column chromatography (EtOAc/heptane, 0:1— 1:1) to afford 39 (3.30 g, 92% yield) as a 
yellow solid. Rf  0.29 (EtOAc/heptane, 1:2). Mp 71.2 °C. [a]D° -53.1 (c 1.09, CH2Cl2). IR (ATR) 3378, 
2971, 2928, 2245, 1668, 1504, 1401, 1258, 1206, 1030, 911, 732 cm-1. 1H NMR (CDCl3, 400 MHz): 5 
7.19 (s, 1H), 6.97 (s, 1H), 5.35 (bs, 1H), 4.59 (d, J  = 6.5 Hz, 1H), 4.19 (dd, J  = 6.5, 12.1 Hz, 1H), 3.86
ynyl]pyrrolidine (39)
hO h
MeO
OMe
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(s, 3H), 3.84 (s, 3H), 3.48-3.38 (m, 2H), 2.20-2.19 (m, 2H), 1.98-1.80 (m, 2H), 1.49 (s, 9H). 13C NMR 
(CDCI3, 75 MHz): 5 157.9, 149.8, 149.0, 121.7, 121.0, 115.4, 90.9, 89.8, 87.1, 80.9, 68.1, 63.0, 56.3,
56.2, 47.9, 29.4, 28.6, 24.1. HRMS (ESI) m/z calcd for C20H27INO5 (M+H)+: 488.0934, found: 
488.0940.
MeO
(£)-N-feri-Butoxycarbonyl-2-[(.R)-1-hydroxy-3-(2-iodo-4,5-dimethoxyphenyl)prop-2- 
ynyl]pyrrolidine (epi-39)
HO .. Prepared as described above starting from alkyne epi-38 (1.00 g, 4.44 
mmol). Purification by column chromatography (EtOAc/heptane, 0:1—>1:2) 
afforded epi-39 (2.01 g, 93% yield) as a yellowish oil. Rf 0.33 
(EtOAc/heptane, 1:2). [a]D° -110.6 (c 1.26, CH2Cl2). IR (ATR): 3343, 2967, 
2932, 2872, 2837, 2254, 1664, 1503, 1405, 1167, 730 cm-1. 'H NMR 
(CDCl3, 400 MHz): 5 7.19 (s, 1H), 6.95 (s, 1H), 6.32 (d, J  = 8 .8  Hz, 1H), 7.71 (d, J  = 8.8  Hz, 1H), 4.15 
(dd, J  = 7.0, 7.0 Hz, 1H), 3.86 (s, 3H), 3.84 (s, 3H), 3.60-3.49 (m, 2H), 2.23-2.14 (m, 1H), 2.08-1.94 
(m, 2H), 1.81-1.72 (m, 1H), 1.48 (s, 9H). 13C NMR (CDCl3, 75 MHz): 5 157.4, 149.8, 149.0, 122.0,
121.0, 115.5, 90.0, 89.2, 87.1, 80.7, 67.8, 63.4, 56.3, 56.1, 48.7, 29.5, 28.7, 24.2. HRMS (ESI) m/z 
calcd for C20H27INO5 (M+H)+: 488.0934, found: 488.0929.
OMe
(£)-N-teri-Butoxycarbonyl-2-{(£)-3-[3'-(benzyloxy)-4,5-dimethoxybiphenyl-2-yl]-1-hydroxyprop-
2-ynyl}pyrrolidine (26)
To a solution of iodide 39 (1.00 g, 2.05 mmol) in DME (16 mL) was 
successively added a solution of aqueous 2.0 M Na2CO3 (5.13 mL, 5.0 
equiv) and LiCl (261 mg, 3.0 equiv). After degassing the solution for 20 min 
by bubbling a stream of argon through the solution Pd(dppf)2Cl2 (83.0 mg,
5.5 mol %) and 3-(benzyloxy)phenylboronic acid (505 mg, 1.08 equiv) were 
added in one portion. After stirring for 3 h at 70 °C, the reaction mixture was 
quenched with saturated aqueous NH4Q  (30 mL) and the product was extracted from the aqueous 
layer with MTBE (3 x 30 mL). The organic layers were combined, dried (Na2SO4), filtered and 
concentrated in vacuo. The residue was purified by column chromatography (EtOAc/heptane, 
0:1— 1:2) to afford 26 (891 mg, 81% yield) as a yellow solid. Rf 0.54 (EtOAc/heptane, 1:1). Mp 56.8 
°C. [a]D0 -49.1 (c 1.01, CH2Cl2). IR (ATR) 3378, 3343, 2971, 2933, 2881, 2842, 2250, 1671, 1514, 
1394, 1251, 1153, 1031, 909, 730, 698 cm-1. !H NMR (CDCl3, 400 MHz): 5 7.46-7.44 (m, 2H), 7.40­
7.36 (m, 2H), 7.33-7.29 (m, 2H), 7.19 (s, 1H), 7.15-7.13 (m, 1H), 7.07 (s, 1H), 6.96-6.93 (m, 1H), 6.81 
(s, 1H), 5.33 (d, J  = 2.7 Hz, 1H), 5.11 (s, 2H), 4.41 (dd, J  = 2.7, 5.4 Hz, 1H), 3.96-3.93 (m, 1H), 3.88 
(s, 3H), 3.89 (s, 3H), 3.36-3.30 (m, 1H), 3.26-3.20 (m, 1H), 1.75-1.59 (m, 4H), 1.46 (s, 9H). 13C NMR 
(CDCl3, 75 MHz): 5 158.4, 157.7, 149.3, 147.9, 142.0, 137.4, 137.1, 129.0, 128.6, 128.0, 127.6, 122.0,
116.0, 115.5, 113.6, 113.0, 112.3, 90.0, 84.7, 80.7, 70.1, 67.9, 62.9, 56.1, 56.0, 47.7, 28.6, 28.5, 23.8. 
HRMS (ESI) m/z calcd for C33H38NO6 (M+H)+: 544.2699, found: 544.2724.
(£)-N-feri-Butoxycarbonyl-2-{(.R)-3-[3'-(benzyloxy)-4,5-dimethoxybiphenyl-2-yl]-1-hydroxyprop-
2-ynyl}pyrrolidine (epi-26)
Prepared as described above starting from iodide epi-39 (1.50 g, 3.08 mmol). 
Purification by column chromatography (EtOAc/heptane, 0:1— 1:2) afforded 
epi-26 (1.41 g, 84% yield) as a yellowish solid. Rf 0.26 (EtOAc/heptane, 
1:2). Mp 55.7 °C. [a]D0 -86.5 (c 1.41, CH2Cl2). IR (ATR): 3516, 3373, 3317, 
2963, 2928, 2846, 2250, 2215, 1665, 1514, 1392, 1251, 1152, 1026, 732
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cm-1. !H NMR (CDCl3, 400 MHz): 5 7.46-7.28 (m, 6H), 7.16-7.12 (m, 2H), 7.04 (s, 1H), 6.96-6.93 (m, 
1H), 6.80 (s, 1H), 6.02 (d, J  = 8.5 Hz), 5.10 (s, 2H), 4.56 (d, J  = 8.5 Hz), 3.99 (dd, J  = 6.9, 6.9 Hz),
3.89 (s, 3H), 3.88 (s, 3H), 3.35-3.32 (m, 1H), 2.88-2.82 (m, 1H), 1.94-1.88 (m, 1H), 1.61-1.44 (m, 
3H), 1.42 (s, 9H). 13C NMR (CDCl3, 75 MHz): 5 158.4, 157.2, 149.2, 148.0, 142.2, 137.1, 129.1,
128.7, 128.1, 127.7, 127.6, 122.1, 116.0, 115.7, 113.6, 113.3, 112.4, 89.0, 84.8, 80.5, 70.2, 67.6, 63.3,
56.2, 56.1, 48.2, 29.0, 28.5, 23.9. HRMS (ESI) m/z calcd for C33H38NO6 (M+H)+: 544.2699, found: 
544.2702.
OMe
(1£,7£)-Tetrahydro-1-{2-[3'-(Benzyloxy)-4,5-dimethoxybiphenyl-2-yl]ethynyl}-1.ff,3fl- 
pyrrolo[1,2-c]oxazol-3-one (41)
To a stirred solution of biphenyl 26 (150 mg, 0.276 mmol) and 2,6-lutidine 
(140 ^L, 4.3 equiv) in dry CH2Cl2 (3 mL) at 0 °C was added dropwise 
TMSOTf (200 ^L, 4.0 equiv). The reaction mixture was stirred for 3 h at rt, 
quenched with H2O (10 mL) and the aqueous layer was extracted with 
EtOAc (3 x 10 mL). The organic layers were combined, dried (Na2SO4) and 
concentrated in vacuo. The crude product was dissolved in dry THF (3 mL) 
and freshly distilled Et3N (115 ^L, 3.0 equiv) and (Im)2CO (160 mg, 3.5 equiv) were added 
successively at rt. The resulting reaction mixture was heated to 50 °C and stirred overnight. After 
cooling to rt the mixture was concentrated in vacuo. Column chromatography (EtOAc/heptane, 
0:1— 1:1) afforded the desired product 41 (1.02 g, 79%) as an off-white solid. Rf 0.31 (EtOAc/heptane, 
1:1). Mp 49.3 °C. [a]D0 -67.6 (c 0.63, CH2Cl2). IR (ATR) 2963, 2928, 2898, 2837, 2228, 1754, 1515, 
1251, 1207, 1155, 1025, 780, 731 cm-1. !H NMR (CDCl3, 400 MHz): 5 7.48-7.45 (m, 2H), 7.41-7.36 
(m, 2H), 7.35-7.30 (m, 2H), 7.21-7.20 (m, 1H), 7.16-7.14 (m, 1H), 7.04 (s, 1H), 6.99-6.96 (m, 1H), 
6.85 (s, 1H), 5.10 (s, 2H), 4.98 (d, J  = 4.0 Hz, 1H), 3.91 (s, 3H), 3.90 (s, 3H), 3.78 (ddd, J  = 4.0, 6.0,
9.7 Hz, 1H), 3.63-3.56 (m, 1H), 3.09 (ddd, J  = 4.6, 9.1, 11.4 Hz, 1H), 2.05-1.94 (m, 2H), 1.85-1.75 (m, 
1H), 1.47-1.37 (m, 1H). 13C NMR (CDCl3, 75 MHz): 5 160.3, 158.5, 150.1, 148.0, 141.5, 138.1,
137.1, 129.1, 128.6, 128.0, 127. 5, 121.9, 115.9, 115.5, 113.8, 112.4, 111.5, 87.8, 86.0, 70.1, 69.9,
65.9, 56.2, 56.1, 45.8, 30.2, 25.5. HRMS (ESI) m/z calcd for C29H29NO5 (M+H)+: 470.1968, found: 
470.1963.
(1.R,7£)-Tetrahydro-1-{2-[3'-(benzyloxy)-4,5-dimethoxybiphenyl-2-yl]ethynyl}-1.ff,3fl- 
pyrrolo[1,2-c]oxazol-3-one (epi-41)
Prepared as described above starting from biphenyl epi-26 (1.20 g, 2.21 
mmol). Purification by column chromatography (EtOAc/heptane, 0:1— 1:2) 
afforded epi-41 (798 mg, 77% yield) as a off-white solid. Rf  0.32 
(EtOAc/heptane, 1:1). Mp 58.7 °C. [a]D0 -17.5 (c 1.05, CH2Cl2). IR (ATR) 
2971, 2928, 2898, 2842, 2232, 1753, 1601, 1515, 1376, 1254, 1221, 1162, 
OMe 1026, 776, 733, 703 cm-1. 1H NMR (CDCl3, 400 MHz): 5 7.47-7.45 (m, 2H),
7.41-7.37 (m, 2H), 7.35-7.30 (m, 2H), 7.12-7.08 (m, 2H), 7.03 (s, 1H), 6.99-6.96 (m, 1H), 6.82 (s, 
1H), 5.39 (d, J  = 7.9 Hz, 1H), 5.10 (s, 2H), 3.92 (s, 3H), 3.91 (s, 3H), 3.90-3.87 (m, 1H), 3.59 (ddd, J  
= 6.9, 8.1, 11.3 Hz, 1H), 3.09 (ddd, J  = 4.3, 8.8, 11.3 Hz, 1H), 1.88-1.48 (m, 4H). 13C NMR (CDCl3, 
75 MHz): 5 160.2, 158.7, 150.1, 148.1, 141.8, 138.4, 137.1, 129.3, 128.7, 128.1, 127.7, 122.1, 116.1,
115.6, 113.8, 112.5, 111.7, 89.6, 83.1, 70.2, 68.1, 62.4, 56.3, 56.2, 46.6, 27.6, 25.5. HRMS (ESI) m/z 
calcd for C29H28NO5 (M+H)+: 470.1968, found: 470.1953.
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(5')-N-ieri-Butoxycarbonyl-2-{(5',£)-3-[3'-(benzyloxy)-4,5-dimethoxybiphenyl-2-yl]-1- 
hydroxyprop-2-enyl}pyrrolidine (47)
To a solution of biphenyl 26 (1.34 g, 2.46 mmol) in dry THF (30 mL) at -20  
°C was dropwise added Red-Al (903 ^L of a 65 wt. % solution in toluene, 2.96 
mmol, 1.2 equiv). After addition was complete, the solution was allowed to 
warm to 0 °C over 3 h and carefully quenched by the addition of aqueous 0.1 
M HCl (2 mL). The resulting solution was diluted with EtOAc (60 mL) and 
H2O (60 mL). The aqueous layer was extracted with EtOAc (3 x 60 mL). The 
organic layers were combined, dried (Na2SO4) and concentrated in vacuo. Column chromatography 
(EtOAc/heptane, 0:1—> 1:1) afforded the desired product 47 (1.14 g, 85°%) as a white foam. R/ 0.29 
(EtOAc/heptane, 1:2). Mp 60.3 °C. [a]D0 -55.6 (c 1.07, CH2Cl2). IR (ATR) 3352, 2971, 2937, 2876, 
2250, 1661, 1510, 1398, 1246, 1162, 1135, 910, 730, 698 cm-1. 'H NMR (CDCl3, 400 MHz): 5 7.45­
7.28 (m, 6H), 7.11 (s, 1H), 6.96-6.91 (m, 3H), 6.76 (s, 1H), 6.54 (d, J  = 15.8 Hz, 1H), 5.98 (dd, J  =
7.7, 15.8 Hz, 1H), 5.42 (bs, 1H), 5.08 (s, 2H), 3.99-3.94 (m, 1H), 3.94 (s, 3H), 3.86 (s, 3H), 3.51-3.39 
(m, 1H), 3.31-3.26 (m, 1H), 1.91-1.65 (m, 4H), 1.47 (s, 9H). 13C NMR (CDCl3, 75 MHz): 5 158.6,
158.1, 158.0, 148.6, 142.3, 137.1, 133.8, 131.1, 129.3, 129.1, 128.7, 128.1, 127.6, 127.4, 122.9, 116.7,
113.3, 112.9, 108.9, 80.7, 78.5, 70.1, 62.9, 56.2, 56.1, 47.6, 28.9, 28.6, 24.0. HRMS (ESI) m/z calcd 
for C33H39NO6N  (M+Na)+: 568.2675, found: 568.2680.
(£)-N-feri-Butoxycarbonyl-2-{(.R,£)-3-[3'-(benzyloxy)-4,5-dimethoxybiphenyl-2-yl]-1- 
hydroxyprop-2-enyl}pyrrolidine (epi-47)
Prepared as described above starting from biphenyl epi-26 (245 mg, 0.451 
mmol). Purification by column chromatography (EtOAc/heptane, 0:1— 1:1) 
afforded epi-47 (143 mg, 58% yield) as acolorless oil. R /0.24 (EtOAc/heptane, 
1:1). [a]D0 -79.1 (c 0.82, CH2Cl2). IR (ATR) 3382, 2971, 2928, 2353, 2332, 
1684, 1511, 1396, 1248, 1167, 1136, 1028, 608 cm-1. !H NMR (CDCl3, 400 
MHz): 5 7.46-7.44 (m, 2H), 7.41-7.37 (m, 2H), 7.35-7.28 (m, 2H), 7.07 (s, 
1H), 6.97-6.90 (m, 3H), 6.76 (s, 1H), 6.53 (d, J  = 15.7 Hz, 1H), 5.94 (dd, J  = 7.5, 15.7 Hz, 1H), 5.12 
(bs, 1H), 5.09 (s, 2H), 4.17-4.10 (m, 1H), 3.94 (s, 3H), 3.87 (s, 3H), 3.50-3.46 (m, 1H), 3.25-3.18 (m, 
1H), 2.01-1.67 (m, 4H), 1.47 (s, 9H). 13C NMR (CDCl3, 75 MHz): 5 158.7, 148.6, 148.5, 142.3, 137.1,
133.8, 131.1, 129.2, 128.7, 128.1, 127.7, 122.9, 116.7, 113.3, 113.0, 109.2, 80.4, 76.3, 70.2, 63.3,
56.2, 56.1, 48.3, 29.8, 28.6, 24.2. HRMS (ESI) m/z calcd for C33H39NO6N  (M+Na)+: 568.2675, 
found: 568.2660.
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Enantioselective Chemoenzymatic 
Synthesis of cis- and trans-2,5- 
Disubstituted Morpholines
A  versatile synthesis o f enantiomerically pure cis- and ¿ra«s-2,5-disubstituted morpholines is 
described. Hydroxynitrile lyase-mediated cyanide addition onto aldehydes provided 
cyanohydrins in virtually quantitative yield and excellent enantioselectivity. Subsequent 
formation o f  diastereomerically pure amino esters via a three-step one-pot reduction- 
transimination-reduction sequence, followed by reduction and simultaneous protection 
provided the cyclization precursors. Finally, cyclization and SmI2-mediated reductive 
detosylation completed the synthesis o f  cis- and fra«s-2,5-disubstituted morpholines in good  
yields and excellent diastereoselectivities.
OH
+
All 4 possible 
diastereoisomers
Part of this chapter has been published: Ritzen, B.; Hoekman, S.; Duran Verdasco, E.; van Delft, F. L.; 
Rutjes, F. P. J. T. J. Org. Chem. 2010, 75, 3461-3464.
Chapter 5
5.1 Introduction
Substituted morpholines have attracted considerable interest due to their presence in a vast 
number o f  therapeutically and biologically active compounds.1 For instance, reboxetine (1), a 
potent antidepressant drug, selectively inhibits the norepinephrine reuptake and is widely 
studied for its pharmacological properties (Figure 5.1).2 Aprepitant (2) has recently been 
approved in combination with other agents as an effective treatment for preventing acute and 
delayed chemotherapy-induced nausea and vomiting (CINV) resulting from highly 
emetogenic chemotherapy in adults.3 The morpholine skeleton is also o f  importance for the 
construction o f a large class o f agrochemical fungicides and bactericides. Fenpropimorph (3) 
and tridemorph (4, both mixtures o f  isomers) for example, both ergosterol biosynthesis 
inhibitors, are used as agricultural fungicides in cereals.4 Furthermore, morpholines have been 
applied as chiral auxiliaries in asymmetric synthesis,5 albeit that general application is 
somewhat limited due to restricted access to stereoselective entries into these kinds o f  
molecules. Despite their importance, applications in organic synthesis are most frequently 
restricted to simple bases or N-alkylating agents. Less attention has been devoted to the 
synthesis o f  C-funtionalized morpholine derivatives, a compound class that may have 
important applications in the ongoing search to new pharmaceutically active compounds. As a 
consequence, the development o f efficient synthetic routes to C-funtionalized morpholines 
has been an important subject o f  investigation over the past decades. Various classes o f chiral 
C-functionalized disubstituted morpholine derivatives have been synthesized.1,5,6 To the best 
o f our knowledge, only two enantioselective synthetic routes to trans-2,5-disubstituted 
morpholines exist,1b,? and only one that provides access to both cis- and trans-2,5- 
disubstituted morpholines.8 However, all three strategies are rather limited in their substitution 
pattern or produce the target morpholines with only modest diastereoselectivity.
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Figure 5.1 Biologically active morpholines.
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5.2 R etrosynthetic strategy
W e recently reported a concise asymmetric synthesis o f  2,3-disubstituted trans-aziridines 
starting from enantiomerically pure cyanohydrins.9 Considering the general value o f  
morpholines, w e felt that a similar cyanohydrin-based strategy could be applied to the 
construction o f  both cis- and trans--2,5-disubstituted morpholines.
The retrosynthetic plan is outlined in Scheme 5.1. W e envisioned obtaining the morpholines 
5 in enantiopure form starting from cyanohydrins 8 and amino esters as building blocks, 
which are readily available in both enantiomeric forms. The target molecules 5 could arise via 
ring-closure o f  the amino diols 6, followed by deprotection under mild reductive conditions. 
The intermediates 6, in turn, might be accessed by coupling amino acid methyl esters with 
cyanohydrins 8 in a transimination reaction. Finally, chemoenzymatic cyanohydrin formation 
was envisioned to provide the starting compounds 8 with high enantioselectivity using 
aldehydes as substrates.
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Scheme 5.1 Retrosynthetic route to chiral morpholines.
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5.3 Chemoenzymatic asymmetric cyanohydrin formation
The synthesis commenced with the preparation o f  enantiomerically pure cyanohydrins10 
Starting from four different aldehydes and using (R)-selective HNL from Prunus amygdalus 
(PaH NL)11 and (<S)-selective HNL from Hevea brasiliensis (HbHNL)12 as catalysts, the 
corresponding cyanohydrins 8 were obtained as crude products. Subsequent protection o f the 
hydroxyl with a methoxy isopropyl (MIP) protecting group, mandatory in order to prevent 
racemization via an equilibrium with the aldehyde, afforded the cyanohydrins 10-13 (Table 
5.1) in virtually quantitative yield and excellent enantiomeric excess.
Table 5.1 HNL-mediated cyanohydrin formation and protection.
OH
A
9
HNL, HCN 
H2 O/MTBE
pH = 5.0
R CN 
8
2 -methoxy propene 
POCl3  (cat)
then Et3 N, rt
OMIP 
R CN 
10-13
entry R enzyme product yield (%) ee (%) config.
Determined by derivatization with Mosher’s acid chloride and comparison with the diastereomeric
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esters prepared from their racemic counterparts. d The stereochemical arrangement is as expected for 
(S)-HNL: however, due to priority changes following the Cahn-Ingold-Prelog rules, the product has 
the (R)-configuration.
5.4 Synthesis of MIP-protected amino alcohols
Inspired by results from van der Gen et a l.,13 cyanohydrin 10 was reacted in a three-step, 
one-pot reduction-transimination-reduction sequence to prepare the N-substituted P-amino 
ester 14. Treatment with a 5-fold excess o f DIBALH at -78  °C followed by protonation of the 
resulting imine-aluminum complex with dry methanol afforded the intermediate primary 
imine. Subsequent transimination with an excess o f glycine methyl ester and Et3N led to rapid 
formation of the more stable secondary imine upon loss o f NH3. Finally, the transimination 
product was reduced in situ with sodium borohydride at 0 °C furnishing 14 in 48% overall 
yield (entry 1, Table 5.2). The somewhat moderate yield for this reaction sequence can be 
mainly explained by overreduction o f the intermediate metallo-imine to the corresponding 
amine with DIBALH as was shown by mass spectrometry analysis. Optimizing the conditions 
to keep this side reaction to a minimum proved to be difficult. Changing the addition speed or 
lowering the amount o f DIBALH gave lower conversions, while longer exposure of the 
starting material under these conditions resulted in increased formation o f the corresponding 
amine. In the course o f determining the optimal conditions, we noticed that the use o f the MIP 
protective group turned out to be critical. When the same sequence was carried out using a 
TBS protective group, considerable side-product formation was observed due to reductive 
cleavage o f the TBS ether by DIBALH.14 Furthermore, we encountered severe difficulties in 
deprotecting the hydroxyl group in a later stage of the synthesis. In contrast, the MIP 
protective group could be readily removed under mildly acidic conditions.
Pleased with these results, we applied the one-pot reaction sequence on cyanohydrins 11-13  
using various commercially available (S)-amino acid methyl esters. Gratifyingly, the desired 
amino esters could be isolated in fair to moderate yields for the three-step sequence. In case of 
entry 5, only 10% yield was obtained, apparently as a result of increased reactivity of the 2- 
furanyl moiety toward DIBALH.
Reduction o f methyl esters 14-21 under standard conditions (LiAlH4 in THF, 0 °C) 
proceeded in all cases to give the corresponding amino alcohols in high yields. Alternatively, 
these amino alcohols might be directly obtained by coupling the cyanohydrins with the 
appropriate enantiopure P-amino alcohols. However, such attempts resulted in considerably
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decreased product formation (10-15% ) so that w e decided to focus on the amino acid methyl 
esters.
Table 5.2 Three-step one-pot coupling and reduction.
1) DIBALH, Et2O
2) H2NCHR1CO2Me
O M P  Et3N OMIPH LiAl H 4 OMIPH OH
^  R^ N^ C° 2 Me ------- 4  R^ / N^
< CN 3) NaBH4 R â t h f  R i
4 R 1 R 1MeOH R 0°C  R
1 0 -1 3  -7 8 °C  to r t  1 4 ' 2 1  2 2 ' 2 9
entry s.m. R1 methyl ester yield (%)a amino alcohol yield (%)a config.
1 10 H 14 48 22 80 (R)
2 10 Me 15 32 23 92 (R,S)
3 10 Bn 16 44 24 89 (R,S)
4 10 Allyl 17 34 25 95 (R,S)
5 11 Bn 18 10 26 88 (R,S)
6 12 Me 19 35 27 87 (SS)
7 12 Bn 20 34 28 92 (SS)
8 13 Allyl 21 47 29 97 (SS)
a Isolated yield after chromatography.
5.5 Synthesis of the morpholine scaffold
Exposure o f amino alcohol 22 to an excess o f  o-nitrobenzenesulfonyl chloride (NsCl) to 
simultaneously react the primary alcohol and the secondary nitrogen provided the desired 
product in only 35% yield. In contrast, subjection o f 22 to /-toluenesulfonyl chloride (1.1 
equiv) and triethylamine (2.0 equiv) in dichloromethane at 0 °C afforded selectively the N- 
tosylated amino alcohol 30 in 82% yield (Scheme 5.2). This product was MIP-deprotected 
under mild acidic conditions (pH 2 -3 ) and then cyclized in one step via selective tosylation o f  
the primary alcohol involving excess sodium hydride in THF, followed by /-toluenesulfonyl 
imidazole at 0 °C. Fortunately, this provided N-tosylmorpholine derivative 32 in 83% yield.
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Scheme 5.2 Synthesis o f  N-tosyl-protected 2-phenylmorpholine.
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0°C  to rt
82%
TsIm, NaH 
THF
0°C  to rt 
83%
MIPO Ts - 1 
N
30
OH
HCI (aq), THF 
pH = 2-3 
quant
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Although the sequence summarized in Scheme 5.2 was highly efficient, attempts to apply 
the same sequence to prepare 2,5-disubstituted morpholines (R1 = methyl, benzyl, allyl; 
compounds 23-29 , Table 5.3) only provided selective O-tosylation, apparently as a result o f  
increased steric hindrance o f the amino group. A  more rewarding result was obtained by 
stirring compounds 2 3 -2 9  in the presence o f p-toluenesulfonyl chloride (4.0 equiv) in 
pyridine containing triethylamine, thereby providing 3 3 -3 9  as summarized in Table 5 .3 .1b To 
facilitate purification o f  the products, ethylenediamine was added to scavenge the excess o f p - 
toluenesulfonyl chloride. Moreover, in some cases under these circumstances cleavage o f the 
MIP protective group took also place (entries 6 and 7). In other cases, subsequent 
deprotection o f  the hydroxyl group proceeded smoothly in high yields, and the crude 
morpholine precursors 4 0 -4 6  were used without further purification for the next step.
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Table 5.3 Simultaneous sulfonylation and deprotection.
OMIP,
23-29
OH
1) TsCl, Et3N 
pyridine, rt
2) ethylenediamine
OR2 TsI
N
OTs
R1
HCl (aq), THF i------  33-39 R2 = MIP
pH = 2-3 1---- ► 40-46 R2 = H
entry s.m. R R product
Yield Yield
product
(%)a (%)a
1 23
2 24
25
26
27
28
29
Me
Bn
Allyl
Bn
Me
Bn
Allyl
33
34
35
36
37
38
39
80
74
85
70
88
n.d.6
n.d.6
40
41
42
43
44
45
46
90
98
95
92
100
96c
80c
Isolated yield after chromatography. n.d. = not determined. Yield over two steps.
Subsequent cyclization under the influence o f NaH in THF at 0 °C successfully provided 
the N-tosyl-protected morpholines 32 and 47-53 in high yields (Table 5.4).
5.6 Reductive detosylation of morpholines
Finally, deprotection completed the synthesis o f  unprotected cis- and tra«s-2,5-disubstituted 
morpholines 54-61 . Generally, the robustness o f  sulfonamides can be problematic in the 
deprotection to the free amines. Traditional deprotection methods involving single electron 
donors such as lithium or sodium are often too harsh for these systems. Upon application o f  
recent methodology developed by Ankner et a l.,15 we found that by using a combination o f  
SmI2/pyrrolidine/H2O, the N-tosyl-protected morpholines 32 and 4 7 -5 3  underwent clean and
R
R
3
4
5
6
7
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instantaneous deprotection. Unfortunately, in the case o f  entries 6 and 7, lower yields were 
obtained. Mass spectrometry o f  the reaction mixture showed that under these reductive 
conditions partial dehalogenation o f the aromatic ring had occurred.
Table 5.4. Ring closure and SmI2-mediated deprotection.
OH Ts
R 1 
40 -46
OTs
NaH
THF
N^ .^R1
i y0 °C  to rt R o
SmÍ2,H2O I 
pyrrolidine, THF
32, 47-53 R3 = Ts 
54-61 R3 = H
entry s.m. R R product
Yield Yield
product 
(%)2 (%)a
Config.
2 40
3 41
4 42
5 43
6 44
7 45
8 46
.0.
Î T '
\
\
\
\
\
H
Me
Bn
Allyl
Bn
Me
Bn
Allyl
32
47
48
49
50
51
52
53
96
99
97
73
94
93
83
54
55
56
57
58
59
60
61
80
92
83
86
82
50
56
86
(R)
(RS)
(R,S)
(R,S)
(5.5)
(5.5)
(5.5)
(5.5)
2 Isolated yield after chromatography.
5.7 Conclusions
3
R
1
In summary, we have described a synthetic route that effectively provides access to 
diastereomerically pure cis- and fra«s-2,5-disubstituted morpholines. Key steps involve HNL- 
catalyzed cyanohydrin formation, a three-step, one-pot coupling sequence, and SmI2-mediated 
detosylation. Important advantages o f this sequence are the ready availability o f the two chiral
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precursors from either simple aldehydes or commercially available amino acids and the 
relatively mild character o f  the route which, in principle, allows for introduction o f various 
functional groups.
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5.9 Experimental section 
General information
For general experimental details, see section 2.8.
(W)-2-[(2-Methoxypropan-2-yl)oxy]-2-phenylacetonitrile (10)
OMIP A solution of benzaldehyde (3.10 mg, 15.1 mmol) in MTBE (50 mL) was added to a 
'on cooled (0 °C) solution of KCN (9.82 g, 151 mmol, 10.0 equiv) in citrate buffer (50 mL, 
pH = 5.0). After addition of (R)-HNL (2.56 mL) the reaction mixture was stirred at 0 °C 
for 1.5 h and quenched with 5 M HCl (15 mL), causing the enzyme to precipitate. The precipitate was 
filtered off. The filtrate was extracted with CH2Cl2 (3 x 150 mL) and the organic layers were 
combined, dried (Na2SO4) and concentrated in vacuo. The residue was dissolved in 2-methoxypropene 
(5.78 mL, 4.0 equiv) and POCl3 (3.0 ^L, 0.2 mol %) was added at rt. The reaction mixture was stirred 
at rt for 15 min. Subsequently Et3N (21.0 ^L, 1.0 mol %) was added. The reaction mixture was stirred 
at rt for 10 min. After diluting the reaction mixture with Et2O (20 mL), the organic layer was washed 
with brine (2 x 30 mL). The resulting organic fraction was dried (Na2SO4), filtered and concentrated in 
vacuo to afford 10 (3.02 g, 99% yield) as a colorless oil. R/ 0.57 (EtOAc/heptane, 1:1). [a]D0 +45.9 (c
1.03, CH2Cl2). {ref.16 [a]D0 +47.0 (c 1.00, CHCl3)}. ee >99% (HPLC eluent hexane: iPrOH = 80:20, 
flow 1.0 mL/min); Rt1 = 4.65 min (S), Rt,2 = 4.97 min (R). IR (ATR) 3413, 2984, 1017, 693 cm-1. 'H 
NMR (CDCl3, 400 MHz): 5 7.51-7.35 (m, 5H), 5.46 (s, 1H), 3.20 (s, 3H), 1.55 (s, 3H), 1.37 (s, 3H). 
13C NMR (CDCl3, 75 MHz): 5 135.0, 129.1, 128.8, 126.8, 119.1, 102.6, 61.1, 49.6, 24.7, 24.1. HRMS 
(FAB) m/z calcd for Ci2Hi6NO2 (M+H)+: 206.1181, found: 206.1185. Data are in agreement with 
literature.3
(S)-2-(2-Furyl)-2-[(2-methoxypropan-2-yl)oxy]acetonitrile (11)
o m ip  Prepared as described above starting from furfural (1.10 g, 11.45 mmol) and (S)-HNL. 
/ o ^ ^ o n  The organic layer was washed and afforded cyanohydrin 11 (2.01 g, 90% yield) as a 
'—  yellowish oil. R/ 0.65 (EtOAc/heptane, 1:1). [a]D0 -48.1 (c 1.10, CH2Cl2). ee >99%
(HPLC eluent hexane: iPrOH = 85:15, flow 1.0 mL/min); Rt,i = 5.51 min (S), Rt2 = 6.05 min (R). IR
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(ATR) 2983, 2352, 1144, 1068, 1014 cm-1. !H NMR (CDCl3, 400 MHz): 5 7.46-7.45 (m, 1H), 6.58­
6.57 (m, 1H), 6.41-6.40 (m, 1H), 5.56 (s, 1H), 3.30 (s, 3H), 1.53 (s, 3H), 1.41 (s, 3H). 13C NMR 
(CDCl3, 75 MHz): 5 147.3, 144.0, 117.1, 110.7, 110.1, 102.9, 54.9, 49.6, 24.8, 24.0. HRMS (FAB) m/z 
calcd for C10H14NO3 (M+): 196.0974, found: 196.0976.
(£)-2-(4-Bromophenyl)-2-[(2-methoxypropan-2-yl)oxy]acetonitrile (12)
° MIP Prepared as described above starting from 4-bromobenzaldehyde (1.00 g, 5.44 
|j  ^ o n  mmol) and (S)-HNL. The organic layer was washed and afforded 12 (1.54 g, 99% 
yield) as a colorless oil. R/ 0.60 (EtOAc/heptane, 1:1). [a]D0 -24.4 (c 1.44, CH2Cl2). 
ee >99% (HPLC eluent hexane: iPrOH = 95:5, flow 1.0 mL/min); Rt,i = 14.32 min (S), Rt2 = 17.27 min 
(R). IR (ATR) 3404, 2932, 2358, 1487, 1074 cm-1. !H NMR (CDCl3, 400 MHz): 5 7.55-7.52 (m, 2H),
7.37-7.35 (m, 2H), 5.44 (s, 1H), 3.19 (s, 3H), 1.54 (s, 3H), 1.37 (s, 3H). 13C NMR (CDCl3, 75 MHz): 5
134.0, 132.0, 128.4, 128.0, 123.3, 118.6, 102.8, 60.5, 49.7, 24.7, 24.1. HRMS (EI) m/z calcd for 
C12H14BrNO2 (M+): 283.0208, found: 283.0215.
(£)-2-[(2-Methoxypropan-2-yl)oxy]hex-5-enenitrile (13)
° MIP Prepared as described above starting from 4-pentenal (600 mg, 7.14 mmol) and (S)- 
HNL. The organic layer was washed and afforded 13 (1.30 g, 99% yield) as a colorless 
oil. R/  0.72 (EtOAc/heptane, 1:2). [a]D0 -41.5 (c 1.36, CH2Cl2). IR (ATR) 2950, 2360, 2333, 1215, 
1077 cm-1. 1H NMR (CDCl3, 400 MHz): 5 5.85-5.75 (ddt, J  = 6.6, 10.2, 17.0 Hz, 1H), 5.13-5.08 (m, 
1H), 5.07-5.04 (m, 1H), 4.44 (dd, J  = 6.7, 6.7 Hz, 1H), 3.26 (s, 3H), 2.35-2.22 (m, 2H), 1.95-1.84 (m, 
2H), 1.46 (s, 3H), 1.37 (s, 3H). 13C NMR (CDCl3, 75 MHz): 5 136.2, 119.8, 116.2, 102.1, 58.8, 49.7,
33.5, 28.7, 24.7, 24.2. HRMS (EI) m/z calcd for C9H14NO2 (M-CH3)+: 168.1025, found: 168.1026.
Methyl (W)-2-(2-(2-methoxypropan-2-yloxy)-2-phenylethylamino)acetate (14)
° m ip h O A solution of cyanohydrin 10 (1.00 g, 4.87 mmol) in dry Et2O (150 mL) was 
N^ ^ < O M e  cooled to -78 °C and DIBALH (24.4 mL of a 1.0 M solution in hexane, 24.4 
mmol, 5.0 equiv) was added dropwise. The reaction mixture was stirred at -78  
°C for 30 min. After quenching with dry MeOH (100 mL), (S)-alanine methyl ester hydrochloride 
(2.50 g, 2.5 equiv) and Et3N (1.70 mL, 2.5 equiv) were added. The reaction mixture was allowed to 
warm to rt and stirred for another 2 h. Then the mixture was cooled to 0 °C and NaBH4 (740 mg, 4.0 
equiv) was added. After 2 h at 0 °C the mixture was quenched with saturated aqueous NaHCO3 (30 
mL) and the product was extracted with EtOAc (3 x 60 mL). The organic layers were combined, dried 
(Na2SO4), filtered and concentrated in vacuo. The residue was purified by column chromatography 
(EtOAc/heptane, 1:3—>1:1) to afford 14 (663 mg, 48% yield) as a colorless oil. R/ 0.17 
(EtOAc/heptane, 1:1). [a]D0 -79.1 (c 1.00, CH2Cl2). IR (ATR) 2980, 2937, 2360, 1735, 1201, 702 
cm-1. :H NMR (CDCl3, 400 MHz): 5 7.36-7.26 (m, 5H), 4.84 (dd, J  = 5.3, 7.0 Hz, 1H), 3.69 (s, 3H),
3.43 (d, J  = 17.3 Hz, 1H), 3.37 (d, J  = 17.2 Hz, 1H), 3.12 (s, 3H), 2.90 (dd, J  = 7.2, 11.9 Hz, 1H), 2.77 
(dd, J  = 5.2, 11.9 Hz, 1H), 2.10 (br s, 1H), 1.42 (s, 3H), 1.14 (s, 3H). 13C NMR (CDCl3, 75 MHz): 5
172.5, 142.9, 128.1, 127.2, 126.4, 101.2, 72.6, 56.3, 51.6, 50.6, 49.1, 26.0, 25.0. HRMS (ESI) m/z 
calcd for C15H23NO4Na (M+Na)+: 304.1525, found: 304.1515.
Methyl (£)-2({(.R)-2-[(2-methoxypropan-2-yl)oxy]-2-phenylethyl}amino)propanoate (15)
° MIPh °  Prepared as described above starting from cyanohydin 10 (500 mg, 2.44 
H ^J^°Me mmol) and glycine methyl ester hydrochloride (850 mg, 2.5 equiv). Column 
Me chromatography (EtOAc/heptane, 1:2— 1:1) afforded 15 (233 mg, 32% yield)
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as a colorless oil.R/  0.76 (EtOAc/heptane, 1:1). [a]D0 -96.2 (c 1.21, CH2Cl2). IR (ATR) 2984, 2360, 
1738, 1206 cm-1. !H NMR (CDCl3, 400 MHz): 5 7.35-7.21 (m, 5H), 4.81 (dd, J  = 4.5, 8.1 Hz, 1H), 
3.69 (s, 3H), 3.34 (q, J  = 6.9 Hz, 1H), 3.14 (s, 3H), 2.85 (dd, J  = 8.1, 11.9 Hz, 2H), 2.61 (dd, J  = 4.5,
11.9 Hz, 2H), 1.85 (br s, 1H), 1.42, (s, 3H), 1.26 (d, J  = 7.0 Hz, 3H), 1.14, (s, 3H). 13C NMR (CDCl3, 
75 MHz): 5 175.8, 143.2, 128.1, 127.1, 126.4, 101.1, 73.2, 56.4, 55.1, 51.6, 49.2, 26.0, 25.1, 18.7. 
HRMS (ESI) m/z calcd for C16H25NO4 (M+H)+: 296.1862, found: 296.1849.
Methyl (£)-2-({(.R)-2-[(2-methoxypropan-2-yl)oxy]-2-phenylethyl}amino)-3-phenylpropanoate
1.10, CH2Cl2). IR (ATR) 2924, 2354, 1734, 1162, 701 cm-1. 1H NMR (CDCl3, 400 MHz): 5 7.28-7.16 
(m, 8H), 7.11-7.09 (m, 2H), 4.76 (dd, J  = 4.9, 7.6 Hz, 1H), 3.60 (s, 3H), 3.49 (dd, J  = 6.8, 6.8 Hz, 1H),
3.07 (s, 3H), 2.92-2.87 (m, 3H), 2.55 (dd, J  = 4.9, 12.0 Hz, 1H), 1.78 (br s, 1H), 1.37 (s, 3H), 1.10 (s, 
3H). 13C NMR (CDCl3, 75 MHz): 5 174.6, 143.1, 137.1, 129.0, 128.1, 128.0, 127.0, 126.4, 126.4,
101.0, 73.0, 62.8, 55.0, 51.3, 49.0, 39.4, 26.0, 25.0. HRMS (ESI) m/z calcd for C22H29NO4 (M+H)+: 
372.2175, found: 372.2170.
Methyl (S)-2-({(,R)-2-[(2-methoxypropan-2-yl)oxy]-2-phenylethyl}amino)pent-4-enoate (17)
Prepared as described above starting from cyanohydin 10 (282 mg, 1.37
1.19, CH2Cl2). IR (ATR) 2989, 2941, 2357, 1737, 1204 cm-1. !H NMR (CDCl3, 400 MHz): 5 7.35­
7.27 (m, 4H), 7.24-7.20 (m, 1H), 5.74-5.64 (m, 1H), 5.07-5.00 (m, 2H), 4.80 (dd, J  = 4.8, 8.0 Hz, 1H). 
3.68 (s, 3H), 3.31 (dd, J  = 6.4, 6.4 Hz, 1H), 3.12 (s, 3H), 2.89 (dd, J  = 8.0, 11.9 Hz, 1H). 2.57 (dd, J  =
4.8, 11.9 Hz, 1H), 2.40-2.36 (m, 2H), 1.95 (br s, 1H), 1.41 (s, 3H), 1.12 (s, 3H). 13C NMR (CDCl3, 75 
MHz): 5 174.6, 143.2, 133.3, 128.0, 127.0, 126.4, 117.7, 101.0, 73.1, 60.9, 55.1, 51.4, 49.1, 37.5, 26.0,
25.0. HRMS (ESI) m/z calcd for C18H27NO4Na (M+Na)+: 344.1838, found: 344.1825.
Methyl (£)-2-({(£)-2-(2-furyl)-2-[(2-methoxypropan-2-yl)oxy]ethyl}amino)-3-phenylpropanoate
(18)
OMIP °  Prepared as described above starting from cyanohydin 11 (500 mg, 2.56
CH2Cl2). IR (ATR) 2993, 2946, 1735, 1206, 1147 cm-1. 1H NMR (CDCl3, 400 MHz): 5 7.33-7.32 (m, 
1H), 7.28-7.14 (m, 5H), 6.28 (dd, J  = 1.8, 3.2 Hz, 1H), 6.19-6.18 (m, 1H), 4.80 (dd, J  = 6.5, 6.5 Hz, 
1H), 3.63 (s, 3H), 3.55 (dd, J  = 6.3, 7.6 Hz, 1H), 3.01 (s, 3H), 2.98-2.92 (m, 2H), 2.87 (dd, J  = 7.6,
13.5, 1H), 2.82 (dd, J  = 6.8, 11.7 Hz, 1H), 1.75 (br s, 1H), 1.32 (s, 3H), 1.19 (s, 3H). 13C NMR 
(CDCl3, 75 MHz): 5 174.4, 154.7, 141.5, 137.1, 129.0, 128.3, 126.5, 110.0, 107.1, 101.1, 65.9, 62.9,
51.6, 51.5, 48.9, 39.3, 24.9, 24.8. HRMS (ESI) m/z calcd for C20H27NO5Na (M+Na)+: 384.1787, 
found: 384.1767.
Prepared as described above starting from cyanohydin 10 (500 mg, 2.44 
‘°Me mmol) and (S)-phenylalanine methyl ester hydrochloride (2.03 g, 2.5 equiv). 
^  Column chromatography (EtOAc/heptane, 1:3— 1:1) afforded 16 (403 mg, 
44% yield) as a colorless oil. R/ 0.61 (EtOAc/heptane, 1:1). [a]D0 -63.2 (c
"°Me mmol) and (S)-allylglycine methyl ester hydrochloride (565 mg, 2.5 equiv). 
Column chromatography (EtOAc/heptane, 1:4— 1:1) afforded 17 (152 mg, 
34% yield) as a colorless oil. R/ 0.49 (EtOAc/heptane, 1:1). [a]D0 -85.2 (c
'°Me mmol) and (S)-phenylalanine methyl ester hydrochloride (1.38 g, 2.5 equiv).
Column chromatography (EtOAc/heptane, 1:5— 1:1) afforded 18 (90 mg, 10% 
^  yield) as a yellowish oil. R/ 0.53 (EtOAc/heptane, 1:1). [a]D0 +23.7 (c 1.88,
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Methyl (£)-2-({(£)-2-(4-bromophenyl)-2-[(2-methoxypropan-2-yl)oxy]ethyl}amino)propanoate
(19)
omiph o Prepared as described above starting from cyanohydin 12 (500 mg, 1.77 
V i O M e  mmol) and (S)-alanine methyl ester hydrochloride (617 mg, 2.5 equiv). 
Me Column chromatography (EtOAc/heptane, 1:5—>1:1) afforded 19 (232 mg,
35% yield) as a colorless oil. Rf 0.37 (EtOAc/heptane, 1:1). [a]D0 +51.5 (c 
2.59, CH2Cl2). IR (ATR) 2997, 2941, 2353, 1737, 1206, 1150, 1071, 1042 cm-1. 'H NMR (CDCl3, 400 
MHz): 5 7.46-7.44 (m, 2H), 7.25-7.23 (m, 2H), 4.75 (dd, J  = 6.3, 6.3 Hz, 1H), 3.68 (s, 3H), 3.35 (q, J  
= 7.0 Hz, 1H), 3.10 (s, 3H), 2.79 (dd, J  = 6.2, 11.6 Hz, 1H), 2.73 (dd, J  = 6.3, 11.6 Hz, 1H), 1.65 (br s, 
1H), 1.40 (s, 3H), 1.24 (d, J  = 7.0 Hz, 1H), 1.13 (s, 3H). 13C NMR (CDCl3, 75 MHz): 5 175.6, 142.0, 
131.2, 128.3, 120.9, 101.1, 71.9, 56.4, 54.2, 51.5, 49.1, 25.8, 24.9, 18.7. HRMS (ESI) m/z calcd for 
Ci6H24BrNO4 (M+H)+: 374.0967, found: 374.0966.
Methyl (£)-2-({(£)-2-(4-bromophenyl)-2-[(2-methoxypropan-2-yl)oxy]ethyl}amino)-3-phenylpro- 
panoate (20)
Prepared as described above starting from cyanohydin 12 (500 mg, 1.77 
mmol) and (S)-phenylalanine methyl ester hydrochloride (953 mg, 2.5 
equiv). Column chromatography (EtOAc/heptane, 1:5— 1:1) afforded 20
OMIP.
Br
HA m
'O (278 mg, 34% yield) as a colorless oil. Rf  0.61 (EtOAc/heptane, 1:1). [a]+60.8 (c 3.02, CH2Cl2). IR (ATR) 2944, 2349, 1735, 1205, 1071 cm-1. 1H 
NMR (CDCl3, 400 MHz): 5 7.40-7.36 (m, 2H), 7.28-7.19 (m, 3H), 7.14-7.10 (m, 4H), 4.69 (dd, J  = 
6.1, 6.1 Hz, 1H), 3.61 (s, 3H), 3.51 (dd, J  = 6.1, 7.7 Hz, 1H), 3.00 (s, 3H), 2.94 (dd, J  = 6.0, 13.5 Hz, 
1H), 2.84 (dd, J  = 7.7, 13.5 Hz, 1H), 2.79 (dd, J  = 5.7, 11.7 Hz, 1H), 2.66 (dd, J  = 6.6, 11.7 Hz, 1H), 
1.70 (br s, 1H), 1.31 (s, 3H), 1.06 (s, 3H). 13C NMR (CDCl3, 75 MHz): 5 174.3, 142.0, 137.0, 131.0, 
129.0, 128.2, 128.2, 126.5, 120.8, 101.0, 71.6, 62.8, 54.5, 51.4, 49.0, 39.2, 25.7, 24.8. HRMS (ESI) 
m/z calcd for C22H28BrNO4 (M+H)+: 450.1280, found: 450.1276.
20
D
Methyl (S)-2-({(R)-2-[(2-methoxypropan-2-yl)oxy]hex-5-enyl}amino)pent-4-enoate (21)
0 MIPH o Prepared as described above starting from cyanohydin 13 (393 mg, 2.15 
— 'NV^OMe mmol) and (S)-allylglycine methyl ester hydrochloride (700 mg, 2.0 equiv).
\  Column chromatography (EtOAc/heptane, 1:5— 1:1) afforded 21 (299 mg, 
 ^ 47% yield) as a colorless oil. Rf 0.54 (EtOAc/heptane, 1:1). [a]D0 -11.5 (c 
1.14, CH2Cl2). IR (ATR) 2991, 2939, 2359, 2337, 1738, 1202 cm-1. 1H NMR (CDCl3, 400 MHz): 5 
5.86-5.73 (m, 2H), 5.12-4.99 (m, 3H), 4.96-4.93 (m, 1H), 3.86-3.80 (m, 1H), 3.70 (s, 3H), 3.29 (dd, J  
= 6.6, 6.6 Hz, 1H), 3.23 (s, 3H), 2.72 (dd, J  = 4.8, 11.4 Hz, 1H), 2.49 (dd, J  = 4.8, 11.7 Hz, 1H), 2.42­
2.39 (m, 2H), 2.10-2.04 (m, 2H), 1.78-1.69 (m, 2H), 1.66-1.58 (m, 1H), 1.36 (s, 3H), 1.35 (s, 3H). 13C 
NMR (CDCl3, 75 MHz): 5 174.8, 138.4, 133.7, 117.5, 114.2, 100.5, 70.0, 61.4, 51.3, 51.0, 48.9, 37.5, 
32.3, 29.4, 25.1, 25.0. HRMS (ESI) m/z calcd for C16H29NO4 (M+H)+: 300.2174, found: 300.2167.
(W)-2-(2-[(2-Methoxypropan-2-yl)oxy]-2-phenylethylamino)ethanol (22)
OMIP ■ A suspension of LiALH4 (81 mg, 2.0 equiv) in dry THF (20 mL) was cooled to
oh 0 °C and a solution of ester 14 (313 mg, 1.06 mmol) in dry THF (10 mL) was 
added dropwise. The reaction mixture was stirred at 0 °C for 2 h. After 
quenching with water (95 ^L, 5.0 equiv) the mixture was concentrated in vacuo and purified by 
column chromatography (CH2Cl2/MeOH, 0.99:0.01—0.90:0.10) to afford 22 (215 mg, 80% yield) as a 
colorless oil. Rf  0.65 (CH2Cl2/MeOH, 0.9:0.1). [a]D0 -78.5 (c 1.10, CH2Cl2). IR (ATR) 3321, 2992,
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2932, 2362, 1453, 1068, 703 cm-1. 1H NMR (CDCl3, 400 MHz): 5 7.36-7.23 (m, 5H), 4.89 (dd, J  =
5.1, 7.5 Hz, 1H), 3.65-3.63 (m, 2H), 3.16 (br s, 2H), 3.13 (s, 3H), 2.93 (dd, J  = 7.5, 12.4 Hz, 1H), 
2.88-2.83 (m, 3H), 1.43 (s, 3H), 1.16 (s, 3H). 13C NMR (CDCl3, 75 MHz): 5 141.8, 128.3, 127.6,
126.4, 101.7, 71.6, 59.4, 55.5, 50.6, 49.7, 25.2, 25.1. HRMS (ESI) m/z calcd for C14H23NO3Na 
(M+Na)+: 276.1576, found: 276.1575.
(S)-2-({(^)-2-[(2-Methoxypropan-2-yl)oxy]-2-phenylethyl}amino)propan-1-ol (23)
omipH Prepared as described above starting from ester 15 (0.14 g, 0.47 mmol).
N^ o h  Column chromatography (CH2Cl2/MeOH, 0.99:0.01—0.90:0.10) afforded 23 
Me (0.12 g, 92% yield) as a colorless oil. Rf 0.76 (C^C^/MeOH, 0.9:0.1). [a]D0 
-47.4 (c 1.10, CH2Cl2). IR (ATR) 3304, 2920, 1038 cm-1. 1H NMR (CDCl3, 400 MHz): 5 7.36-7.30 
(m, 4H), 7.27-7.23 (m, 1H), 4.81 (dd, J  = 6.3, 6.3 Hz, 1H), 3.53 (dd, J  = 4.1, 10.6 Hz, 1H), 3.20 (dd, J  
= 7.2, 10.6 Hz, 1H), 3.13 (s, 3H), 2.93 (dd, J  = 5.6, 12.0 Hz, 1H), 2.82-2.75 (m, 2H), 2.07 (br s, 1H),
1.42 (s, 3H), 1.15 (s, 3H), 1.00 (d, J  = 6.5 Hz, 3H). 13C NMR (CDCl3, 75 MHz): 5 143.0, 128.2, 127.2,
126.5, 101.2, 72.7, 65.2, 54.1, 53.5, 49.3, 25.8, 25.1, 16.9. HRMS (ESI) m/z calcd for C15H25NO3 
(M+H)+: 268.1913, found: 268.1909.
(S)-2-({(^)-2-[(2-Methoxypropan-2-yl)oxy]-2-phenylethyl}amino)-3-phenylpropan-1-ol (24)
0mipH Prepared as described above starting from ester 16 (177 mg, 0.477 mmol).
(j^ sj v N^ o h  Column chromatography (CH2Cl2/MeOH, 0.99:0.01—0.90:0.10) afforded 24 
 ^ " * (146 mg, 89% yield) as a colorless oil. Rf 0.49 (CH2Cl2/MeOH, 0.9:0.1). [a]D0
-71.0 (c 1.15, CH2Cl2). IR (ATR) 2928, 2355, 700 cm-1. 1H NMR (CDCl3, 400 
MHz): 5 7.30-7.16 (m, 8H), 7.08-7.06 (m, 2H), 4.74 (dd, J  = 5.8, 5.8 Hz, 1H), 3.51 (dd, J  = 3.9, 10.7 
Hz, 1H), 3.22 (dd, J  = 6.0, 10.7 Hz, 1H), 3.06 (s, 3H), 2.88-2.80 (m, 3H), 2.68 (dd, J = 6.9, 13.6 Hz, 
1H), 2.63 (dd, J = 6.9, 13.6 Hz, 1H), 1.36 (s, 3H), 1.11 (s, 3H). 13C NMR (CDCl3, 75 MHz): 5 142.9,
138.4, 129.0, 128.4, 128.1, 127.1, 126.4, 126.2, 101.1, 72.5, 62.4, 60.0, 53.4, 49.1, 37.9, 25.8, 24.9. 
HRMS (ESI) m/z calcd for C21H29NO3 (M+H)+: 344.2226, found: 344.2214.
(S)-2-({(^)-2-[(2-Methoxypropan-2-yl)oxy]-2-phenylethyl}amino)pent-4-en-1-ol (25)
OMiPH Prepared as described above starting from ester 17 (131 mg, 0.408 mmol).
n^^ ^oh  Column chromatography (CH2Cl2/MeOH, 0.99:0.01—0.90:0.10) afforded 25
"  20(114 mg, 95% yield) as a colorless oil. Rf 0.54 (CH2Cl2/MeOH, 0.9:0.1). [a]D
-44.7 (c 1.16, CH2Cl2). IR (ATR) 3391, 2983, 2933, 2356, 1038 cm-1. 1H NMR 
(CDCl3, 400 MHz): 5 7.35-7.28 (m, 4H), 7.25-7.21 (m, 1H), 5.71-5.60 (m, 1H), 5.01-4.99 (m, 1H), 
4.97-4.96 (m, 1H), 4.78 (dd, J  = 6.0, 6.0 Hz, 1H), 3.54 (dd, J  = 4.1, 10.7 Hz, 1H), 3.25 (dd, J  = 6.4,
10.7 Hz, 1H), 3.11 (s, 3H), 2.89 (dd J  = 5.9, 11.8 Hz, 1H), 2.82 (dd, J  = 6.2, 11.8 Hz, 1H), 2.68-2.62 
(m, 1H), 2.15-2.10 (m, 2H), 1.41 (s, 3H), 1.14 (s, 3H). 13C NMR (CDCl3, 75 MHz): 5 142.9, 134.5,
128.0, 127.1, 126.4, 117.3, 101.1, 72.6, 62.7, 58.0, 53.5, 49.1, 35.8, 25.8, 24.9. HRMS (ESI) m/z calcd 
for C17H27NO3 (M+H)+: 294.2069, found: 294.2054.
(S)-2-({(S)-2-(2-Furyl)-2-[(2-methoxypropan-2-yl)oxy]ethyl}amino)-3-phenyl-propan-1-ol (26)
0 mipH Prepared as described above starting from ester 18 (86 mg, 0.24 mmol).
^ T ^ ^ N^ oh Column chromatography (CH2Cl2/MeOH, 0.99:0.01—0.90:0.10) afforded 26 
(70 mg, 88% yield) as a yellowish oil. Rf 0.46 (CH2Cl2/MeOH, 0.9:0.1). [a]D0 
+33.4 (c 1.75, CH2Cl2). IR (ATR) 3382, 2981, 2927, 2362, 1675, 1129, 701 
cm-1. 1H NMR (CDCl3, 400 MHz): 5 7.33-7.32 (m, 1H), 7.30-7.26 (m, 2H), 7.23-7.19 (m, 1H), 7.17-
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7.15 (m, 2H), 6.29 (dd, J  = 1.8, 3.2 Hz, 1H), 6.17-6.16 (m, 1H), 4.77 (dd, J  = 5.7, 7.3 Hz, 1H), 3.58 
(dd, J  = 3.9, 10.8 Hz, 1H), 3.30 (dd, J  = 5.3, 10.8 Hz, 1H), 3.01 (s, 3H), 2.99 (dd, J  = 7.3, 12.1 Hz, 
1H), 2.92-2.85 (m, 1H), 2.84 (dd, J  = 5.7, 12.1 Hz, 1H), 2.74 (s, 1H), 2.73 (s, 1H), 1.33 (s, 3H), 1.19 
(s, 3H). 13C NMR (CDCl3, 75 MHz): 5 154.9, 141.5, 138.3, 129.1, 128.5, 126.3, 110.1, 107.1, 101.2,
66.3, 62.2, 59.8, 50.6, 49.1, 38.0, 24.9, 24.9. HRMS (ESI) m/z calcd for C19H27NO4 (M+H)+: 
334.2018, found: 334.2014.
(S)-2-({(S)-2-(4-Bromophenyl)-2-[(2-methoxypropan-2-yl)oxy]ethyl}amino)-propan-1-ol (27)
9 miph Prepared as described above starting from ester 19 (154 mg, 0.413 mmol).
‘oh Column chromatography (CH2Cl2/MeOH, 0.97:0.03^0.90:0.10) afforded 
Me 27 (124 mg, 87% yield) as a colorless oil. Rf 0.35 (C^C^/MeOH, 0.9:0.1). 
[a]D° +90.0 (c 1.30, CH2Cl2). IR (ATR) 3552, 2986, 2920, 2829, 1040 cm-1. 'H NMR (CDCl3, 400 
MHz): 5 7.46-.7.44 (m, 2H), 7.24-7.22 (m, 2H), 4.77 (dd, J  = 5.0, 7.4 Hz, 1H), 3.52 (dd, J  = 4.1, 10.6 
Hz, 1H), 3.22 (dd, J  = 6.8, 10.6 Hz, 1H), 3.11 (s, 3H), 2.94 (dd, J  = 7.4, 12.2 Hz, 1H), 2.76 (m, 1H), 
2.65 (dd, J  = 5.0, 12.2 Hz, 1H), 2.44 (br s, 2H), 1.41 (s, 3H), 1.14 (s, 3H), 1.03 (d, J  = 6.5 Hz, 3H). 13C 
NMR (CDCl3, 75 MHz): 5 142.1, 131.2, 128.1, 120.9, 101.3, 72.3, 65.0, 54.1, 53.6, 49.3, 25.7, 25.0,
17.0. HRMS (ESI) m/z calcd for C15H24BrNO3 (M+H)+: 346.1018, found: 346.1016.
OMIP.
(£)-2-({(£)-2-(4-Bromophenyl)-2-[(2-methoxypropan-2-yl)oxy]ethyl}amino)-3-phenyl propan-1-
ol (28)
Prepared as described above starting from ester 20 (109 mg, 0.243 mmol). 
'oh Column chromatography (CH2Cl2/MeOH, 0.99:0.01^0.90:0.10) afforded
28 (94.1 mg, 92% yield) as a colorless oil. Rf 0.85 (CH2Cl2/MeOH, 
0.9:0.1). [a]D0 +61.4 (c 1.04, CH2Cl2). IR (ATR) 3404, 2930, 2362, 1718,
Br
1042, 1034 cm-1. 1H NMR (CDCl3, 400 MHz): 5 7.42-7.38 (m, 2H), 7.30-7.20 (m, 3H), 7.15-7.13 (m, 
4H), 4.69 (dd, J  = 4.8, 7.3 Hz, 1H), 3.57 (dd, J  = 3.9, 10.8 Hz, 1H), 3.30 (dd, J  = 5.2, 10.8 Hz, 1H),
3.01 (s, 3H), 2.90-2.84 (m, 1H), 2.80 (dd, J  = 7.4, 12.1 Hz, 1H), 2.74-2.67 (m, 3H), 2.27 (br s, 2H),
1.32 (s, 3H), 1.07 (s, 3H). 13C NMR (CDCl3, 75 MHz): 5 142.0, 138.2, 131.2, 129.1, 128.5, 128.1,
126.3, 120.9, 101.2, 72.2, 62.2, 59.9, 53.7, 49.3, 38.0, 25.8, 24.9. HRMS (ESI) m/z calcd for 
C21H28BrNO3 (M+H)+: 422.1331, found: 422.1331.
' I
(S)-2-({(^)-2-[(2-Methoxypropan-2-yl)oxy]hex-5-enyl}amino)pent-4-en-1-ol (29)
Prepared as described above starting from ester 21 (293 mg, 0.979 mmol). 
'oh Column chromatography (CH2Cl2/MeOH, 0.99:0.01^0.90:0.10) afforded 29 
(257 mg, 97% yield) as a colorless oil. Rf 0.43 (C^C^/MeOH, 0.9:0.1).
[a]D0 +27.0 (c 1.20, CH2Cl2). IR (ATR) 3369, 3067, 2988, 2928, 2354, 1639, 
1203, 1033, 911 cm-1. 1H NMR (CDCl3, 400 MHz): 5 5.85-5.73 (m, 2H), 5.13-5.07 (m, 2H), 5.04­
4.99 (m, 1H), 4.97-4.93 (m, 1H), 3.88-3.82 (m, 1H), 3.60 (dd, J  = 4.3, 10.7 Hz, 1H), 3.37 (dd, J  = 5.9,
10.7 Hz, 1H), 3.24 (s, 3H), 2.94 (br s, 2H), 2.69-2.64 (m, 3H), 2.24-2.20 (m, 2H), 2.11-2.04 (m, 2H),
1.69-1.62 (m, 2H), 1.37 (s, 3H), 1.35 (s, 3H). 13C NMR (CDCl3, 75 MHz): 5 138.0, 134.7, 117.2,
114.3, 100.6, 70.4, 62.6, 58.3, 50.4, 48.9, 35.8, 32.6, 29.2, 25.1, 24.8. HRMS (ESI) m/z calcd for 
C15H29NO3 (M+H)+: 272.2226, found: 272.2210.
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(W)-N-(2-Hydroxyethyl)-N-{2-[(2-methoxypropan-2-yl)oxy]-2-phenylethyl}-4-methylbenzene- 
sulfonamide (30)
To a solution of alcohol 22 (155 mg, 0.612 mmol) in dry DCM (20 mL) were 
oh added Et3N (170 ^L, 2.0 equiv) and p-toluenesulfonyl chloride (128 mg, 1.1 
equiv) at 0 °C. The reaction mixture was stirred at 0 °C for 20 min. Then the 
mixture was allowed to warm to rt. After 5 h the mixture was quenched with saturated aqueous 
NaHCO3 (30 mL) and the product was extracted with EtOAc (3 x 50 mL). The organic layers were 
combined, dried (Na2SO4), filtered and concentrated in vacuo. The residue was purified by column 
chromatography (CH2Cl2/MeOH, 0.99:0.01—0.90:0.10) to afford 30 (204 mg, 82% yield) as a 
colorless oil. Rf  0.67 (CH2Cl2/MeOH, 0.9:0.1). [a]D0 -87.2 (c 1.34, CH2Cl2). IR (ATR) 3421, 2937, 
2351, 1348, 1159, 705, 550 cm-1. !H NMR (CDCl3, 400 MHz): 5 7.67-7.65 (m, 2H), 7.38-7.27 (m, 
7H), 5.30 (dd, J  = 4.7, 8.9 Hz, 1H), 4.14 (dd, J  = 5.2, 8.9 Hz, 1H), 3.88-3.81 (m, 1H), 3.76-3.69 (m, 
1H), 3.48 (ddd, J  = 2.8, 4.8, 14.4 Hz, 1H), 3.21-3.17 (m, 2H), 3.15 (s, 3H), 2.83 (ddd, J  = 2.7, 8.2, 14.4 
Hz, 1H), 2.40 (s, 3H), 1.53 (s, 3H), 1.21 (s, 3H). 13C NMR (CDCl3, 75 MHz): 5 143.6, 141.9, 134.9,
129.7, 128.4, 127.7, 127.4, 126.6, 102.3, 74.3, 62.5, 57.9, 54.5, 49.8, 25.8, 25.0, 21.4. HRMS (ESI) 
m/z calcd for C21H29NO5SNa (M+Na)+: 430.1664, found: 430.1687.
(W)-N-(2-Hydroxy-2-phenylethyl)-N-(2-hydroxyethyl)-4-methylbenzenesulfonamide (31)
OH -  A solution of alcohol 30 (135 mg, 0.332 mmol) in THF (6 mL) was acidified
oh with aqueous HCl (0.2 M solution) to pH 2-3. The reaction mixture was stirred 
at rt for 1 h. Then the mixture was diluted with water (18 mL) and neutralized 
with saturated aqueous NaHCO3. The product was extracted with CH2Cl2 (3 x 30 mL). The organic 
layers were combined, dried (Na2SO4), filtered and concentrated in vacuo to afford 31 (111 mg, 100% 
yield) as a colorless oil. Rf 0.45 (C^C^/MeOH, 0.9:0.1). [a]D0 -65.5 (c 1.03, CH2Q 2). IR (ATR) 
3343, 2925, 1335, 1159, 700, 550 cm-1. 1H NMR (CDCl3, 400 MHz): 5 7.69-7.66 (m, 2H), 7.39-7.26 
(m, 7H), 5.14 (dd, J  = 2.3, 9.9 Hz, 1H), 4.31 (br s, 1H), 4.00 (br s, 1H), 3.94-3.89 (m, 1H), 3.83-3.80 
(m, 1H), 3.51 (ddd, J  = 3.3, 5.9, 14.7 Hz, 1H), 3.39 (dd, J  = 2.6, 14.9 Hz, 1H), 3.07-3.00 (m, 2H), 2.40 
(s, 3H). 13C NMR (CDCl3, 75 MHz): 5 143.7, 141.1, 135.0, 129.7, 128.5, 127.9, 127.2, 125.8, 74.1,
62.1, 58.8, 53.5, 21.4. HRMS (ESI) m/z calcd for C17H21NO4SNa (M+Na)+: 358.1089, found: 
358.1102.
..0
(W)-2-Phenyl-4-(4-methylbenzenesulfonyl)morpholine (32)
Ns A solution of alcohol 31 (0.11 g, 0.32 mmol) in THF (15 mL) was cooled to 0 °C and 
NaH (32 mg of 60% NaH in oil, 2.5 equiv) was added. The resulting mixture was
O allowed to warm to rt and stirred for 1 h. Then the mixture was cooled to 0 °C and 1-(p- 
Toluenesulfonyl)imidazole (78 mg, 1.1 equiv) was added. The resulting mixture was 
allowed to warm to rt and stirred overnight. The reaction mixture was cooled to 0 °C again and 
quenched by the dropwise addition of saturated aqueous NH4Cl. The resulting solution was diluted 
with EtOAc (30 mL) and washed with a 1:1 mixture of saturated aqueous NaHCO3 and brine (2 x 20 
mL). The organic layer was separated, dried (Na2SO4), filtered and concentrated in vacuo. Column 
chromatography (EtOAc/heptane, 1:5—>1:1) afforded 32 (83 mg, 83% yield) as a colorless oil. Rf 0.53 
(EtOAc/heptane, 1:2). [a]D0 -106.7 (c 1.11, CH2Cl2). IR (ATR) 2850, 1349, 1165, 554 cm-1. !H NMR 
(CDCl3, 400 MHz): 5 7.62-7.60 (m, 2H), 7.35-7.26 (m, 7H), 4.59 (dd, J  = 2.6, 10.3 Hz, 1H), 4.06 (ddd, 
J  = 1.3, 3.4, 11.6 Hz, 1H), 3.84 (dt, J  = 2.7, 11.6 Hz, 1H), 3.78-3.74 (m, 1H), 3.64-3.60 (m, 1H), 2.49 
(dt, J  = 3.4, 11.6 Hz, 1H), 2.41 (s, 3H), 2.24 (dd, J  = 10.3, 11.6 Hz, 1H). 13C NMR (CDCl3, 75 MHz):
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5 143.8, 138.5, 132.0, 129.7, 128.4, 128.1, 127.7, 125.9, 77.2, 66.1, 51.8, 45.3, 21.4. HRMS (ESI) m/z 
calcd for C17H19NO3S N  (M+Na+: 340.0983, found: 340.0973.
(£)-2-(N-{(,R)-2-[(2-Methoxypropan-2-yl)oxy]-2-phenylethyl}-4-methylbenzenesulfonamido)- 
propyl-4-methylbenzenesulfonate (33)
To a solution of alcohol 23 (8 6  mg, 0.32 mmol) in pyridine (2 mL) were added 
O T s Et3N (0.36 mL, 8.0 equiv) and p-toluenesulfonyl chloride (0.25 g, 4.0 equiv) at 
rt. Upon addition of p-toluenesulfonyl chloride the solution turned red. The 
reaction mixture was stirred at rt overnight. Then ethylenediamine (8 6  ^L, 4.0 equiv) was added. After
2.5 h the mixture was diluted with EtOAc (10 mL). The resulting solution was washed sequentially 
with saturated aqueous NH4Cl (10 mL) and a 1:1 mixture of saturated aqueous NaHCO3 and brine (10 
mL). The organic layer was separated and the aqueous washes were combined and extracted with 
EtOAc (15 mL). The organic extracts were combined, dried (Na2SO4), filtered and concentrated in 
vacuo. The residue was purified by column chromatography (EtOAc/heptane, 1:4— 1:2) to afford 33 
(0.15 g, 80% yield) as a colorless oil. Rf  0.52 (EtOAc/heptane, 1:1). 'H NMR (CDCl3, 400 MHz): 5
7.64-7.59 (m, 4H), 7.33-7.18 (m, 9H), 5.13 (dd, J  = 6.0, 8.3 Hz, 1H) 3.89-3.80 (m, 1H), 3.31 (dd, J  =
6.0, 14.9 Hz, 1H), 3.26 (dd, J  = 5.0, 9.8 Hz, 1H), 3.05, (s, 3H), 2.92 (dd, J  = 9.3, 9.3 Hz, 1H), 2.87 
(dd, J  = 8.3, 14.9 Hz, 1H), 2.47 (s, 3H), 2.42 (s, 3H), 1.42 (s, 3H), 1.15 (s, 3H), 0.83 (d, J  = 6.8  Hz, 
3H).
(S)-2-(N-{(,R)-2-[(2-Methoxypropan-2-yl)oxy]-2-phenylethyl}-4-methylbenzenesulfonamido)-3-
phenylpropyl-4-methylbenzenesulfonate (34)
OM|PTs Prepared as described above starting from alcohol 24 (42 mg, 0.12 mmol).
N>
OTs Column chromatography (EtOAc/heptane, 1:4— 1:1) afforded 34 (59 mg, 74% 
yield) as a colorless oil. Rf 0.46 (EtOAc/heptane, 1:1). 'H NMR (CDCl3, 400 
MHz): 5 7.54-7.51 (m, 2H), 7.50-7.47 (m, 2H), 7.30-7.13 (m, 12H), 6.90-6.88 
(m, 2H), 5.05 (dd, J  = 6 .8 , 6.8 Hz, 1H), 3.95-3.88 (m, 1H), 3.77 (dd, J  = 6.4, 10.5 Hz, 1H), 3.37 (dd, J  
= 5.2, 10.1 Hz, 1H), 3.33 (dd, J  = 5.3, 5.3 Hz, 1H), 3.14 (dd, J  = 6 .6 , 15.5 Hz, 1H), 2.99 (s, 3H), 2.92 
(dd, J  = 8.9, 14.1 Hz, 1H), 2.79 (dd, J  = 6.1, 14.1 Hz, 1H), 2.42 (s, 3H), 2.40 (s, 3H), 1.40 (s, 3H), 1.13 
(s, 3H). 13C NMR (CDCl3, 75 MHz): 5 144.7, 143.4, 142.1, 136.9, 136.4, 129.9, 129.7, 129.6, 129.5,
128.9, 128.8, 128.7, 128.5, 128.3, 127.9, 127.8, 127.6, 127.4, 127.2, 126.8, 126.5, 125.8, 101.5, 72.6,
69.2, 60.0, 53.0, 49.3, 36.9, 25.8, 25.1, 21.6, 21.4.
(£)-2-(N-{(,R)-2-[(2-Methoxypropan-2-yl)oxy]-2-phenylethyl}-4-methylbenzenesulfonamido)pent-
4-enyl-4-methylbenzenesulfonate (35)
Prepared as described above starting from alcohol 25 (110 mg, 0.375 mmol). 
OTs Column chromatography (EtOAc/heptane, 1:6— 1:1) afforded 35 (191 mg, 
85% yield) as a colorless oil. Rf 0.62 (EtOAc/heptane, 1:1). [a]D0 -27.4 (c 1.50, 
CH2Cl2). IR (ATR) 2988, 2366, 1348, 1176, 1157 cm-1. 1H NMR (CDCl3, 400 
MHz): 5 7.62-7.61 (m, 2H), 7.60-7.59 (m, 2H), 7.32-7.21 (m, 9H), 5.14-5.04 (m, 2H), 4.86 (dd, J  =
1.6, 17.1 Hz, 1H), 4.77 (dd, J  = 1.6, 10.1 Hz, 1H), 3.71-3.64 (m, 1H), 3.54 (dd, J  = 5.6, 10.1 Hz, 1H), 
3.40 (dd, J  = 6.2, 15.1 Hz, 1H), 3.06-2.96 (m, 5H), 2.46 (s, 3H), 2.42 (s, 3H), 2.33-2.26 (m, 1H), 2.08­
2.01 (m, 1H), 1.41 (s, 3H), 1.13 (s, 3H). 13C NMR (CDCl3, 75 MHz): 5 144.7, 143.6, 142.0, 136.2,
133.1, 132.5, 129.6, 129.5, 128.2, 127.8, 127.6, 127.5, 127.2, 118.0, 101.4, 72.3, 70.0, 57.7, 52.6,
49.2, 34.3, 25.7, 25.0, 21.6, 21.4. HRMS (ESI) m/z calcd for C31H39NO7S2Na (M+Na)+: 624.2066, 
found: 624.2062.
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(S)-2-(N-{(S)-2-(2-Furyl)-2-[(2-methoxypropan-2-yl)oxy]ethyl}-4-methylbenzenesulfonamido)-3- 
phenylpropyl-4-methylbenzenesulfonate (36)
9 mipts Prepared as described above starting from alcohol 26 (64 mg, 0.19 mmol).
€  ^  "ots Column chromatography (EtOAc/heptane, 1:7—>1:1) afforded 36 (86 mg, 70%
yield) as a colorless oil. R/ 0.59 (EtOAc/heptane, 1:1). [a]D0 +4.5 (c 1.08, 
CH2Cl2). IR (ATR) 2991, 1345, 1176, 1155 cm-1. 'H NMR (CDCl3, 400 MHz): 
5 7.60-7.55 (m, 4H), 7.38-7.37 (m, 1H), 7.26-7.20 (m, 4H), 7.14-7.09 (m, 3H), 6.85-6.83 (m, 2H), 6.30 
(dd, J  = 1.8, 3.2 Hz, 1H), 6.25 (dd, J  = 0.8, 3.3 Hz, 1H), 5.16 (dd, J  = 7.0, 7.0 Hz, 1H), 4.05 (dd, J  =
6.3, 9.6 Hz, 1H), 4.01-3.91 (m, 2H), 3.42 (dd, J  = 6.8, 15.3 Hz, 1H), 3.34 (dd, J  = 7.2, 15.3 Hz, 1H), 
2.98 (s, 3H), 2.44 (s, 3H), 2.42-2.33 (m, 2H), 2.40 (s, 3H), 1.42 (s, 3H), 1.24 (s, 3H). 13C NMR 
(CDCl3, 75 MHz): 5 153.5, 144.7, 143.5, 141.7, 136.7, 136.4, 132.4, 129.6, 129.5, 128.6, 128.5, 127.8,
127.3, 126.5, 110.4, 108.9, 101.6, 68.8, 65.9, 59.3, 49.1, 49.0, 36.1, 24.9, 24.8, 21.5, 21.4. HRMS 
(ESI) m/z calcd for C33H39NO8S2Na (M+Na)+: 664.2015, found: 664.1998.
(£)-2-(N-{(£)-2-(4-Bromophenyl)-2-[(2-methoxypropan-2-yl)oxy]ethyl}-4-methylbenzenesulfon- 
amido)propyl-4-methylbenzenesulfonate (37)
OMIPTs Prepared as described above starting from alcohol 27 (116 mg, 0.336
'ots mmol). Column chromatography (EtOAc/heptane, 1:5— 1:1) afforded 37 
Me (194 mg, 88% yield) as a colorless oil. R/ 0.66 (EtOAc/heptane, 1:1). [a]D0
+56.2 (c 0.98, CH2Cl2). IR (ATR) 3507, 2984, 1341, 1175, 1155, 551 cm-1. 
!H NMR (CDCl3, 400 MHz): 5 7.78-7.76 (m, 2H), 7.61-7.59 (m, 2H), 7.43-7.41 (m, 2H), 7.37-7.35 
(m, 2H), 7.28-7.20 (m, 4H), 5.10 (dd, J  = 5.0, 8.1 Hz, 1H), 4.09-4.00 (m, 3H), 3.04-2.93 (m, 5H), 2.46 
(s, 3H), 2.39 (s, 3H), 1.38 (s, 3H), 1.11 (s, 3H), 0.65 (d, J  = 6.3 Hz, 3H). 13C NMR (CDCl3, 75 MHz): 
5 144.9, 143.6, 141.3, 136.1, 132.5, 131.2, 129.7, 129.6, 128.5, 127.7, 127.0, 121.2, 101.5, 72.2, 71.2,
52.4, 51.0, 49.3, 25.7, 24.8, 21.5, 21.3, 14.0. HRMS (ESI) m/z calcd for C29H36BrNO7S2Na (M+Na)+: 
676.1014, found: 676.0986.
(£)-2-{N-[(R)-2-Hydroxy-2-phenylethyl]-4-methylbenzenesulfonamido}propyl-4-methylbenzene- 
sulfonate (40)
OH Ts A solution of alcohol 33 (93 mg, 0.16 mmol) in THF (3 mL) was acidified
i j ' ^ p N'^ N^ ~ vOTs with aqueous HCl (0.2 M solution) to pH 2-3. The reaction mixture was stirred 
Me at rt for 1 h. Then the mixture was diluted with water (9 mL) and neutralized
with saturated aqueous NaHCO3. The product was extracted with CH2Cl2 (3 x 20 mL). The organic 
layers were combined, dried (Na2SO4), filtered and concentrated in vacuo to afford 40 (73 mg, 90% 
yield) as a colorless oil. R/ 0.37 (EtOAc/heptane, 1:1). [a]D0 -10.6 (c 1.02, CH2Q 2). IR (ATR) 3503, 
2920, 1336 1175, 1152 cm-1. !H NMR (CDCl3, 400 MHz): 5 7.74-7.67 (m, 4H), 7.35-7.23 (m, 9H), 
4.85-4.83 (m, 1H), 4.19-4.06 (m, 2H), 3.88 (dd, J  = 5.9, 10.0 Hz, 1H), 3.27 (br s, 1H), 3.24 (dd, J  =
9.2, 15.6 Hz, 1H), 3.11 (dd, J  = 3.3, 15.6 Hz, 1H), 2.44 (s, 3H), 2.41 (s, 3H), 1.06 (d, J  = 6.9 Hz, 3H). 
13C NMR (CDCl3, 75 MHz): 5 145.1, 143.9, 141.5, 136.3, 132.3, 129.9, 129.8, 128.5, 127.9, 127.2,
125.8, 73.3, 71.5, 53.2, 52.5, 21.6, 21.4, 14.7. HRMS (ESI) m/z calcd for C25H29NO6S2Na (M+Na)+: 
526.1334, found: 526.1327.
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(£)-2-{N-[(.R)-2-Hydroxy-2-phenylethyl]-4-methylbenzenesulfonamido}-3-phenylpropyl-4- 
methylbenzenesulfonate (41)
Prepared as described above starting from alcohol 34 (40 mg, 0.061 mmol). 
y o T s  Extraction of the mixture afforded 41 (35 mg, 98% yield) as a colorless oil. Rf
X" 0.32 (EtOAc/heptane, 1:1). [a]D0 -13.8 (c 1.00, CH2Cl2). IR (ATR) 3512, ^  2958, 2358, 1337, 1176, 1158 cm-1. 'H NMR (CDCl3, 400 MHz): 5 7.65-7.63 
(m, 2H), 7.63-7.61 (m, 2H), 7.37-7.19 (m, 12H), 7.03-7.01 (m, 2H), 4.86-4.82 (m, 1H), 4.23-4.16 (m, 
2H), 4.02-3.97 (m, 1H), 3.25-3.23 (m, 2H), 3.15-3.16 (m, 1H), 2.95 (dd, J  = 8.5, 13.9 Hz, 1H), 2.82 
(dd, J  = 5.7, 13.9 Hz, 1H), 2.42 (s, 3H), 2.40 (s, 3H). 13C NMR (CDCl3, 75 MHz): 5 145.1, 143.9,
141.5, 136.6, 136.3, 132.1, 129.9, 129.7, 128.9, 128.7, 128.5, 127.9, 127.4, 126.9, 125.8, 73.2, 69.3,
59.8, 53.5, 36.2, 21.6, 21.5. HRMS (ESI) m/z calcd for C31H33NO6S2Na (M+Na)+: 602.1647, found: 
602.1621.
(£)-2-{N-[(R)-2-Hydroxy-2-phenylethyl]-4-methylbenzenesulfonamido}pent-4-enyl-4-methyl- 
benzenesulfonate (42)
Prepared as described above starting from alcohol 35 (190 mg, 0.316 mmol). 
OTs Extraction of the mixture afforded 42 (159 mg, 95% yield) as a colorless oil. R/ 
0.47 (EtOAc/heptane, 1:1). [a]D0 -26.5 (c 1.72, CH2Cl2). IR (ATR) 3520, 
2920, 2358, 1339, 1173, 1153 cm-1. 'H NMR (CDCl3, 400 MHz): 5 7.58-7.56 
(m, 4H), 7.23-7.15 (m, 9H), 5.32 (ddt, J  = 6.9, 10.1, 17.0 Hz, 1H), 4.89-4.81 (m, 2H), 4.78 (dd, J  =
4.0, 8.2 Hz, 1H), 4.05-4.01 (m, 1H), 3.96-3.89 (m, 1H), 3.87-3.83 (m, 1H), 3.17-2.91 (m, 3H), 2.30 (s, 
3H), 2.29 (s, 3H), 2.30-2.24 (m, 1H), 2.17-2.09 (m, 1H). 13C NMR (CDCl3, 75 MHz): 5 145.0, 143.8,
141.4, 136.0, 133.0, 132.0, 129.7, 129.6, 128.3, 127.7, 127.3, 125.6, 118.5, 73.0, 69.8, 57.5, 53.1,
33.8, 21.4, 21.3. HRMS (ESI) m/z calcd for C27H31NO6S2Na (M+Na)+: 552.1491, found: 552.1468.
(£)-2-{N-[(£)-2-(2-Furyl)-2-hydroxyethyl]-4-methylbenzenesulfonamido}-3-phenylpropyl-4- 
methylbenzenesulfonate (43)
o 9 H Ts Prepared as described above starting from alcohol 36 (82 mg, 0.13 mmol).
^ '^^OTs Extraction of the mixture afforded 43 (67 mg, 92% yield) as a colorless oil. R/
" %  0.55 (EtOAc/heptane, 1:1). [a]D0 +5.0 (c 1.00, CH2Cl2). IR (ATR) 3512, 2918,
x >^  1169, 1148 cm-1. !H NMR (CDCl3, 400 MHz): 5 7.65-7.62 (m, 2H), 7.62-7.59 
(m, 2H), 7.39-7.38 (m, 1H), 7.27-7.17 (m, 7H), 7.02-6.99 (m, 2H), 6.35 (dd, J  = 1.8, 3.3 Hz, 1H), 6.30 
(m, 1H), 4.97 (dd, J  = 4.1, 8.1 Hz, 1H), 4.25-.4.16 (m, 2H), 4.03-3.99 (m, 1H), 3.47 (dd, J  = 3.6, 15.1 
Hz, 1H), 3.41 (dd, J  = 7.6, 15.1 Hz, 1H), 2.98 (br s, 1H), 2.87 (dd, J  = 5.6, 13.9 Hz, 1H), 2.79 (dd, J  =
8.8, 13.9 Hz, 1H), 2.43 (s, 3H), 2.41 (s, 3H). 13C NMR (CDCl3, 75 MHz): 5 153.7, 144.9, 143.7, 142.2,
136.5, 136.3, 132.3, 129.7, 129.7, 128.8, 128.7, 127.9, 127.4, 126.8, 110.3, 107.0, 68.7, 67.4, 59.4,
49.9, 36.5, 21.6, 21.5. HRMS (ESI) m/z calcd for C29H31NO7S2N  (M+Na)+: 592.1440, found: 
592.1437.
(£)-2-{N-[(£)-2-(4-Bromophenyl)-2-hydroxyethyl]-4-methylbenzenesulfonamido}propyl-4- 
methylbenzenesulfonate (44)
° H Ts Prepared as described above starting from alcohol 37 (190 mg, 0.291
r j ^ V '^ ^ T^^^OTs mmol). Extraction of the mixture afforded 44 (169 mg, 100% yield) as a 
Me colorless oil. R/ 0.65 (EtOAc/heptane, 1:1). [a]D0 +26.5 (c 1.33, CH2Cl2). 
IR (ATR) 3516, 2918, 2359, 1336, 1172, 1151, 553 cm-1. 1H NMR (CDCl3, 400 MHz): 5 7.73-7.70 
(m, 2H), 7.67-7.64 (m, 2H), 7.45-7.41 (m, 2H), 7.33-7.31 (m, 2H), 7.27-7.25 (m, 2H), 7.22-7.20 (m,
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2H), 4.94 (dd, J  = 2.3, 9.3 Hz, 1H), 4.17-4.10 (m, 2H), 4.05-3.99 (m, 1H), 3.20 (dd, J  = 2.5, 15.5 Hz, 
1H), 2.99 (br s, 1H), 2.96 (dd, J  = 9.4, 15.5 Hz, 1H), 2.43 (s, 3H), 2.40 (s, 3H), 0.99 (d, J  = 6.7 Hz, 
3H). 13C NMR (CDCl3, 75 MHz): 5 145.0, 143.8, 140.6, 136.2, 132.3, 131.4, 129.7, 129.7, 127.7,
127.4, 127.0, 121.4, 72.7, 70.9, 52.7, 52.1, 21.5, 21.3, 14.8. HRMS (ESI) m/z calcd for 
C25H28BrNO6S2Na (M+Na)+: 604.0439, found: 604.0428.
(£)-2-{N-[(£)-2-(4-Bromophenyl)-2-hydroxyethyl]-4-methylbenzenesulfonamido}-3-phenyl- 
propyl-4-methylbenzenesulfonate (45)
OH Ts Prepared as described above starting from alcohol 38 (59 mg, 0.14 mmol).
t  OTs Column chromatography (EtOAc/toluene, 1:9—>1:1) afforded 45 (88 mg,
B r^ ^ ^  96% yield) as a colorless oil. R/ 0.60 (EtOAc/toluene, 1:4). [a]D0 +19.6 (c
Ko?  1.12, CH2Cl2). IR (ATR) 3507, 2921, 1336, 1177, 1150, 551 cm-1. !H 
NMR (CDCl3, 400 MHz): 5 7.62-7.59 (m, 4H), 7.48-7.46 (m, 2H), 7.27-7.17 (m, 9H), 6.99-6.97 (m, 
2H), 4.95 (dd, J  = 2.0, 9.3 Hz, 1H), 4.26-4.19 (m, 2H), 4.10-4.04 (m, 1H), 3.27 (dd, J  = 2.0, 15.6 Hz, 
1H), 3.13 (dd, J  = 9.5, 15.5 Hz, 1H), 2.87 (dd, J  = 5.4, 13.9 Hz, 1H), 2.81 (dd, J  = 8.5, 14.0 Hz, 1H),
2.43 (s, 3H), 2.39 (s, 3H), 1.43 (br s, 1H). 13C NMR (CDCl3, 75 MHz): 5 145.0, 143.8, 140.5, 136.4,
136.3, 132.2, 131.6, 129.8, 129.7, 128.7, 128.6, 127.8, 127.4, 127.2, 126.8, 121.6, 72.6, 68.9, 59.4,
53.1, 36.4, 30.2, 21.6, 21.4. HRMS (ESI) m/z calcd for C3:H32BrNO6S2Na (M+Na)+: 680.0752, found: 
680.0739.
(£)-2-{N-[(,R)-2-Hydroxyhex-5-enyl]-4-methylbenzenesulfonamido}pent-4-enyl-4-methylbenzene- 
sulfonate (46)
OH Prepared as described above starting from alcohol 39 (247 mg, 0.911 mmol).
'OTs Column chromatography (EtOAc/toluene, 1:7— 1:1) afforded 46 (370 mg,
80% yield) as a colorless oil. R/ 0.50 (EtOAc/heptane, 1:1). [a]D0 -1 .6  (c
-11.12, CH2Cl2). IR (ATR) 3540, 2924, 1175, 1156, 551 cm-1. !H NMR 
(CDCl3, 400 MHz): 5 7.70-7.66 (m, 4H), 7.33-7.31 (m, 2H), 7.28-7.26 (m, 2H), 5.78 (ddt, J  = 6.6,
10.2, 16.9 Hz, 1H), 5.43 (ddt, J  = 6.9, 10.1, 17.1 Hz, 1H), 5.04-4.92 (m, 4H), 4.17-4.12 (m, 1H), 4.08­
4.01 (m, 2H), 3.81-3.75 (m, 1H), 3.30 (br s, 1H), 3.10 (dd, J  = 2.5, 15.4 Hz, 1H), 2.91 (dd, J  = 9.1,
15.5 Hz, 1H), 2.43 (s, 3H), 2.40 (s, 3H), 2.30-2.13 (m, 3H), 2.12-2.03 (m, 1H), 1.45-1.40 (m, 2H). 13C 
NMR (CDCl3, 75 MHz): 5 145.0, 143.6, 137.9, 136.5, 132.9, 132.3, 129.7, 129.6, 127.8, 127.3, 118.5,
114.9, 69.8, 69.2, 57.2, 51.1, 34.2, 33.8, 29.5, 21.5, 21.4. HRMS (ESI) m/z calcd for C25H33NO6S2 
(M+H)+: 508.1828, found: 508.1839.
(2W,5£)-5-Methyl-4-(4-methylbenzenesulfonyl)-2-phenylmorpholine (47)
Ts Me A solution of tosylate 40 (48 mg, 0.10 mmol) in THF (5 mL) was cooled to 0 °C and 
^  NaH (3.4 mg of 60% NaH in oil, 1.5 equiv) was added. The resulting mixture was
O allowed to warm to rt and stirred for 1 h. Then the mixture was cooled to 0 °C and
quenched by the dropwise addition of saturated aqueous NH4Cl (1 mL). The 
resulting solution was diluted with EtOAc (30 mL) and washed with a 1:1 mixture of saturated 
aqueous NaHCO3 and brine (2 x 20 mL). The organic layer was separated, dried (Na2SO4), filtered 
and concentrated in vacuo. The residue was purified by column chromatography (EtOAc/heptane, 1:2) 
to afford 47 (32 mg, 96% yield) as a colorless oil. R/ 0.44 (EtOAc/heptane, 1:1). [a]D0 -88.2 (c 1.45, 
CH2Cl2). IR (ATR) 2855, 1349, 1166 cm-1. 1H NMR (CDCl3, 400 MHz): 5 7.65-7.63 (m, 2H), 7.35­
7.25 (m, 7H), 4.69 (dd J  = 2.3, 9.1 Hz, 1H), 3.94 (dd, J  = 2.6, 12.1 Hz, 1H), 3.81 (dd, J  = 3.2, 11.7 Hz, 
1H), 3.47 (dd, J  = 9.0, 11.6 Hz, 1H), 2.92-2.84 (m, 1H), 2.66 (dd, J  = 9.2, 12.0 Hz, 1H), 2.43 (s, 3H),
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I.36 (d, J  = 6.4 Hz, 3H). 13C NMR (CDCl3, 75 MHz): 5 143.7, 138.4, 133.7, 129.7, 128.4, 128.1,
127.6, 126.1, 77.1, 71.7, 52.3, 51.9, 21.4, 16.1. HRMS (ESI) m/z calcd for C18H21NO3S (M+H)+: 
332.1320, found: 332.1309.
(2W,5£)-5-Benzyl-4-(4-methylbenzenesulfonyl)-2-phenylmorpholine (48)
Ts Prepared as described above starting from tosylate 41 (34 mg, 0.058 mmol).
C T l l f j  Column chromatography (EtOAc/heptane, 1:4— 1:1) afforded 48 (24 mg, 99% 
O yield) as a colorless oil. R/ 0.56 (EtOAc/heptane, 1:1). [a]D0 -36.9 (c 1.71,
CH2Cl2). IR (ATR) 2925, 2360, 1344, 1164, 699 cm-1. 1H NMR (CDCl3, 400 
MHz): 5 7.74-7.71 (m, 2H), 7.38-7.16 (m, 12H), 4.91 (dd, J  = 3.7, 5.7 Hz, 1H), 3.84 (dd, J  = 3.7, 12.6 
Hz, 1H), 3.56 (dd, J  = 2.3, 11.7 Hz, 1H), 3.53-3.47 (m, 2H), 3.42 (dd, J  = 4.2, 11.6 Hz, 1H), 3.14 (dd, 
J  = 3.6, 13.3 Hz, 1H), 3.04 (dd, J  = 11.1, 13.3 Hz, 1H), 2.44 (s, 3H). 13C NMR (CDCl3, 75 MHz): 5
143.8, 138.2, 137.6, 135.4, 129.8, 129.3, 128.6, 128.4, 127.9, 127.5, 126.7, 126.6, 74.3, 63.8, 56.6,
46.4, 35.2, 21.5. HRMS (ESI) m/z calcd for C24H25NO3S (M+H)+: 408.1633, found: 408.1623.
(2W,5£)-5-Allyl-4-(methylbenzenesulfonyl)-2-phenylmorpholine (49)
Ts Prepared as described above starting from tosylate 42 (159 mg, 0.300 mmol).
f  Column chromatography (EtOAc/heptane, 1:7— 1:1) afforded 49 (104 mg, 97%
o yield) as a colorless oil. R/ 0.62 (EtOAc/heptane, 1:1). [a]D0 -15.5 (c 0.94,
CH2Cl2). IR (ATR) 2919, 2855, 2358, 2381, 1347, 1166 cm-1. 1H NMR (CDCl3, 
400 MHz): 5 7.65-7.63 (m, 2H), 7.37-7.26 (m, 7H), 5.82-5.72 (m, 1H), 5.11-5.07 (m, 2H), 4.77 (dd, J  
= 3.3, 6.9 Hz, 1H), 3.81 (dd, J  = 3.4, 12.4 Hz, 1H), 3.79 (dd, J  = 3.2, 11.9 Hz, 1H), 3.56 (dd, J  = 6.2,
II.9 Hz, 1H), 3.18-3.11 (m, 2H), 2.71-2.63 (m, 1H), 2.55-2.49 (m, 1H), 2.42 (s, 3H). 13C NMR 
(CDCl3, 75 MHz): 5 143.7, 138.2, 134.5, 133.6, 129.7, 128.3, 127.8, 127.4, 126.4, 118.1, 75.1, 66.1,
54.8, 48.4, 33.6, 21.4. HRMS (ESI) m/z calcd for C20H24NO3S (M+H)+: 358.1477, found: 358.1462.
(2^',55')-5-Benzyl-2-(2-furyl)-4-(4-methylbenzenesulfonyl)morpholine (50)
Prepared as described above starting from tosylate 43 (41 mg, 0.072 mmol).
O ^  "J  J  Column chromatography (EtOAc/heptane, 1:7— 1:1) afforded0 5 (21 mg, 73% 
^ ''¡j O yield) as a colorless oil. R/ 0.59 (EtOAc/heptane, 1:1). [a]D0 -11.7 (c 1.05,
CH2Cl2). IR (ATR) 2921, 2854, 2357, 500 cm-1. !H NMR (CDCl3, 400 MHz): 5
7.64-7.61 (m, 2H), 7.42-7.41 (m, 1H), 7.30-7.19 (m, 7H), 6.38-6.36 (m, 2H), 4.47 (dd, J  = 3.0, 11.2 
Hz, 1H), 4.10-4.06 (m, 1H), 3.84-3.77 (m, 2H), 3.59 (ddd, J  = 1.0, 3.0, 11.8 Hz, 1H), 3.48 (dd, J  =
11.2, 13.4 Hz, 1H), 3.12 (dd, J  = 10.2, 13.2 Hz, 1H), 2.79 (dd, J  = 5.1, 13.2 Hz, 1H), 2.41 (s, 3H). 13C 
NMR (CDCl3, 75 MHz): 5 151.1, 143.5, 142.7, 137.6, 137.3, 129.8, 129.4, 128.6, 127.1, 126.6, 110.2,
107.9, 70.9, 67.4, 54.0, 43.2, 34.1, 21.4. HRMS (ESI) m/z calcd for C22H23NO4S (M+H)+: 398.1426, 
found: 398.1420.
(2^',55')-2-(4-Bromophenyl)-5-methyl-4-(4-methylbenzenesulfonyl)morpholine (51)
Me Prepared as described above starting from tosylate 44 (169 mg, 0.259 mmol). 
Column chromatography (EtOAc/heptane, 1:6— 1:1) afforded 51 (100 mg, 94% 
yield) as a colorless oil. R/ 0.58 (EtOAc/heptane, 1:1). [a]D0 +72.1 (c 1.00, 
B r ^ ^  CH2Cl2). IR (ATR) 2971, 2855, 2355, 1341, 1154, 554 cm-1. !H NMR (CDCl3,
400 MHz): 5 7.70-7.67 (m, 2H), 7.49-7.46 (m, 2H), 7.31-7.28 (m, 2H), 7.23-7.20 (m, 2H), 4.37 (dd, J  
= 3.0, 10.9 Hz, 1H), 4.09-4.03 (m, 1H), 3.81 (ddd, J  = 0.5, 2.7, 11.4 Hz, 1H), 3.76 (dd, J  = 1.4, 11.5 
Hz, 1H), 3.72 (ddd, J  = 0.6, 3.1, 13.0 Hz, 1H), 2.94 (dd, J  = 10.9, 13.1 Hz, 1H), 2.41 (s, 3H), 1.14 (d, J
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= 6.9 Hz, 3H). 13C NMR (CDCl3, 75 MHz): 5 143.4, 137.7, 137.2, 131.5, 129.7, 127.5, 126.9, 122.0,
77.0, 71.5, 48.0, 45.7, 21.4, 13.4. HRMS (ESI) m/z calcd for Q s ^ B r ^ S  (M+H)+: 410.0426, found: 
410.0436.
(2^',55')-5-Benzyl-2-(4-bromophenyl)-4-(4-methylbenzenesulfonyl)morpholine (52)
Prepared as described above starting from tosylate 45 (64 mg, 0.097 
mmol). Column chromatography (EtOAc/heptane, 1:9— 1:4) afforded 52 
(44 mg, 93% yield) as a colorless oil. R/ 0.81 (EtOAc/heptane, 1:1). [a]D0 
B '  ^  +22.9 (c 1.35, CH2Cl2). IR (ATR) 2859, 2360, 1346, 1166, 556 cm-1. 1H
NMR (CDCl3, 400 MHz): 5 7.64-7.61 (m, 2H), 7.52-7.49 (m, 2H), 7.32-7.19 (m, 9H), 4.41 (dd, J  =
3.0, 10.9 Hz, 1H), 4.11-4.06 (m, 1H), 3.84 (m, 1H), 3.76 (dd, J  = 3.0, 13.5 Hz, 1H), 3.62 (ddd, J  = 0.9,
3.0, 11.8 Hz, 1H), 3.11-3.04 (m, 2H), 2.72 (dd, J  = 5.1, 13.2 Hz, 1H), 2.40 (s, 3H). 13C NMR (CDCl3, 
75 MHz): 5143.5, 137.7, 137.5, 137.3, 131.6, 129.8, 129.4, 128.6, 127.6, 127.0, 126.6, 122.1, 76.9,
67.6, 53.8, 46.5, 33.9, 21.4. HRMS (ESI) m/z calcd for C24H24BrNO3S (M+H)+: 486.0739, found: 
486.0757.
(2^',55')-5-Allyl-2-(but-3-enyl)-4-(4-methylbenzenesulfonyl)morpholine (53)
Prepared as described above starting from tosylate 46 (289 mg, 0.570 mmol). 
Column chromatography (EtOAc/heptane, 1:8— 1:1) afforded 53 (158 mg, 83% 
yield) as a colorless oil. R/ 0.65 (EtOAc/heptane, 1:1). [a]D0 +21.0 (c 1.31, 
CH2Cl2). IR (ATR) 2918, 2853, 2358, 1339, 1161, 680, 552 cm-1. !H NMR (CDCl3, 400 MHz): 5
7.70-7.68 (m, 2H), 7.30-7.28 (m, 2H), 5.80-5.63 (m, 2H), 5.08-4.94 (m, 4H), 3.82-3.77 (m, 1H), 3.75­
3.72 (m, 1H), 3.58 (dd, J  = 2.6, 13.4 Hz, 1H), 3.41 (ddd, J  = 1.0, 3.0, 11.6 Hz, 1H), 3.26-3.19 (m, 1H), 
2.83 (dd, J  = 11.0, 13.4 Hz, 1H), 2.50-2.44 (m, 1H), 2.41 (s, 3H), 2.23-2.02 (m, 3H), 1.60-1.51 (m, 
1H), 1.48-1.39 (m, 1H). 13C NMR (CDCl3, 75 MHz): 5 143.1, 137.8, 137.4, 134.0, 129.6, 126.8, 117.8,
114.9, 74.3, 67.4, 52.1, 44.9, 32.3, 31.9, 28.8, 21.2. HRMS (ESI) m/z calcd for C18H25NO3S (M+H)+: 
336.1633, found: 336.1618.
(W)-2-Phenylmorpholine (54)
T A solution of SmI2 (9.5 mL of a 0.1 M solution in THF, 0.95 mmol, 10 equiv) and water 
^  (51 ^L, 30 equiv) were added to morpholine 32 (30 mg, 0.095 mmol) under an argon
O'" O atmosphere. Subsequently pyrrolidine (0.16 mL, 20 equiv) was added. The reaction mixture turned white instantaneously upon addition of amine. The resulting mixture was 
quenched by blowing air through the mixture. The mixture was concentrated in vacuo and purified by 
column chromatography (CH2Cl2/MeOH, 0.99:0.01—0.90:0.10) to afford 54 (20 mg, 80% yield) as a 
colorless oil. Rf  0.19 (CH2Cl2/MeOH, 0.9:0.1). [a]D0 -13.3 (c 0.06, CH2Cl2). IR (ATR) 2925, 1360, 
1154, 560 cm-1. !H NMR (CDCl3, 400 MHz): 5 7.41-7.30 (m, 5H), 4.68 (dd, J  = 2.4, 11.0 Hz, 1H), 
4.17-4.13 (m, 1H), 3.93 (ddd, J  = 4.2, 10.4, 12.6 Hz, 1H), 3.29 (dd, J  = 2.3, 11.3 Hz, 1H), 3.20-3.11 
(m, 2H), 2.95 (dd, J  = 11.1, 12.7 Hz, 1H). 13C NMR (CDCl3, 75 MHz): 5 127.7, 127.5, 125.2, 76.1,
64.7, 49.2, 42.8. HRMS (ESI) m/z calcd for C10H14NO (M+H)+: 164.1075, found: 164.1083.
(2Æ,5£)-5-Methyl-2-phenylmorpholine (55)
H Prepared as described above starting from morpholine 47 (29 mg, 0.088 mmol).
r  ^  Column chromatography (CH2Cl2/MeOH, 0.99:0.01^0.96:0.04) afforded 55 (14 
mg, 92% yield) as a colorless oil. R f  0.65 (C^C^/MeOH, 0.9:0.1). [a]D° -7 .9  (c 
0.75, CH2Cl2). IR (ATR) 3434, 2920, 2353, 1453, 1093 cm-1. 'H NMR (CDCl3, 400
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MHz): 5 7.36-7.32 (m, 5H), 5.98 (br s, 1H), 5.00 (dd, J  = 2.2, 11.1 Hz, 1H), 4.10 (dd, J  = 3.6, 12.6 Hz, 
1H), 3.90 (dd, J  = 11.0, 12.4 Hz, 1H), 3.58-3.50 (m, 1H), 3.46 (dd, J  = 2.2, 12.7 Hz, 1H), 3.00 (dd J  =
11.2, 12.7 Hz, 1H), 1.47 (d, J  = 6.6 Hz, 3H). 13C NMR (CDCl3, 75 MHz): 5 137.2, 128.6, 126.0, 75.2,
70.4, 51.0, 49.4, 14.8. HRMS (ESI) m/z calcd for C„H15NO (M+H)+: 178.1232, found: 178.1232.
(2Æ,5£)-5-Benzyl-2-phenylmorpholine (56)
N Prepared as described above starting from morpholine 48 (29 mg, 0.071 mmol).
C Column chromatography (CH2Cl2/MeOH, 0.99:0.01^0.90:0.10) afforded 56
v"- o ^  (1 5  mg, 83% yield) as a colorless oil. Rf 0.56 (C^C^/MeOH, 0.9:0.1). [a]D0 
-38.8 (c 0.75, CH2Cl2). IR (ATR) 2936, 2833, 2353, 1100, 699 cm-1. 1H NMR 
(CDCl3, 400 MHz): 5 7.35-7.23 (m, 10H), 4.51 (dd, J  = 2.5, 10.4 Hz, 1H), 4.04 (dd, J  = 3.1, 11.2 Hz, 
1H), 3.52 (dd, J  = 10.4, 11.1 Hz, 1H), 3.16-3.10 (m, 1H), 3.07 (dd, J  = 2.5, 12.1 Hz, 1H), 2.78-2.72
(m, 2H), 2.56 (dd, J  = 8.8, 13.4 Hz, 1H), 2.27 (br s, 1H). 13C NMR (CDCl3, 75 MHz): 5 140.0, 137.6,
129.1, 128.6, 128.3, 127.7, 126.6, 126.0, 78.7, 72.6, 55.6, 53.2, 38.6. HRMS (ESI) m/z calcd for 
C17H19NO (M+H)+: 254.1545, found: 254.1537.
(2W,5£)-5-Allyl-2-phenylmorpholine (57)
T Prepared as described above starting from morpholine 49 (45 mg, 0.13 mmol).
r  Column chromatography (CH2Cl2/MeOH, 0.99:0.01—0.90:0.10) afforded 57 (13
O mg, 86% yield) as a colorless oil. R/ 0.51 (C^C^/MeOH, 0.9:0.1). [a]D0 -17.2 (c
^  0.65, CH2Cl2). IR (ATR) 3321, 3062, 2842, 2350, 1099 cm-1. !H NMR (CDCl3,
400 MHz): 5 7.36-7.26 (m, 5H), 5.84-5.74 (m, 1H), 5.18-5.12 (m, 2H), 4.45 (dd, J  = 2.5, 10.4 Hz, 1H), 
4.00 (dd, J  = 3.1, 11.1 Hz, 1H), 3.40 (dd, J  = 10.7, 10.7 Hz, 1H), 3.11 (dd, J  = 2.5, 12.1 Hz, 1H), 2.96­
2.89 (m, 1H), 2.83 (dd, 10.5, 12.0 Hz, 1H), 2.21-2.15 (m, 1H), 2.07-2.00 (m, 1H), 1.85 (br s, 1H). 13C 
NMR (CDCl3, 75 MHz): 5 140.2, 134.1, 128.3, 127.7, 126.0, 118.0, 78.9, 72.8, 53.4, 53.4, 36.8. 
HRMS (ESI) m/z calcd for C13H18NO (M+H)+: 204.1388, found: 204.1394.
(2^',55')-5-Benzyl-2-(2-furyl)morpholine (58)
H Prepared as described above starting from morpholine 50 (19 mg, 0.048 mmol).
r ' W * ,  Column chromatography (CH2Cl2/MeOH, 0.99:0.01—0.90:0.10) afforded 58 
< ^ Y  o (95 mg, 82% yield) as a colorless oil. R/ 0.47 (C^C^/MeOH, 0.9:0.1). [a]D0
-50.3 (c 0.31, CH2Q 2). IR (ATR) 2929, 2850, 738, 701 cm-1. !H NMR (CDCl3, 
400 MHz): 5 7.43-7.42 (m, 1H), 7.33-7.21 (m, 5H), 6.42-6.41 (m, 1H), 6.39-6.38 (m, 1H), 4.68 (dd, J  
= 3.6, 6.3 Hz, 1H), 3.79 (dd, J  = 3.0, 11.4 Hz, 1H), 3.66 (dd, J  = 5.2, 11.3 Hz, 1H), 3.39 (dd, J  = 6.4,
12.5 Hz, 1H), 3.11-3.04 (m, 2H), 2.92 (dd, J  = 8.3, 13.4 Hz, 1H), 2.80 (dd, J  = 6.3, 13.6 Hz, 1H), 1.81 
(br s, 1H). 13C NMR (CDCl3, 75 MHz): 5 153.0, 142.1, 138.5, 129.1, 128.6, 126.4, 110.1, 107.9, 70.3,
68.5, 54.4, 45.0, 37.2. HRMS (ESI) m/z calcd for C15H17NO2 (M+H)+: 244.1338, found: 244.1329.
(2^',55')-2-(4-Bromophenyl)-5-methylmorpholine (59)
N M Prepared as described above starting from morpholine 51 (80 mg, 0.195 mmol).
^  n v  *  Me
f  J  Column chromatography (CH2Cl2/MeOH, 0.99:0.01^0.9:0.1) afforded 59 (25 
0  mg, 50% yield) as a colorless oil. Rf 0.12 (CH2Cl2/MeOH, 0.9:0.1). [a]D0 +13.4 
(c 0.18, CH2Q 2). IR (ATR) 3425, 2926, 2852, 2357, 1490, 1010 cm-1. !H NMR 
(CD3OD, 400 MHz): 5 7.53-7.50 (m, 2H), 7.33-7.30 (m, 2H), 4.55 (dd, J  = 3.1, 10.2 Hz, 1H), 3.93 (dd, 
J  = 2.9, 12.1 Hz, 1H), 3.82 (dd, J  = 1.3, 12.1 Hz, 1H), 3.26-3.22 (m, 1H), 3.10 (dd, J  = 10.3, 13.2 Hz, 
1H), 2.99 (dd, J  = 3.0, 13.2 Hz, 1H), 1.41 (d, J  = 6.9 Hz, 3H). 13C NMR (CD3OD, 75 MHz): 5 139.7,
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132.7, 129.1, 122.9, 77.9, 71.1, 48.0, 45.6, 15.0. HRMS (ESI) m/z calcd for C„H14BrNO (M+H)+: 
256.0337, found: 256.0324.
(2^',55')-5-Benzyl-2-(4-bromophenyl)morpholine (60)
Prepared as described above starting from morpholine 52 (39 mg, 0.081 
mmol). Column chromatography (CH2Cl2/MeOH, 0.99:0.01—0.90:0.10) 
afforded 60 (15 mg, 56% yield) as a colorless oil. R/  0.58 (CH2Cl2/MeOH, 
Br  ^^  0.9:0.1). [a]D0 +39.4 (c 0.33, CH2Q 2). IR (ATR) 3019, 2902, 2846, 2353,
1451, 741, 698 cm-1. 1H NMR (CDCl3, 400 MHz): 5 7.44-7.20 (m, 9H), 4.53 (dd, J  = 2.9, 10.3 Hz, 
1H), 3.81 (m, 2H), 3.20 (dd, J  = 10.6, 15.0 Hz, 1H), 3.13 (dd, J  = 10.3, 12.8 Hz, 1H), 3.05-2.99 (m, 
2H), 2.82 (dd, J  = 3.0, 12.8 Hz, 1H). 13C NMR (CDCl3, 75 MHz): 5 141.7, 140.4, 130.4, 129.7, 129.4,
128.9, 127.4, 127.2, 79.9, 69.4, 54.2, 47.6, 36.7. HRMS (ESI) m/z calcd for C17H19BrNO (M+H)+: 
332.0646, found: 332.0639.
(2^',55')-5-Allyl-2-(but-3-enyl)morpholine (61)
Prepared as described above starting from morpholine 53 (26 mg, 0.08 mmol). 
Column chromatography (CH2Cl2/MeOH, 0.99:0.01—0.90:0.10) afforded 61 
' O'  (12 mg, 86% yield) as a colorless oil. R/ 0.26 (CH2Cl2/MeOH, 0.9:0.1). [a]D0
-15.4 (c 0.10, CH2Cl2). IR (ATR) 3417, 2926, 2866, 1645, 1446, 1111, 913 cm-1. 1H NMR (CDCl3, 
400 MHz): 5 5.88-5.76 (m, 2H), 5.16-5.08 (m, 2H), 5.02 (ddd, J  = 1.6, 3.7, 17.2 Hz, 1H), 4.97-4.93 
(m, 1H), 3.66 (dd, J  =2.9, 2.9 Hz, 2H), 3.48 (ddt, J  = 3.2, 4.8, 8.2 Hz, 1H), 2.73 (dd, J  = 8.8, 12.5 Hz, 
1H), 2.70 (dd, J  = 2.9, 10.1 Hz, 1H), 2.65 (dd, J  = 3.2, 12.6 Hz, 1H), 2.47-2.34 (m, 2H), 2.22-2.04 (m, 
2H), 1.70-1.59 (m, 2H), 1.48 (dddd, J  = 4.9, 6.8, 9.3, 14.0 Hz, 1H). 13C NMR (CDCl3, 75 MHz): 5
139.4, 136.6, 117.9, 115.2, 76.4, 69.1, 52.8, 46.2, 35.4, 33.0, 30.8, HRMS (ESI) m/z calcd for 
CnH20NO (M+H)+: 182.1545, found: 182.1535.
5.10 References and notes
(1) a) Wijtmans, R.; Vink, M. K. S.; Schoemaker, H. E., van Delft, F. L.; Blaauw, R. H.; Rutjes, F. 
P. J. T. Synthesis, 2004, 641-662. b) Myers, A. G.; Lanman, B. A. Org. Lett. 2004, 6, 1045­
1047. c) D ’hooghe, M.; Vanlangendonck, T.; Törnroos, K. W.; De Kimpe, N. J. Org. Chem. 
2006, 71, 4678-4681.
(2) a) Hajos, M.; Fleishaker, J. C.; Filipiak-Reisner, J. K.; Brown, M. T.; Wong, E. H. F. CNS Drug 
Rev. 2004, 10, 23-44. b) Versiani, M.; Cassano, G.; Perugi, G.; Benedetti, A.; Mastalli, L.; 
Nardi, A.; Savino, M. J. Clin. Psychiatry 2002, 63, 31-37.
(3) Dando, T. M.; Perry, C. M. Drugs, 2004, 64, 777-794. b) Hale, J. J.; Mills, S. G.; MacCoss, M.; 
Finke, P. E.; Cascieri, M. A.; Sadowski, S.; Ber, E.; Chicchi, G. G.; Kurtz, M.; Metzger, J.; 
Eiermann, G.; Tsou, N. N.; Tattersall, F. D.; Rupniak, N. J. M.; Williams, A. R.; Rycroft, W.; 
Hargreaves, R.; MacIntyre, D. E. J. Med. Chem. 1998, 41, 4607-4614.
(4) Dieckmann, H.; Strockmaier, M.; Kreuzig, R.; Bahadir, M. Fesenius’ J. Anal. Chem. 1993, 345, 
784-786.
(5) a) Enders, D.; Meyer, O.; Raabe, G.; Runsink, J. Synthesis 1994, 66-72. b) Dave, R.; Sasaki, N. 
A. Org. Lett. 2004, 6, 15-18.
(6) a) Yar, M.; McGarrigle, E. M.; Aggarwal, V. K. Angew. Chem., Int. Ed. 2008, 47, 1-4. b) Lupi, 
V.; Albanese, D.; Landini, D.; Scaletti, D.; Penso, M. Tetrahedron 2004, 60, 11709-11718. c) 
Albanese, D.; Salsa, M.; Landine, D.; Lupi, V.; Penso, M. Eur. J. Org. Chem. 2007, 2107-2113. 
d) Sladojevich, F.; Trabocchi, A.; Guarna, A. J. Org. Chem. 2007, 72, 4254-4257.
(7) Leathen, M. L.; Rosen, B. R.; Wolfe, J. P. J. Org. Chem. 2009, 74, 5107-5110.
(8) Breuning, M.; Winnacker, M.; Steiner, M. Eur. J. Org. Chem. 2007, 2100-2106.
146
Enantioselective Chemoenzymatic Synthesis o f  cis- and trans-2,5-DisubstitutedMorpholines
(9) Ritzen, B.; van Oers, M. C. M.; van Delft, F. L.; Rutjes, F. P. J. T. J. Org. Chem. 2009, 74, 
7548-7551.
(10) a) Fechter, M. H.; Griengl, H. In Enzyme Catalysis in Organic Synthesis; Drauz, K.; Waldmann, 
H., Eds.; Wiley-VHC: Weinheim, 2002; Vol. 3. pp. 974-990. b) Wijdeven, M. A.; Wijtmans,
R.; van den Berg, R. J. F.; Noorduin, W.; Schoemaker, H. E.; Sonke, T.; van Delft, F. L.; 
Blaauw, R. H.; Fitch, R. W.; Spande, T. F.; Daly, J. W.; Rutjes, F. P. J. T. Org. Lett. 2008, 10, 
4001-4003. c) Wijdeven, M. A.; van den Berg, R. J. F.; Wijtmans, R.; Botman, P. N. M.; 
Blaauw, R. H.; Schoemaker, H. E.; van Delft, F. L.; Rutjes, F. P. J. T. Org. Biomol. Chem. 2009, 
7, 2976-2980. d) Koch. K; van den Berg, R. J. F.; Nieuwland, P. J.; Wijtmans, R.; Schoemaker, 
H. E.; van Hest, J. C. M.; Rutjes, F. P. J. T. Biotechnol. Bioeng. 2008, 99, 1028-1033.
(11) Glieder, A.; Weis, R.; Skranc, W.; Poechlauer, P.; Dreveny, I.; Majer, S.; Wubbolts, M.; 
Schwab, H.; Gruber, K. Angew. Chem., Int. Ed. 2003, 42, 4815-4818.
(12) Hasslacher, M.; Schall, M.; Hayn, M.; Bona, R.; Rumbold, K.; Luckl, J.; Griengl, H.; Kohlwein, 
S. D.; Schwab, H. Protein Expression Purif 1997, 11, 61-71.
(13) Zandbergen, P.; van den Nieuwendijk, A. M. C. H.; Brussee, J.; van der Gen, A.; Kruse, C. G. 
Tetrahedron 1992, 48, 3977-3982.
(14) Corey, E. J.; Jones, G. B. J. Org. Chem. 1992, 57, 1028-1029.
(15) Ankner, T.; Hilmersson, G. Org. Lett. 2009, 11, 503-506.
(16) Zandbergen, P.; van den Nieuwendijk, A. M. C. H.; Brussee, J.; van der Gen, A.; Kruse, C. G. 
Tetrahedron 1992, 48, 3977-3982.
147
Chapter 5
148
Summary
Summary
Nitrogen heterocycles form the basis o f  many pharmaceuticals and physiologically active 
natural products. Despite an abundance o f methods to synthesize a large variety o f  different 
heterocycles, the relevance o f  these molecules drives a continuous interest in developing new  
synthetic pathways, preferentially with complete control over the relative and absolute 
configuration.
Over the years, non-racemic cyanohydrins have been recognized as versatile starting 
materials for various (bio)synthetic purposes. N ot only because they are cheap and readily 
available chiral building blocks, but mainly because o f  their multifunctional character, 
offering a wide spectrum o f opportunities for further structural modification. The existing 
methods for enantioselective cyanohydrin synthesis, more specifically through catalysis by 
metals, organic molecules and enzymes, have been extensively reviewed. Especially attractive 
is the application o f hydroxynitrile lyases (HNLs) as catalysts for the enantioselective 
addition o f HCN to prochiral aldehydes, since both (R)- and (S)-selective HNLs are readily 
available. Inspired by these unique opportunities, this thesis describes our research on the 
synthesis and application o f enantiomerically pure cyanohydrins in constructing 
functionalized nitrogen heterocyclic compounds.
Chapter 1 provides an overview o f the latest efforts o f  various groups concerning 
applications o f non-racemic cyanohydrins in organic synthesis.
In Chapter 2, a newly developed chemoenzymatic approach to 2,3-disubstituted trans- 
aziridines 4 is detailed (Scheme 1). At the basis o f  this research, HNL-catalyzed cyanohydrin 
formation served to convert the functionalized aldehydes 1 into the corresponding 
cyanohydrins 2. Upon treatment with different Grignard reagents the intermediate imines 
were formed, after which chelation-controlled diastereoselective reduction with NaBH 4 
afforded the amino alcohols 3 in excellent optical purities and good yields. The amino 
alcohols 3 were then transformed via the corresponding azides into the targeted biologically 
relevant aziridine derivatives 4.
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Scheme 1 Chemoenzymatic synthesis o f  trans-aziridines.
1) TfN3, Et3N
1)HNL, pH = 5.0 1 nTRS CUSO4
0  HCN, MTBE/H2O OTRS 1) R MgRr O ' RS 1 MeOH/H2O/CH 2Cl2 H
J L  ----------------------- ** X  ------------ ** R ^ Y R ------------------------
R H 2) TBSCI, Im, DMAP R CN 2) MeOH N H 2 2 )T B A F ,T H F  R ^ ^ R 1
then NaRH4 3) PPh3 , MeCN, A
1 2 >99% ee 4 3 95-99% dr 4
Chapter 3 utilizes the reaction conditions for chemoenzymatic cyanohydrin formation 
described in Chapter 2 on acetylenic aldehydes 5 and subsequently deals with a novel 
approach toward 2,5-disubstituted-4-hydroxy-2-pyrrolines 8 (Scheme 2). Another key step 
involved a mild Au(III)-catalyzed 5-endo-dig cyclization of the diastereomerically enriched 
acetylenic amino alcohols 7, obtained via Grignard addition onto the cyanohydrins 6 and 
Zn(BH4)2-mediated chelation-controlled diastereoselective reduction. Extensive investigation 
on the Au-catalyzed cycloisomerization finally led to the targeted pyrrolines 8 in optically 
pure form and without detectable pyrrole formation after column chromatography. 
Unfortunately, subsequent follow-up chemistry to synthetically elaborate the resulting 
pyrrolidines appeared to be surprisingly troublesome, mostly due to dehydration to the 
corresponding pyrrole analogues.
Scheme 2 Chemoenzymatic synthesis o f  4-hydroxy-2-pyrrolines.
1) R1 MgRr
O 1) HNL, pH = 5.0 OTRS 2) MeOH OTRS OH
" HCN, MTRE/H2O I  Zn(RH4)2 ][ R 1 1) TRAF, THF n—^
H ----------------------------- 'C N  ------------------------------------- ► Y -------JL 1
R 2) TRSCI, Im, DMAP R 3) (Roc)2O R NHRoc 2) N a A u C l 4  R N R' 3)(ROC)2°  THF, 50 °C '
NaHCO3  Roc
5 6  >93% ee 7 up to 97% dr 8  >8 8 %
yield
Stimulated by the results in the previous chapters, Chapter 4 highlights three attempts 
toward an asymmetric synthesis of the potent antitumor phenanthroindolizidine 9 (Scheme 3). 
Two o f these approaches were thought to proceed through chemoselective HNL-mediated 
synthesis of the enantiopure phenanthrene-based cyanohydrin 16. Synthesis of the precursors 
proceeded without difficulty, however, we have not been able to form the desired cyanohydrin 
products via asymmetric HNL-mediated hydrogen cyanide addition. The third route details an 
approach based on diastereocontrolled acetylide addition to Boc-(S)-prolinal 13 with which 
both the relative and absolute stereochemistry could be predictably installed. Despite
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numerous attempts, ring closure o f the biphenyl moiety to arrive at the phenanthrene scaffold  
10 has remained unsuccessful.
Scheme 3 Toward an asymmetric synthesis o f  the phenanthrene natural product 9.
Finally, Chapter 5 details the application o f  cyanohydrins 18 in the synthesis o f  cis- and 
fra«s-2,5-disubstituted morpholines 21 (Scheme 4). Starting from enantiomerically pure 
cyanohydrins 18, subsequent formation o f  diastereomerically pure amino esters 19 via a three- 
step one-pot reduction-transimination-reduction sequence, followed by ester reduction and 
simultaneous protection, provided the cyclization precursors 20. Ring closure under basic 
conditions to arrive at the morpholine skeleton and SmI2-mediated reductive detosylation 
delivered a third set o f  potentially biologically relevant nitrogen-containing heterocyclic 
target structures 21.
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Scheme 4 Chemoenzymatic synthesis o f  cis- and trans-2,5-disubstituted morpholines 21.
X
1) HNL, pH =5.0 
HCN, MTBE/H2O
R H 2) 2-methoxypropene 
1 POCI3, EtaN
OMIP 
R ^ C N  
18 >99% ee
1) DIBALH
2) H2NCHR1CO2Me 
Et3N
3) MeOH, then NaBH4
R
OMIP O
R1 
19
OMe
1) UAIH4
2) TsCI, pyr 
EtaN
3) HCI/H2O
OH Tf 
N^A .
20
OTs
1 )NaH, THF
X t r2) Sml2,H2O r '  'o '
pyrrolidine, THF
21
All 4 possible 
diastereoisomers
R
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Stikstof-bevattende ringsystemen vormen de basis voor veel farmaceutische verbindingen 
en fysiologisch actieve natuurstoffen. Ondanks dat er verschillende methoden bestaan om een 
grote diversiteit van deze heterocyclische systemen te maken, leidt de relevantie van deze 
moleculen tot het continu ontwikkelen van nieuwe syntheseroutes, bij voorkeur met volledige 
controle over zowel de relatieve als absolute configuratie.
Reeds door de jaren heen worden cyaanhydrinen gezien als veelzijdige bouwstenen voor 
verschillende (bio)synthetische doeleinden. D it komt niet zozeer doordat ze goedkoop en 
eenvoudig toegankelijk zijn, maar hoofdzakelijk door hun multifunctionele karakter. De 
aanwezigheid van diverse functionele groepen maakt deze bouwstenen aantrekkelijk voor 
verdere structuurmodificatie. Verschillende katalytische methoden voor de synthese van 
enantiomeerzuivere cyaanhydrinen, gebruikmakend van metalen, organische moleculen o f  
enzymen, zijn beschreven in de literatuur. Doordat zowel (R)- als (S)-selectieve 
hydroxynitrillyasen (HNLs) gemakkelijk te verkrijgen zijn, is de toepassing van deze HNLs 
als katalysatoren voor de enantioselectieve additie van HCN aan prochirale aldehyden een 
aantrekkelijke manier om cyaanhydrinen te synthetiseren. Geïnspireerd door deze unieke 
eigenschappen wordt in dit proefschrift het onderzoek naar de synthese en toepassingen van 
enantiomeerzuivere cyaanhydrinen als bouwstenen voor de ontwikkeling van 
gefunctionaliseerde stikstof-bevattende ringsystemen beschreven.
Hoofdstuk 1 biedt een overzicht van uiteenlopende toepassingen van niet-racemische 
cyaanhydrinen in de organische synthese die in de afgelopen jaren in de literatuur zijn 
verschenen.
In Hoofdstuk 2 wordt een nieuw ontwikkelde chemoenzymatische benadering voor de 
synthese van 2,3-digesubstitueerde trans-aziridinen 4 behandeld (Schema 1). D e basis hiervan 
is een HNL-gekatalyseerde omzetting van aldehyden 1 naar de overeenkomstige 
cyaanhydrinen 2. Middels een reactie met verschillende Grignardreagentia werden de 
instantaan gevormde imines onderworpen aan een chelatie-gecontrolleerde diastereoselectieve 
reductie met NaBH4 wat leidde tot vorming van aminoalcoholen 3 in uitstekende optische 
zuiverheid en hoge opbrengsten. D e aminoalcoholen 3 werden hierna via het overeenkomstige 
azide omgezet in de gewenste biologisch actieve aziridine analoga 4.
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Schema 1 Chemoenzymatische synthese van trans-aziridinen.
1) TfN3, Et3N
1) HNL, pH = 5.0 1 CuSÜ4
0  HCN, MTBE/H2O OTBS 1 ) R M g B r  ? BS 1 MeOH/H2O/CH2Cl2 ¡J
J L  -------------------------------"■ X  -----------------*■ R ^ [ ^ R -------------------------------- "■ v N
R H 2) TBSCl, Im, DMAP R CN 2) MeOH NH2 2) TBAF, THF R ^ V
dan NaBH4 3) PPh3 , MeCN, A
1 2 >99% ee 4 3 95-99% dr 4
In Hoofdstuk 3 worden de reactiecondities voor de chemoenzymatische cyaanhydrinvorming 
toegepast op de acetyleenbevattende aldehyden 5, reeds beschreven in Hoofdstuk 2, en wordt 
vervolgens een nieuwe route naar 2,5-digesubstitueerde 4-hydroxy-2-pyrrolinen 8 beschreven 
(Schema 2). Een andere sleutelstap omvat een milde Au(III)-gekatalyseerde 5-endo-dig  
ringsluiting van diastereomeer-verrijkte acetyleen-bevattende aminoalcoholen 7. Deze laatste 
verbindingen zijn verkregen door een Grignardadditie uit te voeren op de cyaanhydrinen 6 en 
vervolgens een Zn(BH4)2-gekatalyseerde chelatie-gecontroleerde diastereoselectieve reductie 
uit te voeren. Uitgebreid onderzoek naar de Au-gekatalyseerde cycloisomerisatie leidde 
uiteindelijk tot de gewenste pyrrolinen 8 in optisch zuivere vorm en zonder detecteerbare 
pyrroolvorming na kolomchromatografie. Helaas bleek de vervolgchemie om de 
desbetreffende pyrrolidinen te verkrijgen moeilijk. Dit werd voornamelijk veroorzaakt door 
dehydratatie naar de overeenkomstige pyrroolderivaten.
Schema 2 Chemoenzymatische synthese van 4-hydroxy-2-pyrrolinen.
1) R1 MgBr
O 1 ) HNL, pH = 5.0 OTBS 2) MeOH OTBS oh
" HCN, MTBE/H2O I  Zn(BH4)2 1l R 1 1) TBAF, THF n—^
H ---------------------- - 'CN ------------- - Y "  --------------- 4  1
R 2) TBSCl, Im, DMAP R 3) (Boc)2O R NHBoc 2) NaAuCU R N R3)(B°c)2°  thf, 50 °C B
NaHCO3 Boc
5 6  >93% ee 7 groter dan 97% dr 8  >88%
opbrengst
Gestimuleerd door de resultaten verkregen in de voorafgaande hoofdstukken, belicht 
Hoofdstuk 4 drie pogingen naar een asymmetrische synthese van de potentiële antikanker 
verbinding phenanthroindolizidine 9 (Schema 3). Twee van deze routes waren aanvankelijk 
gebaseerd op een chemoselectieve HNL-gekatalyseerde synthese van enantiomeerzuiver 
phenanthreencyaanhydrin 16. De synthese van de bouwstenen verliep probleemloos, echter 
waren we niet in staat om de gewenste cyaanhydrinen te maken via de asymmetrische HNL- 
gekatalyseerde waterstofcyanide additiereactie. De derde route beschrijft een ontwikkeling die
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gebaseerd is op een diastereogecontroleerde acetylide additie aan Boc-(S)-prolinal 13, waarbij 
zowel de relatieve als absolute stereochemie voorspelbaar kon worden ingebouwd. Ondanks 
uiteenlopende pogingen is het echter niet gelukt om een ringsluiting uit te voeren op de 
biphenylstructuur die zou moeten leiden tot het phenanthreenskelet 10.
Schema 3 Naar een asymmetrische synthese van phenanthreen natuurproduct 9.
Tenslotte beschrijft Hoofdstuk 5 de toepassing van cyaanhydrinen 18 in de synthese van cis- 
en trans-2,5-digesubstitueerde morfolinen 21 (Schema 4). Uitgaande van enantiomeerzuivere 
cyaanhydrinen 18, werden door middel van een gecombineerde driestapsreactie bestaande uit 
een reductie-transiminering-reductie, de aminoalcoholen 19 verkregen. Vervolgens werden 
deze structuren omgezet via reductie van de ester en een simultane beschermingsstap waarna 
de precursors 20 werden verkregen.
Een derde set van mogelijk biologisch relevante stikstof-bevattende heterocyclische 
doelstructuren 21 werd gerealiseerd door een ringsluiting onder basische condities uit te 
voeren om te komen tot het morfolineskelet, gevolgd door een SmI2-gekatalyseerde 
reductieve detosylering.
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Schema 4 Chemoenzymatische synthese van cis- en trans-2,5-digesubstitueerde morfolinen 21.
1) HNL, pH =5.0
0  HCN, MTBE/H2O
A  ------- - -- - *R H 2) 2-methoxypropeen
1 POCI3 , EtaN
OMIP 
R ^ C N  
18 >99% ee
1) DIBALH
2) H2 NCHR1 CO2Me
Et3N
3) MeOH, dan NaBH4
R
OMIP O
R 1 
19
OMe
1) LiAIH4
2) TsCI, pyr 
EtaN
3) HCI/H2O
OH T f 
N^
2 0
OTs
1 ) NaH, THF
2) SmI2,H 2O 
pyrrolidine, THF
X JR' O
2 1
A lle 4 d e
diastereoisomeren
mogelijk
R
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Na vele uren aan de labtop te hebben doorgebracht, meestal onder consumptie van de 
nodige “tassen” koffie, en met zo nu en dan wat gefoeter en gevloek (##@$%$##) omdat de 
labtop ineens een ander leven gaat leiden en dat “ding” niet wilt doen wat jij wilt dat gebeurt, 
rest mij eigenlijk nog maar één ding: het schrijven van het dankwoord. Teruggaand naar het 
begin van mijn AiO-periode lijken die vier jaar ruimschoots voldoende om je 
promotieonderzoek af te ronden. Echter na anderhalf jaar hard werken begin je je toch af te 
vragen of dit alles is wat je tot nu toe hebt gepresteerd en dan lijkt het idee om uiteindelijk 
zo’n boekje in elkaar te moeten draaien bijna godsonmogelijk. En dan, zoals “Herr Kaiser” al 
vermeldde in zijn dankwoord in ik quote: “bekruipt je  het gevoel dat de resterende tijd 
omgekeerd evenredig is met de hoeveelheid werk die nog moet worden verzet”. Wat mij 
betreft klopt dat wel degelijk! Gelukkig ontstaat er eindelijk (wel langzaam) een “ent”, of lijkt 
er “een vaag lijntje” aan de horizon op te doemen en voordat je  het in de gaten hebt, is er solid 
ground. Uiteindelijk groeit dit alles uit tot de rode draad van het proefschrift. Gaandeweg 
worden het steeds meer lijntjes waarvan er steeds meer tot een succes gaan leiden Wat 
uiteindelijk tot “best een aardig geheel” heeft geleid. Tijdens het schrijven van het proefschrift 
blijkt dan toch eens te meer dat je  net iets meer te vertellen hebt dan aanvankelijk gedacht. Bij 
het doorspitten van de labjournaals passeren veel leuke momenten en situaties de revue die ik 
zowel op als buiten het lab heb meegemaakt en die ervoor gezorgd hebben dat ik de afgelopen 
vier jaar met veel plezier AiO ben geweest. Eén ding weet ik nu zeker: ik heb er zeker geen 
spijt van gehad. Ik wil dit dankwoord dan ook graag gebruiken om iedereen die hieraan een 
bijdrage heeft geleverd te bedanken.
Om te beginnen wil ik mijn promotor, Floris Rutjes bedanken. Floris, ik herinner me nog 
goed het moment dat ik onverwacht verblijd werd en haast sprakeloos was toen jij samen met 
“andere” Floris op het promotiefeest van Guuske het heugelijke nieuws vertelde dat ik als 
AiO mocht beginnen in je onderzoeksgroep. Gedurende de afgelopen vier jaar was jij altijd 
een onuitputtelijke bron van chemische kennis. Jou frisse kijk op het onderzoek en een 
waterval aan ideeën is van onschatbare waarde geweest voor het tot stand komen van dit 
proefschrift. Ik heb in die periode dan ook met veel plezier gewerkt en ontzettend veel geleerd 
en wil je daarvoor hartelijk danken.
Mijn copromoter Floris van Delft wil ik graag bedanken voor zijn bijdrage aan dit 
onderzoek. Floris, ook jouw enthousiaste en creatieve input tijdens de werkbesprekingen op 
maandag- en donderdagochtend leidde vaak tot nieuwe en goede ideeën en daarnaast stond je 
deur altijd open voor discussies op zowel praktisch als theoretisch vlak, waarvoor mijn 
hartelijke dank. Als tijdelijk medewerker van Synaffix wens ik je heel veel succes met je 
nieuwe spin-off.
Daarnaast bedank ik Martin Feiters, nieuw lid van de Rutjes-groep en tevens hoofd van de 
veiligheidscommissie waar ikzelf ook deel van heb uitgemaakt, voor zijn bijdrage aan de 
vanineremmers.
Uiteraard kon al dat werk, beschreven in dit proefschrift nooit door mij alleen verzet 
worden. Tijdens mijn promotie heb ik het genoegen gehad om verschillende studenten te
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mogen begeleiden (Niek, Matthijs, Elena, Steven, Jody, Laurens, Marleen, Ezra, Gaston). Een 
bedankje is hier zeker wel op zijn plaats! Allereerst wil ik Niek Vermue bedanken voor zijn 
bijdrage aan hoofdstuk 2. Niek jij hebt tijdens je ministage de basis gelegd die ertoe geleid 
heeft dat we na heel wat plezierig experimenteren en klooien in het lab uiteindelijk toch een 
route vonden naar de aziridines. Je verslag heeft een tijdje op zich laten wachten (al met al 
zo’n anderhalfjaar), vermoedelijk stond je al die tijd druk friet te bakken in Zeeland....? Toch 
wil ik je bedanken voor je  bijdrage en je veel succes wensen met je  studie, want ik neem aan 
dat deze nog steeds “in de steigers staat”??!
Matthijs (aka Blondy), tot twee maal toe de snelste op de kartbaan, was jij mijn eerste 
hoofdvakstudent en heb je een enorme bijdrage geleverd aan mijn onderzoek. Je kwam 
precies op het juiste moment om je tanden te zetten in de chemie die ik samen met Niek was 
begonnen en om deze verder in goede banen te leiden. Maar hard werken wordt beloond en 
we hebben dit alles mooi kunnen verpakken in een JOC publicatie. Ik wens je dan ook heel 
veel succes en vooral ook veel plezier tijdens je  promotieonderzoek. P.S.: geen pot met 
rhodamine meer laten vallen he, dat geeft zo’n rommel!
During the summer of 2008 Elena Duran Verdasco visited our laboratory in Nijmegen as an 
Erasmus student. Elena, I can still remember you as a shy Spanish girl the first time we met. 
But along the way, I think you learned a lot, not only about the ups and downs of research (on 
morpholines), but also of the great student life in Nijmegen. I really enjoyed having you in 
our lab and I wish you all the best with your job in Spain.
Steven (aka Stefanie ofwel “the cornerman”), jij zette het onderzoek aan morfolines voort 
en ook al zat de chemie zo nu en dan tegen, je  was nooit snel tevreden en gaf niet op. Je kwam 
er o.a. achter dat de in de literatuur beschreven experimenten niet altijd te reproduceren waren 
en het leek erop dat ook de uitvoering hiervan op papier toch allemaal iets simpeler leek dan 
dat het daadwerkelijk was. Uiteindelijk heb je  toch doorgezet wat resulteerde in een mooie 
publicatie in de JOC. Veel succes met je  promotieonderzoek in Schotland.
Laurens tijdens je korte stage, heb je een enorme werklust getoond en vormde ook jouw 
werk een basis voor succes. Gaston, als HLO’er was jij mijn aller-allerlaatste student die ik 
mocht begeleiden. Jij bent verder gegaan met het werk van Laurens en je geweldige 
gedrevenheid, creativiteit en vastberadenheid hebben ertoe geleid dat je  tijdens je 
afstudeerstage een indrukwekkende hoeveelheid verbindingen hebt gemaakt. Jullie werk 
samen heeft nog een mooie publicatie opgeleverd en fantastisch dat je  aan het eind ook nog 
“even” de gouden spatel hebt weten binnen te tikken. Veel succes met jullie studies!
Jody en Ezra, alhoewel jullie bijdragen aan de vanineremmers niet in dit proefschrift zijn 
opgenomen, is het eindresultaat zeker niet minder waardig. Wat begon als een klein 
onderzoek is uiteindelijk uitgegroeid tot een mooi resultaat (patent, publicatie, 
onderzoeksvoorstel). Marleen ook jouw onderzoek is niet in dit proefschrift verwerkt, maar 
toch wil ik je bedanken voor de geweldige inzet, want de rhodamines waren geen 
gemakkelijke verbindingen om mee te werken.
Mijn mede labgenoot Jando (met je alom bekende toetergeluidje “pfffiiii”, dat ik inmiddels 
ook heb overgenomen), wil ik hartelijk bedanken voor de leuke momenten samen op het lab 
en voor het feit dat ik altijd terecht kon voor de meest uiteenlopende dingen. Datzelfde geldt 
voor Rene, ook bij jou kon ik terecht voor ondersteuning, daarvoor mijn dank. Ook in mijn 
kort verblijf op jouw lab hebben we zeker wat afgelachen.
158
Dankwoord
Voor de gezellige dinertjes samen wil ik Marloes (veel succes bij Synaffix), Roseri (“voetje 
lopen”), Lieke enne (auch enne) natuurlijk mijn persoonlijke taalcoach Jorge bedanken. Jorge, 
tot tweemaal toe waren wij labgenoten van elkaar. Ik heb met jou vele jaren samen op het lab 
mogen staan waar we tijdens het freubelen ontzettend veel plezierige momenten hebben 
beleefd. Super leuk dat je  mijn paranimf wilt zijn! Naamgenoot Bas, ook jou wil ik bedanken 
voor een fijne tijd samen op het lab toen ik nog student was en daarna zeker ook als collega 
AiO en cubicle-mate. Ontzettend tof dat ook jij paranimf wilt zijn!
Uiteraard wil ik alle (ex)collega’s van de Rutjes-groep bedanken voor de leuke en gezellige 
sfeer op en rond het lab: Dennis (veel succes in London, San Fransisco was inderdaad top!), 
mede labgenoot Ferdi (hopelijk krijg je je rode Rovertje ooit nog van de blokken), Candice, 
Mariëlle, herr Kaiser, Henry (roommate in Parijs en Maastricht, volgende keer snurk ik 
minder hard, beloofd!), Jorgen, Susan, Marjoke, Rinske, Angelique, Rene B, Anup, Waqar, 
ex-begeleidster en DSM collega Guuske, Martijn, Sander (roommate in Dublin en ex-baas), 
Valeria, mede labgenoot Meneertje (Dani), Daniel, Koen, Stan, Brain, Kaspar, Pieter, Bas G., 
Roel, Hester, Maarten, Pjotr, Claudia. Mede Limburger Sjef voor onze plezierige ritjes op 
vrijdagmiddag terug naar het “zonnige” zuiden en voor de vele hilarische momenten die we 
samen hebben beleefd en voor het feit dat ik regelmatig heb mogen profiteren van je 
fotografische geheugen. Daarnaast wil ik natuurlijk ook de vele studenten die in deze periode 
zijn gekomen en gegaan en alle (ex)collega’s van onze organische afdeling bedanken.
De altijd lachende Peter van Dijk wil ik bedanken voor al het logistieke management tijdens 
de afgelopen jaren. Veel succes met de bouw van je nieuwe huis. Als het klaar is kom ik een 
keertje op bezoek. Minstens zo belangrijk waren de mensen die zorgden voor de analytische 
ondersteuning. Peter van Galen en Helène Amatdj ais-Groenen voor het meten van de 
massaspectra, en Ad Swolfs voor de NMR ondersteuning. Verder wil ik graag Desiree en 
Jacky bedanken voor de administratieve ondersteuning. Jacky, je  hebt nu een nieuw plekje 
gevonden samen met Jando op een kantoor, en we hebben vooral tijdens je afwezigheid 
kunnen zien dat je van onschatbare waarde bent voor de Rutjes groep. Bedankt nog voor het 
vinden van een geschikte promotiedatum, want dat was zeker niet gemakkelijk!
Bij DSM Pharmaceutical Products (Geleen) wil ik PQ (aka Peter Quaedflieg) bedanken 
voor zijn geweldige insteek bij de sollicitatie en het mij binnenloodsen bij DSM en tevens 
voor zijn fijne begeleiding tijdens mijn (extra) stage binnen DSM. PQ, als je  dit leest zit je 
waarschijnlijk thuis op je kantoor gehuld in dikke sigarenrook na te genieten van de zoveelste 
sigaar die je hebt weg gepaft.
En dan nu het thuisfront. Pap, mam en Pim, het werk is bijna afgerond en ik ben dan ook 
ontzettend dankbaar voor jullie fantastische steun zowel tijdens mijn studie als tijdens mijn 
promotie. Jullie hebben een groot gedeelte bijgedragen aan wat ik in deze tijd heb bereikt. 
Bedankt voor jullie voortdurende belangstelling voor het soms onmogelijk te begrijpen vak 
van jullie oudste zoon en broer. Dankjewel dat jullie me, tot het laatste moment, alle ruimte 
hebben gegeven om dit proefschrift af te ronden.
Bas
159
List o f Publications
List of publications
Publications
-  B. Ritzen; F. L. van Delft; F. P. J. T. Rutjes: “Synthetic Applications o f Enantiopure 
Cyanohydrins” manuscript in preparation.
-  B. Ritzen; G. J. J. Richelle; L. Brocken; F. L. van Delft; F. P. J. T. Rutjes:
“Enantioselective Chemoenzymatic Synthesis o f  4-Hydroxy-2-Pyrrolines” manuscript 
in preparation.
-  B. Ritzen; S. Hoekman; E. Duran Verdasco; F. L. van Delft; F. P. J. T. Rutjes:
“Enantioselective Chemoenzymatic Synthesis o f  cis- and trans-2,5-Disubstituted 
Morpholines” J. Org. Chem. 2010, 75, 3461-3464.
-  B. Ritzen; M. C. M. van Oers; F. L. van Delft; F. P. J. T. Rutjes: “Enantioselective 
Chemoenzymatic Synthesis o f  trans-Aziridines” J. Org. Chem. 2009, 74, 7548-7551.
-  H. H. W. Thijssen; B. Ritzen: “Acenocoumarol Pharmacokinetics in Relation to 
Cytochrome P450 2C9 Genotype” Clin. Pharmacol. Ther. 2003, 74, 61-68.
Patents
-  P. L. J. M. Zeeuwen; P. A. M. Jansen; J. Schalkwijk; F. P. J. T. Rutjes; B. Ritzen:
"Pantothenic Acid Derivatives and Their Use in the Treatment o f  Microbial 
Infections” Patent application filed.
-  P. J. L. M. Quaedflieg; B. J. M. Plum; B. Ritzen; A. J. A. A. Dias; C. Cusan; C. H. M. 
Schepers: “Enzymatic Conjugation o f  Bioactive Moieties” PCT Int. Appl. 2009, WO 
2009101178 A1.
-  P. J. L. M. Quaedflieg; C. Cusan; B. Ritzen; A. J. A. A. Dias: “Process for Selective 
Enzymatic Hydrolysis o f  Pendant Esters o f  a Polymer” PCT Int. Appl. 2008, WO 
2008155381 A1.
160
Curriculum Vitae
Curriculum Vitae
Bas Ritzen was bom on the 20th of June 1982 in Heerlen, the Netherlands. He attended 
Bemardinus College secondary school, which he finished in 1999. He then started a Bachelor 
study in chemistry at the Zuyd University of Applied Sciences where he received his BA.Sc. 
title in 2003 (organic chemistry). Afterwards he started his Master in Chemistry at Radboud 
University Nijmegen, where he obtained his M.Sc. degree in 2005, graduating cum laude. He 
performed his master internship under the supervision of Prof. dr. F.P.J.T. Rutjes and Dr. F.L. 
van Delft. The project involved the synthesis of 4,6-linked peptide-based 2-deoxystreptamine 
derivatives that -  upon incorporation into aminoglycoside structures -  may improve the 
binding to RNA and hence act as antibiotic compounds.
Before the start of his PhD in mid 2006, an additional industrial traineeship was performed 
to expand his knowledge towards the industrial aspects of organic chemistry. During this five 
months period, chemical and enzymatic technologies with regard to peptide synthesis were 
developed. The last three months he was recruited as a temporary employee at the 
aforementioned department.
In September 2006, he started his PhD under the supervision of Prof. dr. F.P.J.T. Rutjes in 
the synthetic organic chemistry group of the Institute for Molecules and Materials at Radboud 
University Nijmegen. The aim of the research was to develop novel synthetic methodologies 
for the synthesis of various nitrogen heterocycles using enantiopure cyanohydrins as strategic 
synthons and application of the newly developed methodology in natural product synthesis. 
The results thereof are described in this thesis.
Moreover, in a project in collaboration with Prof. dr. J. Schalkwijk (dermatology group, 
Radboud University Nijmegen Medical Center), novel analogues of pantetheine were 
synthesized, which were evaluated as inhibitors of pantetheinase activity.
After a short stay at the spin-off company Synaffix, he is currently working as a post­
doctoral fellow within the DSM R&D department (Geleen, The Netherlands).
161
